Global state of harm reduction 2018. by Stone, Katie & Shirley-Beavan, Sam
THE GLOBAL STATE  
OF HARM REDUCTION 2018
HARM REDUCTION
INTERNATIONAL
G
LO
B
A
L
STATE
O
F
H
A
R
M
R
E
D
U
CTIO
N
2018
                                    H
arm
 R
eduction International
Harm Reduction International is a leading NGO dedicated to 
reducing the negative health, social and legal impacts of drug 
use and drug policy. We promote the rights of people who use 
drugs and their communities through research and advocacy to 
help achieve a world where drug policies and laws contribute to 
healthier, safer societies.
If you would like to find out more about Harm Reduction International, 
please contact us at:
Harm Reduction International
61 Mansell Street,
London, E1 8AN,
United Kingdom
Phone: +44 (0) 20 7324 3535
Email: office@hri.global
Web: www.hri.global
HARM
 REDUCTION
INTERNATIONAL
www.hri.global
6TH EDITION
3Contents
ACKNOWLEDGEMENTS 04
FOREWORD: Maia Szalavitz and Ma. Inez Feria 06
INTRODUCTION 08
1. GLOBAL OVERVIEW 08
2. REGIONAL OVERVIEW 
2.1 Asia 29
2.2 Eurasia 47
2.3 Western Europe 61
2.4 Caribbean 81
2.5 Latin America 95
2.6 North America 111
2.7 Oceania 131
2.8 Middle East and North Africa 147
2.9 Sub-Saharan Africa 159
Global State of Harm Reduction 20184
The Global State of Harm Reduction 2018 
Written and edited by Katie Stone and Sam Shirley-Beavan
© 2018 Harm Reduction International
Acknowledgements
This report was made possible by the collaborative input of harm reduction organisations networks, drug user 
organisations, researchers, academics and advocates. Harm Reduction International would like to acknowledge 
the invaluable contribution of these individuals and organisations:
Asia: Zia Ziaurahman, UNODC; Saima Khan, UNAIDS; Choub Sok Chamreun, KHANA; Cherry Cheung, Hong 
Kong Narcotics Division; G Charanjit Sharma and Pemu Bhutia, India HIV/AIDS Alliance; Ignatius Praptoraharjo, 
Gadjah Mada University; Goro Koto, Japan Advocacy Network for Drug Policy; Augusto Nogueira, Assocation of 
Rehabilitation of Drug Abusers of Macau; Yatie Jonet, Malaysian AIDs Commission; Dr Khin Cho Win, UNAIDS; 
Anjay Kumar and Bishnu Sharma Coalition of Drug Users in Nepal; Patrick Angeles, NoBox; Pascal Tanguay; 
Nguyen Tam, Vietnam Ministry of Health; Semjidmaa Choijil, Japan Advocacy Network for Drug Policy; Kristina 
Mendoza, StreetLawPH; Khin Cho Win Htin.
Eurasia: David Otiashvili, Alternative Georgia/Eurasian Harm Reduction Association (EHRA); Igor Kouzmenko, 
ENPUD; Marian Ursan, Carusel; Igor Gordon, EHRA; M Ivanishvili; S Ibisevich; Yuliia Georgieva.
Western Europe: European Monitoring Centre on Drug Use and Drug Addiction; Josep Rovira Guardiola, 
ABD; Tessa Windelinckx, Needle Exchange Flanders; Dirk Schäffer, JES; Heino Stöver, Akzept; Stine Nielson; 
Patrick Klein, Abrigado; Eberhard Schatz, Correlation; Ximene Rego, APDES; Martine Baudin, Première Ligne 
Association; Dominique Schori, Infodrog; Olivier Simon and Gabriel Guarassi, CHUV; René Akeret; Petra 
Baumberger, Fachverbund Sucht; Christopher Hicks, NAT; Zoe Carre and Niamh Eastwood, Release; Linda 
Montanari, EMCDDA; Susanna Ronconi, Antonella Camposeragna, Maria Stagnitta, Pino di Pino and Elise 
Fornero, Forum Droghe.
Caribbean: Clara Alibert, UNODC; Alexandra Rodriguez, Camila Gelpi-Acosta, Gladys Nieves Vásquez and 
Yesenia Aponte, El Punto en la Montaña.
Latin America: Diana Rossi and Paula Goltzman, Intercambios Argentina; Inés Mejía Motta; Isabel Pereira and 
Lucía Ramírez, Dejusticia; Saïd Slim Pasarán, Verter A.C.; Julián Quintero, Acción Técnica Social; Ernesto Cortés, 
ACEID; Juliana Moura Bueno; Mauricio Fiore, Cebrap; Francisco Bastos, FIOCRUZ.
North America: Benjamin Phillips, Harm Reduction Coalition; Shantel Davies, NASEN; Dr Bruce Trigg; Dr Sharon 
Stancliff; Eliza Wheeler; Nazlee Maghsoudi, Centre on Drug Policy Evaluation; Sandra Ko Hon Chu, Canadian 
HIV/AIDS Legal Network.
Oceania: Caitlin Hughes, UNSW; Paul Dietze, Burnet Institute; Lisa Maher, Kirby Institute; Alison Ritter, UNSW; 
David McDonald, Harm Reduction Australia; Kathryn Leafe, NZNEP.
Middle East and North Africa: Lina Brandt, MENAHRA.
Sub-Saharan Africa: Sylvia Ayon, KANCO; Kunal Naik, PILS; Andrew Scheibe, Shaun Shelley, Julie MacDonnell; 
Wamala Twaibu, UHRN; Adeolu Ogunrombi; Wilson Box; Betty Mombo; Massougi Thiandoum and Magatte 
Mbodj, ANCS; Magath Pouye, ANCS; Isidore Obot; Alix Zuinghedau, Alexandra Phaeton, Camille Sarret and Malik 
Samessekou, Coalition Plus; Nicolas Denis, Antoine Henry and Enzo Poultreniez, Aides; Charles Somé; Bernice 
Apondi and Chris Abuor, VOCAL Kenya; Mlewa Kalama, KANCO; Fabienne Hariga; John Ondiek, Haso Seychelles; 
Ancella Voets, Médecins Sans Frontières; Anna Versfeld; John Kimani, KENPUD; Aggey Aluso, OSIEA; Céline 
Grillon, Medicines du Monde. 
5Thanks also to the following people for input and guidance:
Naomi Burke-Shyne, Catherine Cook, Emily Rowe, Edward Fox, Gen Sander, Cinzia Brentari, Sarah Lowther, 
Olga Szubert, Giada Girelli, Rick Lines, Ashley Howard, Maria Pascale, Jamie Bridge, Ruth Birgin, Claire Mawditt, 
Gloria Lai, Anne Bergenstrom, Claudia Stoicescu, Anna Dovbakh, Olga Belyaeva, Marie Nougier, Daniel Wolfe, 
Sarah Evans, Joanne Csete, Ane Maria-Goretti, Anna Versfeld, Dagmar Hedrich, Machteld Busz, Vicki Hanson, 
Ana Martín Ortiz, Jasmine Tyler, Richard Elliot, Wendy Allison, John Ryan, Lisa Maher, Sarah Larney, Louisa 
Degenhardt, Joumana Hermez, Ahmed Sabry, Jallal Toufiq, Maziyar Ghiabi, the International Network of People 
who Use Drugs (INPUD), and the Women and Harm Reduction International Network (WHRIN).
The Global State of Harm Reduction benefits from the generous support of the MAC AIDS Fund, the Robert Carr 
Fund for Civil Society Networks, the Partnership to Inspire, Transform and Connect the HIV response (PITCH is a 
strategic partnership of Aidsfonds, the International HIV/AIDS Alliance and the Dutch Ministry of Foreign Affairs), 
and the Government of Switzerland Federal Office of Public Health; as well as the World Health Organization 
and the UN Office on Drugs and Crime. Harm Reduction International acknowledges the valuable support of 
Elton John AIDS Foundation and Open Society Foundations.
Designed by Mark Joyce
Copy-edited by Richard Fontenoy
Published by
Harm Reduction International
61 Mansell Street
Aldgate, London E1 8AN
United Kingdom
E-mail: office@hri.global  
Website: www.hri.global 
Suggested citation: Stone K, Shirley-Beavan S (2018) Global State of Harm Reduction 2018. Harm Reduction 
International: London.
HARM REDUCTION
INTERNATIONAL
Foreword by Maia Szalavitz 
In 2018, harm reduction faces both major challenges 
and clear opportunities. While the biannual Harm 
Reduction Conference in the US, held this year in 
New Orleans, saw its largest number of attendees 
ever – over 2,000, according to its organisers – the 
toll of overdose death remained relentless. Various 
forms of illicitly-manufactured fentanyl are now the 
leading cause of overdose death in North America 
– a distressing statistic, especially for a form of drug 
that barely had any presence in the US and Canadian 
markets until the last four years.
The harm reduction movement itself is thriving: this 
year also saw Canada’s well-attended Stimulus Harm 
Reduction Conference in Edmonton. In both the 
US and Canada, there is clear movement towards 
expanding needle and syringe exchange services, 
naloxone availability and, in the US, creating safe 
injection facilities (SIFs). Politically, while strong 
opposition remains – especially in the American 
South – the media, parents’ organisations, most 
recovery advocates and even many politicians have 
finally recognised that harm reduction is essential to 
save lives. 
The rise of illicit fentanyls themselves is just 
about the clearest case one can make for harm 
reduction: despite a literally poisonous supply, 
millions of people are still taking street opioids in an 
underground market that lacks quality control. It’s 
hard to argue that anything short of providing a safer 
supply – both through traditional medications like 
methadone and buprenorphine and via prescription 
heroin, hydromorphone (Dilaudid) and perhaps 
others – will be able to end the crisis, if done to scale.
Indeed, while harm reduction itself and its ideas 
are strong, many people in the field are struggling 
in the face of so much death and so little access to 
the best tools to save lives. Naloxone, SIFs, syringe 
programmes and current medication treatments 
are all necessary – but far from sufficient. Progress 
towards racial and economic justice also remains too 
slow.
The death of harm reduction giant Dan Bigg, the man 
who brought naloxone out of the hospital and into 
the street, has been painful – as has the loss of so 
many other loved ones. Many harm reductionists are 
now traumatised by so much rapid loss.
In light of this situation in which real political 
progress has been made – but not quickly enough 
and always, in the US, facing a potential backlash 
from the Trump administration – we need to take 
good care of each other. Harm reduction doesn’t just 
apply to the people who use drugs that people in 
the field work with – it applies to all of us. We need 
to bring the compassion and kindness and non-
judgmental support we want for people who use 
drugs to ourselves, too.
Harm reduction has gone from an idea shared 
by hundreds in the late 1980s and 1990s to an 
international movement of thousands or more. The 
power of the idea that drug policy should focus on 
reducing harm rather than use remains unparalleled: 
more and more people recognise both the racism 
and the futility of the war on certain drugs and those 
who take them. More and more people are asking, 
“If drugs are really a public health issue, why are we 
still locking people up to try to solve it?” More are 
questioning the morality of “sending a message” by 
allowing people who take drugs to die preventable 
deaths.
Kindness will bring us through this time of darkness 
and into the light.
Maia Szalavitz 
Author and journalist
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Foreword by Ma. Inez Feria 
Harm reduction works. This is no longer up for 
debate.
The evidence for harm reduction has only grown 
stronger over the years. Initiatives that emanate from 
a harm reduction framework – that prioritise health 
and welfare, guarantee human rights, and promote 
social justice – save lives.
But only when people are able to access them.
In the past few decades, Asia has made strides in 
increasing the availability of harm reduction services 
such as needle and syringe programmes (NSPs) and 
opioid substitution therapy (OST), as well as access 
to treatment for HIV and viral hepatitis. Significant 
progress has also been made in understanding 
the nuances of how people across Asia in different 
contexts experience psychoactive substances.
Where harm reduction services are available, access 
and retention rates in programmes remain low, 
and many areas that need these services simply do 
not have them. Further, emerging trends in drug 
use, and a better understanding of the needs of 
different populations who use drugs, means that new 
initiatives are required.
The region is witnessing an increase in 
amphetamine-type stimulant (ATS) use without an 
increase in harm reduction for these people. Services 
for ATS that are founded in the same harm reduction 
principles that allowed us to respond effectively to 
opiate and injecting drug use need to be developed 
and provided. 
There is also greater recognition of the need for 
gender-sensitive and gender-responsive harm 
reduction services. Women have experiences with 
drug use and the drug trade that differ from men’s. 
Especially, but not limited to, societies where women 
are idealistically painted as nurturing or pure, their 
involvement with drugs expose them to a greater 
degree of vulnerability to physical and sexual 
violence, exploitation and stigmatisation. In the 
criminal justice system alone, while women make 
up a smaller percentage of the prison population 
compared to men, they are the fastest growing group 
of prisoners. The enforcement of harsh drug policies 
is exacerbating this problem. 
The steps required to develop harm reduction 
services for these different contexts have not 
changed: meet people where they are at; give honest 
and pragmatic information; create programmes and 
responses around their needs, rather than imposing 
unrealistic goals; and, ensure their meaningful 
involvement throughout the process.
Asia’s progress in harm reduction will continue to 
be undercut if we don’t address a prevailing and 
growing culture in many Asian countries, one that still 
believes in punishment as the most effective way to 
deal with any behaviour it deems deviant. Responses 
to drug-related issues continue to be couched in a 
repressively punitive social and policy environment. 
The call for drug-free societies grows louder, and 
with it, the dehumanisation of people who use drugs.
In the Philippines alone, where the current president 
has famously called for an all-out “war on drugs”, 
the past two years has seen thousands of people 
killed and tens of thousands more deprived of 
liberty. Support for such zero-tolerance rhetoric has 
spread, with neighbouring countries adopting similar 
approaches. Compounded with diminishing funding 
for harm reduction in the region, these punitive 
environments risk us backsliding from the progress 
we have worked so hard for.
Yet, there are pockets of hope. Communities 
who recognise the negative consequences of 
dehumanising drug policies. People who are seeking 
better solutions, but are unable to find or understand 
them. People who are unable to reconcile which 
policies and services actually work with what they 
have been taught is good and bad. 
The challenge falls on those of us pushing for 
progress and human rights to extend our reach and 
communicate to those outside the drug policy and 
harm reduction bubble. We must empower people to 
respond based on compassion and evidence instead 
of misguided idealism. It is imperative for us to keep 
developing and delivering services and programmes 
that are responsive to the needs of people who use 
drugs, and also to shift the prevailing mindset in 
many of our countries where they must thrive.
For young advocacy groups (like the one I am 
involved with) that must navigate such extreme social 
and political conditions, the Global State of Harm 
Reduction anchors us in a global context, and builds 
a foundation for the much-needed evidence and 
perspective to do our work. 
Harm reduction reminds us that a deep respect for 
the value and dignity of each person drives all our 
actions. For decades, thousands of lives have been 
ruined in pursuit of an unrealistic drug-free goal. We 
are at a pivotal stage for drug policy in the region, 
and it falls on us to steer it in the right direction.
Ma. Inez Feria
NoBox Philippines
7
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Introduction 
a A copy of The Global State of Harm Reduction 2018 questionnaire can be obtained by contacting office@hri.global.
In 2008, Harm Reduction International (HRI) released 
the first Global State of Harm Reduction, a report that 
mapped responses to drug-related HIV, viral hepatitis 
and tuberculosis (TB) around the world for the first 
time. The data gathered for the report provided a 
critical baseline against which progress could be 
measured in terms of the international, regional and 
national recognition of harm reduction in policy and 
practice. 
Since 2008, the biennial report has become a key 
publication for researchers, policymakers, civil 
society organisations, UN agencies and advocates, 
mapping harm reduction policy adoption and 
programme implementation globally. Over the last 
decade, reports of injecting drug use and the harm 
reduction response have increased; harm reduction 
programmes are currently operating at some level in 
almost half of the 179 countries in the world where 
injecting drug use has been documented. 
With patterns of drug use globally continuing to 
evolve, Harm Reduction International reached out 
in 2017 to civil society networks across the world to 
ask what they wanted to see in this report. The 2018 
Global State of Harm Reduction report has a broader 
scope, containing information on:
  The number of people who inject drugs and 
the number of people imprisoned for drug use 
(where data is available).
  Needle and syringe programmes (NSP), opioid 
substitution therapy (OST), HIV and hepatitis C 
and TB testing and treatment for people who use 
drugs, in both the community and in prisons.
  The harm reduction response for people who 
use amphetamine-type stimulants, cocaine and 
its derivatives, and new psychoactive substances.
  Drug-checking in nightlife settings.
  Harm reduction for women who use drugs.
  Drug consumption rooms.
  Drug-related mortality and morbidity and the 
overdose response, as well as naloxone peer-
distribution in the community and naloxone 
provision in prisons.
  Developments and regressions in funding for 
harm reduction.
This report and other Global State of Harm Reduction 
resources can be found at www.hri.global.
Methodology
The information presented in the two sections of 
the report was gathered using existing data sources. 
These include research papers and reports from 
intergovernmental organisations, multilateral 
agencies, international non-governmental 
organisations, civil society and harm reduction 
networks, organisations of people who use drugs, 
and expert and academic opinion from those 
working on HIV, hepatitis C, TB, drug use and harm 
reduction. Harm Reduction International also 
enlisted support from regional harm reduction 
networks and researchers to gather qualitative 
information on key developmentsa and to review 
population size estimates, prevalence data on HIV 
and viral hepatitis among people who inject/use 
drugs, and the extent of provision for needles and 
syringes, opioid substitution therapy, naloxone, drug-
checking services and drug consumption rooms.
Quantitative data for the tables at the beginning of 
each chapter in Section 2 have been obtained from 
a variety of sources and are referenced in each 
regional update. These data reflect the most recent 
available estimates for each country at the time of 
the data collection exercise (March to November 
2018). Where no source was available, the data were 
unpublished or their reliability were questioned 
by civil society organisations, researchers or other 
experts, we have sought expert opinion to identify 
additional sources and verify their reliability. 
Data in many of the regional chapters have been 
sourced from two global systematic reviews, 
published in the Lancet Global Health in 2017, 
supplemented by national or regional experts.[1,2] 
These reviews identified the prevalence of injecting 
drug use; the socio-demographic characteristics 
of, and risk factors for people who inject drugs; 
the prevalence of blood-borne viruses;[1] and 
coverage of NSP, OST, HIV testing, ART and condom 
programmes.[2] The data from Western Europe and 
some countries in Eurasia has been sourced from 
the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), unless otherwise stated in the 
text. Footnotes and references are provided for all 
estimates reported, together with any discrepancies 
in the data. Where information in the tables is 
outdated, we have provided footnotes with a year of 
estimate.
Figures published through international reporting 
systems, such as those undertaken by the United 
Nations Office on Drugs and Crime (UNODC), the 
World Health Organization and the Joint United 
9Nations Programme on HIV/AIDS (UNAIDS) may differ 
from those collated here due to the varying scope of 
monitoring surveys, reliability criteria and different 
regional classifications. 
Regions have been largely identified using the 
coverage of regional harm reduction networks. 
Accordingly, this report examines Asia, Eurasia 
(Central and Eastern Europe and Central Asia), 
Western Europe, the Caribbean, Latin America, 
North America, Oceania, the Middle East and North 
Africa, and Sub-Saharan Africa. All regional updates 
have been peer reviewed by experts in the field (see 
Acknowledgements).
Data quality
In 2017, two global systematic reviews on the 
prevalence of injecting drug use and prevalence 
of HIV and hepatitis, and on the coverage of 
interventions to prevent and manage HIV and 
hepatitis, were published in the Lancet Global 
Health.[1,2] These reviews were welcomed by the 
international community as an independent source 
of data and analysis. For Western European countries 
and some countries in Eurasia, the EMCDDA has 
continued to be a crucial source of reliable data for 
this edition of the Global State, as in past editions. 
Other sources include global AIDS response progress 
reports submitted by governments to UNAIDS in 
2016/2017/2018, data published by the UNODC 
in the World Drug Report in 2018, bio-behavioural 
surveillance reports, systematic reviews and 
academic studies. 
We have sought input from harm reduction 
networks, researchers, academics and other 
experts to inform our reporting on the existence 
and coverage of harm reduction. Where no updates 
were available, data from The Global State of Harm 
Reduction 2016[3] has been included, with footnotes 
provided on dates of estimate where necessary.
Our data on epidemiology and coverage represent 
the most recent verifiable estimates available. 
However, a lack of uniformity in measures, data 
collection methods and definitions for the estimates 
provided make cross-national and regional 
comparisons challenging. 
The significant gaps in the data are an important 
reminder of the need for a greatly improved 
monitoring and data reporting system on HIV and 
drug use around the world. 
Limitations 
The report aims to provide a global snapshot of harm 
reduction policies and programmes; as such it has 
limitations. It does not evaluate the quality of the 
services that are in place, although where possible it 
does highlight areas of concern. 
While The Global State of Harm Reduction 2018 aims to 
cover important areas for harm reduction, it focuses 
primarily on public health aspects of the response. 
The report does not document all the social and legal 
harms faced by people who use drugs, nor does it 
cover all the health harms related to illicit or licit 
substance use.
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Global Overview
Behind the numbers
It is a decade since Harm Reduction International 
began compiling the Global State of Harm Reduction. 
While our coverage of harm reduction policies and 
services has evolved and broadened in scope, the 
same cannot always be said for harm reduction in 
practice around the world. 
According to a 2017 systematic review in the Lancet 
Global Health, injecting drug use is present in 179 of 
206 countries throughout the world, with HIV and 
hepatitis C prevalence 17.8% and 52.3% respectively 
among the 15.6 million people who inject drugs.[2]
Despite this heavy burden of diseases, effective harm 
reduction interventions that can help prevent their 
spread are severely lacking in many countries. The 
number of countries providing needle and syringe 
programmes (NSP) and/or opioid substitution therapy 
(OST) has more or less stagnated since 2014. Currently, 
just 86 countries implement NSP to varying degrees (a 
drop from the 90 that did so in 2016) and 86 have OST 
(a moderate uptick of six countries compared to two 
years ago). 
Compounding this relative dearth of services is a 
funding crisis for harm reduction that rages in the low- 
and middle-income countries (LMICs) where injecting 
drug use is most prevalent. UNAIDS sounded the 
alarm in 2018 over the 20% shortfall in funding for the 
global HIV response. Our research found that when it 
comes to harm reduction in LMICs, this funding gap is 
close to an alarming 90%.[4] When juxtaposing global 
aspirations to end AIDS by 2030 and the vulnerability of 
people who inject drugs to contracting HIV, it is difficult 
not to question states’ genuine political commitment to 
the agreed-upon goals. 
Harm reduction is not just about commodities 
to address HIV and other blood-borne viruses. It 
encompasses a range of health and social services, 
policies and approaches that address the harms of 
illicit drug use and drug policy. To reflect this, the 
2018 Global State of Harm Reduction is our most 
comprehensive yet, and includes for the first time 
dedicated sections for each region on harm reduction 
for amphetamine-type stimulants (ATS), overdose 
response and funding for harm reduction, as well as 
analyses of harm reduction for women. 
ATS use is increasing around the world, and harm 
reduction interventions for people who use these 
substances remain underdeveloped. Drug-checking 
is having a relative boom in some regions, but only 
in certain settings (for example, festivals and night 
clubs). Drug consumption rooms in many countries, 
meanwhile, remain largely focused on serving people 
who inject drugs rather than including space for those 
who may smoke or snort drugs. 
This says nothing of one of the most pressing crises in 
harm reduction today – fatal drug-related overdose. 
North America and parts of Western Europe continue 
to see overdose deaths climb, primarily those related 
to opioids and linked to polydrug use, while data in 
many regions fail to properly track these fatalities. 
Though naloxone – an opioid antagonist medicine that 
can reverse the effects of an overdose – is increasingly 
being deployed in the countries most affected by this 
crisis, it is not always placed in the hands of those 
who need it most, i.e. people who use drugs and their 
peers. 
Finally, as with the diversification of interventions 
based on drug used, different populations are better 
served by tailored approaches. This report notes, in 
particular, the need for gender-sensitive services to 
address the acute vulnerability faced by women who 
use or inject drugs. Most services worldwide remain 
male-focused. This is compounded by the fact that 
women who use drugs face heightened levels of stigma 
because of unfair (and outdated) expectations of a 
woman’s role in society. Sadly, the most vulnerable 
women who use drugs may be subject to intimate 
partner violence and are effectively excluded from any 
support services. 
Underpinning the gaps in harm reduction is a political 
and legal environment in most countries that continues 
to demonise and/or criminalise people who use 
drugs. This manifests most brutally in countries that 
have pursued a bloody crackdown on the drug trade, 
notably the Philippines, where over 20,000 people have 
been killed (many the result of extrajudicial killings) 
since 2016.[5] 
Hostile political and legal contexts ensure barriers for 
people wanting to access health and social services, 
and put some of the most vulnerable people in society 
at risk of incarceration. Prisons represent high-risk 
environments for the transmission of blood-borne 
viruses, yet there are even fewer harm reduction 
services on offer compared to those available in the 
community. 
While this all paints a bleak picture of harm reduction 
worldwide, there are examples of innovation and 
perseverance in this report that give hope and 
demonstrate that progress is possible. It is important, 
too, to not overlook the fact that harm reduction has 
come a long way over the past two decades. 
The evidence is clearly in favour of harm reduction. 
It is time that more countries acknowledge this and 
implement the services that are proven to advance 
public health and uphold human rights. 
Global State of Harm Reduction 201814
Country or territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational
At least 
one drug 
consumption 
room
At least one 
naloxone peer 
distribution 
programme 
operational
OST in at least 
one prison
NSP in at least 
one prison
ASIA
Afghanistan       
Bangladesh       
Bhutan       
Brunei Darussalam       
Cambodia       
China       
Hong Kong       
India       
Indonesia       
Japan       
Laos       
Macau       
Malaysia       
Maldives       
Mongolia       
Myanmar       
Nepal       
Pakistan       
Philippines       
Singapore       
South Korea       
Sri Lanka       
Taiwan       
Thailand       
Vietnam       
EURASIA
Albania       
Armenia       
Azerbijan       
Belarus       
Bosnia and 
Herzegovina       
Bulgaria       
Croatia       
Czech Republic       
Estonia       
Georgia      a 
Hungary      a 
Kazakhstan       
Kosovo       
Krygyzstan       
Latvia       
Lithuania       
Table 1.1.1: Countries or territories employing a harm reduction approach in policy or practice
a OST is available in prison, but for detoxification purposes only.
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Country or territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational
At least 
one drug 
consumption 
room
At least one 
naloxone peer 
distribution 
programme 
operational
OST in at least 
one prison
NSP in at least 
one prison
Macedonia       
Moldova       
Montenegro       
Poland      a 
Romania       b
Russia       
Serbia       
Slovakia       
Slovenia       
Tajikistan       
Turkmenistan       
Ukraine       
Uzbekistan       
WESTERN EUROPE
Andorra nk nk nk  nk nk nk
Austria       
Belgium       
Cyprus       
Denmark       
Finland       
France       
Germany       
Greece       
Iceland      nk nk
Ireland       
Italy       
Luxembourg       
Malta       
Monaco nk nk nk  nk nk nk
Netherlands       
Norway       
Portugal       
San Marino nk nk nk  nk nk nk
Spain       
Sweden       
Switzerland       
Turkey       
United Kingdom       
CARIBBEAN
The Bahamas       
Dominican Republic       
Guyana       
Haiti       
Jamaica       
b NSPs are officially available in Romanian prisons, but are reported to be inaccessible to prisoners in reality.
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Country or territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational
At least 
one drug 
consumption 
room
At least one 
naloxone peer 
distribution 
programme 
operational
OST in at least 
one prison
NSP in at least 
one prison
Puerto Rico       
Suriname       
LATIN AMERICA
Argentina       
Bolivia       
Brazil       
Chile       
Colombia       
Costa Rica       
Ecuador       
El Salvador       
Guatemala       
Honduras       
Mexico    c   
Nicaragua       
Panama       
Paraguay       
Peru       
Uruguay       
Venezuela       
NORTH AMERICA
Canada       
United States       
OCEANIA
Australia       
Fiji       
Kiribati       
Marshall Islands       
Micronesia       
New Zealand       
Palau       
Papua New Guinea       
Samoa       
Solomon Islands       
Tonga       
Vanuatu       
MIDDLE EAST AND NORTH AFRICA
Algeria       
Bahrain       
Egypt       
Iran       
Iraq       
Israel       
Jordan       
c Though no official DCRs operate in Mexico at the time of reporting, a facility exclusively serving women exists in Mexicali, Baja California.
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Country or territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational
At least 
one drug 
consumption 
room
At least one 
naloxone peer 
distribution 
programme 
operational
OST in at least 
one prison
NSP in at least 
one prison
Kuwait       
Lebanon      d 
Libya       
Morocco      d 
Oman       
Palestine       
Qatar       
Saudi Arabia       
Syria       
Tunisia       
United Arab Emirates   e    
Yemen       
SUB-SAHARAN AFRICA
Benin       
Burkina Faso       
Burundi       
Côte d’Ivoire       
Democratic Republic 
of the Congo       
Ghana       
Kenya       
Lesotho       
Liberia       
Madagascar       
Malawi       
Mali x      
Mauritius       
Mozambique x      
Nigeria       
Rwanda       
Senegal       
Seychelles      f 
Sierra Leone       
South Africa       
Tanzania       
Tanzania (Zanzibar)       
Togo       
Uganda       
Zambia       
Zimbabwe       
TOTALS 85 86 86 11 12 54 10
d OST in prisons is reported to be largely accessible.
e OST is available for detoxification only. 
f The extent to which OST is available in practice in prisons is unknown.
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Needle and syringe programmes (NSPs)
Since the Global State of Harm Reduction last 
reported, there has been a small decline in the 
number of countries implementing NSPs, from 
90 in 2016 to 86 in 2018. This is in part due to the 
withdrawal of services in Latin American countries 
(such as Argentina and Brazil), where civil society 
organisations report there are no longer significant 
populations of people who inject drugs.
However, NSP services have ceased to operate 
due to changes in policy in Bulgaria, Laos and the 
Philippines, where punitive drug policies result 
in people who use drugs experiencing harsh 
criminalisation. On the other hand, three new 
countries in sub-Saharan Africa have adopted NSPs: 
Mali, Mozambique and Uganda. 
According to the available data presented in this 
report, 29 countries have increased the number 
of NSP sites since 2016, while 15 have reduced the 
number of sites. In Eurasia, 10 of the 27 countries 
have expanded the number of NSPs in operation, 
while countries in Asia have seen the greatest decline 
in the number of services. However, it is important 
to note that while the data presented here represent 
the most reliable estimates available, these are not 
always recent, and considerable improvement in the 
availability of accurate and systematically captured 
data at national level is necessary to make this kind 
of monitoring more robust.
The existence of NSP sites in a country does not 
mean these sites are universally accessible to 
people who use drugs. Discrimination and stigma 
are frequently cited by networks of people who use 
drugs, civil society organisations and academics as 
reasons that people who use drugs might decline to 
access such services. This is particularly true among 
already stigmatised or marginalised groups, such 
as women who use drugs, men who have sex with 
men, homeless people, migrants, ethnic minorities 
and indigenous peoples. Geographic variation, where 
services are concentrated only in certain regions or 
exclusively in urban environments, is also a barrier to 
access identified in Oceania, sub-Saharan Africa and 
Western Europe.
Opioid substitution therapy (OST) 
The number of countries in which OST is available 
has increased since 2016, from 80 to 86. The 
countries that have introduced or re-introduced OST 
since 2016 are: Cote d’Ivoire and Zanzibar (Tanzania) 
in sub-Saharan Africa; Bahrain, Kuwait and Palestine 
in the Middle East; and Argentina and Costa Rica in 
Latin America. OST remains entirely unavailable in 
a number of countries, most notably Russia, where 
OST is prohibited by law. 
Data on the total number of sites offering OST in 
a country are often unavailable, for example in 
Western Europe, where there is considerable overlap 
with other medical services. However, according to 
the data that are available, 17 countries worldwide 
(eight of which are in Asia) have increased the 
number of OST sites operating since 2016. There are 
reported to be fewer OST sites in four countries than 
in 2016: Albania, Malaysia, Mexico and Serbia. 
Where OST is available, methadone continues to be 
the most commonly prescribed substance, followed 
by buprenorphine; though in Oceania and Western 
Europe, buprenorphine-naloxone combinations 
are increasingly prevalent. Heroin-assisted therapy 
has been found to be highly effective in increasing 
adherence to OST, reducing use of illicit heroin 
and producing better health outcomes.[6] Despite 
this, it is currently only available in seven countries, 
all of which are in Western Europe or North 
America: Belgium, Canada, Denmark, Germany, the 
Netherlands, Switzerland and the United Kingdom.
As with NSPs, the geographic distribution of OST 
facilities is reported to be a barrier to access in Asia, 
the Middle East, North America and Western Europe. 
In some cases this is due to a scarcity of approved 
prescribers, as in Germany[7] and the United States.[8] 
A lack of specialised and accessible services for 
women and migrants also presents a barrier in all 
regions, as does stigma and discrimination towards 
people who use drugs.
Viral hepatitis and HIV 
Globally, prevalence of hepatitis C antibodies 
among people who inject drugs is estimated to be 
52.3%, prevalence of hepatitis B surface antigens 
is estimated to be 9.0%, and HIV prevalence is 
estimated to be 17.8%.[1] Non-injecting drug use, 
particularly inhalation of crack cocaine and cocaine 
paste, has also been shown to be associated with 
greater risks of viral hepatitis and HIV infection.[9-14] 
There is significant regional variation in prevalence 
of blood-borne viruses among people who inject 
drugs. For example, the early implementation of 
harm reduction approaches (such as NSPs and OST) 
is credited with maintaining low prevalence of HIV 
among people who inject drugs in Australia and 
Switzerland, among others.[15,16]
Integrating viral hepatitis and HIV care with harm 
reduction services, and in particular the use of peer 
workers in such services, is reported to be effective 
in increasing access to healthcare among people who 
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use drugs in Oceania and Western Europe. In other 
regions, including Eurasia, Latin America and sub-
Saharan Africa, the integration of health services for 
blood-borne viruses is sporadic and reliant on civil 
society organisations.
Despite the World Health Organization target of 
eliminating both hepatitis C and hepatitis B by 2030, 
countries in each world region continue to restrict 
access to direct-acting antivirals for hepatitis C for 
people who inject drugs. The Global State of Harm 
Reduction 2018 highlights new efforts to ease these 
restrictions. In Western Europe for example, only 
two countries retain restrictions on access to direct-
acting antivirals for people who inject drugs (Cyprus 
and Malta).[17] High costs associated with treatment 
for both viral hepatitis and HIV, where not covered 
by national health insurance programmes, have 
been reported as a further – sometimes prohibitive – 
barrier to treatment.
In a positive step towards addressing the high 
cost of hepatitis C treatment for both individuals 
and national health systems, in November 2018 
it was announced that the Medicines Patent Pool 
had signed a royalty-free licence agreement with 
pharmaceutical company AbbVie. The license will 
permit the development and sale of affordable 
generic direct-acting antivirals (glecaprevir/
pibrentasvir) in 99 low- and middle-income countries 
and territories.[18]
Even where national policy dictates that people who 
use drugs should be able to access treatment, they 
continue to face stigma and discrimination from 
health professionals when they do so. These issues 
are exacerbated by a lack of specialised services for 
other marginalised populations, such as LGBTQIA+ 
and indigenous people.
Amphetamine-type stimulants (ATS), cocaine 
and its derivatives and new psychoactive 
substances (NPS) 
For the first time, the Global State of Harm Reduction 
dedicates sections in each regional chapter to harm 
reduction programmes for use of ATS, cocaine and 
its derivatives, and NPS. In several regions, notably 
North America, Asia and sub-Saharan Africa, use 
of ATS is increasing, though the harm reduction 
response to ATS remains relatively underdeveloped. 
A recent report by Mainline, a Netherlands-based 
harm reduction organisation, provides the most 
comprehensive review of stimulant harm reduction 
programmes and practices to date. [19] These include: 
safer smoking kits for people who smoke drugs 
(including crack cocaine and methamphetamine); 
drug consumption rooms; substitution therapies; 
outreach and peer-based interventions; drop-in 
centres; housing first; and drug-checking services, 
among others.[19]
Drug-checking services are reported to operate in 
five of the world regions (Eurasia, Latin America, 
North America, Oceania and Western Europe). Such 
services aim to reduce the harm caused by high-
purity and adulterated substances by ensuring 
that people who use drugs are aware of what is 
in the substance they are taking. They include 
on-site services at parties and festivals, fixed-site 
laboratories accessible by post, walk-in services 
and self-testing kits. In almost every case, with the 
notable exception of Canada, drug-checking services 
only receive private funding, meaning their ability 
to roll out large scale programmes to meet need 
is limited. In Canada, drug-checking services have 
increasingly been integrated into safe injection sites. 
The use of cocaine and its derivatives continues 
to be a public health concern, particularly in Latin 
America and the Caribbean, where prevalence of 
use is highest and relatively few harm reduction 
programmes exist to address use of these 
substances. 
NPS present an ongoing challenge to public health 
and drug policy. Synthetic cannabinoids appear 
to be the most widespread form of NPS, and 
have emerged as an issue among homeless and 
incarcerated populations. As with ATS, the harm 
reduction response remains limited; for example, to 
drug-checking services that can identity potency and 
adulteration.
Drug consumption rooms (DCRs) 
Drug consumption rooms, also known as safe 
injecting facilities or safe injecting sites (SIFs/SISs), 
are professionally supervised healthcare facilities 
where people can consume drugs in a safe and 
non-judgmental environment. DCRs attract hard-to-
reach populations who may usually use drugs in risky 
and unhygienic conditions, and reduce morbidity 
and mortality by providing a safe environment and 
training people on safer drug use. 
Drug consumption rooms now operate in 11 
countries around the world, with Belgium 
implementing its first facility in 2018. Australia, 
Canada, France, Spain, Switzerland and Norway have 
also opened new sites since 2016, with at least three 
further countries expected to open new facilities in 
2019 (Ireland, Mexico and Portugal). In total, 117 sites 
operate at the time of reporting, compared with 90 
in 2016. The increase since 2016 is mainly due to 24 
new sites opening in Canada.
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While many DCRs are focused on people who 
use opioids and reducing the incidence of opioid 
overdose, others also serve populations who inject 
or inhale amphetamines and cocaine derivatives. 
For example, in the Netherlands, a number of 
facilities cater primarily to people who inhale drugs, 
in accordance with the landscape of drug use in that 
country. In these circumstances they ensure safe 
equipment is being used, and can serve as a link 
between people who use drugs and other health 
services.
Overdose 
In recent years, a worrying increase in fatal drug-
related overdose has been observed in some 
world regions. The US now has the fastest annual 
percentage rise of drug-related fatal overdose ever 
recorded, with an increase of 21.4% between 2015 
and 2016 alone.[20] In Canada, opioid-related deaths 
have also dramatically increased: 72% of deaths 
involved fentanyl or fentanyl analogues in 2016, and 
81% of overdose deaths in Canada were linked to 
fentanyl.[20,21] Fentanyl and its analogues are highly 
potent synthetic opioids. Canada reports 92% of its 
opioid-related deaths as accidental/unintentional.[21] 
The worrying increase in opioid-related overdose 
deaths has been met with a public health response 
which broadly encompasses the principles of harm 
reduction, but to differing extents in the US and 
Canada.
Naloxone is a highly effective opioid antagonist 
used to reverse the effects of opioid overdose in 
minutes. The medicine, which can be delivered in 
various ways (intra-nasal, sublingual and buccal) 
can, however, only be effective if accessible.[61-64] 
In an evaluation of community opioid overdose 
prevention, researchers found 83-100% survival 
rates post-naloxone treatment, demonstrating 
that non-medical bystanders trained in community 
opioid prevention techniques were effectively able 
to administer naloxone.[61] In Canada, scaled up 
naloxone provision and the establishment of drug 
consumption rooms (DCRs) or safe injecting facilities 
(SIFs) have been critical to the overdose response. In 
the US, naloxone’s status as a prescription medicine 
creates a barrier to distribution.[26,27] 
In Western Europe, overdose deaths have also 
increased in number since 2016.[28] An estimated 
84% of overdose deaths in the region involved 
opioids in 2016, almost two-thirds of which 
occurred in Germany, Turkey and the United 
Kingdom.[28,29] In Turkey for example, the number of 
g In the United Kingdom, this refers to a programme in Glasgow.[33] In Norway, this refers to a multi-site pilot programme.[34]
h Afghanistan, India, Estonia, Ukraine, Denmark, Luxembourg, Norway, the United Kingdom, Mexico, Canada, the United States and Australia.
drug-related deaths almost doubled from 2015 to 
2016, with a particularly stark rise in deaths related 
to amphetamine-type substances and synthetic 
cannabinoids (synthetic cannabinoids were present 
in one third of cases in 2016).[30] In the UK, the 
number of drug-related deaths continued to be 
among the highest on record, with a 101% rise in 
deaths related to heroin and/or morphine from 2012 
to 2017.[31,32] High numbers of drug-related deaths 
have also been observed in Norway and Sweden.[28] 
Naloxone peer-distribution programmes currently 
operate in four countries in Western Europe 
(Denmark, Italy, Norway and the UK)g with take-home 
doses available in a further four (Germany, France, 
Ireland and Spain) and plans in development for 
take-home naloxone in three more (Austria, Cyprus 
and Luxembourg).[35-37]
The emergence in Europe of fentanyl should instil 
greater urgency in preventing drug-related deaths. 
While Europe is not yet experiencing the prevalence 
of fentanyl or fentanyl analogues seen in North 
America, its rise as a public health concern and the 
high risk of overdose adds weight to already strong 
arguments for increasing the availability of naloxone 
and DCRs.[29]
In total, peer-distribution schemes, whereby 
individuals can pass on naloxone without each 
recipient requiring a personal prescription, operate 
in only 12 countries in the world.h
Prisons 
Since 2000, the world prison population has grown 
by 20%, faster than the increase of the general 
population (18%).[38] During this period, while the 
male prison population has risen by 18%, the female 
prison population has increased by 50%.[38] Despite 
some momentum around decriminalisation, the 
global response to drugs remains predominantly 
punitive,[20] with approximately 83% of drug 
offences recorded by law enforcement for simple 
possession.[39] Imprisoning people for drug use is not 
only costly, it is demonstrated to be systematically 
discriminatory.[40]
Very few countries have a decriminalisation model 
that works well in practice. In other countries, only 
cannabis has been decriminalised or reduced to a 
minor offence, e.g. Georgia[41] and several US states 
(although the decriminalisation of cannabis is not 
federally sanctioned in the US).[42] In others, prison 
terms for drug possession have been replaced with 
monetary fines, such as in Kyrgyzstan, Ghana and 
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Tunisia. However, reforms such as these need to 
be closely monitored, as at time of publication, the 
minimum fine for drug possession in Kyrgyzstan was 
the equivalent to 18 months’ full-time salary.[43] 
Prisons continue to represent high-risk environments 
for the transmission of blood-borne infections 
for a number of reasons. These include: the over-
incarceration of populations (including people 
who use drugs) at greater risk of contracting HIV, 
hepatitis C and TB; risky behaviour in prisons, such 
as unsafe injecting drug use; inadequate healthcare 
and late diagnosis of disease; substandard prison 
conditions and overcrowding; poor ventilation 
and repeated prison transfers, which encourage 
transmission of viruses; and the absence of harm 
reduction services.[44,45] United Nations human 
rights mechanisms and the European Court of 
Human Rights [46] have commented on the fact that 
inadequate prevention or treatment of HIV, hepatitis 
C, TB or drug dependence meet the threshold of ill 
treatment and create conditions that aggravate the 
transmission of these diseases.[45,47]
Despite this, only 10 countries in 2018 implement 
needle and syringe programmes (NSPs) in at 
least one prison: Armenia, Canada, Germany, 
Kyrgyzstan, Luxembourg, Macedonia, Moldova, 
Spain, Switzerland and Tajikistan. In 2016, the 
Global State reported eight countries implementing 
programmes.[3] NSPs are entirely unavailable to 
prisoners in six out of the nine regions reviewed 
within this report.
At the time of publication, some form of opioid 
substitution therapy (OST) is provided in prisons 
in 54 countries,i and five countries (Afghanistan, 
Cyprus, Palestine, the Seychelles and Ukraine) began 
implementing this service since 2016. Although an 
increase is important progress, the quality of prison-
based OST varies considerably and serious barriers, 
including stigma and discrimination, persistently 
impede access to this essential service where it does 
exist. OST in prison settings remains unavailable in 
Latin America, but this is often attributed to the low 
prevalence of opioid use in the region.
Availability, accessibility and quality of diagnostics, 
treatment and care for HIV, hepatitis C and TB in the 
world’s prisons continue to fail to meet prisoners’ 
needs in most countries.[48] At the same time, the fact 
that prisoners face a heightened risk of overdose 
following their release remains a very serious yet 
almost universally neglected issue in practice, with 
i Asia: Afghanistan, India, Indonesia, Macau, Malaysia, Vietnam. Western Europe: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, 
Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom. Eurasia: Albania, Armenia, Bosnia and Herzegovina, Bulgaria, 
Croatia, the Czech Republic, Estonia, Kyrgyzstan, Latvia, Macedonia, Moldova, Montenegro, Romania, Serbia, Slovenia, Ukraine. Caribbean: Puerto Rico. North 
America: Canada, the United States. Oceania: Australia, New Zealand. Middle East and North Africa: Iran, Israel, Lebanon, Morocco, Palestine. Sub-Saharan Africa: 
Kenya, Mauritius, the Seychelles.
only five countries providing naloxone to prisoners 
on release: Estonia (all prisons), the United Kingdom 
(not routinely), the United States (two states), 
Canada (most prisons) and Norway (a pilot naloxone 
programme). 
The provision of good-quality and accessible harm 
reduction, both inside and outside prisons, is 
not a policy option, but a legally binding human 
rights obligation.[49] It must be urgently prioritised 
– and resourced – by political leaders and prison 
authorities, and national, regional and international 
prison monitoring mechanisms should systematically 
examine issues relating to harm reduction during 
their prison visits.[47]
International policy and technical 
developments
Commission on Narcotic Drugs Ministerial 
Segment 2019
In 2009, member states at the Commission 
on Narcotic Drugs (CND) adopted the Political 
Declaration and Plan of Action,[50] which set the target 
“for States to eliminate or reduce significantly and 
measurably” illicit drug supply and demand within a 
decade. 
In 2016, the UN General Assembly Special Session 
(UNGASS) on Drugs forged a new international 
agreement on drug policy. [51] The CND will convene 
a Ministerial Segment at its 62nd regular session in 
2019[52] to take stock of implementation of the 2009 
Political Declaration’s commitments.[53]
The CND is yet to undertake a comprehensive review 
of the impacts of drug policies worldwide. However, 
the International Drug Policy Consortium’s 2018 
report Taking Stock: A Decade of Drug Policy – A Civil 
Society Shadow Report found that the targets and 
commitments made in the 2009 Political Declaration 
have not been achieved. [54] The report recommends 
that member states should identify more meaningful 
drug policy goals and targets in line with the 2030 
Agenda for Sustainable Development, the 2016 
UNGASS Outcome Document and international 
human rights commitments.
At the time of writing this report, it remains unclear 
what the objective is for member states as it relates 
to the outcome of the 2019 Ministerial Segment. 
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Global HIV Prevention Coalition
The 2016 Political Declaration on HIV/AIDS noted 
with alarm the slow progress in reducing new HIV 
infections globally.[55] Most significant for harm 
reduction were two commitments in the declaration:
  A 75% reduction in new adult HIV infections to 
less than 500,000 annually by 2020.
  For 90% of people at risk of HIV infection, 
including key populations, to have access to 
comprehensive HIV prevention services. 
In order to galvanise greater commitment and 
investment in HIV prevention to meet the 2020 
targets, the Global HIV Prevention Coalition was 
established in October 2017, and UNAIDS and 
partners developed the Prevention 2020 Road 
Map.[56]
The road map provides the basis for a country-led 
movement to scale up HIV prevention programmes 
and is based on five prevention pillars. The second 
pillar is “combination prevention programmes for 
all key populations” and explicitly includes harm 
reduction services for people who use drugs. The 
road map is relevant for all low- and middle-income 
countries (LMICs), and focuses on 25 countries with 
high numbers of new infections in adolescents and 
adults in 2016. 
Prevention scorecards were developed in order to 
summarise existing data on prevention progress in 
the priority countries. Harm Reduction International 
examined all 25 country scorecards[57] and concluded 
that 13 countries did not include data on HIV 
prevalence and nine did not include population 
estimates for people who inject drugs. It is crucial 
that all countries have population size estimates in 
order to set prevention targets and indicators for 
people who inject drugs. 
Technical guidance 
In 2017 and 2018, new guidance emerged with 
regard to key populations and specific groups of 
people who inject/use drugs, both from UN agencies 
and civil society
  In April 2017, a joint publication by the UN 
Office on Drugs and Crime, the World Health 
Organization, the International Network of 
People who Use Drugs, the Joint UN Mission on 
HIV and AIDS, the UN Development Programme, 
the UN Population Fund, the United States 
Agency for International Development and 
the President’s Emergency Plan for Aids Relief 
was published under the title Implementing 
Comprehensive HIV and HCV programmes with 
People Who Inject Drugs.[58]
  In June 2017, the World Health Organization 
released an update to Consolidated Guidelines on 
Person-centred HIV Patient Monitoring and Case 
Surveillance.[59]
  In September 2017, the World Health 
Organization published an update to 
Consolidated Guidelines on HIV Prevention, 
Diagnosis, Treatment and Care for Key 
Populations.[60]
  In October 2017, the European Monitoring 
Centre for Drugs and Drug Addiction published 
Health and Social Responses to Drug Problems: 
A European Guide, providing a reference point 
for planning or delivering health and social 
responses to drug problems in Europe.[61]
  In November 2017, the European Monitoring 
Centre for Drugs and Drug Addiction and Europol 
published Drugs and the Darknet: Perspectives for 
Enforcement, Research and Policy.[62]
  In July 2018, the World Health Organization 
published new Guidelines for the Care and 
Treatment of Persons Diagnosed with Chronic 
Hepatitis C Infection.[63]
  In July 2018, the European Centre for Disease 
Control and the European Monitoring Centre 
for Drugs and Drug Addiction published a joint 
report on Public Health Guidance on Prevention 
and Control of Blood-borne Viruses in Prison 
Settings.[64]
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A lost decade for harm reduction 
fundingj 
HRI’s research in 2018 found that harm reduction 
funding in low- and middle-income countries (LMICs) 
is in crisis.[4] In 2016, US$188 million was allocated 
to harm reduction in LMICs – the same amount as 
in 2007[65] and just 13% of the US$1.5 billion that 
UNAIDS estimates is required annually by 2020 for 
an effective HIV response among people who inject 
drugs.[66] 
International donor support, which comprises the 
majority of harm reduction funding in LMICs, is 
declining. Donor governments are shifting bilateral 
harm reduction funding to countries in favour of 
contributing to multilateral institutions focused on 
HIV, most notably the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (the Global Fund). Yet this 
does not protect funding for harm reduction, and 
support from the Global Fund – which accounted for 
two-thirds of all donor funding for harm reduction in 
LMICs in 2016 – was 18% lower in 2016 than in 2011. 
Our research found that 10 governments appear to 
be investing significantly (i.e. over $1million annually) 
in their national harm reduction response.k While 
encouraging, domestic investment was identified 
in only 19 LMICs overall, meaning harm reduction 
remains dangerously dependent on international 
donors. 
To help address the funding crisis, a response 
is needed on all fronts. National governments 
should critically evaluate their drug policy spending 
and redirect resources from ineffective drug law 
j This section is a summary of key findings from Cook C and Davies C (2018) The Lost Decade: Neglect for Harm Reduction Funding and the Health Crisis Among People 
who use Drugs. London: Harm Reduction International. To read the full report, please visit www.hri.global/harm-reduction-funding.
k India, China, Vietnam, Iran, Malaysia, Kazakhstan, Georgia, Ukraine, Thailand and Myanmar.
l Key human rights mechanisms have reiterated this principle, such as: the Special Rapporteur on the right of everyone to the highest attainable standard of mental 
and physical health in December 2015, in: ‘Open letter in the context of the preparations for the UN General Assembly Special Session on the Drug Problem (UN-
GASS), which will take place in New York in April 2016.'[49]
enforcement to harm reduction. Our 2016 modelling 
shows that just a 7.5% shift in resources could bring 
about a 94% drop in new HIV infections among 
people who inject drugs by 2030.[33]
International donors must collectively increase their 
support for harm reduction – particularly for priority 
interventions like NSP and OST – to fill the sizeable 
funding gap. Any transition from international to 
domestic funding has to be gradual, with a concrete 
plan in place to ensure that donor withdrawal 
does not result in the disruption of harm reduction 
services.
The Commission on Narcotic Drugs recognises this 
dire situation, and in Resolution 60/8 urged member 
states and donors to continue to provide bilateral 
and other funding to address the growing HIV/AIDS 
epidemic among people who inject drugs.[31] 
Unless the funding landscape for harm reduction 
changes urgently, the goal to end AIDS by 2030 will 
be missed. People who use drugs, as with other key 
populations, are being forgotten in the global HIV 
response. 
Human rights and harm reduction 
Since 2016, an increasing number of UN bodies and 
mechanisms have recognised that the right to the 
highest attainable standard of health requires all 
member states to provide quality, evidence-based 
and gender-sensitive harm reduction services for 
people who use drugs.l  
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In March 2018, the Human Rights Council adopted 
a landmark resolution titled “Contribution of the 
Human Rights Council to the implementation of 
the Joint Commitment to effectively addressing and 
countering the world drug problem with regard 
to human rights”.[67] This situates human rights as 
central to the development and evaluation of any 
drug policy, and calls for a comprehensive, balanced 
and health-centred approach to drugs.
The Human Rights Council also entrusted the Office 
of the High Commissioner for Human Rights with 
the drafting of a report on the implementation 
of the 2016 UNGASS Outcome Document. [51] The 
report, presented in September 2018, highlights 
best practices and human rights violations caused or 
enabled by repressive drug policies.[69] It notes harm 
reduction as an essential measure for people who 
use drugs, building on a growing body of literature 
and jurisprudence of human rights mechanisms.[69,70]
Notably, in late 2017 the Committee on Economic, 
Social and Cultural Rights (CESCR) expressed its 
concerns for the predominantly punitive approach 
of the Russian Federation towards people who 
use drugs, and condemned the absence of harm 
reduction programmes. The CESCR noted that “drug 
users tend to refrain from seeking medical treatment 
under the policy of criminalisation, which contributes 
to increased incarceration of drug users”.[71] 
Despite these developments, people who use drugs 
continue to endure a broad range of rights violations 
and abuses, and thus face significant obstacles in 
accessing health services. 
The inherently discriminatory nature of punitive 
drug control measures was captured by the Special 
Rapporteur on Extreme Poverty and Human Rights, 
Professor Philip Alston, following his 2017 mission to 
the United States. In his scathing report, the Special 
Rapporteur blasted the country’s “confused and 
counterproductive drug policies”, condemning the 
predominantly punitive response to drug use and 
the “racial undertones” of this “urge to punish rather 
than assist the poor”.[72]
Discrimination and prejudice, and ill-informed 
approaches to problematic drug use continue 
to result in systematic violations of the right to 
physical autonomy of people who use drugs, 
which also encompasses a right to refuse medical 
treatment. One manifestation of this violation is the 
implementation of drug courts. 
Two recent reports critically reviewed the adequacy, 
effectiveness and cost-effectiveness of drug courts in 
the Americas, and questioned the alleged voluntary 
nature of the treatment imposed.[40,41] The studies 
revealed that in many cases court officials with no 
health expertise prescribe questionable forms of 
treatment to individuals who do not require it, while 
failing to address the needs of those who would 
actually benefit from treatment. As one report 
concludes, “drug courts aggressively insert the penal 
system into people’s private and family lives and into 
their decisions about their health and medical care, 
reproducing and perpetuating the criminalisation of 
people who use drugs”.[73] 
Compulsory detention of people who use drugs 
remains virtually unopposed in many regions of 
the world. While these programmes vary, all are 
characterised by forms of ill-treatment, physical and 
mental abuse, denial of adequate food and water, 
poor sanitary conditions, imposition of treatment 
with no basis of scientific evidence, and sometimes 
sexual abuse and forced labour. 
Compulsory drug detention centres are found in 
many countries in Asia – such as Laos, Cambodia, 
China, Malaysia,[74] Nepal[75] and Vietnam – where 
in 2017, almost 18,000 individuals were confirmed 
to be undergoing compulsory programmes under 
court orders.[76] Similar rights-violating programmes 
are reported in Latin America and the Caribbean, 
where many are kept in “comunidades terapeúticas”, 
ostensibly providing treatment and rehabilitation 
while in practice imposing inhuman forms of drug 
treatment centred around deprivation and forced 
labour.
Finally, egregious human rights violations continue 
in the form of sentencing people to death for 
non-violent and often minor drug offences, the 
militarisation of anti-drug efforts, and campaigns of 
extrajudicial killings against people who use drugs. 
The brutal crackdown on drugs launched in the 
Philippines in 2016 continues unabated, with over 
20,000 people killed since President Rodrigo Duterte 
came to office.[5] Bangladesh’s prime minister called 
for a crackdown on drugs in May 2018, resulting in in 
over 260 suspected extrajudicial killings and tens of 
thousands of arrests.[77] 
UN agencies and civil society continue to condemn 
human rights violations under the auspices of drug 
control. UN Human Rights Commissioner Michelle 
Bachelet stated in her first address to the Human 
Rights Council in September 2018 that: “Drug issues 
everywhere are best tackled through a focus on 
health, education and opportunities – not the death 
penalty, or death squads”.[78]
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Table 2.1.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Asia 
Country/territory
with reported
injecting
drug usea
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs (%)
Harm reduction response
NSPb OSTc
Peer-
distribution 
of naloxone
Afghanistan
40,900 (13,500-
80,000)[2]
4.4[3] 31.2[3] 6.6[3] 20[4,5] 8[4,5] [4,5]
Bangladesh
26,186-
33,067[6]
18.1d[7] 39.6 - 95e[7] 9.4[8] 21[9] 5[9] nk
Bhutanf nk nk nk nk x x x
Brunei Darussalam nk nk nk nk x x x
Cambodia 4136[11] 15.2[11] 30.4[11] nk 5[12] 2[13] x[13]
China 2,564,000[14] 5.9-18.3[15] 67 (60.9 - 73.1)[8] 23.4[14] 814[16] 767[15] nk
Hong Kong nk 1[17] nk nk nk 20[18] nk
India
170,000-
180,000[19]
9.9[8] 41[8] 10.2 (2.7-17.8)[8] 247[8] 212[19] g[20]
Indonesia 33,492[21] 28.6[22] 63.5[22,23] 2.9[24] 194h[25] 92[26] x
Japan nk nk 64.8 (55-74.5)[8] 3.2 (2-4.3)[8] x[27] x[27] x[27]
Laos 1,317[28] 0.1[29] nk nk x[28] x x
Macau 189[30] 1.3[29] 80.4[29] 10.7[29] 3[29] 4[29] x[29]
Malaysia 120,000[31] 16.3[32] 67[8] nk 692[33] 466[33] x[33]
Maldives 793[34] 0[35] 0.7-0.8[36] 0.8i[36] x 2[36] x
Mongolia nk nk nk nk 1[37] x x
Myanmar 93,000[38] 34.9[38] 56[38] 7.7[38] 271[39,40] 51[41] nk
Nepal 52,174[42] 3.3[43] 38.1[43] 2.7[44] 26[43] 15[43] x
Pakistan 37,137[45] 38.4[46] 84[47] 6.8[46] 28[46] x[46] nk
Philippines 25,500[48] 41.6[49] 70[8] nk x[48] x[48] x
Singapore nk 2[50] 42.5[8] nk x x x
South Korea nk nk 54[8] 4[8] x x x
Sri Lanka 218-423[51] 17[51] 2.3[52] 0[52] x[52] x[52] x
Taiwan 60,000j[53] 17.7[54] 41[8] 16.7[8] 1,254[55] 162[58] nk
Thailand 71,000[56] 21[54] 89.8[5] 30.5[57] 14[58] 147[58] nk
Vietnam 226,860[59] 9.5[59] 74.1[8] 19.5[8] 53[59] 285[59] nk
 nk – not known 
a Countries with reported injecting drug use according to Larney et al. in 2017. The study found no reports of injecting drug use in North Korea.[1]
b Alloperationalneedleandsyringeexchangeprogramme(NSP)sites,includingfixedsites,vendingmachinesandmobileNSPsoperatingfromavehicleorthroughoutreachworkers.(P)
= pharmacy availability.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
d Based on subnational data from Dhaka.
e Based on subnational data: 39.6% prevalence in Dhaka, 70-95% in north-western Bangladesh.
f There is no NSP or OST in Bhutan. In 2015 Bhutan was planning to pilot NSP and OST programmes with Global Fund investment, but updates concerning this are unavailable.[10]
g Naloxone peer distribution is limited to the state of Manipur.
h  There are also numerous grass roots organisations in Indonesia that distribute needles and syringes that are not yet documented.
i Based on subnational data from Addu.
j This estimate is based on longitudinal data from two prison cohorts.
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Harm reduction in Asia
Overview
Although the prevalence of injecting drug use in 
Asia is below the global average, an estimated 46% 
of the global population of people who inject drugs 
live in the region and approximately 30% live in East 
and South East Asia.[60] Overall, the level of harm 
reduction provision in the region has improved 
moderately since 2016, although there remain 
considerable challenges for the health and human 
rights of people who inject drugs. In particular, 
there is an alarming trend of increasingly punitive 
approaches to drugs, both in countries previously 
supportive of progressive drug policy reform and in 
states with questionable human rights records.[61]
Needle and syringe programmes (NSPs) are now 
available in 15 of the 25 countries in the region, 
having been discontinued in Laos and the Philippines 
since the Global State of Harm Reduction 2016. There 
has been a fall in the number of NSP sites in four 
countries (Bangladesh, Macau, Nepal and Pakistan), 
andanincreaseinthenumberofNSPsitesinfive
countries (Afghanistan, India, Malaysia, Myanmar 
and Vietnam), with the greatest increases seen in 
Myanmar and Vietnam. The number of countries in 
which opioid substitution therapy (OST) is available 
appears to have remained stable, and there has been 
an increase in overdose prevention activities, which 
includes peer-distribution of naloxone in Afghanistan 
and India (see Table 2.1.1). 
Considerableadvocacyeffortstopromotecost-free
access to hepatitis C treatment in Asia have resulted 
in success in India,[62] Indonesia[63] and Malaysia.[64] 
Despitetheconcertedadvocacyeffortsofcivil
society organisations across the region, many Asian 
countriescontinuetoofferinadequatehepatitis
C treatment services. Direct-acting antiviral (DAA) 
medicines, which can cure hepatitis C in over 95% 
of cases,[65] remain prohibitively expensive in many 
countries. 
There is an acknowledged correlation between the 
high HIV, hepatitis C and tuberculosis prevalence 
found in Asia and the increased health, social and 
legal risks faced by people who inject drugs.[66] The 
virological risks associated with unsafe injecting 
drug use are exacerbated by entrenched 
stigma, discrimination, criminalisation and 
imprisonment.[67,68]
A trend in the region is the increasing use of 
amphetamine-type substances (ATS), such as 
methamphetamine in the form of yaba. Prevalence 
of use of yaba has superseded the prevalence 
of opioids in many countries, such as Cambodia, 
Indonesia, Laos, Malaysia, Myanmar and 
Thailand.[69-71] Additionally, it has been observed that 
high use of ATS exists amongst already marginalised 
women that use drugs in the region, and that ATS 
use contributes to elevated HIV and hepatitis C risks 
in this population.[72] Many vulnerable populations, 
such as men who have sex with men, male-to-
female transgender people and sex workers, are 
also reporting increased ATS and new psychoactive 
substance (NPS) use.[73] This use of ATS in conjunction 
with increased risky sexual behaviours could lead to 
greater incidence of HIV and viral hepatitis.[74] Harm 
reductionforATSuseinvolvesadifferentsetof
approachesandisanemergingfield,[75] particularly 
given the increase in use all over the globe. Myanmar 
is one of a few countries to have formalised 
guidelines for ATS harm reduction,[76] and Indonesia 
is currently in the formative stages of developing 
similar guidelines.[77] 
A growing area of concern in the region is the 
number of women who use drugs and the lack of 
gender-sensitive harm reduction services.[78-80] This 
population faces heightened stigma, sometimes 
intensifiedbygender-basedviolence,whichincreases
their risk for contracting blood-borne viruses.[81] 
Harm reduction and other drug services remain 
overwhelmingly either gender-neutral or male-
focused,leavingthespecificissuesfacedbywomen
little served or understood.[81] Women also appear 
disproportionatelyaffectedbythe“warondrugs”,
with increasing rates of conviction. In 2016, over 90% 
of women in prison in Indonesia and the Philippines 
wereincarceratedfordrugrelatedoffences.[82] In 
Thailand,drug-relatedoffencesaccountedfor83%
of all sentences for female prisoners, often involving 
methamphetamine.[82] 
The war on drugs continues to be a political trope 
in the region, with state authorities aggressively 
persecuting people who use drugs in several 
countries. In January 2017, the Cambodian 
government of prime minister Hun Sen began mass 
arrests of people who use drugs, with more than 
8,000 arrested by June of that year.[83] In Bangladesh, 
there have been over 200 reported extrajudicial 
killingsfordrug-relatedoffencessinceMay2018.[84] 
Despite an international call for consideration at 
the International Criminal Court by civil society, the 
situation is exponentially worse in the Philippines. 
Officialstatisticsshowthatthedeathtollfrom
President Duterte’s anti-drug campaign reached 
4,500 in July 2018, but civil society organisations fear 
the true number could be as high as 20,000.[85,86]
In contrast, Thailand demonstrated leadership 
in law reform in 2017, reducing penalties for 
drugpossession,traffickingandproduction,and
abolishing the mandatory death penalty for selling 
drugs.[87]
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Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
In Asia, Afghanistan, Bangladesh, Cambodia, China, 
India and Pakistan distributed the highest amount 
of needles per person per annum (see Table 2.1.2). 
However, some reductions in services across the 
regionhavebeeninfluencedbydecliningdonor
support and shifting policies regarding people who 
use drugs and drug control.  
There is a severe lack of support for NSP initiatives 
in many countries in the region, especially Brunei 
Darussalam, Hong Kong, Japan, Laos, the Maldives, 
the Philippines, Singapore, South Korea and Sri 
Lanka. Since the Global State of Harm Reduction 
2016, NSPs have ceased to operate in Laos and 
the Philippines.[28] In the Philippines, there was no 
provision in law until 2018 that would allow for 
the implementation of NSPs, as the possession of 
injectingequipmentandotherparaphernaliafitor
intended for drug use was illegal.[48] However, the 
HIV and AIDS Policy Bill passed by the legislature in 
May 2018 aims to strengthen the HIV response in 
the country.[88] While all explicit references to harm 
reduction, OST and NSP were removed before the 
bill received approval, it contains a commitment 
to evidence-based preventative measures for key 
affectedpopulations,whichincludespeoplewho
inject drugs.[89,90] The only documented instance of 
NSP delivery in the Philippines was through the Big 
Cities Project implemented in Cebu, where needle 
distribution was included among the many services 
provided at the Cebu City Social Hygiene Clinic.[48] The 
project was able to operate as an academic research 
initiative.[91] However, it has closed since 2016 due to 
political pressure.[48]
In countries supportive of NSP implementation, 
service delivery models vary, from programmes 
delivered on an ad hoc basis to those predominately 
delivered by civil society organisations within 
outreach settings. Until March 2013, an NSP in 
India provided up to four needles and syringes in 
exchange for used equipment. However, clients 
reported returning used needles to be problematic, 
and subsequently the exchange component was 
discontinued, and needles and syringes were 
distributed without the requirement of returning 
used ones.[92] This predicament was also reported 
in the seven provinces in Indonesia facilitating 
NSP services.[93] Incorporating NSPs into other HIV 
k WHO recommends a minimum of 300 needles/syringes per person per year.[97]
l According to data from the Macau Association of Rehabilitation for Drug Abusers (Associação Reabilitação Toxicodependentes Macau, ARTM) between 4,000-6,000 
needlesaredistributedmonthly;however,thisisdifficulttoverify.[100]
m Based on distribution data from 2015.
prevention approaches, such as counselling and 
testing,wasidentifiedasasuccessfulapproachto
linking people who inject drugs with HIV testing in 
India.[94] Malaysia has adopted a combined approach 
offixed-siteneedleandsyringedistributioninthe
form of a drop-in centre, as well as distribution by 
peer outreach workers.[95] The Ministry of Health 
channels funds to a national non-governmental 
organisation, the Malaysian AIDS Council, which 
apportions the funds for harm reduction work. Since 
2015, the Malaysian AIDS Council has supported 
11 civil society organisations in implementing the 
NSPin20fixedsitesacross11statesinPeninsular
Malaysia.[96] A breakdown of the number of needles 
distributed for people who use drugs per year by 
region can be seen in Table 2.1.2. 
Table 2.1.2: Overview of needle distribution 
per person who injects drugs per yearK
Country Needles distributed per person who injects drugs per year
Afghanistan 159[54]
Bangladesh 158[98]
Bhutan N/K
Brunei Darussalam N/A
Cambodia 912[12]
China 204[99]
Hong Kong N/A
India 250[20]
Indonesia 26[25]
Japan N/A
Korea (Republic of) N/A
Laos N/A
Macau N/Kl
Malaysia 31[33]
Maldives N/A
Mongolia N/K
Myanmar 358[101]
Nepal 61[102]
Pakistan 178[46]
Philippines N/A
Singapore N/A
Sri Lanka N/A
Taiwan 58m[103]
Thailand 14[58]
Vietnam 76[20]
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In Vietnam, the commercial and social marketing 
sales of low dead space syringes was scaled 
up in 2012. However, despite the WHO global 
endorsement of low dead space syringes, the 
majority of all syringes sold or distributed in Vietnam 
continue to be high dead space syringes. Unsafe 
injecting practices – including needle sharing and 
use of high dead space syringes – as well as sexual 
transmission are contributing to an estimated 11,000 
new HIV infections in Vietnam every year.[104]
Sustainable funding for harm reduction initiatives 
such as NSP continues to be contingent on 
advocating for ongoing support from donors. 
Initiatives funded by national healthcare systems 
could increase sustainability of harm reduction 
initiatives, such as in Indonesia where investment in 
NSPs is paid for by the government. 
Opioid substitution therapy (OST)
In Asia, overall coverage of OST has remained 
relatively stable since the Global State of Harm 
Reduction 2016. In China there are 767 OST sites, in 
Malaysia 466, in Vietnam 285, in India 212, in Taiwan 
162, in Indonesia 92, in Myanmar 51, in Nepal 15, 
inAfghanistaneight,inBangladeshfive,inMacau
four and in Cambodia two. In Hong Kong and the 
Maldives, OST programmes operate despite the 
absence of NSPs.
Although coverage has stabilised, in some countries 
in the region such as China, Malaysia and Vietnam, 
where there is high prevalence of both HIV and 
drug use, adherence to OST has not always been 
optimal, with an overall retention rate of just 40%.[105] 
This may be due in part to extenuating factors 
such as geographical barriers to services, stigma, 
discrimination from providers, low income and 
political investment in OST programmes.[105-107]
Vietnam has demonstrated strong political will to 
implement and scale up OST programmes.[105] OST 
programmeswerefirstpilotedinHaiPhongprovince
in 2008 and by mid-2015 these had expanded to 
reach over 35,000 people in 50 provinces across 
the nation. According to a study published in 2017, 
44,479 people who inject drugs were enrolled in OST 
in 57 provinces in June 2016.[108] OST has also proven 
tobeextremelycost-effectiveinVietnam.Basedon
data from 2012-2015, funding a person who injects 
drugs to stay in a rehabilitation facility has been 
foundtocostthelocalgovernmentVND₫19,670,000
(US$840), which is 2.5 times higher than the cost 
to the government for one OST patient over one 
year(VND₫7,880,000orUS$340,includingcostof
methadone).[109]
In a number of Vietnamese provinces, OST 
programmes collect fees from clients in order to 
covercosts,thoughpatientsidentifiedaspooror
disabled are exempted from paying. This co-payment 
schemehasbeenfoundtoplacesignificantfinancial
burdens on patients, which may have long-term 
implications for adherence and enrolment.[110] There 
are also plans to introduce buprenorphine as an 
alternative treatment option in order to improve OST 
adherence rates.[108] In some provinces, access to OST 
services is impeded by geographical obstacles such 
as distance to OST service providers,[111] which can 
diminish the accessibility of OST clinics and result in 
lower adherence.[112] 
OST programme implementation is championed 
in Nepal due to its status as an evidence-based 
public health intervention for people who inject 
drugs. Due to ongoing advocacy, from 2011 to 2016 
theMinistryofHomeAffairsgraduallybeganto
share responsibility for OST with the Ministry of 
Health. This responsibility allows for the provision 
of OST at public hospitals and by non-governmental 
organisations. In Nepal, OST has been elevated 
to the status of a national programme under the 
Ministry of Health, implemented in accordance 
withcountry-specificpolicydocumentsthatalign
with internationally accepted standards.[113] One 
particularly successful service model in Nepal, 
SPARSHA, works alongside medical and social 
support teams to develop individual care plans 
that respect the needs and preferences of clients. 
This psychosocial approach is supplemented by 
the availability of multiple OST options, with both 
methadone and buprenorphine available. The service 
has continued relatively uninterrupted, even after the 
catastrophic earthquake of April 2015.[113] However, it 
isimportanttonotethatthegovernment’sfinancial
contribution to the programme is negligible at 
present, despite discussions of greater government 
investment in 2016,[113] and much of the future for 
OST programmes in Nepal is uncertain.[43]
Despite an emerging shift from opioid use towards 
increasing amphetamine-type substance use among 
people who inject drugs,[74] there is still a clear need 
for OST services in the region. Ensuring adequate 
OST service provision in Asia will require robust 
political commitment, which should be embedded in 
a human rights and health-based approach to drug 
use. 
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Women who use drugs
Robust data on women who use drugs in the region is 
scarce, but it is estimated that Asia is home to half of 
the 3.8 million women worldwide who inject drugs.[114] 
There are also reported to be one 1 million women 
who use drugs in Afghanistan.[115] Gender disparity, 
poverty, intimate partner violence and unsafe sex work 
environments all contribute to the vulnerable condition 
of women who use drugs in Asia.[81] In Bangladesh, 
sex work and injecting drug use often coincide.[116] 
In Malaysia, gendered poverty exacerbates the lives 
of women who use drugs, and across Asia women in 
intimate partnerships with partners who use drugs often 
trade sex or engage in risky behaviours to maintain drug 
use.[117]
Women who use drugs are susceptible to numerous 
forms of violence, including non-partner assault, 
trafficking,sexualexploitationandintimatepartner
violence.[118] In Bangladesh and Malaysia, academic 
research has found that women who use drugs are 
more likely to be drawn into abusive relationships.[119,120] 
A recent study in Indonesia found that at least 60% of 
women who inject drugs were victim to some form of 
intimatepartnerviolence.Thisfigureisupto24times
higher than the prevalence of partner violence among 
the general Indonesian female population.[118] A study 
in India found that 13% of women who use drugs had 
experienced gang rape.[121]
A small number of tailored harm reduction services (for 
example, a drop-in centre in the Seng Taung-Hpakant 
Township in Myanmar) provide primary health care, 
reproduction services and psychosocial counselling 
to promote safer injecting practices and safer sex for 
women who inject drugs.[122] In the Jhapa, Sunsari and 
Morang districts of eastern Nepal, there are 15 male 
rehabilitation and treatment centres, with only two 
designed for women.[123] To document harm reduction 
services for women, the Women and Harm Reduction 
Network (WHRIN), in collaboration with Harm Reduction 
International, conducted a survey in 2018.[124] It 
discovered that, while overall awareness of the issues 
facing women who use drugs is increasing, there is 
aglaringabsenceofwomen-specificharmreduction
services and persistent stigma towards women seeking 
treatment.[125]
Although there are nascent grass roots movements 
operating in the region, such as the Indonesian Female 
Drug User Network,[72,126] greater advocacy for tailored 
harm reduction for women is needed throughout Asia.
Amphetamine-type substances (ATS) and new 
psychoactive substances (NPS)
Amphetamines remain the second most frequently 
used drug globally, with an estimated 35 million 
people using ATS in 2016,[127] 60% of them in Asia.[128] 
The region has seen a continuous rise in the use of 
ATS. High levels of injecting use of ATS have been 
reported in Cambodia, Indonesia, Malaysia and 
Thailand,[71] particularly within already vulnerable 
populations such as men who have sex with men 
(associated with use in sexual contexts in the 
Philippines and Singapore), female sex workers 
(and their clients) and transgender women.[74] In 
2015, 94% of people in drug treatment facilities in 
Brunei Darussalam were methamphetamine users, 
and in Indonesia 28% people who use drugs sought 
treatment for ATS use.[129] In China in 2016, more 
than 60% of people who use drugs reported using 
methamphetamine.[130] 
A recent study in Indonesia investigated the HIV 
status and associated risk behaviours of people who 
use crystal methamphetamine (known locally as 
“shabu”)insixurbancentresinthearchipelago.[74] 
The study discovered that because of an increasing 
paucity of accessible injectable opioids (such as 
heroin), many people who inject drugs have shifted 
to ATS use.[74] Of the respondents engaged in the 
study, 65% were HIV positive.[74] The results from 
the study indicated that people who use ATS come 
from a variety of communities such as men who 
have sex with men, female sex workers and people 
who buy sex.[74] These trends are found in other 
countries in the region. For example, a study in Hong 
Kong found that 16.2% of men who have sex with 
men interviewed had used recreational ATS before 
or during sex in the past six months,[131] and a 2017 
study in Cambodia found that 55% of a sample of sex 
workers living with HIV reported using ATS.[132]
The association between transmission of HIV and 
other blood-borne viruses and ATS use is increasingly 
acknowledged within contemporary public health 
discourse.[133] However, there is an alarming absence 
of programmes that support people who use ATS.[75] 
Many people who use ATS in Asia do not access 
traditional harm reduction services, such as NSPs, 
and do not identify themselves with opioid users. 
Therecontinuestobeminimalgender-specificharm
reduction services or guidelines for supporting the 
needs of men who have sex with men and female 
sex workers who use drugs in the region.[75] An 
exception is a peer outreach project operated by 
the Karisma non-governmental organisation in 
Jakarta.[75] The project distributes safer smoking 
kitsandinformationalleafletsonhealthanddrug
use to people who use stimulants in the area, as 
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well as linking them to physical and mental health 
services.[75]
There are public health concerns with regard to the 
emergence of new psychoactive substances, such as 
the rising prevalence of synthetic cannabinoid use in 
Indonesia and neighbouring nations. Although data 
on the prevalence of NPS use remains limited, a wide 
rangeofNPShavebeenidentifiedinEastandSouth
East Asia.[127] A number of governments in the region 
have taken steps to categorise and control these 
emerging substances. In late 2015, the government 
of China placed 116 substances under control, 
andidentifiedHongKongasatransitlocationfor
NPS export links.[127,134] In Indonesia, the National 
Anti-NarcoticsAgencyhadidentifiedatotalof56
NPS in the country as of March 2017.[129] Ketamine 
usecontinuestobesignificantintheregion:East
and South East Asia accounted for 97% of the total 
quantity of ketamine seized worldwide in 2015.[127]
Harm reduction service providers and policy makers 
are working to respond to the rise in use of ATS 
and NPS, but are still in the process of putting into 
practice evidence-based psychosocial and health 
support mechanisms to assist people who use these 
substances. A series of interventions for stimulant 
use, which may be relevant to Asia, are beginning to 
emerge worldwide, such as drug-checking facilities, 
housing programmes and safer smoking kits.[75] 
Approximately 500,000 people in Asia are undergoing 
treatment for amphetamine use, but more often 
than not this is as part of compulsory rehabilitation 
programmes.[127] A positive development for the 
region is the WHO Guidelines for Management of 
Methamphetamine Use Disorders in Myanmar, with 
a focus on treatment for methamphetamine use. 
Though primarily treatment-focused, the guidelines 
acknowledgethebenefitsofaharmreduction
approach,inparticulartheavailabilityofspecificand
pragmatic advice on methamphetamine use.[76]
Overdose, overdose response and drug 
consumption rooms (DCRs) 
There is a paucity of data on the drug-related 
mortality and overdose rate in Asia, as no country 
routinely monitors drug-related overdose deaths. 
Additionally, overdose is often not reported 
within drug using communities by people who 
inject drugs.[135]Acrosstheregion,sufficient
overdose response mechanisms are lacking. This is 
notwithstanding the fact that naloxone distribution 
initiatives that engage people who use opioids and 
their support networks have proven to be both 
effectiveinsavinglivesandcost-effectiveinmany
contexts around the world.[136]
Provision of naloxone, an opioid antagonist that 
canreversetheeffectsofoverdose,[137] has been 
increasing throughout the region. In Afghanistan, 
naloxone is distributed by outreach workers in the 
fieldandprovidedatdrop-incentres.[5] In Manipur, 
India, naloxone is distributed by non-governmental 
organisations, predominantly through trained 
outreach workers and peer educators; of note, 
Manipur reports the highest number of overdose 
cases.[20] Organisations in Manipur also run an 
overdose hotline.[20] In Malaysia, naloxone is only 
available in hospital settings and not in take-home 
form.[33]
Twocountriesthathavetakensignificantstepsin
overdose prevention are Thailand and Vietnam. 
In Vietnam, naloxone provision programmes, 
including treatment education and overdose 
identificationskills,arebeingimplementedinHanoi
and Ho Chi Minh City.[138] A 2017 study on overdose 
incidence in Vietnam supports the critical need for 
provision of naloxone in non-clinical contexts. Of 
the respondents, around 70% had witnessed an 
overdose at one time.[138] Similar conditions have 
been reported in Thailand, with an estimated 68% 
of people who inject drugs having witnessed at 
least one overdose in their lifetimes.[139] In order 
to address this, the Servicing Communities with 
Opioid Overdose Prevention project has operated 
since 2014, facilitating access to naloxone in 19 Thai 
provinces.[139] However, due to diminishing funds for 
harmreductioneffortsinThailand,thefuturestatus
of the project is precarious at best.[139]
Viral hepatitis
Blood-borne viruses, particularly viral hepatitis, are 
responsible for considerable mortality and morbidity 
among people who inject drugs in Asia.[127] People 
who use drugs in Asia have some of the highest 
rates of viral hepatitis globally.[127] In Asia, high 
prevalence of blood-borne viruses is exacerbated 
bymanyfactorsthatincludeinsufficientaccessto
testing, lack of treatment, criminalisation of drug 
use, incarceration of people who inject drugs, lack of 
harm reduction services in prisons, social exclusion 
and discrimination from service providers.[140]
In contrast to the provision of anti-retroviral therapy 
for people living with HIV, governments have been 
reticent to invest in treatment for people living 
with hepatitis C. However, Bangladesh, Japan and 
Mongolia have been praised for their pledged 
support for the response to hepatitis C.[141] In 
Pakistan, direct-acting antivirals have been made 
accessible through the public sector.[142] In Indonesia, 
acommunity-led“buyer’sclub”workswiththe
Global State of Harm Reduction 201836
country’s few doctors able to prescribe direct-acting 
antiviralstooffertreatmentatalowercostthan
otherwise available.[143] From 2015 to 2017, the 
scheme supported 139 people to access 12-week 
courses of treatment.[143] Other successes in the 
region have included increased access for people 
who inject drugs in Malaysia, where the government 
acted to ensure the generic version of the direct-
acting antiviral sofosbuvir could be imported,[64] and 
the Sajiwa prison in Manipur, India.[62] Treatment 
with direct-acting antivirals has also proven to 
beextremelyeffectiveinThailand[144]andinfive
hospitals across three provinces in Vietnam.[145] 
A growing evidence base indicates that early testing 
and initiation of hepatitis C treatment is more cost-
effectiveinthelongterm.[146] 
Tuberculosis (TB)
Although there were 2,965,311 reported cases of 
TB in South East Asia in 2017, treatment coverage 
remains steady at 64%.[147] Of the 30 nations with a 
high tuberculosis burden globally, 12 are located in 
Asia: Bangladesh, Cambodia, China, India, Indonesia, 
North Korea, Myanmar, Pakistan, Papua New Guinea, 
Philippines, Thailand and Vietnam.[147] Unfortunately, 
there continues to be a lack of robust regional data 
on TB prevalence among people who inject drugs in 
Asia since the Global State of Harm Reduction 2016. 
High rates of TB among people who use drugs in the 
region, coupled with the punitive drug laws prevalent 
in many countries, lead to the frequent incarceration 
of individuals with TB, for example in Indonesia, 
Bangladesh and Thailand. This increases the risk 
of spreading TB infection due to depreciated life 
circumstances.[148] Testing and treatment coverage 
for TB is low, along with TB prevention measures for 
people who inject/use drugs in the region.
HIV and antiretroviral therapy (ART)
Prevalence of HIV among people who inject drugs 
in Asia is among the highest in the world.[149] For 
antiretroviral therapy to have an impact on HIV 
prevalence and life outcomes for people living 
with HIV, access and coverage at the national 
level must be addressed. For example, stigma and 
discrimination can dissuade people who inject drugs 
from accessing health services such as HIV testing 
and treatment.[27,150,151] 
Access and availability to antiretroviral therapy is 
inconsistent across the region, and there is a lack of 
services to support adherence and prevent attrition 
rates among people who inject drugs. In 2017, 53% 
of the total number of people who were living with 
HIV in Asia accessed treatment.[152] However, the 
coverage and availability of treatment services for 
people who inject drugs was considerably lower.[152] 
For example, Cambodia ranks poorly on the cascade 
of care for people living with HIV. Although there are 
67 sites providing antiretroviral therapy in Cambodia, 
only 270 of the estimated 58,321 people living 
with HIV in the country are receiving treatment.[13] 
Not only is coverage extremely low, extenuating 
circumstancesaffectaccesstoantiretroviraltherapy
for people who inject/use drugs, especially those in 
detentionfor“rehabilitation”.Forexample,people
detained at the Prey Speu facility in Cambodia report 
they are not given access to HIV treatment or OST. 
Cambodian newspapers report a number of deaths, 
apparentlyfordifferentorunknowncauses,within
the detention system.[153] 
Singapore’s draconian approach to drug use and 
people who use drugs unquestionably has an 
impact on the population’s access to antiretroviral 
therapy.[154] Additionally, antiretroviral therapy can 
cost approximately US$1,000 per month, and newer 
drugs can cost around US$2,000.[155] This impacts 
negatively on access for people who inject drugs and 
decisions to undergo testing.[155] According to the 
city-state’s Infectious Disease Act, failure to declare 
one’s HIV status or even status as a person who 
injects drugs can have serious legal consequences.[156] 
In Japan, though antiretroviral therapy is available 
free of charge, individuals are reluctant to inform 
practitioners that they inject drugs as there is the 
high risk of being reported to police.[27] In Mongolia 
the predicament is similar, wherein people who 
inject drugs do not access testing nor treatment 
for HIV for fear of legal repercussions.[150] Although 
there are facilities to support people who use drugs 
during antiretroviral therapy initiation and beyond 
in Pakistan, uptake remains low as many physicians 
are reluctant to engage people who inject drugs in 
the treatment. This is due to anticipated adverse 
treatment outcomes that create a systemic caution 
around prescribing treatment to this population.[151] 
Thailand provides an example of better practice, with 
a total of 3,567 people who inject drugs living with 
HIV currently accessing antiretroviral treatment. This 
represents 47.6% of the total estimated number of 
people who inject drugs living with HIV (7,499).[58] 
The situation in Vietnam, where 34% of people who 
use drugs are living with HIV, is also notable. Many 
one-stop services for people who use drugs in the 
country provide not only antiretroviral therapy but 
also OST.[157] In 2018, the Vietnamese government 
announced that the provision of essential harm 
reduction interventions, including new HIV testing 
services, will be expanded to 32 provinces and cities 
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across Vietnam.[158] In addition, health insurance, and 
thecommunicationofitsbenefits,willreportedlybe
promoted for people who use drugs.[158] Bangladesh 
also scores relatively well across the cascade of care, 
with an estimated 45.5% of people who inject drugs 
and living with HIV currently accessing antiretroviral 
therapy.[98] A best practice service delivery model has 
been adopted in Dhaka, in a programme funded by 
Save the Children to introduce one-stop services and 
comprehensive drop-in centres.[159] 
India has the second largest HIV treatment 
programme in the world, and promotes a one-
stop service model incorporating NSP, OST and 
antiretroviral therapy for people who inject drugs 
who are living with HIV.[160] An estimated 57.9% of 
people eligible for inclusion in this scheme reported 
antiretroviral therapy initiation in such services in a 
study published in 2018.[94] The Indonesian Ministry 
ofHealthsupportsa“testandtreat”servicemodel,
with 495 antiretroviral therapy dispensers across the 
archipelago.[93] 
In Myanmar, a new policy of initiating antiretroviral 
therapy for every person living with HIV in every 
centre providing OST, which includes harm reduction 
organisations, has great potential to improve access 
to HIV treatment for people who use drugs.[40] 
However, the policy is not yet operational[161] and 
access remains impeded due to limited health 
literacyinruralandotheraffectedcommunities,
along with the stigma and discrimination attendant 
to drug use in the country.[40]
Harm reduction in prisons
In Asia, there was a 30.2% increase in the prison 
population between 2000 and 2016, compared to 
a 19.8% rise worldwide.[162] Since the Global State 
of Harm Reduction 2016, prison overcrowding has 
continued to be an issue across the region, but 
in South Asia it is particularly severe. In India, for 
instance, delays in the criminal justice system have 
caused some prisons to operate at more than two or 
three times their capacity.[163] In China, new judicial 
interpretations of drug laws have meant that smaller 
amounts of drugs are now being criminalised, 
and have led to the introduction of penalties for 
online activities related to the sale or distribution of 
drugs.[164,165] 
A number of factors have led to the overall rise 
in prison populations in the region. Thresholds 
adoptedtodefinewhoisauserandwhoisadealer
are rapidly becoming smaller in Asia. A punitive 
approach to drug policing in Cambodia and Thailand 
has also given rise to large numbers of individuals 
incarcerated for possession of small amounts of 
drugs.[166] Another cause of high prison populations 
arepoliciesofsocalled“penalpopulism”.For
exampleinthePhilippines,PresidentDuterte’s“war
ondrugs”hasledtothedetentionofanestimated
142,000 people in facilities meant to house just 
20,000 people.[167] Overcrowding has also been 
reported in Thailand, where Klong Prem prison 
detains 6,267 people serving sentences that range 
from 15 years to life, with 64% convicted of drug-
related crimes.[168]
There continues to be a dearth of harm reduction 
services in prison contexts, as illustrated in Table 
2.1.3. 
Table 2.1.3: Provision of harm reduction in 
prisons a selection of Asian countries
Country NSP OST ART Naloxone
Afghanistan[5] No Yes, in 4 prisons Yes Yes
Bangladesh[9] No No Yes No
Cambodia[13] No No Yes No
India[20] No Yes No No
Indonesia[93] No Yes, in 11 prisons Yes No
Macau[29] No Yes, for those taperingoff Yes No
Malaysia[33] No Yes Yes No
Mongolia[150] nk nk nk nk
Myanmar[40,161] No No Yes No
Nepal[43] No No Yes No
Vietnam[59] No Yes No No
nk = not known
AlthoughnoprisonsintheregionofferNSP,there
are several prisons that continue to support people 
who use drugs and are living with HIV. Many 
offerharmreductionprogrammesthatinclude
antiretroviral therapy provision, and TB testing and 
treatment. Prison systems in two areas of India, 
PunjabandTihar,offertestingandtreatment
of hepatitis C, as well as OST. In Tihar, prisoners 
can access OST at any time; however, in Punjab 
OST is only dispensed temporarily as part of drug 
detoxification.[20] Despite much advocacy in India, 
prison guidelines do not allow for NSPs or condom 
distribution.[169] In Tahir’s 10 prisons, buprenorphine 
is given sublingually as daily directly-observed 
treatment.[170] In prisons in Vietnam, HIV prevention, 
treatment and care services as well as OST provision 
are being carried out at Phu Son prison and soon 
in Than Xuan prison.[171] In addition to these, only 
IndonesiaandMalaysiacurrentlyofferOSTinprisons
in Asia.
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Compulsory drug detention  
and rehabilitation
Compulsory drug treatment centres continue to 
proliferate across Asia, managed by law enforcement 
and other stakeholders, with individuals living in 
conditions comparable to prison settings.[172]
The detention and coercive treatment of people who 
use illicit drugs is currently a dominant approach in 
11 countries in the region, including Cambodia, China, 
Indonesia, Laos, Malaysia, Myanmar, Philippines, 
Thailand and Vietnam.[173] This is despite a 2012 joint 
statement issued by 12 UN agencies calling for the 
closure of compulsory drug treatment centres[174] and 
a lack of evidence that such facilities even achieve their 
stated aims.[175] This trend appears to be escalating 
in Laos and Myanmar.[173] In Sri Lanka, conversations 
have begun on the establishment of compulsory drug 
treatment centres.[176] Elsewhere in South Asia, there is 
continued support for a more evidence-based approach 
incorporating treatment, prevention and care alongside 
othercost-effectiveharmreductioninitiatives.[177] 
In 2017, there were reports of mass arrests of people 
who use drugs by the counter-narcotics department in 
Kabul, Afghanistan, with 150 people who inject drugs 
captured and subjected to forced detention.[178] China 
continues to demonstrate that enforced rehabilitation 
has not been successful in achieving better health 
outcomes for people who use drugs. In 2016, it was 
reported that the estimated 240,000 people held in 
such facilities in the country made a total of 2.9 million 
hospital visits, more than 10 per individual, signalling 
their lack of capacity to prevent and address the 
negative health consequences associated with drug 
use.[179] Academic observers have questioned whether 
China’s support for enforced rehabilitation approaches 
might be based on powerful bureaucratic interests, 
with these centres providing employment and funds 
for judicial and public security agencies.[180] In June 
2018, China appeared to be considering joining in the 
harm reduction conversation by diversifying its drug 
treatment programme.[181]However,thisdiversification
appearstobebasedonpseudo-scientificapproaches
suchas“trans-cranialmagneticsimulation”and
“virtualrealityaddictionassessment”.[182,183] In Thailand, 
authorities have incorporated forced participation in 
military-style training as part of the drug use treatment 
approach.[173,184] 
High relapse rates after release from forced 
rehabilitation centres have been reported in China 
(98% returned to heroin use within a year) and Thailand 
(50% returned to injecting drug use within a year).[175,185] 
People who use drugs receive little access to basic 
healthcare within compulsory drug treatment centres in 
several countries in the region.[186] Other human rights 
abuses are continually documented in Cambodia, Laos 
and Myanmar.[187] In Cambodia, children who use drugs 
have been detained against their will and routinely 
beaten, with many reporting other abuses, including 
sexual abuse.[187] In the state of Kachin, Myanmar, 
people who inject drugs are reportedly detained in 
cell-like conditions in forced rehabilitation centres, 
receivingnomedicalcarewhilesufferingwithdrawal
symptoms.[172] There are also reports of widespread 
beatings, inhumane treatment and other human rights 
abuses.[188] A 2018 submission to the UN Human Rights 
Committee initiated by Harm Reduction International 
and the World Coalition Against the Death Penalty 
highlighted evidence that shows that many centres 
use forced drug testing, lack medical evaluation, use 
forced labour, detain people in unsanitary conditions, 
and that acts of sexual violence have become part of 
the culture of compulsory drug treatment centres in 
Asia.[189] In addition to this, UN agencies hosted a series 
of regional consultations resulting in recommendations 
that included the establishment of national transition 
committees to coordinate a move away from compulsory 
detention across judicial, public health and law 
enforcement divisions.[190] 
There is mounting recognition that compulsory drug 
treatment centres are a counter-productive approach 
toachievingeffectivenationalhealthandsocial
reintegration objectives, and slowly growing interest 
intransitioningfromcompulsorydetoxification
centres towards community-based treatment facilities. 
Community-based treatment facilities are proven 
to improve the life outcomes of people who use 
drugs overall.[58,191] However, strategies for facilitating 
successful transition from compulsory to community-
based services will continue to be largely dependent on 
government priorities, and attitudes towards drug use 
and people who use drugs, as well as the availability of 
investment in these proven initiatives.
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Policy developments for 
harm reduction
There have been considerable shifts in policy in 
the region since the Global State of Harm Reduction 
2016, many of which are counter-productive to 
harm reduction approaches. Punitive drug control 
messages are increasingly being used by politicians 
in order to consolidate power, in which people who 
use drugs are seen as morally culpable and against 
“Asianvalues”.[192] The last two years have seen 
extrajudicial killings, mass arrests of people who 
use drugs and other human rights violations under 
theauspicesofthe“warondrugs”,especiallyin
Bangladesh, the Philippines and Sri Lanka.[193-195] 
Despite advocacy from civil society organisations 
around the world,[193,196,197] the Bangladeshi home 
minister, Asaduzzaman Khan, is implementing a 
Philippines-style“warondrugs”usingtheRapid
Action Battalion.[198,199] This zero tolerance policy 
approachpromotesshort-termpoliticalbenefitsas
opposedtomorelonger-termsocialbenefits.[84,194] 
In June 2018, the UN High Commissioner on Human 
Rights condemned the government’s crackdown, 
highlighting how people who use drugs now fear 
arrest or violence if they access essential health 
services.[200] A wealth of evidence from around the 
world emphatically demonstrates the devastating 
health impact of zero tolerance policies. The 
criminalisation of people who use drugs not only 
reduces their access to health services, but also 
limits the availability of safer drug paraphernalia, 
limits access to essential pain medication, 
disrupts treatment regimes, creates epidemics in 
vulnerable populations such as prisoners and sex 
workers, and increases the prevalence of practices 
associated with a higher risk of blood-borne disease 
transmission.[201-204]
In positive developments, Thailand’s current drug 
policy is being revised to take a more health-based 
approach to drug use. A concrete indication of this 
change came with the announcement in 2016 that 
responsibility for drug treatment services would be 
moved by the end of 2018 from the Ministry of Home 
AffairstotheMinistryofHealth.[205] The move away 
from criminal justice to public health management 
of drug use is a promising step towards the use of 
evidence-based and client-centred harm reduction 
programmes, and the increased meaningful 
involvement of people who use drugs in policy and 
service design.[205] This health-based approach is 
reinforced by amendments to the Thai Narcotics Act 
to reduce penalties for the possession, production, 
import and export of narcotics.[206] 
A process of drug law reform took place in Indonesia 
in 2018, with Indonesia’s new anti-narcotics 
chief, Heru Winarko, calling for an expansion of 
rehabilitation centres across the country.[207] Winarko 
announced his plan to move away from the proposed 
previous proposals to house people who use drugs in 
unsafe environments without adequate facilities.[207] 
While this is a positive development towards a more 
humane and health-centred approach, it is vital that 
drug treatment is only undertaken voluntarily, and 
based on international standards and evidence. 
In 2017, courts in Japan (which has some of the 
strictest drug control policies of any advanced 
democracy globally) have begun to show moderation 
in sentencing people who use drugs, signalling the 
opening of a space in which policy reform could be 
discussed.[208] In addition, there have been increasing 
incidences where Japanese courts have shown 
moderation, moving from harsh sentencing towards 
community rehabilitation.[208]
A drug law reform process is currently underway in 
Myanmar, where a new draft narcotics law (which 
explicitly refers to harm reduction and human 
rights) was released in 2017.[188] Myanmar has also 
embraced the UN Guiding Principles on Alternative 
Development within Myanmar’s drug control 
policies.[188]
A revision of the Mekong Memorandum of 
Understanding between Laos, Myanmar, Cambodia, 
China, Vietnam and Thailand has adopted 
recommendations from the 2016 UN General 
Assembly Special Session on the Global Drug 
Problem, and acknowledges the importance of 
rights-based drug policy to the 2030 Agenda for 
Sustainable Development.[209] Additionally, the 
2016-2025 ASEAN (Association of Southeast Asian 
Nations) Work Plan Against Drugs, adopted in 2016, 
has broadened the regional approach to drugs by 
including recommendations to engage departments 
with responsibility for education, health and social 
matters in the response to drug use.[210] However, 
it retains the ultimate goal of achieving a drug-free 
ASEAN.[210]
Civil society and advocacy 
developments for harm 
reduction
Civil society organisations in Asia have played 
a critical role in advocating for the availability, 
suitability and accessibility of harm reduction 
services in the region for decades.[211] The Asian 
Network of People who Use Drugs (ANPUD), which is 
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based in Bangkok, continues to be the coordinating 
resource body for local networks of people who 
use drugs. A focus of this group is advocacy within 
community organisations in local areas. In some 
countries where stigma and discrimination towards 
people who use drugs is increasing to dangerous 
levels, grass roots networks have reportedly been 
forced to go underground or suspend operations.[212]
In Indonesia, Persaudaraan Korban Napza Indonesia 
has been instrumental in ensuring the availability of 
hepatitis treatment in the country in the last year.[63] 
The Drug User Network, a Pakistani advocacy group 
for people who use drugs, continues to work to 
mobilisecommunityleadershiptoinfluencepolicies,
laws, programme funds and to promote actions that 
empower people who use drugs.[213]
The Japan Advocacy Network for Drug Policy 
(JANDP) is a multidisciplinary collective working 
to increase and strengthen the debate on drug 
policy alternatives in Japan .[27] Japan’s international 
engagement on drugs has progressed since 
the Global State of Harm Reduction 2016.[27,211] 
JANDP gained membership of the New York Non-
Governmental Organisation Committee on Drugs and 
iscurrentlybeingconsideredforaffiliationwiththe
Vienna Non-Governmental Organisation Committee 
on Narcotic Drugs.[27] The Malaysian Welfare 
Association of Recovering Drug Users also continues 
to be active at the national level. In Myanmar, the 
National Drug Users Network of Myanmar and the 
Drug Policy Advocacy Group campaigned around the 
message of the Support. Don’t Punish movement in 
2018, and in 2017 produced a publication outlining 
best practice recommendations for health and 
human rights-based drug policies.[214,215] The Indian 
Drug Users Forum (IDUF), a national-level forum, 
endeavours to promote the meaningful involvement 
of people who use drugs. The IDUF been growing 
inmembershipandlookstoinfluencepolicyand
programme development consistently.[20]
In Afghanistan, there are informal networks of 
peoplewhousedrugsthatarenotaffiliatedwith
regional groups.[5] The Cambodia Network for Drug 
Users is still in its formative stages and ensures 
membership of women who use drugs, and works 
closely alongside law enforcement through a local 
civil society organisation, KHANA.[13] Nepal has a 
long history of drug user activism, with extensive 
networks. The lead organisation, Recovering Nepal, 
works alongside the Coalition of Drug Users, a non-
abstinence-based all-inclusive drug user network[216] 
that includes women and transgender people who 
n Support. Don’t Punish is a global advocacy campaign calling for better drug policies that prioritise public health and human rights. The campaign aims to promote 
drug policy reform, and to change laws and policies which impede access to harm reduction interventions.[218]
use drugs.[43] In Vietnam, the Vietnamese Network 
of People who Use Drugs continues to be active in 
advocacy and campaign work, including fostering the 
global Support. Don’t Punish campaign.[217]n
Regionally, many major milestones have been 
accomplished under the guidance and technical 
support of the International Drug Policy Consortium. 
These include the active involvement and presence of 
civil society and drug user networks in scheduled side 
event sessions at the 61st Session of the Commission 
on Narcotic Drugs in Vienna in March 2018. The 
International Drug Policy Consortium, along with 
regional partners, also ensured that the human 
rights of people who use drugs and the importance 
of harm reduction as a public health measure were 
highlighted at the ASEAN Member State Meeting in 
Kuala Lumpur in May 2018.[61] Global campaigns such 
as Support. Don’t Punish, as well as Harm Reduction 
International’sflagshipbudgetadvocacycampaign,
10 by 20,[15] have been embraced by networks of 
people who use drugs in Asia. At the time of writing, 
there was limited information about the existence of 
networks in Bangladesh, Bhutan, Brunei Darussalam, 
China, Hong Kong, the Philippines, Laos, Macau, 
the Maldives, Mongolia, Singapore, Sri Lanka, South 
Korea and Taiwan.
Funding developments for 
harm reduction
Based on research conducted by Harm Reduction 
International into the funding landscape for harm 
reduction services in Asia in 2017-2018, it is evident 
that there is a paucity of funding for HIV prevention, 
treatment and care programmes for people who use 
drugs.[220-224] There is an overarching lack of political 
andfinancialsupportforharmreductionfrommost
governments in Asia, and most initiatives rely heavily 
on international donors. In Indonesia, for example, 
90% of harm reduction programmes have been 
funded by international donors to date, and these 
funds have been steadily reducing in recent years.[221] 
The revised Global Fund Eligibility Policy states that 
all low- and middle-income countries are eligible to 
access funds, with upper middle-income countries 
that have high disease burdens being eligible to seek 
funding.[225] Fortunately for the region, the majority of 
Asian countries remain eligible to access funds under 
the new criteria. However, funds for harm reduction 
continue to diminish in the region overall.[226]
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Adding to the harm reduction funding crisis is 
a lack of preparedness among governments to 
transition away from international donor support. 
Sustainability of harm reduction work in Asia will 
be largely contingent on domestic governments’ 
willingnesstobearfinancialresponsibilityforthese
programmes in the future. For example, Cambodia 
has seen international funding plummet since its 
status was upgraded to a lower middle-income 
country,[222] a shortfall that must be met by increased 
national investment. The government of Vietnam has 
increased domestic support for OST in recent years 
and is due to be fully funding these programmes in 
2018.[223] In Thailand, there have also been positive 
steps taken by the government to address funding 
shortfalls for harm reduction.[224] However, in both 
Thailand and Vietnam, NSP provision is still heavily 
reliant on international donors, and civil society 
concerns remain as to whether plans and allocations 
will be realised as government priorities continue to 
shift.[43]
The funding situation in other countries in the region 
isalsoprecarious.Afghanistancurrentlybenefits
from Global Fund and World Bank support for harm 
reduction services, with the Global Fund allocating 
US$8.9 million for 2017-2019.[5] However, as the 
World Bank slowly withdraws, support for harm 
reduction services will rely upon budget allocation 
from the subnational government.[5] In Myanmar, 
UN agencies (primarily UNAIDS, WHO and UNODC) 
havebeeninvolvedinnationaleffortstosupport
harm reduction. These developments include a 
National Strategic Plan on HIV/AIDS 2016-2020 and 
the development of a Global Fund funding request.[40] 
The WHO has advocated for increased government 
allocation for OST, and worked with the Myanmar 
government to draft a National Strategic Framework 
on Drug Treatment.[40] The development of a National 
Strategic Framework on Health and Drugs, including 
harm reduction as a core strategic approach to 
addressing health consequences of drugs use, is 
underway by the Ministry of Health and Sports.[161]
In Cambodia, outreach work and technical support 
for HIV-focused organisations continue to be 
supported by the Global Fund, which is predicted to 
end in 2020.[13] Nepal is facing a catastrophic funding 
crisis, with the German Corporation for International 
Cooperation (also known as GiZ) ending its support in 
2016-2019.[43] The Bridging the Gaps project, funded 
bytheMinistryofForeignAffairsoftheNetherlands
in Nepal, will also be ending in December 2018, in 
conjunction with a gradual reduction in support from 
the Global Fund. With such swift donor withdrawal, 
the government of Nepal may be unable to commit 
to support harm reduction services at the same 
capacity in future.[43] Funding for harm reduction 
work in Japan is negligible, and JANDP only receives 
minimal funding from the Open Society Foundations 
for its advocacy activities.[27] The funding predicament 
in Mongolia is also dire, where the Global Fund 
stopped funding at the beginning of 2018.[150] There 
is a dearth of information on funding for harm 
reduction in Macau, and at the time of writing there 
are no funds supporting harm reduction work in 
the Philippines.[48] Advocacy work in the region will 
continue to be funded under the Global Fund Harm 
Reduction Advocacy in Asia project, with the India 
HIV/AIDS Alliance as Principal Recipient until the end 
of 2019.[227]
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2.2 Eurasia
Table 2.2.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Eurasia 
Country/territory
with reported
injecting
drug use
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence 
among
people who  
inject drugs (%)
Harm reduction response
NSPa OSTb
Peer-
distribution 
of naloxone
DCRs
Albania 5,132[1] 0.5%[1] 28.8%[1] 11.5%[1] 2[2,3] 6[2] x x
Armenia 13,000[4] 5.4%[4] 42.7%[4] nk 12[2,3] 4[2] x x
Azerbaijan 71,283[5] 9.7%[4] 62.1%[4] 10.4%[4] 17[4] 2[2] x x
Belarus 40,500[4] 25.6%[4] 58.3%[4] 11.2%[4] 34[2,3] 19[6] x x
Bosnia and 
Herzegovina
9,500-
15,000[7]
0.3%[4] 39.9%[4] 0.5%[4] 5[8] 7[2](M,O) x x
Bulgaria 18,500[4] 1.7-3%[9] 57.8-68.5%[9] 6.6%[4] x[10] 31[11] x x
Croatia 6,344[12] 0.5%[12] 38.3%[12] 0.9%[4] 142[13] [13](M,O) x x
Czech Republic 47,000[4] 0.3%[4] 18.3%[4] 15.1%[4] 153[13] [13](M,B,BN) x x
Estonia 8,500[4] 53.4%[4] 79.2%[4] 3-22%[14] 37[13] 9[2](M,B,BN) [14]c x
Georgia 52,700[15] 2.3%[16] 65-75%[16] 7.2%[4] 22[2] 18[2](M,BN) x x
Hungary 6,707[17] 0.2%[17]d 49.7%[17] 2.2%[4] 43[13] 15[2](M,BN) x x
Kazakhstan 120,500[18] 9.2%[4] 58.8%[4] 7.9%[4] 144[19] 10[19] x x
Kosovo nke nk 26.6%[20] 4.1%[20] [2] 3[2] x x
Kyrgyzstan 28,500[4] 12.4%[4] 43.9%[4] nk 40[21] 31[22] x x
Latvia 12,537[23] 6.5%[23] 52.5%[23] 3.8%[23] 25[13] 10[2](M,B,BN) x x
Lithuania 5,000[4] 8%[4] 41%[4] 10.5%[4] 14[13] [13](M,B,BN) x x
Macedonia nk nk 64%[24] nk 16[24] 16[24] x x
Moldova 12,000[4] nk 50.1%[4] 5.7%[4] 28[25] 19[2]f x x
Montenegro nk 0.2%[4] 43.4%[4] nk 13[2] 5[2] x x
Poland 14,670[26] 3%[26] 58.7%[4] 4.9%[4] 36[13] [26] x x
Romania 81,500[4]g 20.5%[4] 83.8%[4] 5.2%[4] 2[27]h [28] x x
Russia 1,881,000[4] 30.4%[4] 68.7%[4] 9%[4] 20[4] x x x
Serbia 29,000[4] <1%[4] 25.9%[4] 3.6%[4] 2[29] 23[30] x x
Slovakia 20,000[4] 0.1%[4] 56.1%[4] 1.7%[4] 13[13] [13](M,B,BN) x x
Slovenia 6,000[4] 0.5%[4] 30.5%[4] 3.4%[4] 102[13] 10[3](M,B,BN) x x
Tajikistan 23,100[31] 27%[4] 61.3%[4] nk 51[32] 12[32](M) x x
Turkmenistan nk nk nk nk x x x x
Ukraine 319,500[4] 19.1%[4] 53.9%[4] 5.6%[4] 1,667[3] 174[33](M,B) [34] x
Uzbekistan 94,000[4] 7.3%[4] 21.8%[35] nk 230[36] x x x
 nk – not known 
a	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.	(P)	=	needles	and	syringes	
reported	to	be	available	for	purchase	from	pharmacies	or	other	outlets.
b	 (M)	=	methadone,	(B)	=	buprenorphine,	(O)	=	any	other	form	(including	morphine	and	codeine).
c	 Naloxone	can	only	be	provided	by	medical	personnel.
d	 Data	from	2014;	however,	civil	society	report	an	increase	in	HIV	diagnoses	attributed	to	injecting	drug	use	in	2018.
e	 Recent	studies	on	drug	use	and	the	public	health	response	have	not	been	undertaken	in	Kosovo	since	2008.
f	 Of	these	services,	13	are	based	in	prisons.
g	 National	estimates	for	the	number	of	people	who	inject	drugs	in	Romania	vary	widely	among	different	international	agencies.	The	figure	cited	represents	the	most	recent	from	an	
independent study. 
h	 	An	additional	9	NSPs	operate	in	prisons	in	Romania.	However,	this	service	has	never	been	utilised	by	people	in	prison.	Please	refer	to	prison	section	(p56).	
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Harm reduction in Eurasia
i	 Azerbaijan,	Russia	and	Turkmenistan	do	not	have	harm	reduction	within	any	national	policies.
Overview
The region of Eurasia covers diverse countries, with 
varied levels and types of drug consumption. Every 
country	in	the	region	reports	injecting	drug	use,[4]	but,	
as	in	all	other	regions	of	the	world,	cannabis	remains	
the most commonly used drug.[18,37] In Eurasia, there 
is a growing trend in the use of amphetamine-type 
stimulants (ATS) over the last decade.[37] In particular, 
the	Czech	Republic	(and	more	recently,	neighbouring	
countries)	have	been	associated	with	the	production	
of much of Europe’s methamphetamine market, with 
stimulants	reported	as	the	primary	drug	injected	in	
the	Czech	Republic,	Hungary	and	Latvia.[38] Although 
injecting	drugs	as	the	primary	route	of	administration	
has reduced overall in Eurasia over recent years, data 
also reveal a general upward trend in the use of ATS 
and	new	psychoactive	substances	(NPS)	via	other	
routes of administration (e.g. swallowing, snorting or 
smoking).[18,37]
The state of harm reduction in Eurasia has remained 
largely	stable	since	2016,	with	the	exception	of	
certain countries, namely Bosnia and Herzegovina, 
Bulgaria, Hungary and Romania, which have seen 
the	closure/scaling	back	of	harm	reduction	services.	
Harm reduction is still mentioned in national 
government policies in 26 of the 29 countries in 
the region.i Needle and syringe programmes are 
available	in	27	of	the	29	countries	in	the	region,	
the	notable	change	being	the	closure	of	NSPs	in	
Turkmenistan and Bulgaria since the Global State of 
Harm Reduction last reported. 
Opioid	substitution	therapy	(OST)	remains	available	
in 26 of the 29 countries in the region. In Russia, 
which	retains	considerable	influence	in	parts	of	
the region, the government’s punitive policies 
and practices towards drug use continues, with a 
national	ban	on	OST	and	extremely	limited	NSP	site	
provision, despite increasing rates of HIV[38] and 
hepatitis	C	in	the	country	among	people	who	inject	
drugs.[38] Ideology surrounding drug use in Russia, 
often	entrenched	in	unscientific	drug	prevention	
and treatment measures which deny people access 
to essential medicines and services, has led to gross 
violations	of	a	number	of	human	rights,	including	
exploitation	by	law	enforcement	officials,	pain	and	
suffering	associated	with	withdrawal,	and	coerced	
confessions regarding drug use.[39,40] OST is also 
unavailable	in	Turkmenistan	and	Uzbekistan.	
Civil	society	in	Russia	and	neighbouring	countries	
continues to advocate for the implementation 
of the nine core harm reduction interventions 
recommended	by	the	World	Health	Organization	
(WHO).[2]
Across	the	region,	HIV	transmission	attributed	
to	injecting	drug	use	has	seen	a	decline	in	some	
countries	(detailed	below).	In	contrast,	Russia	and	
Hungary have seen an increase in HIV prevalence,[38] 
and	according	to	a	2018	report	from	UNAIDS,	
people	who	inject	drugs	account	for	39%	all	of	
new HIV infections in the region.[41] In 2016, people 
accessing harm reduction services in Hungary 
reached their lowest level in seven years.[17]	Ukraine	
bears	the	second	largest	HIV	epidemic	in	the	region,	
concentrated among key populations.[42] In many 
countries there also remains a distinct lack of 
integration of HIV testing and treatment services 
within harm reduction programmes.[2] 
The funding crisis for harm reduction is having 
a	negative	impact	on	a	number	of	countries	in	
Eurasia.[43] Austerity, international donor retreat 
and poor political support for harm reduction 
are the primary factors underpinning this.[43] In 
some countries in Eurasia, the withdrawal of the 
Global	Fund	has	left	gaps	in	service	provision	that	
government	support	is	yet	to	fill.[43] Civil society 
in the region reports the closure of community 
organisations and the closure of services. In some 
cases, the transition to government support impacts 
upon quality of services, such as poor-quality needles 
being	supplied.[2,44] Often where harm reduction 
services do exist, they are not inclusive; for example, 
women	experience	greater	difficulty	in	accessing	
services and very few, if any, adapted models of 
harm reduction service provision for women are 
in operation.[45] The role of NGOs and community-
led service providers in harm reduction is still not 
supported	by	the	majority	of	governments	in	the	
region of Eurasia. 
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
The	number	of	countries	in	Eurasia	in	which	NSPs	
operate	has	reduced	by	one	since	the	Global State of 
Harm Reduction 2016,	with	services	currently	available	
in 27 of the 29 countries. Notwithstanding this, 
restrictive opening hours, poor-quality equipment 
and	stigma	remain	barriers	to	NSPs	in	many	
countries in the region.[2] In 2016, it was reported that 
Turkmenistan	had	two	NSPs,	but	these	services	no	
longer exist. In 2017, due to the withdrawal of donor 
funding and the lack of government support, all NSPs 
in Bulgaria have closed down or ceased providing 
needles and syringes.[10]	In	2016,	the	WHO	adjusted	
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its targets for high coverage syringe programmes, 
from its 2009 target of 200 syringes per person who 
injects	drugs	per	year	to	a	target	of	300	syringes	
per	person	who	injects	drugs	per	year	by	2030.[46] 
Increases	and	decreases	in	accessibility,	availability	
and	coverage	of	NSPs	have	been	observed	in	Eurasia.	
When	looking	specifically	at	the	number	of	sites	
providing NSPs, this increased in eight countries 
since the Global State of Harm Reduction reported in 
2016	(Croatia,	the	Czech	Republic,	Estonia,	Georgia,	
Latvia,	Poland,	Slovakia	and	Slovenia).	In	the	Czech	
Republic,	just	short	of	6.5	million	syringes	have	been	
dispensed	since	2007	and	the	number	of	people	who	
use drugs accessing NSP services increased, with 
over 8,000 new clients in 2016 alone.[47]	With	injecting	
more frequently associated with methamphetamines 
rather	than	opioids	in	the	Czech	Republic	(estimates	
suggest around 75% of needles procured are for 
methamphetamine	use),	a	greater	number	of	
syringes are required due to the fact people who 
inject	stimulants	often	inject	more	frequently.	
Syringes	are	accessible	via	vending	machines	in	the	
Czech	Republic[47]j and Hungary.[13]
A	number	of	countries	in	the	region	also	have	mobile	
NSPs or outreach programmes which deliver needles 
and	syringes	alongside	other	injecting	equipment	
and, in many cases, healthcare services or referrals. 
In	Estonia,	two	mobile	NSP	units	began	operating	
in	2018	via	van,	and	combine	HIV/hepatitis	C/
tuberculosis	and	STI	testing	and	treatment,	although	
treatment	for	hepatitis	C	is	not	available.[48] In 2016, 
2.1	million	syringes	were	distributed	via	NSPs	(at	
both	mobile	and	fixed	sites)	in	Estonia,	and	although	
regional	coverage	could	be	improved,	overall	
satisfaction	has	been	reported	by	people	using	the	
services.[48]	In	Slovakia	between	2015	and	2016,	an	
increase	in	the	number	of	syringes	distributed	was	
reported	which,	similarly	to	the	Czech	Republic,	is	
due	to	an	increase	in	stimulant	injecting.[49]	Latvia	and	
Hungary also report stimulants as the primary drug 
injected.[37]	However,	in	Latvia	NSP	site	provision	has	
increased since 2016, whereas in Hungary, two key 
needle	and	syringe	sites	have	been	closed	down.[17,50] 
The	number	of	syringes	distributed	per	person	who	
inject	drugs	per	year	was	already	only	10%	(n=30)	
of	the	recommended	WHO	standard	of	300[46] prior 
to the closure of these services and concerns have 
been	raised	over	the	gradual	increase	in	HIV	among	
people who use drugs.[17,52]	With	the	closure	of	all	NSP	
services in Bulgaria there are similar fears.[10]
Decreases	in	NSP	site	provision	have	been	also	
been	observed	in	Serbia	and	Uzbekistan	since	
the Global State of Harm Reduction last reported in 
2016.	In	15	countries	(Albania,	Armenia,	Azerbaijan,	
j	 Vending	machines	do	not	supply	needles	and	syringes	free	of	charge.
Belarus,	Bosnia	and	Herzegovina,	Kazakhstan,	
Kosovo,	Kyrgyzstan,	Lithuania,	Macedonia,	Moldova,	
Montenegro,	Tajikistan,	Russia	and	Ukraine)	provision	
of	NSP	has	remained	stable.	In	Russia,	there	are	
reported	to	be	100,000	new	HIV	diagnoses	each	
year,	with	a	high	proportion	believed	to	be	attributed	
to	unsafe	injecting	drug	use	and	a	lack	of	harm	
reduction provision and funding.[38] Civil society in 
Kazakhstan	reports	poor-quality	syringes	distributed	
by	government-funded	programmes,	leading	to	
the	potential	for	increased	unsafe	injecting.[2,44] 
In Romania, two NGOs provide NSPs; however, 
geographical coverage remains poor and services 
are	only	available	in	Bucharest	and	Ilfoy	County.[28] 
In	Ukraine,	women	experience	a	high	level	of	stigma,	
discrimination and violence, making them harder 
to reach with NSP services.[45] Adapted services are 
therefore	needed	and	are	being	advocated	for	by	
the	Women’s	Harm	Reduction	International	Network	
(WHRIN).[45] 
Opioid substitution therapy (OST)
As reported in 2016, 26 countries in the region have 
some	form	of	OST	provision	available	for	people	
who	inject/use	opioids.	OST	is	prohibited	in	Russia,	
Turkmenistan	and	Uzbekistan,	despite	the	WHO’s	
recommendation	that	where	injecting	drug	use	
occurs, the country must prioritise implementation 
of	both	OST	and	NSP	as	a	public	health	concern.[51] 
Table	2.2.1	shows	high	rates	of	HIV	and	hepatitis	C	
are	reported	for	the	1.8	million	people	who	inject	
drugs	in	Russia.	To	put	the	figures	in	perspective,	
between	2011	and	2016	the	annual	increase	of	HIV	
prevalence	globally	was	10%	(including	sub-Saharan	
Africa	with	the	highest	burden	of	disease).	In	Russia	
during the same period, HIV prevalence increased 
75%.[52] Harm Reduction International’s research 
found that while Russia accounts for 20% of all 
people	who	injects	drugs	in	low-	and	middle-income	
countries	(LMICs),	investment	in	harm	reduction	is	
so	low	that	it	is	equivalent	to	only	1%	of	all	identified	
harm	reduction	funding	in	LMICs.[53]
Across	the	26	countries	in	the	region	that	offer	
OST,	provision	has	been	largely	stable	over	the	last	
two	years;	however,	coverage	varies	considerably	
and is extremely low in some states.[2] Heroin 
assisted therapy (HAT) as a form of OST remains 
unavailable	in	Eurasia.	In	Romania,	civil	society	
reports a reduction of OST provision.[27]	In	Kosovo,	
less	than	0.3%	of	the	estimated	number	of	people	
who	inject	drugs	receive	OST.[20]	In	Lithuania,	
OST	can	be	prescribed	via	specialist	centres	and	
psychiatrists only, and the person must have health 
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insurance. [30,54] Methadone remains the most widely 
used form of OST in the region; however, the lack 
of take-home dosing in many countries due to 
rigid regulatory frameworks, the position of law 
enforcement	officials	and	a	lack	of	trust	between	
service	providers	and	attendees	serve	to	exacerbate	
issues	of	access	for	people	who	inject	drugs.[2] 
Unlike	NSP	services,	many	governments	fully	fund	
OST	provision	in	the	region,	including	Azerbaijan,	
Bulgaria,	Croatia,	the	Czech	Republic,	Estonia,	
Hungary,	Latvia,	Lithuania,	Poland,	Serbia,	Slovakia,	
and Slovenia.[2] In Belarus and Georgia, government 
funding for OST has recently increased.[2] In 
Belarus, the state now funds OST provision, with 
the exception of the medication costs (funded 
through	the	Global	Fund).[2]	In	2017,	Georgia	began	
to fully fund all methadone programmes, covering 
approximately 6,000 people. An additional 1,200 
people	receive	buprenorphine	through	the	private	
system.[2,55] In Estonia, coverage of OST is considered 
stable	and	state	funding	for	harm	reduction	services	
has	been	increasing;	however,	there	are	waiting	
lists for those initiating treatment.[48] In 2018, the 
government	of	Ukraine	committed	to	fund	and	
expand access of OST to over 10,000 people at 178 
health-care facilities.[56]
In	Kazakhstan,	reduced	Global	Fund	funding	and	
limited political support has seen OST restricted to 
pilot programmes at 10 sites across three cities, with 
less than 1% of people who use drugs accessing 
the programme.[53] A repressive policy and legal 
environment,	unequal	coverage	between	rural	
and	urban	settings,	stigma,	and	the	requirement	
to	abstain	from	illegal	drugs	all	form	barriers	to	
access and adherence to OST. Earlier in 2018, the 
government	of	Kazakhstan	threatened	to	close	the	
country’s OST programmes, highlighting the political 
vulnerability	of	the	service.	The	prompt	civil	society	
advocacy response appears to have paused this 
decision.[57]
Amphetamine-type stimulants (ATS), cocaine 
and its derivatives, and new psychoactive 
substances (NPS)
Cannabis	is	the	most	commonly	used	drug	in	nearly	
every	county	in	the	region,	but	a	growing	trend	in	the	
use of amphetamine-type stimulants has emerged 
in Eurasia over the past decade.[37] In particular, the 
Czech	Republic	(and	more	recently,	neighbouring	
countries)	have	been	associated	with	much	of	
Europe’s methamphetamine market, with stimulants 
reported	as	the	primary	drug	injected	in	the	Czech	
Republic,	Hungary	and	Latvia.[37]	Although	injecting	
drugs as the primary route of administration has 
declined in general over the last decade,[37] data in 
many countries reveal a general upward trend of ATS 
use via swallowing, snorting or smoking; for example, 
in Poland,[26] Estonia[14] (where amphetamines are 
the	most	commonly	used	stimulant),	Lithuania[54] 
(with the city of Vilnius having the highest levels of 
methamphetamine residue detected in wastewater 
in	the	whole	of	the	European	Union)	and	Slovakia.[49] 
A	recent	report	by	Mainline,	a	Netherlands-based	
harm reduction organisation, provides the most 
comprehensive review of stimulant harm reduction 
programmes and practices to date.[58] The report 
provides a literature review on various types of 
stimulants, routes of administration and harm 
reduction strategies, case studies from across the 
globe	and	reviews	interventions	specific	to	people	
who use stimulants. The potential health-related 
harms	of	stimulant	use	are	different	to	those	
experienced	by	people	who	use	opioids.	People	
who	use	stimulants	report	feeling	that	they	belong	
to	different	(social)	networks	of	people	who	use	
drugs, meaning they may feel opioid-focused harm 
reduction	services	are	irrelevant	or	inaccessible	
to them.[58] However, similarly to people who use 
opioids/inject	drugs,	there	is	no	single	intervention	
which	is	recommended,	but	a	comprehensive	body	
of interventions.[58] These include: safer smoking 
kits for people who smoke (crack cocaine and 
methamphetamines); prevention of sexual risk; 
female-focused interventions; drug consumption 
rooms;	self-regulation	strategies;	substitution;	
outreach	and	peer-based	interventions;	drop-in	
centres;	housing	first;	therapeutic	interventions;	and	
drug-checking services.[58] 
Harm reduction responses for people who use 
stimulants, including cocaine and its derivatives, 
MDMA	and	psychedelics	such	as	LSD	(commonly	
referred to as “party drugs”) are relatively limited 
in Eurasia. The response to ATS use in all countries 
in	Eurasia	is	almost	exclusively	abstinence-based,	
the	exceptions	being	harm	reduction	approaches	
in	the	Czech	Republic	and	Poland.[2] In the Czech 
Republic,	given	the	high	proportion	of	people	who	
inject	methamphetamines,	together	with	data	that	
suggests more than half of people surveyed had 
ever	shared	their	injecting	equipment	with	peers,[47] 
many harm reduction programmes (including NSPs) 
distribute	gelatine	capsules	as	an	oral	alternative	to	
injecting.[47] This simple and low cost approach can 
contribute	to	the	reduction	in	risk	of	blood-borne	
viruses and of smoking with toxic materials.[59] The 
European Monitoring Centre for Drugs and Drug 
Addiction	(EMCDDA)	reports	that	there	has	been	a	
steady	increase	in	the	number	of	people	coming	into	
contact with harm reduction services in the Czech 
Republic.[47]	In	Poland,	a	pilot	project	operating	in	
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Warsaw	offers	drug-checking	via	pre-distribution	of	
testing	strips	at	clubs,	festivals	and	events.[60] The 
project	also	procures	samples	from	online	shops,	
tests	and	evaluates	the	substance	and	shares	
information with people who use drugs.[60] In many 
cases,	NPS	are	advertised	as	synthetic	cannabinoids	
but	contain	synthetic	opioids.[60]	In	a	number	of	
countries,	a	barrier	to	drug-checking	services	is	the	
requirement	that	service	providers	obtain	licences	to	
possess	and	work	with	scheduled	substances;	many	
countries do not accept drug-checking as a valid 
reason to issue such licences.[61] 
New	psychoactive	substances	contribute	to	the	
growth	in	ATS	use	in	Eurasia.	In	2018,	the	United	
Nations	Office	on	Drugs	and	Crime	(UNODC)	World 
Drug Report	noted	that	36%	of	all	NPS	on	the	global	
market were stimulants.[18] Since the Global State of 
Harm Reduction last reported in 2016, many countries 
in Eurasia report an increase in NPS use.[2] NPS can 
be	swallowed,	snorted,	smoked	or	injected;	but	
in	most	cases,	injecting	is	associated	with	either	
synthetic stimulants or opioids.[2]	In	a	number	of	
cases, people using heroin or methamphetamine, 
specifically	where	these	substances	may	be	
temporarily	unavailable,	will	switch	to	a	NPS.[2] 
Reasons for switching to NPS rather than traditional 
substances	are	often	based	on	price,	availability	
and	less	fear	of	detection	of	the	substance	by	police	
and	law	enforcement	officials.[2]	NPS	have	been	
associated with younger people, representing a 
challenge to harm reduction programmes in terms of 
reach,	particularly	if	young	people	are	injecting	and	
unaware of potential harms.[2,37] 
In	Hungary,	a	shift	from	injecting	established	drugs	
(such	as	heroin	or	amphetamines)	to	injecting	
NPS (namely synthetic cathinones similar to 
amphetamines	and	MDMA)	has	been	observed	in	
recent years.[17]	Other	NPS,	consumed	via	different	
routes of administration (e.g. swallowing, snorting 
or	smoking)	have	become	popular	among	younger	
people and are increasing in use.[17] In 2018, the 
EMCDDA	reported	that,	although	the	number	of	
new	psychoactive	substances	was	down	from	the	
peak	reached	in	2015,	around	400	new	substances	
are reported each year.[37] NPS, mostly synthetic 
cannabinoids	and	cathinones,	are	mainly	imported	
from	the	Czech	Republic,	Poland	and	Hungary,	or	
arrive directly from countries in East Asia (mainly 
China).[49]
NPS present an evolving challenge to harm reduction 
practices and the harm reduction response fails to 
meet need in the region. Even in countries where 
there	is	political	will	for	greater	syringe	distribution	
k	 Fentanyl	and	its	analogues	are	synthetic	opioids	which	can	be	50	times	more	potent	than	heroin	and	100	times	more	potent	than	morphine.
for	people	who	inject	stimulants/NPS,	services	are	
often	unable	to	provide	a	sufficient	number	of	
syringes or syringes of good quality.[44]
Overdose, overdose response and drug 
consumption rooms (DCRs) 
Overdose	continues	to	account	for	the	majority	
of	morbidity	and	mortality	associated	with	opioid	
drug use in Eurasia.[37]	From	estimates	of	drug	use	
in	the	European	Union	(of	which	some	countries	in	
the Eurasia region of this report overlap), opioids 
were found in 84% of fatal overdoses.[37] In 2018, 
Estonia had the highest rate of fatal overdose of 
all	the	European	Union	countries,	with	fentanylk 
found	in	the	majority	of	these	cases.[37]	It	is	difficult	
to	assess	the	true	scale	of	overdose	and	morbidity	
and mortality, due to inconsistent reporting and 
differences	in	surveillance	systems,	which	have	led	
to systematic under-reporting of overdose-related 
death.	In	Lithuania,	for	example,	the	drug-induced	
mortality	rate	among	adults	between	the	ages	of	15-
64	was	more	than	double	the	European	average.[54] 
In Hungary, approximately one quarter of all drug-
related deaths involved opioids, always found in 
combination	with	other	substances.[17] Although 
in	the	Czech	Republic	a	lower	proportion	of	drug-
induced deaths were recorded with opioids as the 
principal drug involved in 2015, the proportion of 
prescribed opioid-related death increased in 2016.[47] 
In Slovakia, similarly to many other countries in the 
region,	although	the	number	of	drug-induced	deaths	
is relatively small, approximately nine out of 10 were 
linked to opioids.[49] 
Naloxone	is	a	highly	effective	opioid	antagonist	used	
to	reverse	the	effects	of	opioid	overdose	in	minutes.	
The	medicine,	which	can	be	delivered	in	various	ways	
(intra-nasal,	sublingual	and	buccal)	can,	however,	
only	be	effective	if	accessible.[62-65] In Estonia, a total 
of	five	service	providers	(in	Harju	County	and	Ida-Viru	
County)	provide	naloxone,	but	kits	must	be	provided	
via medical personnel. People who use opioids and 
their relatives are trained in how to recognise an 
overdose,	administer	naloxone	and	provide	first	aid	
until the emergency services have arrived.[14] Between 
2013 and 2016, 1,770 people had undergone 
naloxone	training	and	1,764	pre-filled	syringe	kits	
had	been	distributed.[48]	Four	hundred	and	sixty-six	
kits were issued to repeat clients, with 95% of the 
reason	for	requesting	a	repeat	because	the	pre-filled	
syringe	had	been	used	to	save	someone’s	life.[48] 
In	Lithuania,	a	small-scale	pilot	naloxone	initiative	
began	in	late	2016,	but	naloxone	is	given	to	
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people	only	upon	completion	of	a	detoxification	
programme.[54] In 2013, two pilot naloxone 
programmes	were	launched	in	Kyrgyzstan	and	
Tajikistan,	where	people	who	inject	drugs	were	
trained in overdose prevention and naloxone 
use.[66] Over the course of the pilot, 81.5% of 
participants	in	Kyrgyzstan	and	59.3%	of	participants	
in	Tajikistan	reported	receiving	naloxone	to	reverse	
an overdose.[66]	In	Tajikistan,	naloxone	programmes	
remain	operational,	with	people	able	to	access	the	
medication through harm reduction programmes.[2] 
In	Ukraine,	with	funding	from	the	Global	Fund,	
naloxone	is	available	through	healthcare	and	
social workers trained in overdose prevention and 
distributed	via	harm	reduction	programmes	and	
outreach.[34] In Russia, organisations like the Andrey 
Rylkov	Foundation	provide	naloxone	to	people	who	
use drugs via outreach harm reduction programmes. 
In 2018, production of naloxone stopped in Russia 
and civil society reports they now face challenges in 
accessing the medicine.[67] 
In many other countries in the region, naloxone 
is	only	available	via	a	prescription.[2] Although 
emergency	medical	staff	have	access	to	the	
medication in all countries, for those most likely to 
witness an overdose, access is extremely limited.[2] 
Harm	reduction	programmes	distribute	naloxone	
in	Belarus,	Georgia,	Estonia,	Lithuania	(to	some	
degree),	Kazakhstan	and	Kyrgyzstan.[2] However, 
overdose prevention (if undertaken in countries) 
is often fragmented due to a lack of funding, 
a	lack	of	resources	and	a	lack	of	awareness	by	
states	regarding	the	effectiveness	of	a	life-saving	
medication.[2] 
In 2018, there remain no drug consumption rooms 
(also known as overdose prevention sites) or safe 
injecting	facilities	in	Eurasia.
Viral hepatitis
In 2016, the Global State of Harm Reduction reported 
that	hepatitis	C	prevalence	among	people	who	inject	
drugs was over 50% in 16 countries in Eurasia (see 
Table	2.2.1)	and	the	same	is	true	in	2018.	Since	2011,	
for example, the rate of hepatitis C infection among 
people	who	inject	drugs	in	Hungary	has	doubled[17] 
and	in	2014,	a	study	in	Latvia	reported	prevalence	
rates	of	85.4%	among	people	who	inject	drugs.[23] 
Few	countries	in	the	region	have	national	hepatitis	
C treatment programmes, irrespective of action 
plans or policy statements.[2] Treatment for hepatitis 
C	is	often	at	a	high	financial	cost	to	the	person	and	
not free at the point of access.[2]	Where	treatment	
is	available,	there	are	often	restrictive	criteria;	for	
example,	in	Belarus	and	Kazakhstan,	the	state	will	
only cover the cost of treatment if the person is co-
infected with HIV.[2] In Hungary, while treatment is 
available	and	cost-neutral,	long	waiting	lists	restrict	
access.[2]	In	Estonia	and	Lithuania,	treatment	is	only	
available	at	no	cost	to	the	person	during	the	late	
stages	of	fibrosis.[2] In Estonia, hepatitis C treatment 
is provided primarily through health insurance; this 
represents	a	barrier	for	many	people	who	use	drugs	
who do not have private heath insurance.[48] 
In	the	Czech	Republic	and	Slovenia,	treatment	for	
the	hepatitis	C	virus	is	available	to	all	people	who	
inject	drugs	via	public	health	facilities,	but	access	
remains limited.[47,49] Access to hepatitis C testing 
and	treatment	in	Lithuania,	Moldova,	and	Romania	
is	specifically	limited	to	those	who	have	state	health	
insurance or are willing to cover the cost of testing 
and	treatment	themselves,	and	in	Lithuania	only	
four units in the whole country provide viral hepatitis 
testing.[54]	In	Ukraine,	through	funding	provided	by	
the	Global	Fund,	hepatitis	C	treatment	is	available	
free of charge to key populations, including people 
who use drugs (the government funds treatment for 
the general population).[68,69] In Armenia, Russia and 
Tajikistan,	hepatitis	C	treatment	is	only	available	to	
those who can cover the cost in full themselves.[2] In 
Latvia,	Montenegro,	Serbia	and	Albania,	people	who	
inject	drugs	are	required	to	stop	using	drugs	prior	to	
receiving treatment for hepatitis C.[2]  
Hepatitis C testing and treatment: 
the integrated care approach in 
Georgia
Georgia	is	the	first	country	in	the	region	to	launch	a	
nationwide hepatitis C elimination programme for 
people	who	inject	drugs.	The	programme	launched	in	
April 2015, with partnership and technical assistance 
provided	by	the	United	States	Centres	for	Disease	
Control and Prevention, and commitment from Gilead 
Sciences to donate direct-acting antivirals (DAAs).[70] As 
of March 2018, 31 sites for hepatitis C treatment were 
in	operation	throughout	the	country,	being	integrated	
into OST services in 2017, and NSPs in 2018.[2,55] To date, 
500,000	people	have	been	screened	and	just	over	40,000	
people enrolled in treatment.[55]
Civil	society,	researchers	and	public	health	advocates	
believe	that	Georgia’s	hepatitis	C	elimination	programme	
will provide lessons for future hepatitis treatment 
programmes,	particularly	as	treatment	becomes	more	
affordable	and	more	countries	seek	to	provide	care	and	
treatment services.[71] 
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Tuberculosis (TB)
Data	on	TB	prevalence	among	people	who	inject/
use drugs are often sparse, and without these it is 
difficult	to	assess	the	true	prevalence	of	TB	among	
this population in the region. Overall incidence of 
TB	in	countries	within	the	European	Union	(Bulgaria,	
Croatia,	the	Czech	Republic,	Estonia,	Hungary,	Latvia,	
Lithuania,	Poland,	Romania,	Slovakia	and	Slovenia)	is	
low.[72] However, new cases of multi-drug resistant TB 
rates remain at the highest in Eurasia,[72] with Belarus, 
Moldova	and	Uzbekistan	accounting	for	35.8%,	
31.1% and 44.6% of all cases of multi-drug resistant 
TB respectively.[72]	Kazakhstan,	Kyrgyzstan,	Russia,	
Tajikistan	and	Ukraine	all	had	prevalence	between	
20-29%,	whilst	Armenia,	Azerbaijan,	Estonia	and	
Latvia	all	had	a	prevalence	rate	of	between	10-19%	
of multi-drug resistant TB.[72]	The	Russian	Federation	
is	a	high-burden	country	that	has	seen	rates	of	TB	
in	decline,	dropping	13%	between	2013-2017.[73] 
However, Russia remains one of the three countries 
that account for almost half of the world’s cases of 
multi-drug resistant TB.[73]	Tuberculosis	also	remains	
the main AIDS-related cause of death among people 
living	with	HIV	in	Ukraine.[42] 
The level of integration of TB into harm reduction 
programmes varies across the region, and 
theoretically	TB	screening	and	treatment	is	available	
across Eurasia. In Estonia, taking into account that 
tuberculosis	remains	a	significant	health	challenge	
among	people	who	live	with	HIV,	free	tuberculosis	
screening	is	provided	on	a	regular	basis	for	high-
risk	groups	not	covered	by	health	insurance,	
including	people	who	inject	drugs.[14] In Romania, 
the treatment of TB and HIV infection is universally 
provided	for	anyone	infected,	but	levels	of	access	to	
treatment for chronic HCV infection remain low.[28] 
The DETECT-TB (Early Detection and Integrated 
Management	of	Tuberculosis	in	Europe)	project	
launched	in	2016	aims	to	contribute	to	the	decline	
and eventual elimination of TB in the European 
Union.	The	project	emphasises	the	importance	
of	the	early	diagnosis	of	vulnerable	populations,	
including	people	who	inject	drugs	and	prisoners,	and	
the	sharing	of	best	practices	between	programme	
countries.	The	project	works	through	a	network	of	
partners in six states, two of which are in Eurasia 
(Bulgaria	and	Romania)	using	a	mobile	van.[74,75] 
Good practice notes that outreach to marginalised 
populations	may	help	to	mediate	between	these	
groups and formal health services.[76] Similar to 
other	infectious	diseases	associated	with	injecting	
drug use, stigma and a lack of awareness also play 
a	significant	role	in	compounding	the	TB	epidemic	
among	people	who	inject	drugs.[76-78]
l	 It	is	believed	the	transmission	route	remains	unreported	in	a	large	proportion	of	new	infections	in	Poland,	meaning	the	data	may	not	be	representative.
HIV and antiretroviral therapy (ART)
In	a	2018	UNAIDS	report,	39%	of	all	new	HIV	
infections	in	Eurasia	were	due	to	injecting	drug	
use.[41] However, transmission patterns vary from 
country	to	country.	Notably,	HIV	attributed	to	
injecting	drug	use	has	seen	a	decline	in	Poland	and[26]l 
Latvia,[23] and in Estonia it is estimated that only 30 
new	HIV	infections	were	associated	with	injecting	
drug use in 2016, lower than in previous years.[14] 
In Slovakia, only one case of HIV was linked to 
injecting	drug	use	in	2016.[49] Overall, the proportion 
of	new	HIV	infections	linked	to	injecting	drug	use	
in	Lithuania	declined	from	more	than	60%	in	2010	
to	less	than	30%	in	2015,	but	increased	to	around	
40% in 2016.[54]	In	Latvia,	the	number	of	new	HIV	
infections	over	the	last	decade	has	remained	stable	
among	people	who	inject	drugs;	however,	findings	
from	a	study	among	people	who	inject	drugs	in	Riga	
(the country’s capital) indicated that around a quarter 
tested positive for HIV.[23] This example illustrates 
the	difficulty	in	assessing	true	rates	of	HIV	among	
a heavily criminalised and stigmatised population. 
In	Russia	there	has	been	a	75%	increase	in	new	HIV	
infections	between	2011	and	2016.[38] 
In many countries in the region, there also 
remains a distinct lack of integration of HIV testing 
and treatment services within harm reduction 
programmes.[2]	Where	integration	of	these	services	
does	exist,	it	often	depends	on	ad-hoc	collaboration	
between	harm	reduction	services	and	specialised	
medical facilities.[2]	In	Lithuania,	rapid	HIV	testing	for	
people who use drugs now occurs in medical centres, 
whereas previously NGOs employed an outreach 
nurse to carry out testing.[2] Civil society organisations 
are concerned that this change may lead to reduced 
uptake amongst an already stigmatised and hard-to-
reach population.[2]	In	2016,	a	study	in	Kazakhstan	
and	Kyrgyzstan	found	that	a	fear	of	being	registered	
with the Narcological Register prevented people 
who use drugs from accessing healthcare services.[79] 
Further	regulatory	barriers	to	uptake	of	HIV	testing	
and	treatment	have	been	noted	in	Armenia	and	
Tajikistan,	where	NGOs	are	prohibited	from	
performing rapid testing and treatment unless they 
hold	a	special	medical	licence.	To	bypass	this,	some	
NGOs	collaborate	with	medical	institutions	to	provide	
testing.[2] 
To	achieve	the	90-90-90	target	set	by	UNAIDS,[52] 
urgent scaling up of the nine core harm reduction 
interventions	as	recommended	by	the	WHO	is	
needed in the region,[51] particularly given rising rates 
of	HIV	attributed	to	unsafe	injecting	in	countries	like	
Russia,	Turkmenistan	and	Uzbekistan.	
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Harm reduction in prisons
UNAIDS	have	estimated	that	56-90%	of	people	
who	inject	drugs	will	be	incarcerated	at	some	stage	
in their lives.[80]	In	Eurasia,	drug	offences	are	a	
major	contributor	to	high	incarceration	levels,[81] 
though the proportion of prisoners incarcerated 
for	drug-related	offences	in	the	region	varies.	In	a	
2015 survey, more than one-third of prisoners in 
Slovenia reported ever having used a drug in their 
lifetime, with one in four stating they had used 
drugs in prison.[49]	In	Latvia,	approximately	69%	of	
prisoners had used drugs at some point in their life, 
with 40% having done so in the last month.[23] Drug 
use	was	also	found	to	be	more	common	among	
female rather than male prisoners.[23] In 2016, a 
survey conducted in Czech prisons found that more 
than half of those imprisoned had used an illicit 
drug prior to imprisonment, 41% of whom had 
used methamphetamine.[47]	Injecting	drug	use	also	
occurs within the prison setting, with around 7% of 
people	injecting	in	prisons	and	6%	reporting	sharing	
injecting	equipment	inside	prisons	in	the	Czech	
Republic.[47]	At	the	time	of	publication,	NSPs	did	not	
operate	in	prisons	in	the	Czech	Republic.	In	Russia,	
around	23%	of	people	in	prison	have	been	convicted	
of	drug-related	offences.[82]
Needle and syringe programmes only operate 
in	prisons	in	five	of	the	29	countries	in	the	
Eurasia region: Armenia (all prisons),[83] 
Kyrgyzstan	(7	prisons),[21]m Macedonia (no details 
available),[84] Moldova (18 prisons),[85]	Tajikistan	(1	
prison).[86]n Romania also operates NSPs in nine 
of its 45 prisons;[13] however, reports suggest the 
service	has	never	been	utilised[28] as prisoners must 
register formally for the programme.[84,87] Moldova 
is one of the only countries in the region that has 
scaled up its NSP provision since the Global State of 
Harm Reduction last reported in 2016, going from 13 
prisons in 2016 to 18 in 2018.
Access to OST in prisons is stronger than access 
to	needles	and	syringes,	and	is	currently	available	
in	18	countries:	Albania,[88] Armenia,[83] Bosnia and 
Herzegovina,[89] Bulgaria,[9] Croatia,[12] the Czech 
Republic,[47] Estonia,[14,48] Georgia,[90]	Kyrgyzstan,[21] 
Latvia,[23] Macedonia,[84] Moldova,[85] Montenegro,[2] 
Poland,[84]oRomania,[84]	Serbia,[84]p Slovenia[91] and 
Ukraine.	In	2016,	the	Global State of Harm Reduction 
reported	that	OST	was	available	in	Lithuania;[54] 
however, research in 2018 indicates that OST is 
only	available	when	a	person	is	in	police	custody	
and already enrolled in an OST programme. OST 
is discontinued when the person is transferred to 
prison.[54] 
m	 Figure	from	2014.
n	 Figure	from	2014.
o	 However,	this	is	only	available	for	detoxification.
p	 OST	cannot	be	initiated	in	prison,	only	delivered	as	a	continuation	of	treatment.
Although OST is provided in 18 countries, quality and 
accessibility	vary	considerably	within	and	between	
countries.	Estonia	has	OST	available	in	all	prisons.[48] 
Moldova’s OST scale-up in prisons positions it as a 
regional leader; services are implemented via 10 non-
governmental organisations and the Department 
of Penitentiary Institutions.[85] In Slovenia, the most 
recent data from 2016 indicates that around two-
thirds of prisoners who were using opioids accessed 
OST.[92]	In	Georgia,	OST	is	only	available	in	three	
out of the country’s 15 prisons, and is provided for 
detoxification	purposes	only,	for	a	maximum	of	three	
months.[2] This approach is the same in Poland and is 
entwined	within	an	abstinence-based	framework.[84] 
Both	models	are	insufficient	to	be	deemed	harm	
reduction; however, the existence and provision 
of	the	service	must	be	noted.	In	Hungary,	OST	is	
reportedly	available,	but	is	primarily	provided	as	
a	form	of	detoxification	treatment.[17] In the Czech 
Republic,	the	initiation of OST only occurs on an 
exceptional	basis,	but	is	provided	to	people	who	
accessed	it	prior	to	imprisonment	and	is	available	
at six prisons in the country. At the time of writing, 
only 63 people were receiving OST in the Czech 
Republic.[47,92]	In	Montenegro,	Serbia,	Albania	and	
Latvia,	OST	cannot	be	initiated	within	the	prison,	but	
is	available	as	a	continuation	of	medication.[2] 
As	reported	in	2016,	a	blanket	prohibition	remains	
on	OST	in	Russia,	Turkmenistan	and	Uzbekistan,	both	
in	prisons	and	in	the	broader	community.	OST	also	
remains	unavailable	in	prisons	in	Azerbaijan,
Belarus,	Hungary,	Kazakhstan,	Kosovo,	Lithuania,	
Slovakia	and	Tajikistan.	Research	has	indicated	that	
prisoners	are	more	likely	to	be	exposed	to	blood-
borne	viruses	in	the	prison	setting,[93,94] and reports of 
injecting	drug	use	in	prisons	are	found	worldwide.[95] 
A recent systematic review looking at the risk of 
HIV acquisition among people with a history of 
incarceration	found	that	being	incarcerated	for	drug	
offences	as	an	injecting	drug	user	was	associated	
with an 81% increase in HIV acquisition risk.[96] 
The continuity of access to needle and syringe 
programmes	and	OST	between	the	broader	
community and prisons is important in preventing 
transmission	of	blood-borne	viruses	and	avoidable	
deaths	in	people	who	inject	drugs	and	those	who	
use opioids.[97]	A	2016	ruling	by	the	European	Court	
of Human Rights determined that denying OST 
treatment to a prisoner while in detention violates 
Article 3 of the European Convention on Human 
Rights,	which	prohibits	inhuman	or	degrading	
treatment.[98] 
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People	who	inject	drugs	are	also	most	vulnerable	to	
overdose on release from prison,[100-103] yet naloxone 
is	reportedly	unavailable	to	prisoners	post-release	
in	every	country	in	the	region,	bar	Estonia.	Since	
September	2013,	a	take-home	naloxone	programme	
has	been	available	in	the	two	most	affected	counties	
of Estonia and in 2015 the programme was extended 
to	prisoners	before	release.[14,48] 
HIV	testing	and	treatment	is	available	in	prisons	in	all	
countries in Eurasia, although the regulation, quality 
and	coverage	of	these	services	vary	considerably.[2] 
Hepatitis C testing, treatment and care in the region’s 
prisons	is	scarce,	which	typically	reflects	the	situation	
outside prisons.[2]	Only	a	few	countries	offer	hepatitis	
C treatment in all prisons: Slovakia,[84] Slovenia[84] 
and Estonia.[48]	In	Hungary	and	Ukraine,	hepatitis	C	
treatment	is	available	in	less	than	half	of	prisons.[84] 
In Georgia, prisoners have had access to DAAs 
since the launch of the 2015 elimination strategy, 
with 2,753 people accessing treatment.[103] Hepatitis 
C	treatment	is	reportedly	unavailable	for	people	
in prisons in Bosnia and Herzegovina, Croatia, 
Macedonia and Poland.[84]
Civil society reports that in most countries, condoms 
are	not	available	or	available	to	only	a	limited	
extent in prisons.[2]	Although	Estonia	offers	OST	and	
naloxone, condoms for people in prison remain 
inaccessible.[48] Since August 2017, a pilot condom 
distribution	programme	has	been	operating	in	one	
prison	in	the	Czech	Republic	(prior	to	which	condoms	
were	only	available	in	canteens	in	prisons	and	in	
some private visiting rooms).[92]	Under	the	pilot	
programme, four condom vending machines were 
installed	in	bathrooms/toilets,	together	with	adjusted	
disposal	bins	for	dangerous	and	infected	waste.	
Four-thousand	condoms	were	distributed	in	the	first	
12 months, resulting in the extension of the pilot 
programme and with a proposal for implementation 
of similar pilots in other prisons in the country in 
2018/2019.[92]
Policy developments for 
harm reduction
Twenty-six of 29 countries in Eurasia have national 
HIV or drug policies that include explicit references 
to harm reduction. The three countries which do not 
include harm reduction in national policy remain the 
same	as	reported	in	2016:	Azerbaijan,	Russia	and	
Turkmenistan.	At	least	three	countries	(Albania,	the	
Czech	Republic	and	Estonia)	have	harm	reduction	
as one of the four main pillars of their national 
Drugs Strategy.[1,47] Despite the implementation of 
harm reduction services in many countries in the 
region,	for	the	vast	majority	of	countries,	the	policy	
environment	is	dominated	by	punitive	drug	policies	
focused on supply reduction and criminalisation. 
Within	this	policy	environment,	hostility	towards	
harm reduction is common. National legislation on 
drugs in the former Soviet states set low thresholds 
for	possession	offences,	leading	to	prison	sentences	
that are disproportionate in length to the associated 
drug arrest.[2] 
In 2016, the Global State of Harm Reduction 
reported	that	Armenia	and	the	Czech	Republic	had	
decriminalised the possession of small quantities 
of drugs.[104] Although the use and possession of a 
small amount of drugs in Armenia is not a criminal 
offence,	the	administrative	fine	for	possession	
remains	so	high	that	many	cannot	afford	to	pay	
and instead are arrested for non-payment.[2] In 
the	Czech	Republic,	the	low	prevalence	of	both	
HIV and hepatitis C (the latter in relation to the 
region)	among	people	who	inject	drugs	has	been	
attributed	to	sustained	and	scaled	up	provision	
of	harm	reduction	services	in	combination	with	
decriminalisation.[105]	In	January	2017,	Lithuania	
criminalised possession of small quantities of 
illicit drugs. Prior to this date, possession of small 
quantities	had	been	an	administrative	offence,	rather	
than a criminal sanction. This caused hundreds 
of	people	to	be	imprisoned.[106] The Eurasian 
Harm Reduction Association (EHRA) conducted 
an	assessment	in	Lithuania,	finding	that	over	€25	
million	was	spent	by	the	state	on	imprisoning	people	
for drug possession.[107]	In	2018,	Kyrgyzstan	stated	
drug	use	would	be	decriminalised	under	the	new	
Criminal Code; however, the implementation and 
impact	of	reforms	need	to	be	further	assessed	as	at	
present	the	minimal	fine	for	drug	possession	is	the	
equivalent to 18 months’ salary.[108] 
In	2017,	a	report	was	submitted	to	the	UN	
Committee on Economic, Social and Cultural Rights 
(CESCR)	which	addressed	a	number	of	human	rights	
violations	in	Estonia	regarding	the	enjoyment	of	
social rights among women who use drugs and/or 
living with HIV in Estonia.[109] 
Civil society and advocacy 
developments for harm 
reduction
Civil society organisations continue to form an 
important part of the harm reduction movement in 
Eurasia, as service providers, campaigning groups 
and	advisory	bodies	to	governmental	agencies.	
In many countries, NGOs deliver harm reduction 
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services and either make referrals to healthcare 
services or provide testing and treatment for a 
number	of	communicable	infections.[2] A regional 
network, the Eurasian Harm Reduction Association 
(EHRA),	forms	the	hub	of	250	harm	reduction	
organisations and activists from 29 countries 
in	Eurasia,	and	works	to	create	a	favourable	
environment	for	sustainable	harm	reduction	
programmes, non-repressive drug policies and a 
good standard of living for people who use drugs.[111] 
Country-based	drug	user	networks	also	exist	in	
Estonia,	Macedonia,	Georgia,	Azerbaijan,	Kyrgyzstan	
and Montenegro.[2,48] The Belarusian national 
OST organisation Your Chance,[108]	the	Lithuanian	
drug	users’	organisation	Yang	Wave[108,111] and the 
Ukrainian	Network	of	Women	who	Use	Drugs	have	
also	recently	been	established.[45]	In	Kazakhstan,	
a	collective	of	people	who	use	drugs	has	been	
formed, with representatives active in national harm 
reduction and healthcare advocacy.[108] 
Drug	policy	reform	has	become	an	important	
issue	in	Georgia,	and	has	been	a	prominent	theme	
in	political	debate	for	the	last	two	years.[2] Drug 
policy in Georgia is among the harshest in the 
region, with possession of any amount (for any 
purpose)	a	punishable	offence	attracting	long	prison	
sentences.[2] In addition, mandatory drug testing on 
the	street	has	become	a	flagship	intervention	for	law	
enforcement in the country.[2] The Georgian National 
Drug Policy Platform (a coalition of 41 NGOs) 
developed a series of legislative amendments aimed 
at changing the current drug-related legislation, 
and decriminalising drug use and possession of 
small amounts for personal use.[55] In June 2017, 
a	group	of	MPs	from	the	parliamentary	majority	
submitted	the	amended	bill	to	parliament.	Hearings	
of the proposed legislative amendments revealed a 
polarising	attitude,	both	among	decision	makers	and	
the	general	public,	with	the	amendments	still	under	
review	at	the	time	of	publication.[2] The Georgian 
National Drug Policy Platform is an example of the 
coordinated and consolidated work of civil society, 
drug user activists, drug-related service provider 
organisations, human rights groups, clinicians, 
researchers, politicians and other interested 
groups.[2] 
Funding developments for 
harm reduction
A	2017	report	by	Harm	Reduction	International	
found	that	a	number	of	countries	in	Eurasia	are	
experiencing a funding crisis for harm reduction, with 
particularly grave situations in Bulgaria, Romania, 
Poland and Hungary.[43] Austerity, international donor 
retreat and poor political support for harm reduction 
are the primary factors underpinning the continued 
funding crisis.[43] In 2016, a study on the allocated 
funding of HIV prevention and treatment for people 
who	inject	drugs	in	eight	countries	in	the	region	
(Armenia,	Belarus,	Bulgaria,	Georgia,	Kazakhstan,	
Kyrgyszstan,	Moldova	and	Ukraine)	found	that	across	
Eurasia there was diversity in domestic and donor 
resourcing for services.[112] Bulgaria, for example, 
allocated	just	4%	of	its	budget	to	HIV	services	for	
people	who	inject	drugs,	whereas	Georgia	allocated	
40%.[112]
A	2018	report	by	Harm	Reduction	International	
also	highlights	the	impact	of	Global	Fund	retreat	on	
harm reduction funding and service provision.[53] 
Several	countries	that	have	been	heavily	reliant	on	
the	Global	Fund	for	their	harm	reduction	responses	
have seen dramatic reductions in their allocations for 
the period 2017-2019.[53]	For	example,	on	a	per-year	
basis,	Moldova’s	2017-2019	allocation	represented	
a 43% drop from 2014-2016.[113]	Kazakhstan	had	
relied	on	the	Global	Fund	for	a	large	proportion	of	
its harm reduction funding, with much of this paying 
for needle, syringe and condom provision.[53]	When	
Kazakhstan	gained	upper	middle-income	status,	this	
(combined	with	its	low	overall	HIV	prevalence)	led	to	
the	country’s	ineligibility	for	Global	Fund	grants	in	the	
2014-2016 allocation period. Although the national 
government also provided support to NSP sites, only 
4.7%	of	the	country’s	total	HIV	budget	went	towards	
prevention activities, and only 2.7% targeting people 
who	inject	drugs.[53] In 2018, threats to OST services 
have	escalated	in	Kazakhstan,	with	the	government	
considering ceasing their operation.[53,114] There 
are also reports from civil society of poor-quality 
syringes	being	distributed	by	the	government,	
leading to the potential for unsafe and risky 
injecting	behaviours.[2,44]	The	example	of	Kazakhstan	
illustrates	the	political	vulnerability	of	harm	reduction	
programmes, and has prompted civil society action 
to hold the government to account.[53] 
In Poland, Georgia, Belarus and Estonia, state 
allocations for HIV programmes, including harm 
reduction,	have	been	increasing	since	the	Global 
State of Harm Reduction last reported.[2,48] In Poland, 
a government decision to allocate funding to harm 
reduction	from	monies	accumulated	from	gambling	
taxation	has	reportedly	led	to	an	increase	for	both	
harm reduction and drug treatment in the country.[2] 
Here,	harm	reduction	programmes	are	co-financed	
by	local	governments	and	the	National	Bureau	for	
Drug prevention.[26]
Central	to	the	challenge	of	ensuring	the	sustainability	
and quality of harm reduction in the region is the lack 
of political acceptance for harm reduction.
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Table 2.3.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Western Europe 
Country/
territory
with reported
injecting
drug use
People who
inject 
drugs[1]a
HIV prevalence
among people
who inject 
drugs(%)[1]a
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)[1]a
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs(%)[1]a
Harm reduction response
NSPb[1] OSTc[1,2]
Peer-
distribution 
of naloxone
DCRsc
Andorra nk nk nk nk nk nk x x
Austria
12,000-
17,000[3]
4 38 4.4e 39 (B, M,O) x x
Belgiumf 23,828 10.5 22 5.6 116 (B, H,M) x[4] 1g[8]
Cyprus 126 1.5 43.3 1.5 2 (B, O)[9] x x
Denmark nk nk 52.5h nk  (B, H,M) [10] 5[11]
Finland 15,611i 1.2j 74k nk 53 (B, M,O) x x
France 108,607lm 4.7n 63.8o 0.81p 509 (B, M) xq[12] 2[13]
Germany nk 1.6-9.1r 62.6-73s 0.4-1.2t u (B, H,M,O) x[15] 24[14,15]
Greece 4,173 5.1 63.5 1.6 13 (B, M) x x
Iceland nk nk 45[16] nk [16] [16] x x
Irelandv 1,151[3] w 6 41.5 0.5  (B, M) xx[17] x
Italy nk 28.8 56.6 nk 66[18] (B, M,O) [18] x
Liechtenstein nk nk nk nk nk nk x x
Luxembourg 1,467y 13.2 nk nk 11 (B, M,O) x 1[19]
Malta 688[3]z 1.2 46.3 nk 8 (B, M)[20] x x
Monaco nk nk nk nk nk nk x x
Netherlands 840aa 3.8ab 57 0ac 175 (B, H,M,O) x 24[21]
Norway 8,888ad 1.5 nk 0.9ae 51 (B, M) [22] 2[22]
Portugal 13,162 14.3 82.2 2 2,099 (B, M) x x
San Marino nk nk nk nk nk nk x x
Spainaf 11,048ag 31.5 66.5 10.5 838 (B, M) x 16[23]
Sweden 8,021ah 7.4ai 96.8aj nk 10 (B, M)[24] x x
Switzerland 42,000[3]ak 10-12[25] 42.1[25]al nk  (B, H,M,O) x 14[26]
Turkey 12,733am[27] nk 39.8an 3.9ao x (B, M,O) x x
United Kingdom 122,894ap 0.9aq 51-58[28,29]ar 0.4as 606at (B, H,M,O) au[31,32] x
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a Unless otherwise stated, data is from 2016.
b	 All	operational	needle	and	syringe	exchange	programme	(NSP)	sites,	including	fixed	
sites, vending machines and mobile NSPs operating from a vehicle or through outreach 
workers. (P) = pharmacy availability.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B), (H) 
medical heroin (diamorphine) and any other form (O) such as morphine and codeine. 
Figures for the number of sites are often not available in Western Europe due to a 
variety of service providers, which includes general practitioners.
d Drug consumption rooms, also known as supervised injecting sites.
e Based on subnational data from 2016.
f People who inject drugs population estimate refers to lifetime injecting drug use and 
is based on national data from 2015. Infectious disease prevalence estimates based on 
subnational data from the Flemish community from 2015.
g One drug consumption room operates in Liège with the approval of local government, 
though no national legislation permits such facilities.[5-7]
h Year of estimate: 2008.
i Year of estimate: 2012.
j Based on subnational data from 2014.
k Year of estimate: 2014.
l Derived from treatment data based on self-reported injecting in the last three months.
m Year of estimate: 2015.
n Year of estimate: 2015.
o Based on subnational data from 2011.
p Based on subnational data from 2011.
q While take-home naloxone is available in France, it can only be acquired with a person-
al prescription.
r Based on subnational data from 2013-2014.
s Based on subnational data from 2013-2014.
t Based on subnational data from 2013-2014.
u A total of 172 syringe dispensing machines operate in Germany, but the total number 
of NSPs is unavailable.[14,15]
v Year of estimates: 2010.
w Year of estimate: 2015.
x While take-home naloxone is available in Ireland, it can only be acquired with a person-
al prescription.
y Year of estimate: 2015.
z Year of estimate: 2015.
aa Year of estimate: 2015.
ab Based on subnational data.
ac Based on subnational data.
ad Year of estimate: 2015.
ae Based on subnational data from 2015.
af Year of estimates: 2015.
ag Estimate derived from treatment data and relates to people reporting injecting in past 
year.
ah Years of estimate: 2008-2011.
ai Based on subnational data from 2013.
aj Based on subnational data from 2013.
ak Year of estimate: 2015.
al Year of estimate: 2011.
am Based on a subnational estimate and number of high-risk opioid users, including but 
not exclusively people who inject drugs.
an Year of estimate: 2015.
ao Year of estimate: 2015.
ap Years of estimate: 2004-2011.
aq Based on data from England and Wales only.
ar Hepatitis C prevalence among people who inject drugs is 51% in England, Wales and 
Northern Ireland, and 58% in Scotland.
as Based on data from England, Northern Ireland and Wales only.
at	 This	figure	does	not	include	NSPs	in	England	due	to	a	lack	of	national	data.
au In the United Kingdom, peer-distribution of naloxone is limited to a small number of 
projects.
nk – not known
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Harm reduction in Western Europe
Overview
The state of harm reduction in Western Europe 
has remained largely stable since the Global State 
of Harm Reduction last reported in 2016. From a 
global perspective, the region has an extensive harm 
reduction response to illicit drug use, with a wide 
range of services adapted to the needs of people 
who inject drugs operating in almost all countries. 
Despite this, there remains room for improvement. 
As reported in 2016, opioid substitution therapy 
(OST) is available in all countries in Western Europe 
for which there is data on harm reduction services, 
and needle and syringe programmes (NSPs) are 
available in every country except Turkey. In this 
respect, Western Europe is one of the regions in the 
world with the widest availability of these key harm 
reduction services. Within countries, experiences 
have varied. In Spain and the Netherlands, the 
number of syringes distributed has reduced since 
2016 in line with decreases in the population of 
people who inject drugs in those countries,[32,33] 
while elsewhere in the region (for example in Ireland 
and Sweden) programmes have been expanded 
and more syringes have been distributed over the 
period.[24,34] Expansions of existing NSP programmes 
have also incorporated the increasing use of syringe 
dispensing machines, for example in Cyprus and the 
United Kingdom.[9,35,36] 
A rising concern in Western Europe is overdose 
deaths, which have increased in number since 
2016.[1] An estimated 84% of overdose deaths in 
the region involved opioids in 2016, and almost two 
thirds occurred in Germany, Turkey and the United 
Kingdom.[1,37] As part of the public health response 
to this, 89 drug consumption rooms (DCRs) exist in 
Western	Europe,	with	Belgium	opening	its	first	facility	
in 2018. However, at the time of publication no DCRs 
existed in the UK. Naloxone, an opioid antagonist 
that	can	reverse	the	effects	of	overdose,	is	available	
to medical personnel in most countries in the region. 
However, take-home naloxone, in accordance with 
World Health Organization recommendations, is 
only available in eight countries (Denmark, France, 
Germany, Ireland, Italy, Norway, Spain and the UK), 
and peer-distribution networks are only permitted 
in four (Denmark, Italy, Norway and the UK). An 
emerging phenomenon of fentanyl presence in drug-
related deaths in England and Wales makes overdose 
responses even more vital, and is a development that 
must be monitored closely across the region.[38]
Interventions targeted at the use of amphetamine-
type stimulants (ATS) and new psychoactive 
substances (NPS) form an increasing proportion 
of harm reduction services in Western Europe. 
This includes needle and syringe programmes and 
DCRs, which in some locations provide facilities 
specifically	for	inhaled	or	injected	consumption	of	
ATS.[23,39] On-site drug-checking services at parties 
and festivals have expanded greatly since 2016, and 
are now available in at least seven countries (France, 
Italy, Luxembourg, the Netherlands, Portugal, Spain, 
Switzerland and the UK) to address harms caused by 
high-purity and adulterated substances. However, in 
many countries drug-checking services continue to 
suffer	from	a	lack	of	legal	and	financial	support	from	
the state. Beyond drug-checking, the harm reduction 
response to new psychoactive substances, such as 
synthetic cannabinoids and synthetic cathinones, 
remains stunted.
Controlling infectious diseases among people who 
inject drugs remains a primary driver of harm 
reduction in the region. Unrestricted universal 
access to direct-acting antivirals for hepatitis C is 
only available in 10 out of 25 countries (see viral 
hepatitis section below), with most countries placing 
limitations on access based on either disease stage 
or injecting drug use.[13,18,23,40,41] Incidence of HIV 
among people who inject drugs halved between 
2007 and 2016, though injecting drug use was 
still responsible for 5% of new HIV infections in 
the European Union (EU) in 2016.[37] People who 
inject drugs continue to face formal and informal 
barriers to testing and treatment for blood-borne 
diseases. Stigma, self-stigma and criminalisation all 
contribute to lower testing and access to treatment 
among people who inject drugs than the general 
population[18,42], and migrants, women and people 
in rural areas are reported to face compounded 
barriers.[15,43] 
The policy environment has continued to progress 
gradually in favour of harm reduction. At least 
17 of the 25 countries in the region have policy 
documents supportive of harm reduction, and the 
EU has renewed and expanded its commitment 
to harm reduction through the Action Plan on 
Drugs 2017-2020.[44]	Perhaps	the	most	significant	
development in the region was in Italy, where harm 
reduction	programmes	were	for	the	first	time	
included in the Livelli Essenziali di Assistenza, the 
package of basic services that must be guaranteed 
across the country.[18] While policy has progressed 
in the region, funding for harm reduction remains 
a key concern. The funding landscape varies 
across the continent, from near-crisis in Greece 
to	sustainable	and	sufficient	investment	in	harm	
reduction in the Netherlands.[45] In all countries of 
Western Europe, however, the transparency of state 
investment	in	harm	reduction	is	insufficient	or	poor,	
with investment rarely disaggregated from other 
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spending.[45] Civil society organisations across the 
region have warned that the sustainability of harm 
reduction services and funding remains vulnerable to 
changes in the political make-up of national and local 
governments.[18,45]
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
The number of countries in Western Europe in which 
NSPs operate is unchanged since the Global State of 
Harm Reduction 2016, with services available in all 
countries except Turkey (and no data on Andorra, 
Liechtenstein, Monaco and San Marino). However, 
individual countries in the region have experienced 
both increases and decreases in availability and 
coverage. 
Austria, Belgium, Finland, Ireland, Luxembourg, 
Portugal and Sweden have all seen increases in 
the number of syringes distributed over recent 
years.[24,34,40,46-49] In Sweden, low threshold NSPs now 
operate in eight council areas, compared with three 
in	2015,	and	changes	in	legislation	effective	from	
March 2017 have facilitated the establishment of 
new NSPs.[24] In Luxembourg, a new mobile outreach 
service was launched in November 2017.[49] In Ireland, 
NSPs	operate	through	fixed-site	facilities,	outreach	
services and pharmacies, where packs are distributed 
containing injecting equipment for between three 
and 10 injections, with an average of 1,614 people 
using the services per month.[34] Since 2016, syringe 
dispensing machines have been introduced in 
Cyprus, meaning that they are now available in at 
least six countries in the region (Cyprus, Denmark, 
France, Germany, Luxembourg and the United 
Kingdom).[9,11,15,36,49,50] Though there has been an 
increase in the number of NSPs operating in the 
Flemish areas of Belgium, and from 2014 to 2016 
the total number of syringes distributed annually 
increased to 1.1 million, 80% of people who inject 
drugs in the country claim to know other people 
who use drugs who do not use NSPs.[47] This is a 
clear indication that, despite successes in increasing 
coverage, more outreach work is necessary to ensure 
that all people who inject drugs have access to sterile 
injecting equipment.
In other countries in the region, distribution of 
needles and syringes has decreased over recent 
years. In some cases, such as in Spain and the 
Netherlands, this is the continuation of a long-term 
trend attributed to a reduction in heroin use and 
injection in general, as well as the success of harm 
reduction programmes.[32,33] Due to budget cuts 
in Italy, the number of harm reduction services 
offering	NSPs	fell	from	106	in	2012	to	66	in	2015,	
a negative trend that civil society organisations 
expect will continue unless the new Livelli Essenziali 
di Assistenza is implemented properly.[18,51] Though 
the proportion of people sharing needles in 
England, Wales and Northern Ireland appears to 
have fallen from 23% in 2006 to 17% in 2016, a 
survey of people who inject drugs in the United 
Kingdom found that only 46% indicated that service 
provision was adequate in 2016.[28,30] Civil society 
organisations in the UK report that there has been 
no	government	effort	to	expand	coverage	to	address	
this	deficiency.[30,52]
A recurrent issue in the implementation of NSPs 
in Western Europe is the geographical distribution 
of services within countries. For example, six of 
Italy’s 20 regions have no NSPs (though civil society 
organisations expect this to improve over the coming 
years), and coverage is decreasing in southern 
Portugal even while it increases elsewhere in the 
country.[18,42,51] There are no NSPs in the German-
speaking part of Belgium.[47] In Austria, Greece and 
Spain, people who use drugs living in rural areas 
have	difficulty	accessing	harm	reduction	services	
that are primarily located in provincial capitals and 
other large cities.[23,46,53] In Berlin and North-Rhine 
Westphalia in Germany, syringe dispensing machines 
have	been	effective	in	providing	access	to	these	
populations,[14,15] a model which could be introduced 
elsewhere in Western Europe.
A further concern is whether current NSPs are 
meeting the needs of all groups of people who inject 
drugs. For example, in Portugal and the United 
Kingdom, it is unclear whether the needs of people 
who inject performance- and image-enhancing drugs 
are being met in harm reduction services focused 
on people who inject opioids.[31,42] Similarly, men 
who have sex with men are forming an increasing 
proportion of people who inject drugs (up from 
4.4% in the United Kingdom in 2006 to 7.9% in 2016) 
and	have	a	distinct	profile	from	other	people	who	
inject drugs; for example, being more likely to inject 
methamphetamines or ketamine, and more likely 
to share syringes.[28] In England and Wales, injection 
of crack cocaine is also an increasing phenomenon, 
up from being reported by 35% of people who inject 
drugs in 2006 to 53% in 2016.[28]	Some	efforts	have	
been	made	to	create	services	for	specific	groups	
of people who inject drugs; for example, an NSP 
for women who inject drugs in Malta.[20] Also of 
note, in 2015 a Health Service Executive Ireland 
review recommended that the contents of injection 
packs be better adapted to the needs of people 
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using the equipment by including a wider range of 
paraphernalia,	such	as	sterile	spoons,	filters	and	
foil.[34,54]
Opioid substitution therapy (OST)
In the European Union and Norway there were 
636,000 people receiving OST in 2016, corresponding 
to approximately half of people who are dependent 
on opioids in these countries.[37] This is a small 
decrease of 1.2% since 2016 and a decrease of 10% 
since 2010.[55] Coverage in most countries has been 
largely stable over the last two years, with no serious 
contractions or expansions in access. 
Methadone remains the most commonly prescribed 
medication for OST across the region, and is 
especially dominant in outreach services such as 
those in Portugal.[42] A buprenorphine-naloxone 
combination (sold under the brand name Suboxone) 
forms a growing proportion of OST in Germany, Italy 
and Spain, and is the main substitution medicine in 
Finland. However, the cost to the patient is higher 
in Spain and it is only available in high-threshold 
facilities in Portugal.[23,42] In Germany and Switzerland, 
slow-release morphine is also available for 
OST. [14,15,26,39,56,57]
Heroin-assisted therapy (HAT), the prescription of 
medical heroin (diamorphine) for OST, continues 
to be available in six countries in the region: 
Belgium, Denmark, Germany, the Netherlands, 
Switzerland and the United Kingdom.[2,14] A pilot 
programme using diamorphine also started recently 
in Luxembourg[19] and in 2018 the Norwegian 
government announced a diamorphine trial that will 
begin in 2020.[58] Implementation varies by country, 
but HAT is generally reserved, as in Denmark, for 
people who use opioids for whom other substitution 
therapies have not been successful.[2,11] Studies and 
trials in Belgium, as well as elsewhere in the region 
and the world, have found that HAT can be highly 
successful among this population in that it produces 
greater adherence than other forms of OST, reduces 
street heroin use and criminal involvement, and 
leads to better health outcomes.[59] In the UK, HAT 
remains available, but civil society organisations 
report that there are fewer prescribing doctors 
than in 2012, and that services are reluctant to 
prescribe diamorphine because of the high cost.[31] 
In Switzerland, the availability of HAT in the French-
speaking region is poor, and there is no HAT in the 
Italian-speaking region.[26]
A key barrier to the successful implementation of 
OST programmes is that they often continue to target 
abstinence from illicit drug use rather than harm 
reduction. Even low-threshold OST programmes in 
Luxembourg require abstinence from all illicit drugs 
while undergoing therapy, as do higher-threshold 
services in Portugal.[19,42] On the other hand, new 
regulations in Germany (driven by harm reduction 
organisations and people who use drugs) have 
changed	the	official	objective	of	OST	from	striving	
for abstinence from all illegal substances to striving 
for abstinence from heroin only.[14] While this is 
still problematic for some people who use drugs, it 
represents	a	significant	step	in	the	right	direction.	
In the United Kingdom, civil society organisations 
report that some OST clients are being forced to 
reduce their dosage to a sub-optimal level, and can 
be subject to drug testing.[30,31] This appears to be 
the result of a lack of funding combined with clinical 
guidelines and key performance indicators that lack 
commitment to a harm reduction framework.[30,31] A 
2018 United Kingdom government report into drug-
related deaths indicated that the role of sub-optimal 
doses of methadone in opioid overdose deaths 
requires greater attention and research.[60]
Migrants	also	frequently	experience	difficulties	
in accessing OST, as reported in Belgium and 
Switzerland.[4,57] Conversely, OST was included in 
new guidelines on basic medical care in Italy in 2017, 
ensuring	that	it	is	officially	available	to	all	in	the	
country, including non-citizens and undocumented 
migrants (though civil society organisations report 
some issues in access for these populations in 
practice).[18] In Germany, people living in rural areas 
are often forced to travel 30 to 50km in order to 
access OST due to the low number of physicians 
who apply to be authorised to prescribe substitution 
medication. A 2017 revision of the legal framework 
seeks to address this issue.[14] Further barriers to 
accessing OST in the region include age restrictions, 
limited opening hours and long waiting lists, all of 
which contribute to limiting the proportion of people 
who inject drugs able to access OST.[4,14,31,42] A 2018 
Freedom of Information request to the Northern Irish 
government found that the average waiting time for 
OST in Belfast is 29 weeks.[61] In particular, women 
are reported to face more restrictions than men, 
including a lack of childcare at OST services, hostile 
and judgemental attitudes from health professionals, 
and	an	absence	of	women-specific	services.[31,42,62] 
A Swedish study published in 2017 found that people 
who have received OST are four times more likely 
to die from a drug-related death during periods 
away from treatment than while on treatment.[63] 
This emphasises the need to reduce barriers to OST 
adherence, such as stigma and the requirement to 
abstain from illegal drugs. 
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Amphetamine-type stimulants (ATS) and new 
psychoactive substances (NPS)
Use of ATS in Western Europe has stabilised over 
the last two years following a decline since the early 
2000s.[37] However, consumption varies considerably 
between countries in the region. For example, 
last-year prevalence of MDMA use among people 
aged 15-34 ranges from 0.2% in Portugal to 7.4% in 
the Netherlands.[37] Evidence from across Europe 
suggests ATS are primarily used by young people 
(with a mean age of 23 years) in party contexts.[18,64] 
As with ATS, prevalence of NPS use varies by 
country and substance. Synthetic cannabinoids, 
often referred to as “Spice,” are the most prevalent 
category of NPS in Western Europe, with high 
prevalence reported in France, Germany, Spain, 
Sweden and the United Kingdom.[65] For example in 
2016, prevalence of use among students in Germany 
was 6%.[65] The potential harms from synthetic 
cannabinoids vary considerably with the strength of 
particular strains. These can include severe seizures, 
psychosis and heart attacks, and there have been 
several outbreaks of fatal poisoning, including in 
Manchester in the United Kingdom in 2018.[65] The 
harm reduction response to synthetic cannabinoids 
in Western Europe appears to be limited to providing 
information on the potential risks of use, such as that 
provided by Release in the United Kingdom.[66]
NPS are also present in party contexts. In the 
Netherlands, almost one quarter of young adults 
in the nightlife scene have used 4-FA, a stimulant 
associated with around 8% of drug-related 
health incidents in the country.av[67] In Italy, 3.5% 
of people aged 15-19 have ever used an NPS, 
mostly hallucinogens such as DMT at psychedelic 
trance parties.[18]	This	figure	increases	to	11.9%	
when including synthetic cannabinoids.[18] Across 
the	region,	a	significant	barrier	to	data	collection	
and harm reduction for NPS is that use is often 
unintentional or people do not know what they are 
taking.[18,23,26,42] For example, the Be Aware On Night 
Pleasure Safety (BAONPS) drug-checking project 
has found that one third of NPS samples collected 
in Italy do not contain what was expected.[18] This 
has been found to be a particular issue with online 
purchases.[18] For this reason, drug-checking services 
offer	an	opportunity	to	people	who	use	these	
substances to ensure they are aware of the contents 
and the potential harms they may cause.
Drug-checking services operate in at least nine 
countries in the region: Austria, France, Italy, 
Luxembourg, the Netherlands, Portugal, Spain, 
av There were 456 health incidents related to 4-FA in 2016, two of which were fatal.[67]
Switzerland and the United Kingdom. Services 
operated by civil society organisations have served 
people who use drugs in Italy for many years, and 
since 2016 now do so with support from public 
institutions in some regions.[18] In the region of 
Piedmont, drug-checking has been included as 
an essential public health service in regional 
guidelines.[18] The Loop in the UK and the Pipapo 
project	in	Luxembourg	offer	on-site	drug-checking	
services at festivals,[31,68] while the Drug Information 
and Monitoring System (DIMS) in the Netherlands is a 
national network of permanent testing facilities that 
offers	consumers	the	chance	to	check	their	drugs	
anonymously.[69] In Switzerland, on-site drug-checking 
services are now operated with local government 
approval at nightclubs and festivals in Basel, Bern, 
Zürich and since 2018, Geneva.[26] In Bern and Zürich, 
walk-in	services	are	offered	on	a	weekly	and	twice-
weekly basis respectively.[70] 
Drug-checking	services	offer	harm	reduction	for	
both high-purity and highly adulterated substances, 
though the former category appears to be more 
prevalent in Western Europe. For example, DIMS 
has found that the average dose per MDMA pill 
increased 27% from 123mg in 2012 to 156mg in 
2016.[69] The strongest pill checked by DIMS in 2016 
contained 266mg of MDMA, more than twice the 
maximum dose recommended by harm reduction 
organisations.[69] In one year from 2015-2016, the 
average MDMA content of samples checked in Zürich 
rose by 27% from 120mg to 152mg.[71] DIMS has 
found that common adulterants include substances 
such as PMMA, which can cause an overdose at lower 
doses than MDMA.[69]
Legal and regulatory issues related to the handling of 
illegal substances continue to be a barrier to drug-
checking services. For example, the Danish national 
health board has declined to permit drug-testing 
services, pending evidence from the United Kingdom 
and the Netherlands.[72] Though legislation allowing 
for drug-checking exists in Portugal, it is restricted to 
on-site testing and samples cannot be removed to a 
laboratory for further checks.[42] The geographically 
isolated nature of some festivals with heavy ATS 
and	NPS	use	in	Portugal	has	also	been	identified	as	
a barrier to harm reduction programmes.[42] A lack 
of state funding for drug-checking has also been 
highlighted as a major obstacle to carrying out these 
projects, for example in Italy and Portugal.[18,42]
In addition to drug-checking services, other harm 
reduction interventions exist in Western Europe to 
address ATS and NPS use. Informational projects 
run by civil society organisations or groups of people 
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who use drugs operate in several countries to ensure 
people who use drugs are aware of the potential 
risks and best practices.[4,14,31] Ensuring that water and 
calm spaces are accessible at parties and festivals 
forms part of the harm reduction response in the 
Netherlands and elsewhere.[21] To reduce the harm 
caused by inhaling MDMA and cocaine, organisations 
in	Italy	provide	“safer	sniffing	kits”.	These	include	
paper straws to prevent nasal damage, chewing gum 
and sweets to prevent excessive teeth grinding, and 
water and fruit juice to prevent dehydration.[18]
Though routine data collection in Western 
Europe	often	does	not	differentiate	between	
amphetamine and methamphetamine use, there 
is some evidence that methamphetamine use has 
increased over recent years in some populations 
in the region.[37] Civil society organisations in both 
the United Kingdom and the Netherlands report 
that there has been a rise in the prevalence of 
methamphetamine and NPS use among men 
who have sex with men, sometimes associated 
with use in sexual contexts.[30,67,73] While data on 
this relatively recent phenomenon (known as 
“chemsex”) is generally unavailable and the extent 
of these practices may be overstated,[31,74,75] a 
sharp rise was observed in men who have sex with 
men accessing health services for issues related 
to methamphetamines, GHB and mephedrone 
from 2005-2012.[30,73] From the available data, it is 
impossible to determine if this is related to drug use 
in sexual contexts or other factors.[76] Nevertheless, 
there is a clear demand in the UK from patients in 
sexual health clinics for harm reduction measures 
associated with the use of these substances, which 
may include NSPs and other services adapted to the 
needs of this population.[77] For example, the Dean 
Street	Clinic	in	London	offers	an	NSP	together	with	
informal	counselling	and	advice	specifically	tailored	
to men who have sex with men who use drugs in 
sexual contexts.[31,78]
Chem-Safe, a website operated from Spain by Energy 
Control since 2017, aims to provides online harm 
reduction information to men who have sex with 
men who use drugs in sexual contexts.[79,80] The 
anonymity	and	confidentiality	provided	by	an	online	
platform is considered particularly important, given 
the sensitive nature of the information and service 
users who may be stigmatised because of their 
sexual orientation, HIV status or drug use.[80] Despite 
early successes in accessing this population, Chem-
Safe	currently	has	no	ongoing	financial	support	and	
relies on the uncompensated work of the project’s 
coordinator.[80]
People who inject amphetamines are able 
to access NSPs and most drug consumption 
rooms in the region. Furthermore, facilities in 
Germany, Switzerland and Catalonia, Spain 
specifically	serve	people	who	inhale	drugs	such	as	
methamphetamines.[15,23,39] However, civil society 
organisations in Portugal and the United Kingdom 
report that an emphasis in harm reduction facilities 
on people who use opioids can discourage people 
who inject ATS from accessing them, indicating the 
need for tailored harm reduction services for people 
who use ATS.[31,42]
Cocaine remains the most commonly used illicit 
stimulant in Western Europe.[37] There appear to be 
marked	differences	in	consumption	patterns	and	
behaviours	between	different	populations	of	people	
who use cocaine in the region, particularly between 
those who use powder cocaine and those who 
use crack.[18,37] Most datasets in the region do not 
distinguish between crack and powder cocaine use, 
making the observation of trends in use of each form 
challenging.[37]
Harm reduction for cocaine use varies considerably 
according	to	differing	patterns	of	use.	For	people	
who use powder cocaine recreationally, drug-
checking	services	can	have	a	significant	impact	in	
identifying high-purity and dangerously adulterated 
samples.	Purity	of	cocaine	has	increased	significantly	
in samples checked in Zürich, with the average 
cocaine content rising from 41.7% in 2009 to 76.7% 
in 2016.[81] An increase in purity has also been 
observed in the Netherlands.[67] Harm reduction 
for crack use appears to be mostly absent from 
Western Europe, though innovations providing 
sterile inhalation equipment to prevent the spread 
of infectious diseases are being implemented in 
Ireland, in development in Spain and in demand in 
Portugal.[23,42,54,82] Portuguese civil society organisation 
GIRUGaia operates a harm reduction outreach 
programme in Porto providing clients, 90% of 
whom use crack, with legal support and assistance 
in attending court appointments.[42] The harm 
reduction response to crack use in Western Europe is 
significantly	smaller	than	the	response	to	opioid	use,	
in part because of lower prevalence. The European 
Monitoring Centre for Drugs and Drug Addiction have 
highlighted the need for more research to establish 
best practices in harm reduction in this area.[83] 
Overdose, overdose response and drug 
consumption rooms (DCRs)
According to data covering the European Union, 
Norway and Turkey, there were 9,138 overdose 
deaths in the region in 2016, approximately 84% of 
which involved opioids.[1] Drug-related deaths have 
steadily declined in some countries (such as Spain, 
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Denmark and Portugal),[1,23] and increased in others, 
with almost two thirds of drug-related deaths taking 
place in just three countries: Germany, Turkey and 
the UK.[37] In Germany, there were 1,333 drug-related 
deaths in 2016, up 40% compared with 2012.[1] In 
Turkey, the number of drug-related deaths almost 
doubled from 2015 to 2016, with a particularly 
stark rise in deaths related to amphetamine-type 
substances and synthetic cannabinoids (synthetic 
cannabinoids were present in one third of cases in 
2016).[84] 
In the UK, the number of drug-related deaths 
continued to be among the highest on record 
with 3,756 in 2017, and experienced a 101% rise 
in deaths related to heroin and/or morphine from 
2012 to 2017.[30,38] The situation is particularly grave 
in Scotland, where 2017 was the fourth consecutive 
year that drug-related deaths have been the highest 
on record (934 deaths).[85]	In	2017,	there	were	five	
times	as	many	deaths	from	drug	use	as	from	traffic	
accidents in the country.[85,86]	According	to	official	
statistics, 87% of these deaths involved opioids and 
59% involved benzodiazepines; in all but 52 cases, 
more than one drug was found in the body.[85] High 
numbers of drug-related deaths have also been 
observed in Scandinavia.[1]
In 2014, the European Harm Reduction Network 
published a report recommending the widespread 
implementation of overdose prevention sites, 
also known as drug consumption rooms (DCRs), 
and naloxone distribution in order to counter the 
rise in opioid use across the region.[87] As of 2018, 
implementation has been highly varied.
Eight countries in the region (Belgium, Denmark, 
France, Germany, the Netherlands, Norway, Spain 
and Switzerland) now host a total of 89 DCRs. Since 
the Global State of Harm Reduction last reported, 
new facilities have opened in Belgium, France, 
Spain, Switzerland and Norway, with Belgium 
being the only new country to open such a facility. 
Lisbon	is	preparing	to	open	its	first	three	DCRs:	a	
mobile	facility	in	2018	and	two	fixed-site	DCRs	in	
2019.[8,42] Plans and legislation exist for a facility in 
Dublin[88] and for a second drug consumption room 
in Luxembourg.[19] In Belgium, a DCR in Liège has 
operated since September 2018 with the support 
of	local	officials,	but	is	not	officially	sanctioned	at	
the national level.[5-8] Civil society organisations, 
harm reduction service providers and people who 
use drugs succeeded in winning the support of the 
Scottish Parliament for the establishment of a DCR 
in Glasgow in 2018, in response to the high number 
of drug-related deaths, high HIV prevalence among 
aw Inhalation rooms in Spain always share a site with injection rooms.
people who inject drugs, and concern over public 
injecting and publicly discarded injecting equipment 
in the city. However, the Scottish government’s 
proposal for a DCR was blocked by the United 
Kingdom government.[30,31,89] 
In 2016, 1,717 people used DCRs in Luxembourg,[49] 
3,110 people used DCRs in Spain,[33] and 7,155 people 
used DCRs in Denmark.[11] Four DCRs in Frankfurt, 
Germany oversee 200,000 injections annually,[15] and 
the DCR in Oslo, Norway has supervised more than 
300,000 injections since opening.[22] 
Western European DCRs are increasingly adapting 
to the needs of people who use drugs. For example, 
two mobile DCRs operate in Berlin in order to access 
harder-to-reach populations. [14,90] In Luxembourg 
and Switzerland, all DCRs permit the consumption 
of drugs through inhalation as well as injection,[39,49] 
and	three	rooms	specifically	for	inhalation	exist	
in Spain.aw[23] This enables not only people who 
inject drugs, but also people who smoke cocaine, 
heroin	and	methamphetamines	to	benefit	from	the	
enhanced safety and supervision in DCRs. In the 
Netherlands, DCRs mainly target people who smoke 
their substances (in line with the breakdown of drug 
use in the country and harm reduction information 
promoting smoking over injecting).[80] As well as 
providing safer equipment and a safer environment 
for drug use, DCRs in the Netherlands increasingly 
offer	integrated	social	services	to	clients,	which	
include warm meals, recreational activities and 
employment-oriented projects.[80] In Basel and Zürich 
in Switzerland, feasibility studies are currently being 
carried out into providing drug-checking services in 
DCRs.[26]
While DCRs operate in many cities of the 
Netherlands,[32,56] in other countries regional variation 
in service provision presents a barrier to access for 
people who inject drugs. For example, only two of 
Spain’s 19 autonomous communities (Catalonia 
and the Basque Country) have DCRs,[23] leaving 
people who inject drugs elsewhere in the country 
(including in Madrid) without such services. Only 
eight of Switzerland’s 26 cantons have a DCR, with 
fewer available in the French- and Italian-speaking 
regions.[26] Similarly, only six of Germany’s 16 states 
offer	DCRs.[14,90] In Bavaria, the state government 
has consistently rejected calls from civil society to 
introduce DCRs, despite a high number of drug-
related deaths in its major cities, such as Munich, 
Augsburg and Nuremberg.[15]
By law, in Luxembourg and some regions of 
Germany, DCRs exclude people on OST.[14,19] However, 
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since 2016 two German states (Hesse and North-
Rhine Westphalia) have amended state laws to allow 
access to people on OST.[14] Migrants are also often 
unable to access services, particularly undocumented 
migrants, for example in Dutch DCRs.[80] In several 
countries, access is also limited to people over the 
age of 18.[19]
A 2016 qualitative study of the experience of people 
who use drugs in Danish DCRs found that the 
facilities provide the population with a safe place in 
which they are protected from police and others in 
the community. The non-judgmental interaction with 
staff	and	peers	was	reported	to	have	helped	forge	
a sense of social acceptance and trust that made 
them more likely to be comfortable when referred to 
other	health	services.	This	was	identified	as	the	most	
important feature of DCRs for people who inject 
drugs, and paves the way for overdose prevention 
and greater access to general healthcare.[91]
World Health Organization guidelines recommend 
that all people likely to witness an overdose, not 
only medical professionals but also people who 
inject drugs, their family and their peers, should 
have access to naloxone, an opioid antagonist that 
can	reverse	the	effects	of	overdose.[92] Evidence 
from Norway suggests that take-home naloxone 
distribution	programmes	are	effective	in	ensuring	
naloxone reaches these populations and ensuring 
that naloxone is present at a target proportion of 
witnessed overdoses.[93] A new, more concentrated 
nasal spray form of naloxone was approved by the 
European Commission in November 2017.[37] These 
nasal forms have the advantage of reducing injuries 
and may be perceived as being easier to use.[94]
Naloxone peer-distribution programmes currently 
operate in four countries in Western Europe 
(Denmark, Italy, Norway and the UK)ax with take-
home doses available in a further four (Germany, 
France, Ireland and Spain). Plans are in development 
for take-home naloxone in three more countries 
(Austria, Cyprus and Luxembourg).[9,19,46] Peer-
distribution programmes for naloxone have existed 
in Italy since 1991, and people who inject drugs are 
heavily involved through both training and policy-
making.[18,96] The national health system in Italy 
is able to access large amounts of relatively low-
cost naloxone by buying in bulk for distribution to 
healthcare facilities, pharmacies and harm reduction 
services.[96] In Norway and Ireland, take-home 
naloxone pilots have recently been extended,[22,34,94,97] 
while in Catalonia, Spain over 7,000 people (including 
people who use or have used drugs, prisoners, 
families and professionals) have been trained in 
ax In the United Kingdom, this refers to a programme in Glasgow.[95] In Norway, this refers to a multi-site pilot programme.[93]
naloxone delivery and more than 9,500 doses have 
been distributed.[23] An increase in drug-related 
deaths has led to the implementation of small-
scale naloxone distribution in some German states, 
where nasal sprays have been approved and are 
reimbursable by health insurance since September 
2018.[14,15] In France, nasal spray, approved in 2017 
and initially only given out by emergency services 
and hospitals during a trial phase, is now also being 
distributed in all harm reduction services, with those 
who have undergone OST prioritised due to the 
higher risk of overdose.[13] In Belgium, a recent pilot 
of naloxone peer-distribution was closed down due 
to legal issues, with naloxone only permitted for use 
by medically trained personnel.[4]
While take-home naloxone is available in the United 
Kingdom, research from Release found that 9% of 
local authorities in England were not supplying it in 
2017, and only 12 naloxone kits were distributed for 
every 100 people who use opioids in 2016/17.[31,98] 
Barriers to access in parts of the country include 
requirements that people who use opioids have 
a prearranged appointment, are assessed by a 
naloxone provider or are referred into a service 
providing naloxone.[31,98] Additionally, people under 
the age of 18 are given access to naloxone on a 
more limited basis than adults.[31,99] Despite this, a 
successful peer-distribution network for naloxone 
exists in north-eastern Glasgow, and more than 
40,000 naloxone kits have been distributed in 
Scotland, Northern Ireland and Wales.[100] In Wales 
alone, naloxone is reported to have been used in 
1,654 overdoses from 2009-2017, with all but 23 
(98.6%) incidents ending without fatality.[101]
The emergence in Europe of fentanyl, a highly potent 
synthetic opioid, should instil greater urgency in 
preventing drug-related deaths. While Europe is not 
yet experiencing the level of fentanyl use seen in 
North America, its rise as a public health concern 
and its high risk of overdose adds weight to already 
strong arguments for increasing the availability of 
naloxone and DCRs.[37] From 2016 to 2017, fentanyl- 
and fentanyl analogue-related deaths increased by 
80% in England and Wales, though the total number 
of deaths remained relatively small (106).[38] New, 
non-injectable formulations of naloxone (such as 
nasal spray) may facilitate its use in a wider range 
of settings, for example by bystanders not used 
to injecting.[37] In order to address the current rise 
in overdose deaths, a combination prevention 
approach including naloxone, DCRs, OST and drug-
checking services should be encouraged across 
Western Europe.[96]
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Viral hepatitis
The prevalence of hepatitis C antibodies varies 
widely across Western Europe, with reported 
prevalence among people who inject drugs ranging 
from 22% in Belgium to 96.8% in Sweden (as shown 
in Table 2.3.1). Data from the European Union and 
Norway indicates that prevalence is higher among 
older people who inject drugs, demonstrating 
the accumulation of risk over years of potential 
exposure.[37] Overall, the availability and quality of 
national-level data on viral hepatitis among people 
who inject drugs is poor.
With the advent of new direct-acting antivirals, 
capable of curing 95% of cases, prevalence of 
hepatitis C is projected to fall over the coming 
years.[102] However, there is some evidence that 
prevalence of hepatitis C has grown since 2012 in 
the United Kingdom, where 92% of new infections 
occur among people who inject drugs; and[28,30] there 
was an outbreak of hepatitis C among people who 
inject drugs in Northern Ireland in 2016.[28] While 
prevalence of viral hepatitis is expected to decrease 
in the region in future, morbidity and mortality 
is projected to rise,[103] highlighting the need for 
ongoing interventions to address the viral hepatitis 
epidemic.
Though viral hepatitis screening is available to people 
who inject drugs for free or at a nominal cost in most 
of the region, several countries report low uptake of 
testing. For example, in Italy only 27% of people who 
inject drugs have ever been tested for hepatitis C[18] 
and approximately half of people living with hepatitis 
C in the UK are unaware of their condition.[28] From 
2012-2016, the number of tests undertaken rose 
by 23.7% in the UK, in part thanks to policy changes 
such as the adoption of routine opt-out testing of 
people who inject drugs in Wales.[28,30] In Switzerland, 
accessing other harm reduction services, such as NSP 
and OST, is linked to a greater likelihood of being 
tested for hepatitis C: levels of testing are lowest 
among people who inject drugs who do not access 
any other services.[26] 
Previously, the high cost of direct-acting antivirals 
has led to limitations being placed on eligibility 
for treatment under national and private health 
insurance schemes; for example, caps on the 
number of patients or prioritisation of those with 
advanced liver damage. These costs have fallen 
over the last two years, and as of 2018 only four 
countries in the region enact these restrictions on 
access to treatment (Austria, Belgium, Greece and 
Switzerland).[56,103] A recent study by the European 
Monitoring Centre for Drugs and Drug Addiction 
found	only	two	Western	European	countries	officially	
continue to restrict access to hepatitis C treatment 
for people currently using drugs (Cyprus and 
Malta).[104] In Denmark (from November 2018),[105] 
France, Germany, Iceland, Ireland, Italy, Luxembourg, 
the Netherlands, Portugal and Spain, the treatment 
is	officially	available	to	all	people	who	inject	drugs	
living with hepatitis C, regardless of the state of the 
disease.[13,18,23,40,41,103] In Austria and the Netherlands, 
guidelines state that people who inject drugs and 
people on OST should be actively sought out to 
receive treatment.[32,46] In Iceland, the Treatment as 
Prevention	programme	focused	efforts	on	treating	
people who inject drugs with free direct-acting 
antivirals in order ultimately to achieve hepatitis C 
elimination, and saw a 65% reduction in hepatitis C 
prevalence among people who inject drugs accessing 
addiction treatment from 2015-2017.[106]
Despite advances in accessibility, cost remains a 
significant	barrier	to	hepatitis	C	treatment	for	people	
who inject drugs, particularly for those without health 
insurance in insurance-based health systems (such 
as in Germany, Luxembourg and Switzerland).[15,19,39] 
In	September	2018,	the	European	Patent	Office	
dismissed a challenge to Gilead Science’s patent 
on sofosbuvir, a key component of hepatitis C 
treatment. The ruling allows Gilead Science to 
continue charging extremely high costs for patented 
direct-acting antiviral treatments as the production 
of generic alternatives in Europe remains a violation 
of the patent.[107] Stigma and discrimination, related 
to a lack of knowledge and awareness among both 
health professionals and people who inject drugs, 
has also been cited as a barrier to treatment across 
the region.[18,42,56,108] People currently using drugs also 
face exclusion from hepatitis C treatment by health 
professionals, even where this is explicitly against 
national guidelines (for example in Germany and 
Portugal).[14,42] The result is that many people living 
with hepatitis C go without treatment, even though it 
is available to them. For example in the UK, no health 
authority outside London regularly meets its quota of 
people treated with direct-acting antivirals.[30]
Modelling studies for three settings in the United 
Kingdom underline the importance of direct-acting 
antiviral treatment in combination with harm 
reduction interventions in preventing hepatitis C 
among people who inject drugs. One suggests that 
without OST, new infections would rise by 483% by 
2030.[109] Scaling up current NSP and OST services 
could achieve a 90% reduction in incidence.[109] This 
must be combined with awareness-raising campaigns 
and proactive testing to reduce stigma and ensure 
everyone who requires treatment receives it, as 
recommended by people living with hepatitis C in 
a 2017 survey.[108] Direct-acting antivirals present 
an opportunity to eliminate hepatitis C in Western 
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Europe. However, this can only be achieved by 
ensuring that all people at risk of hepatitis C 
have access to preventative services, testing and 
treatment.
Tuberculosis (TB)
Incidence of TB in Western Europe is generally low, 
ranging from 2.4 cases per 100,000 in Iceland and 4.5 
per 100,000 in Greece, to 18 per 100,000 in Turkey 
and 23 per 100,000 in Portugal.[110] These cases 
are predominantly concentrated among certain 
groups, such as recent migrants, prisoners and 
people who inject drugs.[110] The level of integration 
of TB into harm reduction programmes also varies 
across the region, with good integration in Belgium, 
the Netherlands, Spain and Switzerland, and little 
integration in Italy and Portugal.[4,18,21,23,56,103] Good 
practice notes that outreach to marginalised 
populations may help to mediate between these 
groups and formal health services.[42] Similar to 
other infectious diseases associated with injecting 
drug use, stigma and a lack of awareness also play 
a	significant	role	in	compounding	the	TB	epidemic	
among people who inject drugs.[18,42,56]
The DETECT-TB (Early Detection and Integrated 
Management of Tuberculosis in Europe) project 
launched in 2016 aims to contribute to the decline 
and eventual elimination of TB in the European 
Union. Its objectives state the importance of the early 
diagnosis of vulnerable populations, including people 
who inject drugs and prisoners, and the sharing of 
best practices between programme countries. The 
project works through a network of partners in six 
states, four of which are in Western Europe (Italy, the 
Netherlands, Sweden and the United Kingdom).[111]
HIV and antiretroviral therapy (ART)
Across the EU, 5% of new HIV infections in 2016 
were due to injecting drug use, a proportion that has 
remained low and stable for a decade. [37] Overall, 
new HIV cases among people who inject drugs in 
the region have declined 51% from 2007-2016.[37] 
However, in Cyprus, Denmark, Luxembourg, Malta, 
Spain and Sweden there were increases in the 
number of new HIV cases among people who inject 
drugs from 2015-2016.[9,11,20,24,33,49] Challenges remain 
in ensuring that people who inject drugs receive 
timely and adequate treatment: in 2016, half of 
new HIV infections among people who inject drugs 
were diagnosed late (when the immune system 
had already sustained damage) and 13% of AIDS 
diagnoses were from HIV infections due to injecting 
drug use.[37]	Early	diagnosis	and	treatment	offers	
people living with HIV a normal life expectancy; 
health systems must ensure that people who inject 
drugs	are	able	to	benefit	from	these	services	on	the	
same basis as the general population.
Organisations in Spain, Switzerland and the United 
Kingdom attribute the region’s success in maintaining 
low HIV prevalence among people who inject 
drugs to the implementation of harm reduction 
interventions, notably NSPs and OST, early in the 
HIV epidemic.[23,30,31,112] A 2017 Swiss study found 
that harm reduction programmes in the country 
had prevented 15,903 new HIV infections up to the 
end of 2015, and warned that an abrupt closure of 
services	would	result	in	a	significant	outbreak	of	
HIV.[112] Similarly, civil society organisations in the UK 
have noted that the continued low prevalence of HIV 
relies on access to harm reduction services, and that 
further investment in these services is required.[30] 
In recent years, outbreaks of HIV in Greece, Ireland, 
Luxembourg and the UK have demonstrated the 
importance of continued provision of harm reduction 
services.[52,113,114]
While prevalence of HIV among people who inject 
drugs in the United Kingdom as a whole is estimated 
at 0.9%, the prevalence in Glasgow is 20-25%, with 
more than 100 of Glasgow’s 400-500 people who 
inject opioids thought to be living with HIV.[52] The 
outbreak began rapidly in 2015 and has been 
durable, with similar numbers of new infections each 
year from 2015 to 2017.[52,115] In 2016, provision of 
low-dead space syringes (associated with a lower risk 
of blood-borne virus transmission) was rolled out 
in Scotland, and a new NSP was opened at Glasgow 
Central railway station.[28,52] The new NSP became 
Scotland’s busiest, serving 2,000 individuals and 
providing more than 40,000 sterile injecting kits over 
the course of its operation.[52] However, it was closed 
just 14 months after opening, with the building’s 
owner citing the fact that used injecting equipment 
was being left nearby in public areas as the reason.[52] 
Civil society organisations cite the closure of the 
Glasgow Central NSP as a major factor in the failure 
to control the HIV epidemic in the city.[30] 
HIV testing and treatment is available to people 
who inject drugs on the same basis as the general 
population in much of the region, covered either by 
health insurance or public health services.[4,23,30,42] 
Coverage of ART is generally very high, with 80-90% 
of people living with HIV receiving treatment in most 
countries.[116] Pre-exposure prophylaxis is increasingly 
available in Western Europe; for example, Portugal 
launched a pilot programme for men who have sex 
with men in 2017.[42] 
People who inject drugs continue to face formal 
and informal barriers to HIV treatment in Western 
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Europe. A decreasing trend in people who inject 
drugs accessing HIV testing has been noted in 
Italy, while in the UK, people who inject drugs are 
less likely to access treatment after HIV diagnosis 
than the general population.[18,30] Homelessness, 
poverty and social isolation, as well as stigma and 
discrimination (often based on the criminalisation 
of drug use), are also reported as key barriers to 
accessing HIV treatment for people who inject drugs 
in Italy and Portugal.[18,30,42] The unequal geographic 
distribution of service providers within countries 
also forms a barrier to people who inject drugs 
living in underserved regions. For example, in some 
areas of Portugal a lack of integration between 
harm reduction services and hospitals means that 
people who inject drugs are less likely to access 
treatment.[42] In addition to these informal barriers, 
some people who inject drugs face higher formal 
barriers to treatment. For example, the UK recently 
introduced higher charges for undocumented 
migrants accessing health services, and civil society 
organisations also report that migrants in Germany 
may	also	face	difficulties	in	accessing	services.[15,30] 
Under the new Italian national AIDS plan, non-
governmental organisations are increasingly 
able	to	offer	community-based	HIV	services,	and	
have seen good uptake of their services. HIV self-
testing kits also became available in 18,000 Italian 
pharmacies.[18] Community-based and outreach 
services are essential to ensuring that people who 
inject drugs can access HIV treatment. Furthermore, 
it is necessary for these community-led services 
to have resilient referral mechanisms, in order for 
people	testing	positive	for	HIV	to	be	effectively	linked	
with care.
Harm reduction in prisons
Drug-related	offences	continue	to	be	a	major	
contributor to incarceration in Western Europe. In 
all but four countries in the region (Luxembourg, 
Malta, Portugal and Spain), simple possession of 
even a small amount of illegal drugs can lead to a 
prison sentence.[117] The proportion of prisoners 
incarcerated	for	drug-related	offences	varies	across	
the region, from 8% in Turkey to 33% in Italy.[27] Civil 
society organisations across the region continue 
to campaign for decriminalisation of personal drug 
use and possession, for example during the 2018 
elections in Italy.[4,18] In the United Kingdom, Release 
launched a smartphone app in 2017 which serves as 
a guide to self-representation for drug possession 
offences,	assisting	people	who	use	drugs	to	navigate	
the criminal justice system and avoid punitive 
penalties.[31,118]
Portugal decriminalised personal possession and 
use	of	all	drugs	in	2001,	with	positive	effects	on	the	
health and wellbeing of people who use drugs in 
the country.[119] However, a 2018 community-led 
report by the International Network of People Who 
Use Drugs (INPUD) raised several concerns about 
the use of Portugal as a model for advocacy.[119] The 
report expressed concerns over the continuation 
of stigma, discrimination and abstinence-oriented 
interactions people who use drugs have with health 
professionals, as well as about the absence of full 
legalisation of drugs, which means that people who 
use drugs still encounter the dangers of obtaining 
substances on the illicit market.[119]
Across Western Europe, drug use in prisons is 
prevalent. For example, according to the most recent 
available data (from 2010-2014), 32.9% of prisoners 
in Belgium, 34% in Portugal and 42% in Norway 
report having used illicit drugs at some point while 
incarcerated.[1] Cannabis is the most used drug 
in Western European prisons; however, 13.3% of 
Belgian prisoners, 9.4% of Portuguese prisoners 
and 31.4% of Spanish prisoners report having 
used heroin at some point while incarcerated.[1] 
In addition, prevalence of blood-borne infections 
such as viral hepatitis and HIV are known to be 
significantly	higher	among	people	with	a	history	
of incarceration.[37,120] This information clearly 
demonstrates the need for harm reduction services 
in prisons.
A notable development since 2016 has been the 
rapid emergence of new psychoactive substance 
(NPS) use in prisons. In particular, the use of 
synthetic cannabinoids in prisons is an issue of 
concern in Germany, Sweden and the United 
Kingdom.[31,121] At least 58 deaths in British prisons 
have been attributed in part to NPS use, for example 
through psychotic episodes, suicide and/or drug 
poisoning.[122] Non-fatal overdoses related to NPS 
have also been reported in Germany and Italy.[121] 
Responses to these issues in Western European 
prisons remain focused on supply reduction, drug 
testing and smoking bans.[121] 
Access to harm reduction services in prisons 
varies	significantly	between	and	within	countries	
in the region. For example, services appear to be 
widespread in Spain, with service coverage similar in 
prison to in the community.[23] Conversely, no harm 
reduction services are available in Turkish prisons.[84] 
Ensuring that all prisoners have access to harm 
reduction services is essential in order for states to 
be compliant with their right to health obligations, 
as prescribed under Article 12 of the International 
Covenant on Economic, Social and Cultural Rights.
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As reported in the Global State of Harm Reduction 
2016, NSP provision in prisons is inadequate, with 
only four countries in Western Europe providing 
such programmes. These are: Spain (all prisons), 
Switzerland (15 out of 117 prisons), Luxembourg (one 
of two prisons) and Germany (one female prison 
in Berlin).[14,19,26,123,123] In Italy, a pilot programme 
was launched by the Ministry of Health in 2017 to 
distribute safe injecting equipment to prisoners on 
release from four prisons.[18] 
The continuity of access to OST between the broader 
community and prisons is particularly important 
in preventing overdose deaths in people who use 
opioids, as well as helping to reduce high-risk 
injecting behaviour.[124] In all countries in the region 
except Turkey, Iceland and the Western European 
microstates,ay OST is available to prisoners. However, 
OST is very often available on more limited terms 
than in the broader community. For example, in 
Flanders, Belgium OST is only available to those 
who began the therapy outside prison.[4] In Malta 
and Portugal, prisoners in certain prisons must be 
transferred to external medical facilities before they 
can commence OST, raising a barrier to access as 
they rely on prison authorities for travel.[20,42] OST 
provision in prisons can also vary within countries. 
For example, 30% of Swiss prisons provide no OST at 
all.[26] Similarly, in Ireland, only 11 out of 14 prisons 
provide OST.[34] In the UK, regulations state that 
OST should be available on the same basis as in 
the broader community.[126] However, in practice its 
availability can depend on the authorities at each 
prison, and data is generally unavailable on the 
extent to which it is accessible.[31]
A 2016 ruling by the European Court of Human 
Rights determined that denying OST treatment to 
a prisoner while in detention violates Article 3 of 
the European Convention on Human Rights, which 
prohibits inhuman or degrading treatment.[127] Every 
country in Western Europe is currently subject to the 
convention, and therefore is obliged to provide OST 
in prisons.
The period after release from prison is a particularly 
high-risk time for opioid overdose, due to lower 
tolerance after a period of abstinence or low 
dosage, making the availability of naloxone vital.[37] 
Four countries (Denmark, France, Norway and the 
UK) provide naloxone to prisoners on release.[128] 
While the practice is not universal in the UK (for 
example, only half of Welsh prisons distribute 
take-home naloxone), 1,355 naloxone kits were 
ay Andorra, Liechtenstein, Monaco and San Marino. In total, the four countries are estimated to hold fewer than 100 prisoners.[125]
az Data for England and Northern Ireland is unavailable.
ba Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Switzerland and the 
United Kingdom.
distributed by Scottish and Welsh prisons alone 
in 2016-2017.az[101,129] Naloxone is also available in 
some prisons in the Netherlands, Switzerland and 
an estimated 82% of prisons in Italy, but can only 
be used by medical personnel and is not given to 
prisoners on release.[21,32,57] Pilot projects delivering 
naloxone kits and training directly to prisoners while 
incarcerated have operated since 2016 in Italy and 
Norway, with evidence from Norway suggesting that 
naloxone	training	and	provision	has	significantly	
increased prisoners’ awareness of overdose 
prevention measures.[18,90,130] Studies in the UK clearly 
demonstrate that increasing provision of take-home 
naloxone on release from prison would prevent 
overdose deaths among prisoners, their peers and 
the wider community, and therefore it should be 
a priority for prison health authorities across the 
region.[131]
With HCV prevalence considerably higher among 
prisoners than the general population, the EU must 
urgently scale up testing and treatment among 
prisoners if it hopes to eliminate the virus. [37,132] HIV 
prevalence is also alarmingly high among prisoners 
in Western Europe: prevalence is 9.5 times higher 
among prisoners than the general population in 
Ireland and 13.5 times higher in Spain.[133] A recent 
overview of hepatitis C and harm reduction services 
in prisons found that all Western European countries 
studied	offered	hepatitis	C	treatment	in	prisons.	
However, it also found a distinct lack of data on the 
extent of treatment coverage in prisons in these 
countries.[123] HIV testing and treatment are broadly 
available in prisons across the region, with Italy, 
Portugal and the UK all routinely testing incoming 
prisoners for HIV.[18,30,42] However, implementation of 
these services is sometimes inadequate or uneven 
within countries. This gap between policy and 
implementation risks leaving behind a key population 
in viral hepatitis and HIV control, in clear violation of 
individuals’ fundamental human rights.
Policy developments for 
harm reduction
At least 17 of the 25 countries in Western 
Europe have adopted national drug or addiction 
strategies that express support for harm 
reduction.ba	In	at	least	five	of	these	countries	
(Cyprus, Germany, the Netherlands, Portugal and 
Switzerland), harm reduction forms a pillar of 
national drug policy separate from treatment and 
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rehabilitation.[9,32,39,40,90,134] In Turkey, the National Anti-
Drug Strategy Paper contains no reference to harm 
reduction.[84] National plans for the response to HIV 
and viral hepatitis also frequently include references 
to the role of harm reduction. For example, the new 
HIV policy documents introduced since 2016 in Italy, 
Luxembourg and Portugal include harm reduction as 
a key element of the response.[18,19,42]
Several countries and entities in the region have 
introduced new drug policy documents since 2016. 
An independent evaluation of the European Union 
Action Plan on Drugs 2013-2016 found that harm 
reduction was lagging behind other pillars of the 
EU Drug Strategy 2013-2020, noting that there was 
more	significant	opposition	to	this	element	of	the	
strategy from certain member states.[135] Following 
this evaluation, the EU adopted the Action Plan on 
Drugs 2017-2020. The new plan includes emphasis 
on scaling up harm reduction, with reference to OST, 
NSPs, naloxone peer-distribution, DCRs and drug-
checking.[44] 
In Italy, harm reduction is not mentioned in the 
National Action Plan on Drugs, which has not been 
updated since 2010.[18] However, harm reduction 
interventions	were	included	in	2017	for	the	first	time	
in the Livelli Essenziali di Assistenza, the package of 
basic health services that must be guaranteed across 
the country; as of 2018, civil society organisations 
are in negotiations for the implementation of 
this policy.[18] In 2018, the health ministry of the 
Piedmont region of northern Italy created new harm 
reduction guidelines in collaboration with civil society 
organisations. The new document includes drug-
checking as a basic health service, and is considered 
by civil society organisations to be Italy’s most 
advanced policy plan for harm reduction.[18]
In 2017, the United Kingdom adopted a new National 
Drugs	Strategy	for	the	first	time	since	2010,[30] which 
mentions OST and NSPs, but only uses the term 
“harm reduction” in reference to tobacco.[30,31,136] 
New clinical guidelines brought in alongside the 
new strategy are comparatively more supportive of 
evidence-led policy, and give a greater role to harm 
reduction.[30,126] 
On the international stage, Western European 
governments have been largely supportive of 
harm reduction agendas. The Irish delegation at 
the Commission on Narcotic Drugs in 2018 made a 
statement supportive of harm reduction,[137] and a 
joint EU statement (also supported by Norway and 
Liechtenstein) in the same forum later in 2018 was 
strongly supportive of shifting to a human rights and 
health-centred response to drugs.[138] Civil society 
organisations in Germany, Italy, the Netherlands 
and Spain have also highlighted that their respective 
governments have been vocally supportive of harm 
reduction in international fora.[15,18,21,23] 
Civil society and advocacy 
developments for harm 
reduction
Civil society organisations continue to form an 
important part of the harm reduction movement in 
Western Europe, as service providers, campaigning 
groups and advisory bodies to governmental 
agencies. In several countries, civil society 
cooperation in harm reduction is led by national 
harm reduction networks, such as the English 
Harm Reduction Group in the United Kingdom[31] 
and Suchtverband Leutzebuerg in Luxembourg.[19] 
Akzept is a national umbrella organisation for harm 
reduction in Germany, and has published alternative 
drug	and	addiction	reports	in	response	to	official	
government documents.[14,15] In Italy, the Rete 
Italiana Riduzione del Danno (ITARRD) is an informal 
organisation of approximately 200 individuals, 
including professionals, activists, researchers, people 
who use drugs and harm reduction groups.[18] 
Though no national harm reduction network exists 
in Switzerland, regional networks exist in most 
cantons.[26,39]
A longstanding European regional network of civil 
society	organisations	working	in	the	field	of	drugs	
and harm reduction received a grant in 2018 from 
the European Commission and began to operate 
under the name Correlation – European Harm 
Reduction Network.[8,21] Correlation works to improve 
international collaboration on harm reduction 
through a network of focal points in each country.[21] 
In November 2018, the European Harm Reduction 
conference was held in Bucharest, Romania.[21]
Networks of people who use drugs exist at a national 
level in several countries, including Germany and 
Portugal, and at a local or regional level in Spain 
and the UK.[14,15,23,31,42] These groups often work in 
association with the European Network of People 
who Use Drugs (EuroNPUD), which was launched 
in 2011 to coordinate advocacy strategies in the 
European Union and its neighbourhood.[42,139] 
Civil society organisations in Western Europe have 
organised advocacy campaigns on a national and 
international basis. Internationally coordinated 
campaigns, such as Support. Don’t Punish, 
International Overdose Awareness Day and World 
AIDS Day have been used for harm reduction 
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advocacy purposes in several countries, including 
Portugal and Spain.[23,42] Campaigns aiming to directly 
influence	national	policy	since	2016	have	included	
Belgian movements in favour of decriminalisation 
(such as 1921 in Wallonia and Smart on Drugs in 
Flanders);[4] campaigns by Release in the UK in favour 
of drug consumption rooms and improving naloxone 
provision;[31] ITARRD’s Harm Reduction Works, Let it 
Work! (La Riduzione di Danno Funziona, Facciamola 
Funzionare!) campaign pressing for increased 
political	and	financial	support	in	Italy;[18] and civil 
society campaigns for drug consumption rooms and 
increased funding in Portugal.[42] Additionally, there 
have been several civil society-led events, such as 
a conference dealing with ATS use (among other 
topics) in Berlin called NIGHTS: Stadt Nach Acht 
(NIGHTS: City After Eight),[14] and an annual training 
event on harm reduction and recreational drug use 
in Switzerland.[26]
In Germany, Portugal, Spain and Switzerland, civil 
society organisations have been regularly and 
systematically involved in policy consultations at 
both regional and national levels; for example, the 
Portuguese National Harm Reduction Network 
(R3) has an ongoing informal relationship with the 
government drug and addiction agency, and met with 
the Secretary of State for Health in 2017.[42] In 2018, 
the	Swiss	Federal	Office	of	Public	Health	launched	
an Expert Group on Harm Reduction, bringing with 
it greater involvement of civil society in the policy 
development process;[26] however, some actors have 
expressed concern at a lack of representation of 
people who use drugs in government consultations 
with civil society.[57] Though civil society organisations 
in Italy and the United Kingdom have been regularly 
involved in national policy consultations on harm 
reduction and drug policy in the past, they report 
that this cooperation has reduced in recent years. 
In the UK, civil society was not consulted in the 
development of the 2017 National Drugs Strategy, 
and in Italy non-governmental service providers now 
only participate in policy processes sporadically.[18,31] 
Significant	civil	society	advocacy	successes	have	
occurred in Western Europe since 2016. In Italy, 
civil society organisations lobbied the national 
government to include harm reduction in the 
National	HIV	Plan	2017-2019,	resulting	in	specific	
reference to harm reduction interventions and 
indicators	in	the	final	plan.[18,140] In Portugal in 2018, 
the Agência Piaget para o Desenvolvimento (APDES) 
succeeded in securing a non-binding resolution in the 
Portuguese parliament for the full funding of harm 
reduction programmes.[42] A coalition of civil society 
organisations in the United Kingdom successfully 
campaigned to have drug-related deaths included 
as an indicator of public health outcomes for local 
authorities, where previously the main indicator of 
drug policy success was completed treatments.[30,31] 
These examples demonstrate the concrete progress 
that has been made in the region through the 
dedication of civil society actors to the cause of harm 
reduction, and can serve as an example to actors 
elsewhere in the region and across the world of the 
impact on national policy that is possible through 
targeted campaigns.
Funding developments for 
harm reduction
A 2017 report by Harm Reduction International 
found that certain parts of the European Union are 
experiencing a funding crisis for harm reduction.[45] 
This crisis is observed to be more serious outside 
Western Europe; however, in several countries of the 
region, particularly Greece, concerns were raised. 
Six Western European countries (Belgium, France, 
Germany, Ireland, the Netherlands and the United 
Kingdom) were assessed to have a high levels of 
government investment in harm reduction, providing 
over 90% of funding (see Table 2.3.2).[45]
Trends in harm reduction investment since 2016 
vary across the region. Belgium is the only country 
in which funding for harm reduction is reported 
to have increased over recent years, though civil 
society organisations there still note that gaps 
remain in the public health response to illicit drug 
use.[45] In the Netherlands, civil society organisations 
report that the level of investment has remained 
stable since 2016 and the quality and availability of 
services	is	sufficient.[21,45] Elsewhere in the region, 
the	long-term	effects	of	European	austerity	since	the	
economic	and	financial	crisis	continue	to	be	felt.	In	
Germany, Greece, Ireland and the UK, investment 
in harm reduction has fallen over recent years due 
to broader budget cuts.[45] In the United Kingdom, 
funding for harm reduction and prevention fell by 
8%	from	the	2015/2016	financial	year	to	2016/2017,	
a disproportionately greater cut than in other areas 
of public health.[30,31] In Ireland, harm reduction 
interventions now operate with 30% less investment 
that in 2009.[45] Civil society organisations have 
expressed concerns that these reductions in funding 
will lead to rising HIV and hepatitis C incidence 
among people who inject drugs, among other drug-
related harms.[45]
Local, regional and national government bodies 
provide the majority of investment for harm 
reduction in Western Europe. For example, all 
funding for NSPs and OST in Belgium, Germany, 
Luxembourg, Sweden; 95% of harm reduction 
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funding in Italy; and 80% of funding in Portugal 
and Greece come from either national or local 
governments.[18,19,42,45] In Belgium and Germany, 
state funding is sourced from a mixture of national 
and regional or city-level governments, while in 
Switzerland all harm reduction funding comes 
from the cantonal and city governments.[26,39,45] 
Significantly,	implementation	of	harm	reduction	
services, though state-funded, is often left to non-
governmental organisations, as in Greece, Norway 
and Switzerland.[26,45] Where funding cuts result 
in threats of service closure, it is essential that 
emergency funding (such as from the European 
Commission) is made available to sustain these 
programmes. However, emergency funding must be 
available without cumbersome application processes 
or the requirement to match funding.[45] A potential 
model for this is the Norway NGO Fund, where 
local civil society is involved in the management of 
grants.[45]
Harm Reduction International’s research also 
highlighted poor transparency on harm reduction 
investment across the region (see Table 2.3.2). 
No country in Western Europe received a positive 
rating for the transparency of their harm reduction 
investment, and Greece and Italy were given the 
lowest rating. Levels of budgetary disaggregation 
vary across Western Europe, and rarely allow 
identification	of	harm	reduction	investment	in	
wider budgets. Where harm reduction services 
are managed locally, a lack of national-level data 
collection also contributes to a lack of transparency, 
bb	 This	table	uses	a	traffic	light	system	designed	to	provide	an	at-a-glance	indication	of	the	health	of	harm	reduction	funding,	and	first	appeared	in	a	2017	report	
from Harm Reduction International entitled Harm Reduction Investment in the European Union.[45]
for example in Germany, Switzerland and the United 
Kingdom.[45,57] Small improvements have been noted; 
for example, eight of the 20 regions of Italy currently 
disaggregate harm reduction investment from other 
spending.[18,45] 
In Western Europe, there is limited data on the 
proportion of total state drug spending that is 
invested in harm reduction. From what little 
information is available, it is clear that harm 
reduction investment is dwarfed by spending on 
drug law enforcement. In Italy, an estimated €1.1 
billion is spent on drug law enforcement annually, 
including €953 million on prisons, while the United 
Kingdom spent an estimated £1.6 billion on drug law 
enforcement in 2014/2015.[18,141] 
The sustainability of harm reduction investment 
in the EU has been recorded by Harm Reduction 
International as ranging from fairly certain to 
extremely insecure.[45] The continuing impact of 
austerity policies in certain countries threatens the 
effectiveness	of	harm	reduction	services.	This	has	
had the greatest impact in Greece, where cuts to 
harm reduction services put the country at risk of 
public health emergencies.[45] In the UK, civil society 
organisations anticipate further reductions in harm 
reduction investment over the coming years, driven 
by increasingly limited resources available to local 
authorities for overall spending and the fact that they 
are not obliged to provide any drug services.[30,45] The 
European Monitoring Centre for Drugs and Drug 
Addiction has highlighted the role of austerity and 
cuts to the budgets of drug-related health initiatives 
in the rise of public health emergencies.[142]
Table 2.3.2: Harm reduction funding in selected Western European countries at a glance[45]bb
Country Harm reduction coverage
Transparency of 
spending data
Government investment 
in harm reduction
Civil society view on the 
sustainability of funding
Greece
Italy
Sweden
Portugal
Finland
United Kingdom
Ireland
Belgium
France
Germany
The Netherlands
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Table 2.4.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in the Caribbean 
Country/territory
with reported
injecting
drug usea
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs(%)
Harm reduction responsei
NSPb OSTc
Peer-
distribution 
of naloxone
DCRsd
The Bahamas 0[2] nk nk nk x x x x
Dominican Republic <1,359e[3] 3.2f[3] 22.8g[4] nk 2[5,6] xh x x
Guyana nk nk nk nk x x x x
Haiti nk nk nk nk x x x x
Jamaica nk nk nk nk x x x x
Puerto Rico 28,000[7] 11.3i[8] 78.4 - 89j[10,11] nk 6[9] (M,B)[9] x x
Suriname nkk[12] nk nk nk x x x x
 nk – not known 
a Countries with reported injecting drug use according to Larney et al. in 2017. The study found no reports of injecting drug use in Antigua and Barbuda, Barbados, Cuba, Dominica, 
Grenada, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines or Trinidad and Tobago.[1]
b Alloperationalneedleandsyringeexchangeprogramme(NSP)sites,includingfixedsites,vendingmachinesandmobileNSPsoperatingfromavehicleorthroughoutreachworkers. 
(P) = pharmacy availability.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
d Drug consumption rooms, also known as supervised injecting sites.
e There are an estimated 56,632 people who use illegal drugs in the Dominican Republic, less than 2.4% of whom are reported to be people who inject drugs.
f Estimate from 2012 for people who use drugs.
g Based on data from 2008.
h ApilotprogrammeofferingOSTwithabuprenorphine-naloxonecombinationoperatedintheDominicanRepublicfrommid-2017tomid-2018;however,thisprojecthasnowclosed.
i Based on subnational data from 2015.
j Basedonsubnationaldatafrom2006-2015.Civilsocietyorganisationsreportthatthereisnoeffectivesystemmonitoringviralhepatitisinfectionamongpeoplewhoinjectdrugsin
Puerto Rico.[9]
k A 2008 government study estimated that 0.3% of Suriname’s estimated 1,000 people who use drugs are people who inject drugs.
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Harm reduction in the Caribbean
Overview
Since 2016, the harm reduction response to illicit 
drug use appears to have remained relatively stable 
intheCaribbean.Giventhedevastatingeffects
of Hurricanes Irma and María in 2017 on several 
islands in the region, this stagnation should not be 
over-emphasised. That harm reduction services, 
particularly in Puerto Rico, continue to be available 
to people who use drugs can be viewed as a success 
and can be attributed to the dedication of civil society 
organisations in the region.
Puerto Rico and the Dominican Republic remain 
the only territories in the region in which injecting 
opioid use is regularly reported. With scarce data 
on injecting drug use elsewhere in the Caribbean, it 
is impossible to make an authoritative judgement 
on its prevalence. However, from the limited data 
available, injection appears to be rare.[13-15] Cocaine 
and its derivatives tend to be the second most widely 
used illicit substances after cannabis, and their use 
is overwhelmingly associated with inhalation rather 
than injection.[13-15] 
As in 2016, needle and syringe programmes (NSPs) 
are only available in the Dominican Republic and 
Puerto Rico, in response to the presence of injecting 
drug use in those territories. These NSPs are 
exclusively provided by civil society organisations 
in both countries, who rely wholly on funding from 
international donors.[5,9] Also as reported in 2016, 
opioid substitution therapy (OST) is only currently 
available in Puerto Rico, where it is provided by both 
state and private actors.[9] In mid-2017 an OST pilot 
wasinitiatedintheDominicanRepublic;however,it
is due to be closed in late 2018.[5,6] Despite reports 
of a rising number of overdoses in Puerto Rico since 
2016, the response to overdose remains limited and 
hindered by legal barriers. No drug consumption 
rooms exist in the region, and naloxone is only 
available on a limited basis in Puerto Rico and only 
in major hospitals in the Dominican Republic.[6,9] 
Legislation to liberalise access to naloxone in Puerto 
Rico is currently being considered by the Puerto 
Rican assembly.[9]
The Caribbean is home to a limited, nascent harm 
reduction response to the use of cocaine and its 
derivatives. The informal use of cannabis as a 
substitution therapy, or to counter certain side-
effectsofcrackcocaineuse,hasbeendocumented
in Jamaica and Saint Lucia.[16,17] Data on the use of 
new psychoactive substances and amphetamine-type 
stimulants is virtually absent, and no harm reduction 
response has been recorded. 
Infectious diseases are largely divorced from drug 
use in policy documents published by Caribbean 
governments, with little or no acknowledgement 
of the intersection between HIV, viral hepatitis, 
tuberculosis and illicit drug use. For example, only six 
of the 17 countries in the region make any reference 
to people who use drugs in their latest national 
HIV policy plans (the Dominican Republic, Jamaica, 
Puerto Rico, Saint Lucia, Suriname, and Trinidad and 
Tobago).[3,12,18-21]
Despite the existence of some harm reduction 
programmes, the response to drug use in 
the Caribbean continues to be dominated by 
rehabilitation and abstinence-centred interventions. 
As reported in the Global State of Harm Reduction 
2016, and is evident from data published over the 
past two years, there are reports of people being 
held in rehabilitation centres against their will.[22,23] 
The problem is particularly grave in the Dominican 
Republic and Puerto Rico.[24,25] In the latter, 85% of 
treatment facilities are privately operated with little 
or no independent or state oversight, while only 
one of every six treatment centres in the Dominican 
Republic is authorised by the state.[23] 
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
Due to the low reported prevalence of injecting 
drug use, NSPs are absent from most countries 
and territories of the Caribbean. For example, the 
Bahamas, Saint Lucia, and Saint Kitts and Nevis 
report no injecting drug use, and therefore no NSPs 
exist.[2,20,26] In only a few countries has injecting drug 
usebeenfoundtohaveasignificantroleinthe
transmission of blood-borne diseases in the region, 
these being Puerto Rico, the Dominican Republic and, 
to a lesser extent, Cuba and Barbados.[27] 
NSPs only operate in Puerto Rico and the Dominican 
Republic. A 2013 study found that 38% of people 
reporting active heroin injecting in the Dominican 
Republic had shared needles.[25] Evidence from both 
countries also suggests that NSPs play a role in 
linkage to healthcare for people who use drugs but 
do not inject.[27] 
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In both the Dominican Republicl and Puerto Ricom, 
NSPs are exclusively provided by civil society and 
private organisations. Two organisations in the 
Dominican Republic  and four in Puerto Rico  deliver 
services distributing sterile injecting equipment, 
condoms and antiseptic liquid.[5,9] Since the Global 
State of Harm Reduction last reported, an outreach-
led NSP was established by COIN as a pilot in 
August 2017 in the Capotillo and La Zurza areas of 
Santo Domingo in the Dominican Republic, with 
plans to expand into other areas with populations 
of people who inject drugs.[28] As of late 2017, 32 
people who inject drugs were regularly accessing 
the programme.[28] Outreach is also central to the 
projects run by Intercambios and El Punto en la 
Montaña in Puerto Rico, who reach out to people 
who inject drugs in housing projects, on the streets, 
in private homes and in abandoned buildings.[9]
COIN in the Dominican Republic and Intercambios 
and El Punto en la Montaña in Puerto Rico all train 
and employ current or former people who inject 
drugs to act as outreach NSP workers.[5,6,28] Evidence 
from elsewhere in the world has found that such 
peer-led outreach programmes have a greater ability 
to reach marginalised groups, as well as providing 
enhanced acceptance, self-esteem, community 
inclusion and empowerment among clients.[29] A 
further means of lowering barriers to accessing NSPs 
is the use of 24-hour syringe dispensing machines: 
thefirstofwhichintheUnitedStateswasestablished
by Iniciativa Comunitaria in Puerto Rico in 2009.[30]
Asafurtherefforttotailorservicestotheneedsof
people who inject drugs, El Punto en la Montaña 
in Puerto Rico collects feedback from clients.[9] 
Since 2007 until the time of reporting, the project 
has enrolled 1,534 individuals, all of whom were 
at the time of enrolment injecting drugs on a daily 
basis.[9] According to data collected from these 
clients, 92% were men.[9] This appears to be in line 
with the population of people who inject drugs on 
the island, 90% of which has been found to be men 
in both rural and urban environments.[10,11] Only half 
of people accessing the service had a high school 
diploma, a third were homeless and 100% were living 
in poverty.[9] Notably, 80% were living with hepatitis 
C and 6% were living with HIV.[9] More than half 
(55%) of participants self-report sharing injection 
paraphernalia, including needles, syringes, cookers, 
water and cotton.[9]
l These are Mesón de Dios and COIN (Centro de Orientación y de Investigación Integral, Centre for Comprehensive Guidance and Research), though the service 
operated by Mesón de Dios is reportedly only intermittent.[6]
m Intercambios Puerto Rico, Iniciativa Comunitaria, Migrant Health Centre Inc. and El Punto en la Montaña.
Opioid substitution therapy (OST)
With illicit opioid use low or non-existent in much 
of the Caribbean, OST is often not a priority in the 
harm reduction response to illicit drug use.[2,14,31] A 
recent systematic review of access to harm reduction 
interventions found that just 8% of people who inject 
drugs in the Caribbean are enrolled in OST.[32] This 
maybeareflectionofthefactthatcocaineisthe
most commonly injected drug in the region, rather 
than opioids.
As reported in the Global State of Harm Reduction 
2016, Puerto Rico remains the only territory or 
country in the Caribbean in which OST is available. 
Data from 2013 to 2014 notes a 3.2% prevalence 
among the adult population of illicit opiate use in 
the last 12 months, with 0.58% prevalence of heroin/
opium use and 0.21% methadone use (from the 
available data it is unclear what accounts for the 
remaining opiate use).[33] In addition, according 
to Intercambios, one quarter of people in Puerto 
Rico have a legal prescription for opioid-based 
medication.[34] The Administration of Mental Health 
and Anti-Addiction Services (Administración de 
Servicios de Salud Mental y contra la Adicción, 
ASSMCA) is the Puerto Rican government agency 
responsible for OST, and operates six clinics, three 
mobile units and two satellite clinics across the island 
providing methadone maintenance therapy.[9,35] 
ASSMCA’s eligibility criteria make accessing their 
services impossible for people under the age of 18 
or people without a formally diagnosed opioid use 
“disorder”.[35]
These government-led OST services are 
supplemented in Puerto Rico by private actors. 
Iniciativa Comunitaria and the Migrant Health Centre 
both provide buprenorphine-based OST at clinics on 
the island.[36,37] The Migrant Health Centre’s clinic at 
Mayaguez integrates OST, NSP, HIV and viral hepatitis 
services on the same site.[36] These programmes are 
generally funded either by the national insurance 
scheme, Mi Salud, or the Puerto Rican government’s 
Section 330 programme.[9] 
No recent estimates were found for the prevalence 
of opioid use in the Dominican Republic, with the 
only available data over a decade old. A pilot OST 
programme operated in the Dominican Republic 
from mid-2017 until late 2018, funded by the Spanish 
Agency for International Development Cooperation 
andmanagedbyUNODCwiththesupportofCOIN,
UNAIDS,theNationalCouncilonDrugsandthe
national HIV programme (CONAVIHSIDA).[5,22] The 
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programmeofferedtherapywithabuprenorphine-
naloxone combination to reduce risk behaviours 
related to HIV, hepatitis C and other infectious 
diseases.[5] Over the 12 months of operation, 70 
people who inject drugs were involved in the pilot.[5] 
The pilot was discontinued when the government’s 
temporary approval for the importation of 
buprenorphine-naloxone came to an end,[5] pending 
further approval and investment when results 
from the programme have been presented to the 
government.[6]
Amphetamine-type stimulants (ATS), cocaine 
and its derivatives and new psychoactive 
substances (NPS)
TheCaribbean’spositiononamajortraffickingroute
between South America and North America, and the 
practice of using cocaine as payment in kind, has 
contributed to access to cocaine and its derivatives in 
the region.[27,38] In 2016, average lifetime prevalence 
of cocaine use among secondary school students 
across 13 Caribbean countries was recorded as 2.4%, 
with 2.2% prevalence of crack cocaine.[15] The highest 
prevalencefigureforcocainewasinAntiguaand
Barbuda(3.3%);forcrackcocaineitwasinSaintKitts
and Nevis (3.4%).[15] Crack cocaine is most commonly 
inhaled, often in combination with cannabis (the 
Caribbean’s most used illicit drug).[15,27]Useofecstasy
and ATS appears to be considerably lower than use 
of cocaine derivatives,[15] except for in Puerto Rico, 
where last-year prevalence of amphetamine use 
was 2.5% compared with 2.2% last-year prevalence 
of cocaine derivative use.[39] Data on NPS use in the 
Caribbean is unavailable.[5]
Few harm reduction programmes operate for people 
who use cocaine and its derivatives in the Caribbean. 
The use of improvised smoking equipment for crack 
cocaine is a potential source of harm, such as the 
practice of “bullino” in Cuba, whereby makeshift 
pipes are made from soft drink cans.[40,41] Ensuring 
that people who smoke crack cocaine have access to 
safer smoking equipment has been shown to reduce 
harm caused by lesions, burns and respiratory 
problems.[42] Additionally, crack cocaine use has been 
associated with transmission of HIV and hepatitis 
C.[43] Pipe distribution programmes ensure people 
do not share equipment (a practice associated with 
the transmission of hepatitis C) and have been 
shown elsewhere to be related to reducing other 
health problems related to crack cocaine use.[44,45] 
In the absence of widespread injecting drug use 
and demand for NSPs, the implementation of such 
programmes in the Caribbean should be a priority in 
addressing health concerns among people who use 
drugs. 
 
 
There is some evidence for the use of cannabis as 
a harm reduction measure for crack cocaine use in 
the Caribbean. In Jamaica, a 2002 study reported 
that cannabis is used in the community to alleviate 
negativeside-effectsassociatedwithsmokingcrack
cocaine, such as paranoia and weight loss.[17] A 2007 
Saint Lucian study found that 73% of people using 
crack cocaine also used cannabis, and 38% said that 
cannabis could be used as a substitution for crack 
cocaine.[46] The use of cannabis as a substitution 
therapy for crack cocaine has been found to be 
effectiveinqualitativeandlongitudinalstudiesin
CanadaandtheUnitedStates.[47,48] There remains a 
needforfurtherresearchtoexploretheefficacyof
cannabis as a harm reduction measure for people 
who use cocaine and its derivatives.
Overdose, overdose response and drug 
consumption rooms (DCRs) 
The overdose response in the areas of the Caribbean 
where opioids are more commonly used is severely 
lacking. No drug consumption rooms exist in any 
countryorterritory.Naloxone,ahighlyeffective
opioidantagonistusedtoreversetheeffectsof
overdose, is only authorised for use by medical 
professionals in Puerto Rico and only in major 
hospitals in the Dominican Republic.[6,9,49]
Data on overdoses is not collected in the same way 
inPuertoRicoasintherestoftheUnitedStates,
making a comparative assessment of the situation 
intheterritorydifficult.However,civilsociety
organisationsreportasignificantincreaseinopioid
overdose since Hurricane María hit the island in 
September 2017.[50] Fentanyl, a synthetic opioid up 
to 50 times more potent than heroin, is reportedly 
present in an increasing number of overdoses, 
with Intercambios reporting two to three fentanyl 
overdoses per week in the cities of Caguas and 
Fajardo in February 2018.[50] Intercambios has also 
been testing used injecting equipment for fentanyl 
since Hurricane María, and has found that it is 
present in 77% to 90% of cases.[50]
Restrictions on the availability of naloxone in Puerto 
Rico make it unlawful for civil society organisations 
to ensure, as recommended in World Health 
Organization guidelines,[51] that anybody likely to 
witness an overdose has access to the medicine. In 
Puerto Rico, there is no legal protection for peers, 
friends or family using naloxone to save a life.[50] 
Despite these restrictions, Intercambios continues to 
train people who use drugs in the use of naloxone, 
though they are unable to distribute the drug itself.[50] 
El Punto en la Montaña have been working with local 
police and mayors to educate them about naloxone 
and overdose prevention in Puerto Rico.[9]
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Following advocacy by civil society organisations, 
a bill is currently in the Puerto Rican legislative 
assembly to create and implement an island-wide 
overdose prevention programme, including naloxone 
provision, and a Good Samaritan law to protect 
those who call the emergency services in case of 
overdose.[9,50] On Overdose Awareness Day (31 
August) 2018, the governor of Puerto Rico introduced 
plans for a new opioid overdose prevention task 
force to be led by the Administration of Mental 
Health and Anti-Addiction Services (Administración 
de Servicios de Salud Mental y Contra la Adicción) 
and including civil society representation.[9,50]
Viral hepatitis
Hepatitis C prevalence among people who have 
injected drugs in the last year in the Caribbean is 
estimated at 47.6%, with 16.7% of all people living 
with hepatitis C reporting last-year injecting drug 
use.[52] High prevalence of both hepatitis C and 
hepatitis B has also been observed among people 
who use drugs but do not inject, associated with 
sharing paraphernalia and indirectly linked to 
unprotected sex.[27] Despite a lack of any systematic 
monitoring system,[9] prevalence of hepatitis C among 
Puerto Ricans who inject drugs has been estimated 
at 78.4% in rural areas and 89% in San Juan.[10,11] El 
Punto en la Montaña have found that approximately 
half of people who inject drugs living with hepatitis 
C are not aware of their status, enhancing the risk of 
transmission.[9] Among all people living with hepatitis 
C, a recent global systematic review estimated that 
only 18% in Puerto Rico and 10% in the Dominican 
Republic are diagnosed.[52]
In Puerto Rico, there is no publicly funded treatment 
of hepatitis C for people who inject drugs, with the 
Department of Health imposing a requirement for 
six months of abstention from drug and alcohol 
use before treatment.[53] Hepatitis C treatment 
is not covered by the Mi Salud state insurance 
programme.[53]
Inanefforttoincreasethenumberofpeopleaware
of their hepatitis C status in Puerto Rico, El Punto en 
laMontañahascollaboratedwiththeUniversityof
Nebraska-Lincoln in the VAS One (Vida Acción Salud, 
Life Action Health) research project since 2015.[9] 
The project, funded by the National Institute for 
Drug Abuse, provides testing to people who inject 
drugs living in rural areas. [9,54] Some civil society 
organisations in Puerto Rico, such as the Puerto Rico 
Community Network for Clinical Research on AIDS, 
integrate viral hepatitis testing with HIV testing.[9]
InonlyfiveCaribbeancountries,ofthe17in
the region, is care for both hepatitis C and 
hepatitis B publicly funded: Cuba, the Dominican 
Republic, Dominica, Jamaica, and Trinidad and 
Tobago.[55] People who inject drugs face further 
barriers, including discrimination by health 
authorities and professionals, and burdensome time 
commitments.[9]
Tuberculosis (TB) 
As reported in the Global State of Harm Reduction 
2016, there is a dearth of up-to-date information 
on TB services for people who inject drugs. The 
highest general population incidence is in Haiti, with 
181 cases per 100,000 people in 2017, followed by 
Guyana (86), the Dominican Republic (45) and Belize 
(36).[56] Haiti also has the region’s highest HIV/TB 
co-infection incidence at 20 per 100,000,[56] and in 
2017 was among four countries (with Brazil, Mexico 
and Peru) that account for 62% of new TB infections 
in the Americas.[57,58] More research is necessary to 
determine the extent to which people who use drugs 
areaffectedbyTBintheCaribbean,andtheextentto
which they receive treatment.
HIV and antiretroviral therapy (ART)
From 2010 to 2017, the Caribbean saw an 18% 
reduction in new HIV infections and a 23% reduction 
in AIDS-related deaths.[59] Almost 90% of new 
diagnosesareconfinedtojustfourcountries:
Cuba, the Dominican Republic, Haiti and Jamaica.[59] 
Despite this progress, only 64% of people living with 
HIV in the Caribbean are aware of their status.[60] 
Approximately 1% of new infections across the 
region in 2017 were due to injecting drug use.[59]
In most countries of the region, few new HIV 
infections are associated with injecting drug use. 
For example, only 0.2% of new HIV cases in Jamaica 
in 2015 were among people who inject drugs.[61] 
However, non-injecting drug use has been observed 
to be indirectly related to HIV transmission, through 
thedisinhibitingeffectofsomedruguseonsexual
risk behaviours such as condom use.[27] Prevalence 
studies in Jamaica and Saint Lucia have found 
high prevalence of HIV among people living on the 
streets who use drugs but do not inject, and have 
found that this population overlaps with other key 
populations for HIV, such as men who have sex with 
men, sex workers and transgender people.[18,20,38,62,63] 
In Jamaica, the National Council on Drug Abuse 
operates an outreach programme to people living on 
the streets, providing counselling, linkage to mental 
and physical healthcare, hygiene items (such as 
toothbrushes, sanitary products and body wash) and 
clothing.[62] It is unclear to what extent this outreach 
is done within a harm reduction framework without 
the ultimate aim of abstinence.
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People who use drugs are consistently left out as 
a key population in HIV reporting and planning in 
the Caribbean. Despite being a small proportion of 
new infections, they remain a group at high risk of 
infection.Stigmaanddiscriminationplayasignificant
role in limiting access to HIV testing and treatment, 
with evidence that a large proportion of people 
across the Caribbean demonstrate discriminatory 
attitudes towards people who inject drugs.[59] Only 
four countries (Puerto Rico, Saint Lucia, Suriname, 
and Trinidad and Tobago) make any reference to the 
stigma faced by people who use drugs in national HIV 
policy documents, and only Puerto Rico’s document 
recommends concrete actions that can be taken 
to address this barrier to healthcare.[12,19-21] The 
continued criminalisation of people who use drugs 
also contributes to discouraging this population from 
accessing treatment.[5]
HIV transmission in Puerto Rico is mostly related to 
injecting drug use.[24] In 2015, it was estimated that 
11.3% of people who inject drugs in Puerto Rico were 
livingwithHIV;[8] El Punto en la Montaña report that 
6% of all people registered by their NSP are living 
with HIV.[9] In 2015, it was found that 89.5% of people 
who inject drugs in San Juan had ever been tested 
for HIV and 42.4% had been tested in the last year.[8] 
Of those tested in the previous year, more than half 
(50.7%) were tested in a non-clinical setting (such 
as an outreach centre, mobile unit, NSP or family 
planning clinic).[8]
In Puerto Rico, there are no restrictions on access 
to antiretroviral therapy for people actively using 
drugs.[9] In the Dominican Republic, people who 
inject drugs are able to access antiretroviral therapy, 
howeverstaffarenottrainedinthespecificneeds
of this population, meaning many people who inject 
drugs are alienated by the healthcare system.[5] In 
September2018,UNODCandUNDPlauncheda
training plan for health personnel in the provision of 
comprehensive HIV treatment and care for people 
who inject drugs.[5]
Several organisations in Puerto Rico provide 
specialised HIV care for people who inject drugs. 
TheseincluderapidtestingofferedbyIniciativa
Comunitaria,[37] and integrated NSP, OST and HIV 
services at the Migrant Health Center in Mayaguez.[36] 
The Community Network for Clinical Research on 
AIDS hosts the Tod@s project targeted at young 
people (aged 13 to 29) with no limitations placed on 
accessforpeoplewhoinjectdrugs,offeringrapidHIV
testing, referrals and specialised services for people 
living with HIV.[64] In the Dominican Republic, the 
COIN NSP integrates HIV treatment, and is able to 
enrol clients in antiretroviral therapy.[28]
Harm reduction in prisons
People who use drugs in the Caribbean consistently 
face criminalisation and the risk of imprisonment, 
despite movement towards decriminalisation 
of cannabis in certain countries (see below). 
For example, in the Bahamas suspicion of drug 
possession is legal grounds for property searches 
without a warrant,[65] and Law No. 50-88 on Drugs 
and Controlled Substances in the Dominican Republic 
classifiesatraffickerasanypersoninpossession
of any quantity of opium derivatives.[5] Since 2017 
in the Dominican Republic, at least 60 people who 
use drugs have reported being arrested without 
havingcommittedanoffence,andyoungpeople
report being charged with drug possession when not 
carrying any illegal substances.[22,66]
There were an estimated 109,176 people imprisoned 
in the Caribbean in 2016, a 22% increase in the 
prison population since 2005.[67,68] Prisons in several 
countries in the Caribbean are reported to lack 
adequate hygiene and medical facilities[65,69-71] 
and prisons across the region are consistently 
severely overcrowded, including the world’s most 
overcrowded prison system in Haiti which operates 
at 454% capacity.[65,66,69,71-74] This combination creates 
an environment in which drug-related harms, such 
asthetransmissionofHIV,HCVandTB,areamplified
rather than reduced.[75] 
NoprisonintheCaribbeanoffersaccesstosterile
injecting equipment, and only one prison in the 
region, in Puerto Rico, provides OST in prison.[5,9] 
ThelackofaccesstoOSThasbeenidentifiedby
civil society organisations as a form of cruel and 
unusual punishment, and a violation of the right to 
health.[76] Hepatitis C treatment is not available in 
Puerto Rican prisons.[9,77]
Drug treatment courts have operated in the 
Caribbean since the early 2000s, and now operate 
infivecountriesandterritories(Barbados,the
Dominican Republic, Jamaica, Puerto Rico, and 
Trinidad and Tobago) with two further countries 
implementing pilot programmes (the Bahamas and 
Belize).[78] These programmes seek to divert people 
chargedwithminor,non-violentdrugoffencesaway
from the penal system and into drug treatment 
services, and tend to focus on abstinence.[78] An 
almost complete lack of data collection in the region 
makes it impossible to assess whether drug courts 
achievetheirsetobjectives;however,drugcourts
in other parts of the world have been criticised as 
biased towards those least in need of treatment and 
ineffectiveinsupportingpeopletoimprovetheir
health outcomes.[78]
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Another issue in the Caribbean is the prevalence 
of forced rehabilitation centres, often associated 
with drug treatment courts.[23] A 2016 Open Society 
Foundations report raised concerns over such 
facilities, reporting that people who use drugs in 
both the Dominican Republic and Puerto Rico are 
involuntarily interned without committing any 
crime, subjected to physical and psychological 
abuse, and to cruel, dehumanising and humiliating 
treatment.[23] The centres, often operated by religious 
organisations, reportedly force those admitted to sell 
products on the street for little to no pay, and refuse 
to provide medical care for either opioid withdrawal 
symptoms or minor illness.[23] No evidence has 
beenpresentedfortheeffectivenessofthese
rehabilitation centres in achieving their stated aims 
of reducing drug use and drug-related crime, and 
they have been condemned as violating fundamental 
humanrightsbytheUNSpecialRapporteuron
torture and other cruel, inhuman or degrading 
treatmentorpunishment,andtheUNSpecial
Rapporteur on health.[79]
2017 Atlantic hurricane season
The 2017 Atlantic hurricane season saw two category 
fivehurricanesintheCaribbean,IrmaandMaría.The
worst-affectedislandswerePuertoRico,Dominica,and
Antigua and Barbuda, with all experiencing widespread 
destruction of infrastructure, including hospitals, across 
the islands. In Dominica, 80% of buildings were damaged 
byHurricaneMaría;[80] on the island of Barbuda, 
Hurricane Irma damaged 90% of buildings and all 1,800 
residents were evacuated to Antigua.[81]
Puerto Rico experienced unprecedented devastation 
when Hurricane María hit in September 2017,[9] and the 
effectsonharmreductionservicesweredebilitating.The
broaderhealthcaresystem,alreadydrainedoffinancial
and human resources by austerity and emigration 
over the preceding decade, was brought to the brink 
of collapse. Local media estimate that ten doctors left 
the island every day in the months following Hurricane 
María, and a survey indicated that one third of deaths 
in the wake of the hurricane can be attributed to 
interrupted healthcare.[82] Ten days after the storm, only 
nine of the island’s 69 hospitals had been reconnected 
to the electricity network.[83] Thousands of Puerto Ricans 
remained without power until August 2018, 11 months 
later.[84] 
El Punto en la Montaña in Puerto Rico was forced to 
scale back its harm reduction services due to a lack 
of shipments of supplies arriving from the mainland 
UnitedStates.[85] Sterile water and bleach became 
scarce on the island, making even last-resort methods 
of needle sterilisation unavailable.[85] The organisation 
reports that the frequency of sharing needles and other 
injecting paraphernalia increased 27% in the wake of 
the hurricane.[9]TheUSJonesActrestrictspermission
for ships travelling between domestic ports, and the 
federal government’s refusal to provide a long-term 
waiver of the law for Puerto Rico has reportedly 
exacerbated shortages of essential equipment for harm 
reduction.[86,87] Since Hurricane María, there has also 
been a dramatic increase in the detection of fentanyl on 
the island,[50] bringing concern due to the high overdose 
risk it presents. 
Economicandsocialcrisesareknowntoeffectpatterns
of drug use and infectious disease transmission,[27] 
including increasing the prevalence of illicit substance 
use, according to evidence from previous disasters 
in the region (such as Hurricane Katrina in 2004 
and the 2010 Haitian earthquake) – meaning harm 
reduction commodities and interventions remain 
critical.[88-90] In Puerto Rico in particular, the failure of 
theUSgovernmenttorespondtothecrisisadequately
represents an extreme abdication of duty to its citizens, 
including those who use drugs.
 
Policy developments for 
harm reduction
Formal policy plans across the Caribbean do not take 
a harm reduction approach to drug use. Only two 
countries in the region have drug policy documents 
that make any reference to harm reduction, the 
Bahamas and the Dominican Republic. Both do so 
withoutspecificmentionofinterventionsorclear
commitments, instead making passing reference to a 
health-led approach to drug use and acknowledging 
the work of civil society organisations.[91,92] Elsewhere, 
any reference to reducing harm among people 
who use drugs is explicitly set in a rehabilitation 
and abstinence-focused framework, for example 
in Guyana,[93] or harm reduction is not mentioned 
at all (for example in Belize, Grenada, and Trinidad 
and Tobago).[94-96] The Organization of American 
States’ Plan of Action on Drugs 2016-2020 makes no 
reference to harm reduction, and only refers once 
to the need to address HIV among people who inject 
drugs.[97] 
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Limited progress has been made in the 
decriminalisation of cannabis since 2016. Following 
decriminalisation in Jamaica in 2015,[98] the prime 
minister of Antigua and Barbuda announced his 
intention to decriminalise the drug in 2018.[99] In 
Puerto Rico, cannabis was legalised for medical 
purposesin2017;however,therecreational
decriminalisation bill reported by the Global State of 
Harm Reduction 2016 has not been passed.[100] 
In the Dominican Republic, Law No. 50-58 on Drugs 
and Controlled Substances makes possession of any 
quantityofopioidsorLSDatraffickingoffence,with
nodifferentiationofpossessionforpersonaluse
(threshold amounts apply for other substances).[6,101] 
Inresponsetothis,UNODCandUNDPhave
supported the development of a proposal to revise 
the law and consider the decriminalisation of drug 
use.[5]Theproposalwasfinalisedinlate2018,and
will form a basis for future advocacy for drug law 
reform.[6]InthewakeoftheUNGeneralAssembly
SpecialSessiononDrugs(UNGASS)in2016,a
national strategy working group is now operating in 
SantoDomingoontheimplementationofUNGASS
recommendations, including promoting a public 
health approach to drug use.[5]
Cuba has consistently been heavily in favour of 
drug prohibition, with the state failing even to 
acknowledge the presence of illicit drugs other than 
cannabis on the island, despite incontrovertible 
evidence of use of cocaine derivatives.[40,102]  
According to a recent report by the Igarapé Institute, 
Cuba’s increasing openness to international trade 
may lead to a greater presence of illicit substances on 
the island, and in turn may necessitate an alternative 
approach to drug use.[40] Small movements towards a 
public health-led approach are apparent in Cuba. For 
example, the National Drug Commission advocates 
prevention and treatment of people who use drugs 
over repression, and the Centre for Academic 
Development on Drug Dependence (Centro para el 
Desarrollo Académico sobre Drogodependencias) is 
reported to have begun to explore harm reduction 
initiatives at a symposium in May 2017.[40]
Civil society and advocacy 
developments for harm 
reduction
Harm reduction services in both the Dominican 
Republic and Puerto Rico are largely carried out by 
civil society organisations.[5,9] These organisations 
also engage in advocacy activities. In the Dominican 
Republic, this has included a Support. Don’t Punish 
campaign organised by COIN around International 
DayAgainstDrugAbuseandIllicitTrafficking,aswell
as advocating for a redistribution of government 
fundsfromineffectivelawenforcementspending
to harm reduction, in line with Harm Reduction 
International’s 10 by 20 campaign.[5]
In Puerto Rico, El Punto en la Montaña leads 
advocacy campaigns on access to viral hepatitis 
treatment, decriminalisation of people who use 
drugs, and the approval of the Good Samaritan law 
currently in front of the Puerto Rican assembly.[9] The 
viral hepatitis campaign achieved national media 
attention and the creation of a National Hepatitis 
C Coalition, while the decriminalisation campaign 
has established links with local law enforcement.[9] 
El Punto en la Montaña has also disseminated 
promotional material raising awareness of the harms 
caused by stigma towards people who use drugs, 
andworkedwiththeAmericanCivilLibertiesUnion
to assist people who use drugs to understand their 
rights and access justice.[9] 
Though no network of people who use drugs 
operates in the Caribbean, an island-wide 
harm reduction network exists in Puerto Rico 
(Coalición Puertorriqueña de Reducción de Daños, 
CoPuReDa).[9] A regional Network of Outreach 
Centres and Harm Reduction in the Caribbean was 
founded in 2002, and has continued to meet up to 
2018.[5]
Funding developments for 
harm reduction
Investment for civil society organisations providing 
harm reduction services in the region is largely 
provided by private foundations and international 
donors. For example, El Punto en la Montaña in 
Puerto Rico receives support from Open Society 
Foundations, MAC AIDS Fund and the Drug Policy 
Alliance, as well as a number of other national 
and international foundations.[9] Civil society 
organisations report that there are limited funding 
opportunities beyond a small set of institutions, 
and that the continual need to re-apply for 
funding represents a considerable burden.[9] In the 
DominicanRepublic,UNODCsupportsTREATNET
technical training, which, though primarily focused 
on treatment package design for treatment centres, 
also includes harm reduction and OST.[5]
National government funding in the Caribbean is 
focused on supply reduction and rehabilitation 
programmes. For example, the Surinamese 
National Strategic Plan on Drugs 2011-2015 (the 
Global State of Harm Reduction 201890
latest iteration) assigned 41% of its budget to law 
enforcement and just 0.1% to the HIV response, with 
no other allocation for harm reduction.[103] Similarly, 
finescollectedintheDominicanRepublicfordrug
offencesarechannelledintodrugprogrammes,with
40% spent on drug control, 15% on rehabilitation and 
no money allocated to harm reduction.[5] In total, less 
thanUS$0.04isspentonharmreductionperperson
who injects drugs in the Dominican Republic.[104] The 
Puerto Rican government funds inpatient treatment 
facilities, which are mostly faith-based and operate 
without any qualitative evaluation.[50]
The funding environment for harm reduction, and 
health more broadly, is made even more challenging 
in Puerto Rico by its relationship with the rest of the 
UnitedStates.Forexample,thefederalgovernment
funds only 19% of Puerto Rico’s Medicaidn (known 
as Mi Salud) costs, compared with an average of 
70% across the 50 states.[105] This is particularly stark 
as 49% of Puerto Ricans were eligible for Medicaid 
beforeHurricaneMaríainSeptember2017,afigure
which is likely to have risen considerably in the past 
year.[105] Since the establishment of the Financial 
Oversight and Management Board for Puerto Rico by 
theUSgovernmentin2016,theboardhasimposed
millions of dollars of further cuts on the island’s 
healthcare system.[9] Medicaid is the only health 
insurance available to people who inject drugs in 
Puerto Rico,[9] and as such any cuts represent a 
significantthreattothehealthandwellbeingofthe
population of the island.  
n MedicaidisajointprogrammebetweenfederalandstategovernmentsintheUnitedStateswhichassistspeoplewithlimitedincomewiththecostofhealthcare.
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Table 2.5.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Latin America 
Country/territory
with reported
injecting
drug use
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)(1)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs (%) (1)
Harm reduction responsei
NSPa OSTb
Peer-
distribution 
of naloxone
DCRsc
Argentina 8,144[1] 3.5[2] 4.8[3] 1.6[3] xd[4] (1)(M)[4] x x
Bolivia nk nk nk nk x x x x
Brazil nke 9.9 f [5] nk nk xd[4,6] x x x
Chile nk nk nk nk x x x x
Colombia 14,893[7] 5.5[8] 31.6[8] nk (9) (M)[9] xg x
Costa Rica nkh nk nk nk x (1)(M)[9] x x
Ecuador nk nk nk nk x x x x
El Salvador nk nk nk nk x x x x
Guatemala nk nk nk nk x x x x
Honduras nk nk nk nk x x x x
Mexico 164,157i [13] 4.4 [14] 96k [15] 0.2[3] 6l(19) (6) (M)[12,16] [12] xm
Nicaragua nk nk nk nk x x x x
Panama 5,714[17] nk nk nk x x x x
Paraguay nk nk 9.8[18] nk x x x x
Peru nk nk nk nk x x x x
Uruguay nk nk nk nk xd[4] x x x
Venezuela nk nk nk nk x x x x
 nk – not known 
a All operational needle and syringe exchange programme (NSP) sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers. (P) 
= pharmacy availability.
b Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
c Drug consumption rooms, also known as supervised injecting sites.
d In Argentina, Brazil and Uruguay, needle and syringe programmes previously operated when injecting cocaine use was more prevalent. However, as injecting drug use declined, these 
programmes have since closed or been redirected towards harm reduction for non-injecting drug use.[4]
e Unpublished data from a national household survey coordinated by Francisco Bastos found very little evidence of injecting drug use in Brazil.
f Based on data collected in 2009 in eight Brazilian cities
g Between 2015-2017, naloxone peer distribution networks existed in Colombia, but the programme was closed in January 2018.
h  Civil society organisations indicate that injecting drug use is minimal in Costa Rica.[10]
i Based on data from 2011 National Addiction Survey. There may be limitations to the representativeness of this data, as household surveys are known to exclude people living outside 
traditional households, such as people who are homeless or incarcerated.[11] Civil society organisations believe that this figure may be an overestimate, with the true number of people 
who inject drugs in the country being around 30,000.[12]
j Based on data collected in 2006-2007.
k Based on data collected in 2005.
l Of these, four NSPs operate year-round and two for six months per year.
m Though no official DCRs exist in Mexico, a small facility exclusively serving women exists in Mexicali, Baja California.[12]
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Map 2.5.1: Availability of harm reduction services
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Harm reduction in Latin America
n  This is a cumulative figure based on UNODC estimates of the number of opioid, cocaine and amphetamine users in Latin America, and does not account for poly-
drug use.
o Also known as basuco, paco, base paste or oxi, cocaine paste is an intermediate product in the production of cocaine. It is marketed as a cheaper alternative to 
cocaine in South America.
Overview
There are approximately 4.5 million people who use 
illicit drugs excluding cannabis in Latin America,n  and 
levels of injecting drug use are very low compared 
with other regions.[3] This is largely due to the fact 
that injecting opioid use has been confined to the US-
Mexico border and Colombia, and is not widespread 
elsewhere.[19,20] In other parts of the region, cocaine 
injection has historically been more common than 
opiate injection, but currently is relatively rare.[1,6] 
Conversely, Latin America has the world’s highest 
levels of smokable cocaine use,[21] and this is 
therefore the focus of much of the harm reduction 
effort in the region. Innovative harm reduction 
responses in the region are also increasingly 
tailored towards people who use amphetamine-type 
substances (ATS), in line with growing prevalence of 
ATS use in the region.
Data on drug use in Latin America, especially injecting 
drug use, is scarce and there is a clear need for more 
research in this field. Civil society organisations 
report that states in the region do not regularly or 
systematically collect data on injecting drug use and 
people who use drugs, meaning that policies are 
often built on minimal, inaccurate and out-of-date 
evidence that has little relation to reality.[22] Based on 
the limited data available, prevalence of HIV, hepatitis 
C and tuberculosis are all higher among both people 
who inject drugs and non-injecting drug users than 
the general population. However, prevalence varies 
considerably across the region, as demonstrated in 
Table 2.5.1.
Latin America and the Caribbean is the only 
world region in which use of cocaine derivatives 
is greater than that of opioids.[3] Almost all the 
world’s coca leaf cultivation takes place in just three 
Latin American countries – Bolivia, Colombia and 
Peru – and prevalence of the use of cocaine and 
its derivatives in the region is among the highest 
in the world.[3,21] Harm reduction programmes for 
people who use non-injectable cocaine derivatives 
are in place in several countries in the region, with 
a particular focus on use of the smokable forms of 
crack cocaine and cocaine paste.o  For example, the 
Casa Masantonio project in Buenos Aires, Argentina 
and the Casa Normal project in Rio de Janeiro, Brazil 
both offer advice and support on accommodation, 
employment and legal proceedings to people who 
use cocaine derivatives.[2,24] Elevated prevalence 
of HIV and other blood-borne diseases have been 
observed among crack and cocaine paste users, 
and have been associated with higher-risk sexual 
practices.[25-27] The Casa Masantonio project, funded 
by the city of Buenos Aires, also offers HIV, hepatitis 
C, tuberculosis and syphilis treatment to cocaine 
paste users free of charge.[24]
In recent years a slight increase in opiate use across 
Latin America has coincided with an increase in 
opium poppy cultivation in Mexico, Colombia 
and Guatemala.[3,19] In 2016, a small population 
of people injecting opiates was identified for the 
first time in Mexico City.[20] However, opiate use 
remains uncommon outside northern Mexico and 
Colombia.[12,19,20] Harm reduction programmes for 
people who inject drugs, including opioid substitution 
therapy (OST) and needle and syringe programmes 
(NSP), operate in the Mexican and Colombian 
cities where injecting drug use is most prevalent. 
Developments since 2016 have been mixed: some 
NSP services in Mexico have been expanded to open 
year-round, but sites in Bogotá and Dosquebradas in 
Colombia have been closed.[12,16,23]
A range of harm reduction services for ATS and 
new psychoactive substances (NPS) have been 
implemented in Latin America. Since 2012, the 
Colombian Échele Cabeza (Use Your Head) project 
has operated drug-checking services at festivals 
and raves to test samples of ATS and NPS for purity.
[28,29] Between 2012 and 2015, the organisation saw 
a 25% reduction in adulterated samples and a 50% 
reduction in emergency room visits due to ATS use in 
Bogotá, which civil society organisations attribute in 
part to the success of harm reduction interventions.
[30] However, in 2016 the incoming mayor of Bogotá 
ended support for these projects.[16] Similar services, 
supplemented by hydration points, staff training 
workshops and awareness-raising campaigns, 
also now operate in Argentina, Brazil, Mexico and 
Uruguay.[4,31]
There are examples from recent years of progress 
towards less punitive drug policies in Latin America. 
Colombia’s supreme court ruled that individuals 
should not be automatically criminalised for 
possession of illicit drugs for personal use in 2012, 
and Uruguay became the first country to legalise 
cannabis for non-medical use in 2013.[32,33] However, 
since 2016, concerning political developments have 
restricted harm reduction programmes and space 
for civil society engagement with governments.[34] For 
example, a new government in Brazil has explicitly 
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rejected harm reduction as a response to illicit drug 
use and closed successful programmes, replacing 
them with abstinence-based, rehabilitation and law 
enforcement-led projects.[6,35] The election of Iván 
Duque as president in Colombia in June 2018 was 
met with concern by civil society organisations who 
fear a resurgence of prohibitionist policies.[22] Similar 
developments have occurred in local government, 
with newly elected city-level administrations in 
Bogotá, Colombia and São Paulo, Brazil also rolling 
back harm reduction projects.[4,16,36] In several other 
countries in the region, such as El Salvador and 
Guatemala, the response to drug use continues to be 
dominated by abstinence-centred programmes, often 
led by non-specialist and religious organisations.[37,38] 
Across the region, rehabilitation centres continue 
to operate with little or no oversight by health 
authorities, meaning that the human rights of people 
who use drugs can be neglected with impunity.[22]
With reductions in funding from some donors in 
the region, including the Global Fund, the funding 
landscape for harm reduction in Latin America is 
increasingly difficult. With some exceptions, such 
as the Colombian government taking responsibility 
for funding certain NSPs, national governments 
have failed to meet the funding shortfall left by 
the departure of these international donors.[22,39] 
An additional funding challenge for programmes 
in Latin America is that internationally funding 
for harm reduction is largely drawn from HIV 
prevention budgets. As injecting drug use is low, 
many harm reduction programmes do not have an 
HIV component and therefore have limited funding 
opportunities.[9,12,16]
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
Although the prevalence of injecting drug use is 
low, the Latin America and the Caribbean region 
has one of the lowest per user rates of needle 
distribution in the world. Where injecting drug use 
has been identified, only between 0.1-0.5 needles are 
distributed per person per year, compared with the 
World Health Organization (WHO) recommendation 
of 200.[40] Since the Global State of Harm Reduction 
last reported, developments in the region have been 
mixed. NSPs are known to operate in Colombia 
and Mexico, but in other countries with very low 
prevalence of injecting drug use, such as Costa Rica, 
they are largely deemed unnecessary.[6,10] 
Outside Colombia and Mexico, injecting cocaine 
was prevalent two decades ago and has been more 
common than opiate injecting; however, levels today 
are very low. Cocaine injection is associated with a 
higher risk of blood-borne infection transmission, 
due to the greater frequency of injection.[41] In 
parts of the region where cocaine injection has 
been prevalent, for example in Argentina, Brazil 
and Uruguay, NSPs have served these populations. 
However, as injecting drug use in these countries 
declined to minimal levels, these services closed or 
were redirected towards harm reduction for non-
injecting drug use.[4,42] This therefore represents 
a decline in the need for NSP services for this 
population, rather than a decline in harm reduction 
service provision.
Needle and syringe programmes have operated in 
Colombia since 2014, in the cities of Cúcuta, Cali, 
Pereira, Dosquebradas and Bogotá.[4,16] The sites 
have served over 2,000 individuals during the course 
of their operation.[16] Though the sites in Bogotá and 
Dosquebradas closed in late 2017, NSPs still operate 
in Cali, Cúcuta and Pereira. However, services are 
intermittent due to unreliable revenue streams 
and cash flow issues.[4,16,23] In Pereira, civil society 
organisations report that opening hours, dress codes 
and locations for sites have been heavily regulated, 
and people who use drugs are required to provide 
official identification in order to receive safe injecting 
materials.[16,22,23] No NSP services exist in Medellín 
due to significant local government opposition, 
despite this being the Colombian city with the highest 
population of people who use drugs.[16] 
According to a study carried out by Verter in Mexico, 
there are six active NSPs, at least one of which 
exclusively serves women who inject drugs.[12] These 
sites have seen an expansion in their services since 
2016: four now operate year-round, whereas before 
2016 all but two only operated for six months of 
the year.[12] All are run by civil society organisations, 
such as Verter and PrevenCasa, and funded by 
the national HIV prevention body.[12] In Tijuana, an 
unusually high prevalence of use of high dead-space 
syringes has been noted.[43] These are associated 
with a greater risk of blood-borne virus transmission 
through syringe-sharing than low dead-space 
syringes, due to the larger volume of blood left in 
the needle after injection.[43,44] To address the risk of 
blood-borne virus transmission in this particularly 
high-risk group, the Tijuana NSP operated by 
PrevenCasa distributed approximately 50,000 
syringes to the estimated 10,000 people who inject 
drugs in the city in 2015.[45] This remains considerably 
below the WHO recommendation of 200 needles per 
person who injects opiates. 
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A primary barrier to accessing NSPs in Mexico is law 
enforcement. Despite the possession of needles and 
syringes being legal, police are known to destroy 
needles when interacting with people who inject 
drugs, therefore decreasing the effectiveness of NSPs 
and increasing the risk of unsafe practices such as 
needle-sharing.[12,45] To ensure the effectiveness of 
NSP programmes in Mexico, greater cooperation 
between health services and law enforcement is 
necessary. Other key barriers to access to NSPs 
include the fact that syringes provided by the 
government are not the gauge preferred by people 
who inject drugs, and government funding is limited 
to nine months of the year.[23]
From 2015 to 2018, Verter has operated three 
sites specifically serving women who inject drugs 
in Mexico, funded by a private women’s rights 
foundation, Fondo Semillas. The programme, called 
Las Colectas, provides sexual and maternal health 
services, and support and care groups. Across the 
three cities, 100 women are estimated to attend 
the services regularly, and there are plans to share 
experiences with other organisations with the aim of 
expanding the service.[12]
Despite the low prevalence of injecting drug use 
in the region, there is still a clear need for NSPs to 
facilitate safe injecting practices among those who 
do inject drugs. A recent government study found 
that 41% of people who inject drugs in Colombia had 
shared a needle in the preceding six months.[7] In 
Argentina the figure is 32% for those who had ever 
injected drugs in their lives.[1]
Opioid substitution therapy (OST)
Latin America has one of the lowest levels of OST 
provision per person who injects drugs in the 
world,[40] with OST available in Colombia, Costa 
Rica, Argentina and Mexico.[4,9,10,12,16,22,46] This lack of 
provision reflects the low prevalence of opioid use in 
the region.
OST is publicly available in Colombia, in the form 
of 10mg and 40mg methadone pills.[9,16,22] However, 
significant barriers to accessing OST in the country 
have been noted, and it is increasingly used as part 
of a detoxification process rather than for harm 
reduction.[9] Demand for OST outstrips the capacity 
of the few existing facilities, formal identification 
is necessary to join the state health insurance 
programme, there are long waiting times for 
appointments with specialists, and many medical 
practitioners and patients still consider methadone 
therapy to be a case of replacing one addiction with 
another.[22] Women who inject drugs have been 
known to be excluded from OST centres, where 
some practitioners consider them to be difficult 
patients and even a distraction to the rehabilitation 
of men.[22] Additionally, stocks of methadone in the 
country have been known to encounter difficulties 
in reaching communities, leading to people who use 
opioids reverting to sourcing heroin or unregulated 
methadone from the black market.[16,23]
In Mexico, methadone is also available for OST. 
However, it can only be purchased privately at a cost 
to the person, and is only available at six centres 
in the three cities where injecting drug use is most 
concentrated: Tijuana, Mexicali and Ciudad Juárez.[12] 
Since 2016, methadone clinics in Nogales and San 
Luis Río Colorado have been closed due to a lack of 
government funding.[12] In Argentina, OST is available 
in both public and private institutions in Buenos 
Aires.[4] In Costa Rica, a single facility provides OST 
to a small number of people, including pain and 
palliative care patients, and healthcare professionals 
who use non-prescription opioids.[10]
Amphetamine-type stimulants (ATS), cocaine 
and its derivatives, and new psychoactive 
substances (NPS)
Harm reduction in nightclubs and 
festivals
In five Latin American countries (Argentina, Brazil, 
Colombia, Mexico and Uruguay), harm reduction 
interventions have been developed for the use 
of amphetamine-type substances (ATS) and new 
psychoactive substances in nightclubs and festivals. 
Since 2012, Colombian NGO Acción Técnica Social has 
operated its Échele Cabeza (Use Your Head) drug-
checking project at festivals and raves.[29] To date, the 
project has tested over 4,000 samples, with 75% of 2CB 
samples, 12% of ecstasy pills and 13% of MDMA powders 
testing negative for any trace of the expected drug.
[16,28] Over 80% of service users chose not to consume 
samples that had tested negative, and from 2012-2017 
the organisation saw a 25% reduction in adulterated 
samples and a 50% reduction in emergency room visits 
due to ATS use in Bogotá, which they attribute in part to 
the drug-checking service.[30] However, due to a lack of 
state funding, the project can only operate where private 
actors are willing to pay for the service, meaning that the 
most at-risk populations cannot access the services.[4,16]
Following the deaths of five young people due to 
stimulant use at a rave in 2016, civil society organisations 
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in Argentina successfully lobbied the city government 
in Buenos Aires to support them to carry out harm 
reduction interventions at festivals and raves.[4] Since 
early 2018, Proyecto Atención en Fiestas (PAF!) has been 
financially backed by the city and national governments 
to attend 28 events, where it has distributed 
informational flyers, condoms, fruit and sweets.[4,56] 
A motion was unanimously passed by the municipal 
council in Rosario to allow state-sanctioned testing of 
pills in bars and nightclubs, but was rejected by the city’s 
executive.[57,58]
Drug-checking and information services have been 
operating in several Brazilian cities  since 2011, in 
coordination with the Brazilian Harm Reduction 
Association (ABORDA).[4,59,60] Civil society organisations 
report that at least 31 such initiatives operate in the 
country, though they receive no public financial support 
and rely on volunteers and private funding.[4] In Uruguay,  
a drug-checking facility operated at an electronic music 
rave for the first time in 2016,[61] and the National 
Drugs Board has provided funding for harm reduction 
measures (including hydration points, specialised 
training for staff and awareness-raising campaigns).[62] 
Drug-checking programmes are also operated in Mexico 
by the ReverdeSer Colectivo, where ATS use has 
increased significantly in the last ten years.[4,12,63]
The World Drug Report 2017 notes that the use 
of hallucinogenic new psychoactive substances is 
increasing in South America, in particular derivatives 
of the psychedelic 2CB, a series of compounds whose 
use is associated with harmful and life-threatening 
intoxications.[3] In both Chile and Colombia, evidence has 
been found that samples sold as LSD actually contained 
2CB.[3] The Échele Cabeza programme in Colombia found 
that 33% of LSD samples tested negative for LSD.[28]
Harm reduction services in nightclubs and festivals, 
particularly drug-checking, have been shown to be an 
effective way to reduce harm and deaths caused by illicit 
drugs. The introduction, expansion and funding of such 
projects has the potential to save many lives, and should 
therefore form part of the national drug strategy for all 
countries in the region.
Latin America has high prevalence of use of three 
forms of coca leaf derivatives: cocaine powder, 
crack cocaine and cocaine paste.[19] Crack cocaine 
and in particular cocaine paste are reported to be 
the most commonly used substances among many 
socio-economically deprived people who use drugs 
in Latin America.[21] Use of cocaine paste has been 
noted across South America, having previously been 
confined mostly to Colombia and Peru.[16,47] A 2015 
study by the Organisation of American States found 
that crack cocaine use was higher in Central America, 
with general population prevalence in the region of 
approximately 0.3%.[19] Brazil is thought to be home 
to more crack users than any other country in the 
world, with an estimated 370,000 in 2014,[36] while 
Colombia is the world’s largest cocaine powder 
producer and has the lowest-priced cocaine powder 
in the world (€5.40/gram).[3,48]
A key issue highlighted by harm reduction 
organisations is purity. Acción Técnica Social have 
found that only 4% of powder cocaine samples 
they tested at raves and festivals in 2017 contained 
more than 75% cocaine, and 5% contained no 
cocaine at all.[28] Frequent adulterants include 
levamisole, caffeine, local anaesthetics and dairy 
products.[16] Similarly, a 2015 study of the purity of 
smokable cocaine found proportions of adulterated 
samples ranging from 28.2% in Chile to 89.5% in 
Uruguay. Adulterated samples most often contained 
phenacetin, a local anaesthetic considered to 
have carcinogenic properties. Other common 
adulterants included caffeine and analgesics such as 
aminopyrine, paracetamol and lidocaine.[49] 
A diverse range of facilities aiming to reduce and 
mitigate the consequences of crack and cocaine 
paste use, rather than eliminate it, exist across 
Latin America.[50] These range from low-threshold 
harm reduction services providing food, shelter and 
basic hygiene in Costa Rica[10] to more extensive 
programmes among people who use crack and 
cocaine paste in Argentina, Brazil and Uruguay. The 
Casa Masantonio project, opened in 2016 in Buenos 
Aires, Argentina, provides people who use cocaine 
paste with HIV, hepatitis C, tuberculosis and syphilis 
testing and treatment, as well as advice related to 
accommodation, employment, relationships and 
legal proceedings.[24] This is all provided free of 
charge, funded by the city of Buenos Aires.[4] As 
of May 2018, it had an adherence rate of 92%.[4] A 
similar service for crack and alcohol users, Casa 
Normal, opened in 2018 in Rio de Janeiro, Brazil.[4] In 
Colombia, an initiative reducing harm among people 
smoking cocaine paste previously operated in 
Bogotá, but was closed in early 2017 by the new 
mayor.[16] Acción Técnica Social in Colombia has 
developed an as-yet unfunded project to distribute 
safer pipes to cocaine paste users, and to use coca 
leaves for substitution therapy.[16] Pilot projects have 
operated in Brazil, Colombia and Uruguay using 
cannabis as a means of controlling crack cocaine 
use.[34]
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A recent report from Mainline, a Netherlands-
based harm reduction organisation, highlighted 
projects that view the use of cocaine derivatives as a 
symptom of wider social challenges, and implement a 
harm reduction approach. The Atitude project in four 
cities in the Brazilian state of Pernambuco is fully 
financed by the state government to assist people 
who use crack cocaine.[51] It provides four services. An 
outreach service in areas with a high level of drug-
related crime offers information, water, condoms and 
family counselling. Night shelters and drop-in centres 
provide around 30 clients per day with a space to 
sleep, wash and attend workshops, as well as eat two 
meals per day. Intensive shelters offer stays of up 
to six months with joint meals, housekeeping tasks 
and participation in groups and workshops, where 
people can acquire skills which can be used in the 
labour market. One intensive shelter is for use only 
by women and transgender women who use drugs, 
with a focus on those threatened by violence, who 
are pregnant or who are mothers. Finally, Atitude 
offers an independent social housing programme, 
which provides accommodation at low rent for up to 
one year, and also includes a monthly food parcel.[51] 
In evaluations of the project, Atitude’s clients report 
increased self-care, strengthened family relations, 
increased sociability and protection against violence, 
and a feeling of being welcomed and respected.
[51,52] These effects are particularly strong among 
those enrolled in the social housing programme.[51] 
Substance use is not permitted within the project’s 
facilities, as this would risk closure of the project, 
but clients are permitted to leave the building to use 
drugs, and are not excluded for ongoing drug use.[51] 
While providing a positive experience to clients able 
to access the service, Atitude is consistently over-
subscribed and cannot provide services to all people 
who use crack cocaine who need them.[51] Staff are 
also concerned that current political developments 
in Brazil may create a considerably more challenging 
legal and financial environment for the project in the 
future.[51]
Another project, Achique de Casavalle, provides 
support for social and labour-market integration 
to people who use cocaine paste in Montevideo, 
Uruguay. Funded by a mixture of city, state and 
national government bodies, the project provides a 
low-threshold drop-in centre, where service users 
prepare and eat meals together, can access personal 
hygiene and therapeutic services, and attend group 
leisure activities, as well as employment-oriented 
courses including computer use, carpentry and 
construction.[51] Like Atitude, Achique de Casavalle 
focuses on increasing the self-esteem, independence 
and autonomy of its clients. However, it also suffers 
from a lack of resources: there is no computer or 
internet connection on site, and it lacks the staff 
necessary to accompany clients to referral services. 
Staff at the project also report that access for women 
is insufficient. Many women who use cocaine paste 
in the area are mothers, but Achique de Casavalle is 
unable to accommodate children.[51]
In the 2016 edition of the Global State of Harm 
Reduction, it was reported that the De Braços Abertos 
(Open Arms) project in so-called Crâcolandia, a 
stigmatising name for the open crack scene in 
São Paulo, Brazil, was to be closed under the city’s 
new mayor, João Doria.[29] Since then, De Braços 
Abertos has been replaced by the new Redenção 
(Redemption) project. Whereas De Braços Abertos 
provided health, employment and accommodation 
support to people who use crack with no 
precondition of abstinence or treatment,[29] Redenção 
rejects the harm reduction approach.[4] There have 
been reports that it requires that participants abstain 
from crack use and undergo mandatory drug tests 
or face eviction from the programme, though civil 
society organisations report that this has not yet 
happened.[53,54] In its first eight months, Redenção 
saw an adherence rate of just 17%.[55] In early 2017, 
there was a significant armed police operation to 
clear Crâcolandia. Local health workers have been 
recorded as saying that this operation increased 
mistrust of state services among people who 
use drugs, meaning they are less likely to access 
remaining health and harm reduction services.[36] 
Projects similar to De Braços Abertos continue to 
operate elsewhere in Brazil, but many across the 
country have faced similar repressive government 
action since the 2016 municipal elections.[6]
Overdose, overdose response and drug 
consumption rooms (DCRs) 
Since the Global State of Harm Reduction last reported 
in 2016, opioid overdose response mechanisms in 
Latin America have stalled or reversed. Naloxone, a 
highly effective opioid receptor antagonist used to 
reverse the effects of an overdose, had previously 
been available outside hospitals in Paraguay, 
Colombia and Mexico.[12,22,64] Despite being on the 
WHO List of Essential Medicines,[65] there is no 
indication it remains available in Paraguay in any 
context. In Colombia, a naloxone peer-distribution 
programme operated by Acción Técnica Social 
saved 70 lives from 2014 to 2017, and included peer 
training in naloxone use and distribution.[16] However, 
this programme was discontinued in 2017 due to 
Ministry of Health regulations stating that naloxone 
is only available for use in hospitals.[16,22] New 
Ministry of Health guidelines on naloxone were due 
to be published in 2017, but there is no sign of their 
publication.[16,22]
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In Mexico since 2016, naloxone has been made 
available in Tijuana, Mexicali, San Luis Río Colorado 
and Ciudad Juárez. In Mexicali and San Luis Río 
Colorado, Verter has established peer distribution 
networks for naloxone, and La Casa del Centro 
has created a network in Tijuana.[12,23] At the time 
of publication, distribution of naloxone has been 
minimal, with only 200 doses distributed in Verter’s 
programmes.[12] 
Naloxone’s availability remains highly limited across 
the region. The primary barriers to its distribution 
are a lack of funding and restrictive legislation.[12,22] 
Naloxone has been shown to be highly effective 
in reducing overdose deaths, particularly when 
doses and training are made accessible in the 
community.[66] For this reason, peer distribution of 
naloxone, such as the limited programme in Mexico, 
should form part of the harm reduction programme 
in those areas in the region where opiate use is 
prevalent.
Although no state-sanctioned drug consumption 
rooms exist in the region, a small facility run by 
Verter in Mexicali, Mexico provides a safe space for 
women to inject drugs as part of the Las Colectas 
project.[12] The facility is limited to those already 
involved in other Las Colectas programmes for 
women who inject drugs.[12] Civil society organisations 
note that they expect the region’s first official drug 
consumption room to open in Mexicali in 2018,[12] 
and that debates were held on their implementation 
in the Colombian congress in 2017.[9,22] However, 
during the 2017 presidential campaign, the new 
president of Colombia, Iván Duque, committed to 
blocking the introduction of such facilities.[16]
Viral hepatitis
Data on viral hepatitis among people who inject 
drugs is sparse and largely outdated in Latin America. 
Hepatitis C prevalence among people who inject 
drugs in the region has been recorded ranging from 
6.7% in Bogotá, Colombia to 96% in two cities in 
Mexico, with a pooled regional prevalence of 49% 
according to a 2015 systematic review based on 
research carried out between 2000 and 2013.[7,67] This 
is in line with the worldwide estimated prevalence 
of hepatitis C among people who inject drugs of 
50%.[67,68] The same systematic review estimated 
hepatitis B prevalence of 3.3% among people who 
inject drugs in the region.[67,68]
The integration of viral hepatitis services with HIV 
and harm reduction services remains sporadic in 
Latin America. In northern Mexican cities where 
injecting drug use is more common, state-funded 
hepatitis C diagnostics and treatment are available to 
people who injects drugs[12]. By contrast in Colombia, 
hepatitis C services are only intermittently integrated 
with HIV and harm reduction services.[9,16]
Four Brazilian studies published since 2016 have 
found evidence suggesting people who use crack 
and cocaine paste are also more vulnerable to viral 
hepatitis infection. Studies have suggested that this is 
associated with sharing pipes (with blood transferred 
from bleeding lips or gums) as well as higher-risk 
sexual practices.[25-27,69,70] The Casa Masantonio 
project in Buenos Aires, Argentina opened in 2016, 
and integrates hepatitis C treatment into harm 
reduction services for cocaine paste users.[24]
The need to address viral hepatitis among people 
who use drugs is clear from Table 2.5.1. It is essential 
that diagnosis and treatment is routinely integrated 
into harm reduction services, and that more data is 
collected on viral hepatitis prevalence among people 
who use drugs.
Tuberculosis (TB)
TB incidence in Latin America is generally high and 
stable. For example, in 2016 there were 117 cases 
per 100,000 people in Peru and 42 per 100,000 in 
Brazil, representing only minimal declines since 
2014.[71] Although data on TB prevalence among 
key populations is lacking, research suggests higher 
prevalence among people who inject drugs and 
prisoners than the general population.[3,72]
TB testing and treatment is generally available 
across the region; for example it is offered free of 
charge or on state insurance in Brazil, Argentina 
and Peru.[24,73,74] However, targeted TB services for 
people who use drugs are lacking. TB diagnosis 
and treatment is not integrated into HIV or harm 
reduction programmes for people who inject drugs 
in Colombia or Mexico.[12,16] As with viral hepatitis, 
cocaine paste and crack use is associated with 
higher TB prevalence. The Casa Masantonio project 
in Buenos Aires, Argentina, integrates TB in its work 
with cocaine paste users.[24]
HIV and antiretroviral therapy (ART)
In Latin America, new HIV infections among the 
general population have plateaued since 2010 
having previously been declining, though small 
decreases were noted in 2015 and 2016.[39] There is 
considerable variation in trends across the region: 
Colombia and Nicaragua both saw decreases of over 
10% in the number of new HIV infections between 
2010-2016; Chile, Costa Rica, Guatemala and 
Honduras all saw increases of more than 10%.[39]
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Of particular concern for HIV response in the region 
is the case of Venezuela. Since the escalation of 
the deep political and economic crisis in 2015, HIV 
prevention has largely collapsed, with 95-100% of 
hospitals holding no stock of antiretroviral drugs 
and the government unable to supply even basic 
means of prevention such as condoms.[75,76] Isolated 
and indigenous communities have been particularly 
affected, with HIV prevalence of around 10% and 
rising by 10% each year in some communities, with 
no state capacity to respond to the epidemic.[77]
Data on HIV among people who inject drugs is 
scarce. A Colombian study published in 2017 
estimated HIV prevalence among people who inject 
drugs in the country at 5.5% (compared with the 
general population prevalence of 0.4%).[8,78,79] In 
several countries, including Costa Rica, Mexico and 
Colombia, ART is unavailable or limited for people 
currently using drugs despite being available to the 
general population, with a lack of adherence cited 
as a reason.[9,10,12] This is in contrast to evidence 
from several studies suggesting there is no clear link 
between drug use and ART adherence, particularly 
when the person is receiving OST.[80-82] Additionally, in 
Colombia people must provide formal identification 
in order to access ART, making people who use 
drugs less likely to access services for fear of 
criminal repercussions and social stigma.[16] Recent 
developments in the region have made pre-exposure 
prophylaxis and post-exposure prophylaxis for HIV 
– courses of medication that can reduce the chances 
of HIV infection either before or after exposure to 
the virus – available to key populations such as men 
who have sex with men. However, neither is currently 
available to people who inject drugs anywhere in the 
region.[39]
High HIV prevalence has been found among crack 
and cocaine paste users as well as people who inject 
drugs. A 2017 study found prevalence of 2.8% among 
people who use crack in Goiás, Brazil, compared 
with a national general population prevalence of 
0.6%.[69,79] It is suggested that this is associated with 
pipe-sharing and higher-risk sexual behaviour, as has 
been shown by studies in Mexico and Brazil.[25–27] HIV 
treatment is integrated into harm reduction services 
for cocaine paste users in the Casa Masantonio 
project in Buenos Aires, Argentina;[24] however, 
outside this example, the population remains 
underserved in terms of a specialised response to 
HIV.
Harm reduction in prisons
As of 2016, there were approximately 1.4 million 
people incarcerated in Latin America, with a total 
incarceration rate of 242 per 100,000.[83] This 
population has grown over the past decade, but 
the growth of the population incarcerated for drug 
offences has been significantly faster. In Brazil from 
2006-2014, the general population grew 8%, the 
prison population grew 55% and the population of 
people imprisoned for any drug offence grew 267%.
[84] In Colombia from 2000-2015 the figures are 19%, 
142% and 289% respectively.[84] In Argentina from 
2002-2014 they are 13%, 49% and 127%.[84] It is 
estimated that 20% of the region’s prisoners have 
been detained for drug-related offences.[84] The 
specific drugs involved vary by country. For example, 
in Colombia the most common is cocaine (47% of 
cases), while in Mexico and Brazil it is marijuana (62% 
of cases in both).[84,85]
Though drug use and/or possession for personal 
use is decriminalised in some Latin American 
countries, these laws are often not implemented by 
law enforcement at street level.[84,86,87] In practice, 
consumption and possession for personal use 
remain criminalised. Across the region, it is estimated 
that 25% of those in prison for drug offences 
in Latin America are there for crimes related to 
consumption.[84,85] 
Of particular concern is the rapid increase in the 
number of women incarcerated for drug offences. 
In Latin America, women are more likely than men 
to be convicted of non-violent drug offences, occupy 
low levels in the drug trade and tend to be primary 
caregivers.[84,88] For example, since 1991, the number 
of female prisoners in Colombia has increased by 5.5 
times (compared with 2.9 times for men) and 93% 
of women in prison are thought to be mothers.[89] As 
a result of this trend, which is replicated across the 
region, a phenomenon has been noted in Argentina 
and Bolivia of children of women incarcerated for 
drug offences living inside detention centres with 
their mothers.[90,91] Approximately 600 children as 
old as 12 were living in Bolivian prisons with one 
or both parents in 2017.[92] A recent Inter-American 
Commission on Human Rights report recommended 
that states take gender into account in the judicial 
treatment of women who use drugs and women in 
the drugs trade, in order to limit the wider effects of 
incarceration on children and families.[88]
The region has a high proportion of prisoners in pre-
trial detention.[84,88] In some countries, for example 
Mexico, pre-trial detention is obligatory for all drug 
offences (including possession and consumption). In 
others, such as Costa Rica, where pre-trial detention 
is not obligatory, it is often extended for drug 
offences.[84,93] This practice of applying compulsory 
pre-trial detention to a specific category of offence 
has been condemned by the Inter-American 
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Commission on Human Rights, on the grounds that it 
frequently represents a punishment disproportionate 
to the crime committed.[88]
Many Latin American prisons are characterised by 
overcrowding, violence, and scarce hygienic and 
medical resources.[84,86,94] HIV, hepatitis C and TB 
prevalence are all elevated among Latin American 
prisoners compared with the general population, 
with health risks also transferred to non-prisoners 
who visit or work in prisons.[84] A recent study of 
prisoners in Argentina found an HIV prevalence 
of 2.68%, rising to 44.6% among prisoners with a 
lifetime incidence of injecting drug use. This pattern 
was mirrored in the prevalence of both hepatitis C 
and hepatitis B.[72] 
Access to harm reduction services for people who 
inject drugs in prisons is severely limited; currently 
no country in Latin America offers NSP or OST in 
prison. Prior to 2016, NSP services operated in 
two Mexican prisons (in San Luis Río Colorado and 
Mexicali).[12] As of 2018, however, neither Mexico 
nor Colombia, where NSP and OST are available 
to the general population, offer NSP or OST in 
prisons.[12,16,22] Condoms, HIV testing and ART are 
available in both Mexican and Colombian prisons, 
but hepatitis C treatment is available in neither.[12,16] 
As in the continent at large, injecting drug use is 
largely absent from prisons in most countries in the 
region.[10] However, use of cocaine (as powder, crack 
and paste) has been documented in the region’s 
prisons.[10,72,95] Harm reduction services for people 
who use cocaine are also largely absent in this 
setting.
Since 2012, drug treatment courts have operated 
in several countries  in the region, with the aim of 
removing people who use drugs from the penal 
system. This option officially is available only to first-
time offenders with diagnosed drug dependence, 
though it is frequently used for people accused 
of simple possession.[94] However, an emphasis 
on abstinence and drug testing limits both the 
efficacy and the harm reducing potential of these 
programmes.[94] The Inter-American Commission 
on Human Rights has noted that the use of drug 
courts in parts of the region has resulted in the 
criminalisation of drug possession or use, rather than 
providing a public health alternative to the criminal 
process.[96]
As noted in the Global State of Harm Reduction 2016,[29] 
privately run (though sometimes publicly funded) 
forced rehabilitation centres that violate the human 
rights of people who use drugs exist in several 
countries in Latin America. This continues despite 
the practice being condemned by the UN Special 
Rapporteur on torture and other cruel, inhuman or 
degrading treatment or punishment, and the UN 
Special Rapporteur on health. In most, medication 
for withdrawal and even trained medical staff are 
unavailable.[97] 
Policy developments for 
harm reduction
In 2016, the Global State of Harm Reduction 
reported that Latin America was experiencing a 
shift away from a punitive approach to drug use 
and towards a model favouring harm reduction.[29] 
Policy developments in favour of harm reduction 
in the region have slowed or stalled over the past 
two years, though. In Brazil, a new government 
came to power in 2016, and in 2018 implemented 
a new drug strategy explicitly rejecting the harm 
reduction approach and closing several programmes.
[6,98] At both a national and a local level, similar 
developments have been seen in Argentina, 
Colombia and in São Paulo, Brazil.[4,16,52]
Despite these setbacks, harm reduction continues to 
progress in other parts of the region. In January 2017, 
the Costa Rican government, with the involvement 
of civil society groups, published a National Harm 
Reduction Model as part of national drug policy, 
with the explicit objective of implementing harm 
reduction services.[10,99] Costa Rica has promoted 
harm reduction on the world stage, with statements 
in favour during the UN General Assembly Special 
Session on Drugs in 2016 and a side-event on harm 
reduction at the Commission on Narcotic Drugs 
in 2018.[10,100] In Mexico, a commitment to harm 
reduction was included in the government’s 100 day 
action plan on HIV prevention submitted to UNAIDS 
in 2018.[101]
The Colombian national government remained 
supportive of harm reduction programmes up to 
2018, and the Ministry of Health has developed 
guidelines on harm reduction (including the 
distribution of naloxone). However, the publication 
of these guidelines has been delayed without 
explanation.[16,22] The peace deal signed in 2016 
between the Colombian government and the Fuerzas 
Armadas Revolucionarias de Colombia (FARC) 
guerrilla group includes a commitment to take a 
human rights and public health approach to illicit 
drug consumption, and specifically references the 
role of harm reduction.[103] Despite this, civil society 
organisations report that few policy steps have been 
taken to implement the peace agreement, and a 2017 
reform to the police code introduced new sanctions 
for those found in possession of illicit drugs.[16,22]
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The election of Iván Duque as president of Colombia 
in June 2018 has cast further doubt on the future 
position of the Colombian government. Though 
Duque has a history of supporting harm reduction 
programmes, including a bill to introduce drug 
consumption rooms, his presidential campaign 
focussed heavily on a law enforcement-oriented 
approach to drugs.[22,104] This included criminalising 
possession for personal use, rejecting harm 
reduction programmes and opposition to the 2016 
peace deal.[16,104] 
The political pendulum
Since 2016, harm reduction in Latin America has been 
shown to be highly vulnerable to electoral outcomes, 
and to changes in public opinion at the local and national 
level. The pendulum effect brought on by changes in 
local or national administrations can make long-term 
planning and consistent service delivery difficult.
The case of Crâcolandia, São Paulo’s massive open drug 
scene, is representative of this issue. Local elections 
occurring every four years have triggered overhauls of 
the local government’s approach to crack use in the city. 
The abstinence and rehabilitation-centred Recomeço 
project operated under state government control before 
2012, when it was joined by the city government-funded, 
harm reduction-led De Braços Abertos project from 
2014-2016.[4,29,54] Since 2016, De Braços Abertos has 
been replaced by Redenção in a return to abstinence-
focused projects.[4,53] Civil society organisations identify 
these swings between administrations in favour of and 
against harm reduction as a reason for Crâcolandia’s 
resilience.[36] Civil society programmes operating while 
state-led harm reduction is absent are interrupted when 
the state enters their space, and are unable to build 
legitimacy.[36] The progress made under the state-led De 
Braços Abertos project, particularly in establishing trust 
between healthcare workers and Crâcolandia residents, 
was lost once the project was closed and civil society 
organisations fear it will be difficult to regain.[36,55] In this 
way, swings between political positions (not only the 
direction of political travel) have had a negative impact 
on the delivery of harm reduction programmes. This 
process has been mirrored in other parts of Brazil, where 
the national government, installed in 2017, has turned 
away from harm reduction and closed the majority of 
state-sponsored programmes.[6,98]
Cyclical changes in levels of political commitment have 
also had an impact in Colombia. At times when local 
governments are in favour of harm reduction, state 
agencies operate the programmes with no operational 
input from civil society (sometimes as a result of donor 
conditions stating that services must be provided directly 
by the state).[16] This means that civil society groups are 
unable to build operational capacity, and therefore 
cannot provide services when the pendulum swings and 
the programmes are closed by the state.[16] In Bogotá, a 
recent change in city government has led to the closure 
of NSP and OST programmes, with civil society ill-
equipped – both financially and operationally – to fill the 
gap.[16] This has left people who inject drugs in the city 
without harm reduction services.
Presidential elections in 2018 in Brazil, Colombia and 
Mexico have had the potential to advance or reverse 
harm reduction in each country, with leading candidates 
on both sides of the debate in all three elections.[9,105-107] 
Civil society organisations have expressed concern that 
as long as there is no consensus among the political 
class on the benefits of harm reduction, there will always 
be a degree of uncertainty about their financial and legal 
sustainability.[36] This is particularly relevant at a time 
when international donors are withdrawing from the 
Latin America region.
Civil society and advocacy 
developments for harm 
reduction
The Latin American Conference on Drug Policy 
continues to provide a forum for civil society to 
network, share experiences of best practice and 
develop advocacy strategies for harm reduction.[52] 
The seventh iteration of the event was held in Mexico 
City in conjunction with the Mexican Conference on 
Drug Policy in October 2018, and sought to assess 
the current challenges in Latin American drug policy, 
the strength of the global reformist movement 
and proposals for the future of drug policy in the 
region.[108]
Latin American regional meetings have taken 
place to discuss broadening the definition of harm 
reduction to include the wider social consequences 
of drug policies[4]. These three meetings, held in 
Argentina, Uruguay and Brazil, have established a 
network of activists, academics and government 
officials that acts as a collaborative group, updating 
its members on progress and setbacks of the harm 
reduction movement across Latin America.[4,109] The 
first meeting, held in Buenos Aires with participation 
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from Argentina, Brazil, Uruguay and Paraguay, 
produced a document that was widely distributed 
among different harm reduction groups in the 
region, sharing experiences in harm reduction 
implementation.[109] The third of these meetings, 
held in Rio de Janeiro, produced the Letter from 
Manguinhos, calling for the protection of harm 
reduction programmes in the face of a growing 
wave of conservative politics and drug policy in Latin 
America. It also called for the inclusion of wider 
social issues into the harm reduction arena, such 
as the way drug policies have been used to target 
marginalised populations (e.g. women, indigenous 
peoples, black, LGBTI and youth).[4,110]
Civil society groups, including Intercambios 
with support from the International Drug Policy 
Consortium, successfully opposed an amendment 
to the Argentinian National Mental Health Law 
that would have removed the obligation for the 
government to treat addiction as a mental health 
issue in Argentinian law, allowing for an expansion 
in the use of involuntary detention (either in 
prison or mental health facilities) for people who 
use drugs.[4,111,112] Also in Argentina, an open letter 
was written in 2016 by 253 magistrates urging 
the government to enact a drug policy based on 
principles of human rights and harm reduction, 
rather than criminalisation and law enforcement.[4,113]
The Latin American Network of People who Use 
Drugs (LANPUD) was founded in 2012 and continues 
to advocate on behalf of people who use drugs in the 
region, including signing the Letter from Manguinhos 
in 2017.[110] In Brazil, two harm reduction networks, 
ABORDA (Associação Brasileira de Redução de 
Danos, Brazilian Harm Reduction Association) and 
REDUC (Rede Brasileira de Redução de Danos e 
Direitos Humanos, Brazilian Harm Reduction and 
Human Rights Network), have worked to create 
national networks of people who use drugs,[6] 
complementing the work of LANPUD.[29] A new 
Brazilian initiative launched in 2017, Intercambiantes, 
seeks to maintain a network of information on harm 
reduction programmes, conferences and meetings, 
publications, at the intersection of mental health 
and drug use[4]. The Black Initiative for a New Drug 
Policy and the National Network of Anti-Prohibitionist 
Feminists aim to broaden the debate about drug 
policy to include the specific impacts on the black 
community and women respectively.[4,114]
Although the Mexican Network for Harm Reduction 
has not been through any major developments 
since 2016, a meeting of civil society organisations 
in the country was held to present harm reduction 
proposals to the national HIV prevention body.[12] 
In Argentina, 22 organisations from five provinces 
created a network, launched on 26 June 2017, to 
advocate for the decriminalisation of drug users, 
less strict sentencing for low-level drug crime and 
drug policy focused on health outcomes and harm 
reduction.[4] This was followed up in 2018 with a 
campaign based on the principles of Support. Don’t 
Punish, highlighting the specific problems faced by 
women who use drugs.[115]
Civil society groups in both Colombia and Costa Rica 
have been advocating for harm reduction policies. 
Colombian organisations have actively contributed 
to United Nations meetings supporting changes 
and reforms in drug policy,[9] while in Costa Rica, the 
new national harm reduction model was developed 
with the participation of civil society.[10] The Costa 
Rican Association for Study and Intervention on 
Drugs (ACEID), has used the Support. Don’t Punish 
campaign to organise various high-level meetings 
with policy makers on the need for drug policy 
reform and harm reduction, and in 2016 held a 
workshop for NGOs working with the Global Fund 
on harm reduction.[10] Colombian civil society groups 
remain optimistic that they are in a stronger position 
to oppose the new presidential administration’s 
prohibitionist agenda than they were under the 
similarly inclined presidency of Álvaro Uribe two 
decades ago.[16]
In April 2018, Colombian organisation Acción Técnica 
Social held its third Semana Psicoactiva (Psychoactive 
Week) conference on public policy to address 
psychoactive substances, with a strong emphasis on 
harm reduction. The conference brought together 
projects from across the Americas.[16] Discussions and 
workshops were held on themes such as heroin use 
in Latin America, the role of psychoactive substances 
in the transmission of sexually transmitted diseases, 
and substance analysis of new psychoactive 
substances.[116]
Funding developments for 
harm reduction
As reported in the 2016 edition of the Global State 
of Harm Reduction, the Global Fund and Open 
Society Foundations (OSF) have been the significant 
international donors funding harm reduction 
programmes in Latin America.[4] Both funded NSPs 
and OST in Mexico and Colombia before 2016; 
however, since 2016 the Global Fund has gradually 
withdrawn funding.[9,12,16,22] While efforts have 
been made by donors and civil society to ensure 
alternative sustainable funding is found, these have 
sometimes been unsuccessful. For example, in Cali 
and Pereira, Colombia, harm reduction measures 
have been funded by a combination of the Ministry 
of Health, National Drug Fund, local government 
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funding and OSF, since the withdrawal of the Global 
Fund. However, in other cities, such as Bogota and 
Dosquebradas, harm reduction programmes have 
been closed.[22] Under the revised Global Fund 
Eligibility Policy, Argentina, Brazil and Mexico remain 
ineligible for funding.[4,117]
Civil society organisations in Colombia have raised 
concerns that the requirement for Global Fund 
resources to be managed by the state leads to 
bureaucratic delays and inefficiency. For example, 
non-governmental organisations only received their 
funding for 2017 in July of that year, meaning that 
they had only six months to achieve targets intended 
for the entire year.[16] They also fear that the explicit 
involvement of the state in all projects may dissuade 
people who inject drugs from accessing services.[16] 
Reducing barriers for civil society organisations to 
access funds directly may help to alleviate these 
issues.
A key funding issue reported by civil society 
organisations is a focus on HIV programmes by both 
international donors and national governments. 
For example in Colombia, Global Fund support 
has prioritised programmes with an explicit HIV-
prevention dimension (such as NSPs), leaving few 
financing opportunities for forms of harm reduction 
without an HIV focus.[22] In Mexico, the only state 
funding for harm reduction comes through the 
national HIV programme; this means that harm 
reduction organisations compete with those working 
with other key populations, such as men who have 
sex with men and sex workers. The result is that, on 
average, only five harm reduction projects per year 
receive government funding.[12] In Costa Rica, Global 
Fund support for harm reduction is only available 
for projects working with people who inject drugs, 
despite high HIV prevalence among people who use 
smokable cocaine, meaning that this population has 
no access to harm reduction services and abstinence-
based models prevail.[10]
With respect to national government investment, 
Resolution 518/2015 in Colombia allowed territories 
to pay for harm reduction measures from the 
Public Health Fund. However, the amount available 
is insufficient and there are other priorities that 
compete for these funds.[9] Similar issues have 
been faced in Costa Rica, where the national 
harm reduction model states support for civil 
society organisations, but no funding has been 
made available.[10] There is a clear, urgent and 
demonstrated need for declarations of political 
support for harm reduction programmes to be 
accompanied by financial support.
As international donors withdraw from the region, 
the trend has been an increase in the proportion 
of harm reduction funding provided by national 
governments. When harm reduction services were 
first implemented in Colombia, 90% of funding came 
from international donors and 10% from national 
government; today civil society organisations 
estimate that 75% is from international donors 
and 25% from national government.[9,16] However, 
national funding consistently falls short of what 
international donors have previously provided, 
leaving services without a sustainable source of 
financing and unable to provide continuous services 
to vulnerable populations.[16]
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Table 2.6.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in North America 
Country/territory
with reported
injecting
drug usea
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs(%)
Harm reduction responsei
NSPb OSTc
Peer-
distribution 
of naloxone
DCRsd
Canada
90,000 
(72,000-
108,000)[1]
11%[2] 68%[3] nk [4,18] 
[4,18] 
(M,B,BN,O)
[4,18] 26[4]
United States 2,248,500[5] 8.7%[5] 53.1%[5] 4.8%[5] 335[6] e 
[15] 
(M,B,BN,O)
[15] x
 
nk – not known 
a	 There	are	no	identified	reports	of	injecting	drug	use	in	Greenland.
b	 The	number	in	brackets	represents	the	number	of	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	
workers.
c The number in brackets represents the number of operational OST sites, including publicly and privately funded clinics, and pharmacy dispensing programmes. (M) = methadone, (B) = 
buprenorphine, (BN) = buprenorphine-naloxone combination, (O) = any other form (including morphine and codeine).
d	 DCR	=	drug	consumption	room,	also	referred	to	as	a	safer	injecting	facility	(SIF),	a	safe	injecting	site	(SIS)	or	an	overdose	prevention	site	(OPS).
e	 These	services	operate	in	44	of	the	50	states,	as	well	as	in	Puerto	Rico.	However,	the	number	in	Table	2.6.1	does	not	include	Puerto	Rico	and	civil	society	state	that	the	actual	figure	in	
the table is higher as it does not include NSPs which operate clandestinely.
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NALOXONE
NALOXONE
CANADA
Map 2.6.1: Availability of harm reduction services
Both NSP and OST available
OST only
NSP only
Neither available
Not Known
DCR available
Peer-distribution of naloxoneNALOXONE
Harm reduction in North America
f Year: 2015.
g	 This	figure	does	not	include	Puerto	Rico.	Please	refer	to	the	Caribbean	chapter	(p81)	for	information	on	Puerto	Rico.
h Estimates based on data gathered between 2006 and 2016.
i	 Naloxone	is	a	highly	effective	opioid	antagonist	used	to	reverse	the	effects	of	opioid	overdose	in	minutes.
Overview
North America is estimated to have 17% of the total 
number	of	people	who	inject	drugs	in	the	world,	
and the highest prevalence of past-year opioid 
use.[7] During 2015, an estimated 47.7 million people 
in the United States (US) used illicit drugs or used 
prescription drugs for non-medical purposes, 2% of 
which were stimulants,[8] the second most commonly 
used drugs after cannabis in the region.[7] In Canada, 
13% of people had used at least one illicit drug in the 
past year,f an increase of 2% since 2013.[9] 
The prevalence of opioid use is particularly high 
in North America, and the region continues to 
experience the world’s highest drug-related mortality 
per capita.[7] The US now has the fastest annual 
percentage rise of drug-related fatal overdose ever 
recorded, with an increase of 21.4% between 2015-
2016 alone.[7] In Canada, opioid-related deaths 
have also dramatically increased: 72% of deaths 
involved fentanyl or fentanyl analogues in 2016, and 
81% of overdose deaths in Canada were linked to 
fentanyl.[7,10]	Fentanyl	and	its	analogues	are	synthetic	
opioids which can be 50 times more potent than 
heroin and 100 times more potent than morphine. 
Canada reports 92% of its opioid-related deaths as 
accidental/unintentional.[10] The worrying increase in 
opioid-related overdose deaths has been met with a 
public health response which broadly encompasses 
the	principles	of	harm	reduction,	but	to	differing	
extents in the US and Canada. 
Needle and syringe programmes (NSPs) have been 
scaled up in the US and Canada overall. In Canada, 
provinces and territories are responsible for 
providing public health harm reduction services such 
as NSPs, and therefore information is not tracked 
at the national level.[11] However, it is estimated 
that	94.5%	of	people	who	inject	drugs	used	sterile	
injecting	equipment	at	last	injection.	In	the	US,	335	
NSPs operate across the country,[6]g an increase of 
91 in total and a 37.3% rise in programmes since 
the Global State of Harm Reduction last reported.[12] 
OST provision is less well established in the US and 
was only available in 8.5% of all facilities, both public 
and private, which can provide the medication.h[13] In 
Canada OST is available in all ten provinces (but there 
is	no	national-level	figure	for	the	total	number	of	
sites across the country). 
Scaled up naloxone provision and the establishment 
of	drug	consumption	rooms	(DCRs)	or	safer	injecting	
facilities	(SIFs)	have	been	critical	to	the	overdose	
response in this region. In 2016, the Canadian 
Ministry of Health replaced the National Anti-Drug 
Strategy with the Canadian Drugs and Substances 
Strategy, which includes harm reduction as one of 
its four core pillars.[14] This ushered in a number 
of developments in harm reduction, including a 
regulatory amendment making naloxonei available 
without prescription (enabling pharmacies and 
others to proactively distribute the medicine to those 
who might experience or witness an opioid overdose) 
and new front-line harm reduction interventions.[14] 
At the time of publication there were 26 supervised 
consumption sites granted licenses in Canada, a scale 
up of 24 since the Global State of Harm Reduction last 
reported.[4] 
In the US, community-based naloxone programmes 
are in operation, but the greatest barrier to 
distribution is its status as a prescription medication, 
making wider peer/community distribution more 
complex.[15][16] In September 2018, the governor 
of	San	Francisco	rejected	legislation	which	would	
have	authorised	the	establishment	of	the	first	SIF	in	
the US.[17] Other US cities that have recently voiced 
support for the implementation of DCRs include 
New York City, Seattle, Denver, Ithaca (NY) and 
Philadelphia.[15]
A noteworthy harm reduction development in this 
region is the increased availability of fentanyl testing 
strips, which have been distributed nationally in the 
US since 2016 through harm reduction programmes 
and activists,[15] and are available at harm reduction 
sites and within some DCRs operating in Canada.[4,18] 
Drug-checking services have been funded on a pilot 
basis by the Canadian government and operate to 
varying extents across the region for opioids and 
other drugs, such as MDMA, methamphetamines, 
cocaine and LSD. 
Given	that	North	America	has	the	highest	annual	
prevalence of amphetamine-type stimulant (ATS) 
use in the world,[7,8] the harm reduction response for 
people who use stimulants continues to fall short 
of need, and there remains a need to support the 
development, evaluation and expansion of harm 
reduction	interventions	specific	to	ATS	use.[19,20] There 
is one best practice harm reduction programme for 
people who stimulants in Toronto [19] (please see ATS 
section, p.9). 
Although certain harm reduction interventions 
have been scaled up in the community, provision 
of harm reduction in prisons continues to be 
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woefully	inadequate,	falling	far	short	of	meeting	
both international human rights and public health 
standards.[21] In the United States, one in nine arrests 
are for drug possession,[22] and 47% of people 
incarcerated in federal prison are sentenced for drug 
offences.[23] 
This regional chapter highlights a distinction between 
the United States and Canada. Under the current US 
administration, the “War on Drugs” and abstinence-
focused rhetoric drive punitive approaches, 
disproportionate criminal penalties and resistance 
to	harm	reduction	interventions	(including	SIFs	
and naloxone distribution). This punitive approach 
further	manifests	in	involuntary	confinement	and	
forced treatment (in places like Massachusetts, 
Pennsylvania, New Jersey and Wisconsin) and 
discriminatory criminalisation of black and Latinxj 
people	for	drug-related	offences.[24,25] Even given the 
difficult	political	climate,	civil	society	organisations	
all over the United States continue to promote and 
practise evidence-based harm reduction. In contrast, 
the Canadian government has publicly, politically 
and	financially	committed	to	and	endorsed	harm	
reduction. 
As in every other part of the globe, there remains a 
distinct lack of harm reduction services for women 
in the region.[26,27] Women who use drugs face a 
range	of	gender-specific	barriers	to	accessing	harm	
reduction programmes and healthcare services and, 
in some states in the US, may face prosecution for 
child abuse for using drugs while pregnant, or may 
have their children removed by the state on grounds 
of drug use alone. [28,29] 
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
NSPs operate in both Canada and the US, with 
the US seeing an increase in the number of states 
operating these services since 2016. The US now 
has 335 NSPs operating across the country,[6]k an 
increase of 91 in total since 2016,[12]	equalling	a	37.3%	
rise	in	programmes.	The	US	also	saw	its	first	NSP	
vending machine open in Las Vegas in 2017.[30] The 
increase in NSPs is a result of the federal government 
changing its position on NSPs, leading to a partial 
repeal of the ban on federal funding for this service. 
While the use of federal funds to purchase sterile 
needles	or	syringes	to	inject	illicit	drugs	remains	
j	 Latinx	is	the	gender-neutral	alternative	to	Latino,	Latina	and	Latin@.
k	 This	figure	does	not	include	Puerto	Rico.	Please	refer	to	the	Caribbean	chapter	(p81)	for	information	on	Puerto	Rico.
prohibited, the Consolidated Appropriations Act 
2016 enables federal funds to be allocated to other 
aspects of NSPs, including HIV and HCV testing, 
naloxone provision, human resources, rent and other 
expenditures needed to keep them in operation.[15,31] 
The partial repeal of the ban on federal funding has 
had the most impact across the Appalachian region 
and in the Southern states.[15] In the Appalachian 
region in 2013, prior to the government changing 
its legal position on NSPs, only one service was 
operational, with NSPs illegal in Kentucky and North 
Carolina.[32] Since the partial repeal of the ban, both 
Kentucky and North Carolina have legalised NSPs; 
there are now 53 NSPs in operation across these 
two states. [32] North Dakota, Montana and Michigan 
have also seen an increase in NSPs.[15] Although NSP 
coverage has improved in some states, provision of 
this service overall remains patchy, with other states, 
such as Iowa, having only one registered NSP in 
operation.[6]
The United States saw annual HIV diagnoses among 
people	who	inject	drugs	decrease	by	approximately	
48% between 2008 and 2014.[33] Of note, however, is 
a	shift	in	trends	in	injecting	drug	initiation	and	unsafe	
injecting	practices.	Overall	heroin	use,	for	example,	
has increased more than 114% among white 
people,[15,33]	and	46%	of	new	injectors	(people	who	
have	been	injecting	drugs	for	a	period	of	five	years	or	
less)	are	reported	to	practice	unsafe	injection,	such	
as the sharing or reusing of needles and syringes.[33] 
Large hard-to-access rural areas are often neglected, 
and	major	gaps	in	service	provision	exist	in	the	
Mountain, South and Midwest regions of the US, 
where there is sometimes no NSP access at all.[15] 
These states, due to sanctions and funding, leave 
people with no safety net, and rural outreach is 
often a tricky and costly pursuit when not utilising 
peers and community health workers.[15] Pregnant 
or parenting women are also often fearful of 
seeking services from NSPs due to stigma and 
punishment,	which	forms	a	major	barrier	for	them.	
While	targeted	efforts	to	reach	women	exist,	they	
are limited and often small-scale.[26] Awareness and 
cultural relevance of NSPs also remain issues, which 
not	all	services	are	addressing.	The	vast	majority	
of messaging and materials cater to people who 
inject	opioids,	unintentionally	excluding	populations	
which	would	benefit	from	harm	reduction	tailored	to	
ingestion	techniques,	particularly	given	the	changing	
cohort of people who use opioids in the United 
States.[15]
In Canada, provinces and territories are responsible 
for providing public health prevention services, such 
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as NSPs.[11] It is estimated that 94.5% of people who 
inject	drugs	used	sterile	injecting	equipment	at	last	
injection.[34] Barriers to access remain, especially in 
northern, rural and remote communities (where 
there is a lack of access to healthcare more broadly, 
especially for people who use drugs), with a 
disproportionate impact on the many Indigenous 
(First	Nations,	Métis	and	Inuit)	communities	who	
reside in northern, rural and remote regions of 
Canada.[4] Some municipalities have also passed 
discriminatory zoning bylaws that prevent NSPs and 
other harm reduction services from operating in 
certain areas, thus imposing geographical barriers.[4]
Opioid substitution therapy (OST)
OST provision is available in both the United States 
and Canada. In the US, approximately 2.1 million 
people had used either medically prescribed or illicit 
opioids during the course of 2015. During the same 
period, 411,331 people accessed OST services.[35]l 
OST in the US is available in the form of methadone, 
buprenorphine and naltrexone.[15]m It was estimated 
that between 2006 and 2016, OST was only available 
in 8.5% of all facilities, both public and private, that 
can provide this medication in the United States.[35] 
Methadone is more strictly regulated through federal 
and state laws in the United States, and although it is 
available both publicly and privately, 64% of people 
who received methadone in 2016 received it from 
a private facility.[35] Buprenorphine is more widely 
available, with access broadened in 2016 when 
President Obama signed into law Section 303 of the 
Comprehensive Addiction Recovery Act (CARA).[37] 
This law extended buprenorphine prescribing 
privileges to nurse practitioners and physician 
assistants, following the successful completion 
of 24 hours of training. Physicians who dispense 
buprenorphine	must	qualify	for	a	physicians’	waiver	
and complete eight hours of training.[37,38] Although 
the law enables the extension of OST services, in 
practice 28 states prohibit nurse practitioners from 
prescribing buprenorphine unless they are working 
in collaboration with a doctor who has a federal 
licence, and half of all the counties in the US do not 
have a single physician with a licence.[39] 
There are, however, pockets of good practice 
emerging, with the state of Vermont integrating 
hub-and-spoke models of OST provision.[15,40,41] 
This	model	uses	regional	hubs	offering	daily	OST	
support together with local spokes, including doctors, 
nurses and counsellors for people using opioids or 
l	 This	figure	does	not	include	the	number	of	people	using	extended	release	naltrexone	for	detoxification.
m	 As	naltrexone	requires	people	to	stop	using	opioids	and	to	undergo	a	detoxification	programme,	and	its	links	to	overdose	mortality	since	last	injection	remain	
unclear,[36] it will not be covered within the body of this report.
transitioning to OST who can oscillate between the 
two,	subject	to	need.[41] Vermont now has the highest 
capacity for OST in the USA, seeing a 64% increase 
in physicians able to prescribe buprenorphine, 
and a 50% increase in people seen per (waivered) 
physician.[40] A small study in New York demonstrated 
harm reduction service providers are the preferred 
site of buprenorphine provision for 51% of people 
who use opioids.[13] Expanding prescribing authority 
to harm reduction service providers across the US 
could	best	meet	user	preferences	and	significantly	
increase access. 
Upselling OST: the state of America
In the United States, corporate sub-markets have 
mushroomed	around	OST,	creating	additional	financial	
implications	for	access.	The	requirement	for	people	to	
undertake urine test analysis, which must show evidence 
only of the prescribed substance (i.e. buprenorphine 
or methadone) to continue OST medication, is not 
uncommon in the US.[15] Urine testing has become 
big business, with clinic-owned laboratories rapidly 
appearing in treatment centres billing around US$4,000 
per test.[42]	Given	that	people	may	be	tested	either	daily	
or a few times a week, these costs (either in terms of 
Medicare or private health insurers) soon soar, with 
private labs often making 2,375% of the government rate 
(US$80.00) per test.[42] On top of this is the regulatory 
framework behind urine testing, which states that for 
every	test	a	doctor	must	sign	a	requisition,	providing	a	
note that the person’s urine should be tested for illicit/
licit drugs.[42] In some cases doctors charge a fee for the 
requisition	of	between	US$3,000-$8,000	per	month	for	
each person or facility.[42] 
It is widely known and acknowledged that retention in 
both methadone and buprenorphine treatment are 
associated with substantial reductions in risk for all 
causes of death and overdose mortality.[43] OST has also 
be	shown	to	be	effective	in	self-reported	abstinence	
from street opioids[44] and has a positive impact on drug-
related HIV risk behaviours (making it both a treatment 
and a harm reduction approach).[45] Yet coverage of 
existing programmes in the US remains substantially 
below the levels recommended by international 
guidance.[35,46] 
In	September	2017,	the	US	Food	and	Drug	
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Administration	(FDA)	released	a	safety	announcement	
stating that buprenorphine and methadone should not 
be withheld from people taking benzodiazepines or 
other drugs that depress the central nervous system 
(CNS).[47] Although combined use can increase the 
risk	of	serious	side-effects,	the	FDA	concluded	that	
withholding OST causes greater harm, and that risks can 
be reduced through careful management by healthcare 
professionals.[47] 
In Canada, OST is available in the forms of 
methadone, buprenorphine, buprenorphine/
naloxone combinations (for example, Suboxone) 
and	injectable	prescription	heroin	known	as	heroin-
assisted therapy (HAT).[4,18] OST is available in all 10 
provinces in Canada through a variety of models, 
including government-funded programmes, private 
clinics and family practice; but the total number of 
sites is unknown due to a lack of aggregated national 
surveillance.[4,18] 
In Ontario, Canada’s largest province, the number 
of people receiving OST has increased from 6,000 
in 2000 to over 40,000 in 2016,[48] highlighting 
the scaling up of services. However, even with 
the increases in provision, a number of barriers 
to accessing OST remain. These include a lack 
of treatment providers, particularly in rural and 
remote	areas;	burdensome	requirements	such	
as	weekly	clinic	visits	(not	required	by	treatment	
standards); a lack of OST integration into primary 
care	services;	unaffordable	clinic	fees;	and	until	
March	2018,	the	requirement	for	physicians	to	obtain	
an exemption from the federal Controlled Drugs and 
Substances Act (CDSA) to prescribe methadone.[4,18] 
Policy developments to reduce barriers to the 
implementation of HAT have taken place in Canada. 
For	example,	in	2015	the	Supreme	Court	in	British	
Columbia ruled that people who were receiving HAT 
as part of a clinical trial (at time of publication the 
only mode of accessing HAT in Canada) would be 
able to continue receiving the medication outside 
a research setting.[49] Although clinical trials have 
illustrated	significant	positive	outcomes,	including	
a reduction in street heroin use of 70%, HAT had 
not been expanded outside research settings at the 
time of reporting.[18] In March 2018, the Canadian 
government took measures to facilitate access to OST 
by removing regulatory barriers to the prescription 
of methadone and heroin-assisted therapy (HAT). 
These	amendments	removed	the	requirement	for	
physicians to apply for a CDSA exemption to obtain 
and prescribe methadone, and allow both physicians 
n During 2015, 4,828,000 people used cocaine in the past year, 1,713,000 used methamphetamine and 5,251,000 misused prescription stimulants.
and nurse practitioners to administer methadone 
and HAT outside of hospital setting.[50]
Amphetamine-type stimulants (ATS), cocaine 
and its derivatives, and new psychoactive 
substances (NPS)
North America has the highest annual prevalence of 
amphetamine-type stimulant use in the world, with 
2% of 15-64 year olds using a stimulant in the past 
year.[7,8] Stimulants, including cocaine and the non-
medical use of prescription stimulants such as Ritalin, 
were used by nearly 11 million people in the United 
States in 2015.[8]n In Canada, although prevalence of 
past-year use of at least one illicit drug had increased 
by 2% (from 11% in 2013 to 13% in 2015), the number 
of people in Canada reporting using a stimulant in 
the past year remained unchanged at 1%.[9] 
As in other regions of the world, ATS use is generally 
increasing, including within the market of new 
psychoactive substances (NPS), with 36% of all 
NPS on the global market being stimulants.[7] And 
although there are a small handful of harm reduction 
services for people who use stimulants, there 
remains a serious need to support the development, 
evaluation and expansion of harm reduction 
interventions	specific	to	ATS.[19,20] This need is 
apparent when looking at the increase in emergency 
room visits related to the use of methamphetamine 
(rising from 68,000 in 2007 to 103,000 in 2011) in the 
US,[51] and rates of drug overdose deaths involving 
(psycho)stimulants, which increased 23% between 
2008 and 2015.[8] The rise in ATS use in the US, 
particularly	methamphetamines,	is	not	adequately	
covered by the harm reduction response.[20,19] 
A recent report by Mainline, a Netherlands-based 
harm reduction organisation, provides the most 
comprehensive review of stimulant harm reduction 
programmes and practices to date.[19] The report 
provides a literature review on various types of 
stimulants, routes of administration and harm 
reduction strategies; seven case studies from across 
the	globe;	and	reviews	interventions	more	specific	
to people who use stimulants. The potential health-
related	harms	of	stimulant	use	are	different	to	that	
experienced by people who use opioids. People 
who use stimulants report feeling that they belong 
to	different	(social)	networks	of	people	who	use	
drugs, meaning they may feel opioid-focused harm 
reduction services are irrelevant or inaccessible 
to them.[19] However, similar to people who use 
opioids/inject	drugs,	there	is	no	single	intervention	
which is recommended but a comprehensive body 
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of interventions.[19] These include: safer smoking 
kits for people who smoke crack cocaine and/
or methamphetamines; prevention of sexual risk; 
female-focused interventions; drug consumption 
rooms; self-regulation strategies; substitution; 
outreach and peer-based interventions; drop-in 
centres;	housing	first;	therapeutic	interventions;	and	
drug-checking services.[19] 
In the US, a small handful of the above interventions 
exist. DanceSafe is one popular harm reduction and 
peer-based	education	intervention	which	offers	a	
drug-checking service (EcstatsyData.org) and the 
only publicly accessible laboratory analysis of ecstasy 
data in the US.[52] It also provides testing kits to 
purchase online, including for methamphetamines, 
opioids, MDMA and psychedelics such as LSD, as 
well as fentanyl test strips. [52] One of the central 
issues for drug-checking services is they often have 
to overcome legal challenges around licences to 
possess and work with scheduled substances, with 
many countries still not accepting drug-checking as a 
valid argument to issue an exemption.[53] The limited 
programmes that exist in the US do not meet need 
and are underfunded. With a steadily increasing 
prevalence of ATS use in the United States,[54] it is 
clear that comprehensive, accessible harm reduction 
services are much needed.
In Canada, the harm reduction response for people 
who use ATS is a little more established, and over 
recent years federal and provincial governments 
have scaled up drug-checking services in the 
country.[4,18] These services are more recently funded 
by the federal government and operate at a number 
of	supervised	injection	and	overdose	prevention	
sites (see DCR section).[18] Although much of the 
emphasis on the scaling up and adoption of new 
harm reduction services has been in response to the 
opioid crisis,[18] drug-checking services throughout 
the country also target other subpopulations of 
people who use drugs and some technologies (e.g. 
fentanyl test strips) are available for purchase.[55] In 
late 2017, Health Canada committed to authorising 
and	funding	pilot	projects	providing	drug-checking	
services at supervised consumption sites in British 
Columbia and Ontario.[56] British Columbia has also 
funded publicly available anonymous drug-checking 
services, acknowledging that some overdose deaths 
are caused by fentanyl contamination of non-opioid 
drugs such as cocaine.[4] 
Other harm reduction programmes for stimulant 
users have also been established in Canada, such 
as	COUNTERfit	in	Toronto,	a	best	practice	example	
of a harm reduction programme for people who 
smoke either crack cocaine or methamphetamine.[19] 
COUNTERfit	has	around	73%	of	service	users	using	
ATS and around 90% of service users engaging in 
polydrug use.[19]	Operating	since	2000,	COUNTERfit	
was	the	first	in	Canada	to	address	the	needs	of	
non-injectors	by	distributing	kits	for	safer	crack	and	
methamphetamine smoking.[19] The programme’s 
success comes in meeting the health and social 
needs of people who use drugs via a number of 
access	points:	a	fixed	site;	mobile	outreach	services	
offering	an	out-of-hours	delivery	service;	and	at	the	
homes of trained service users within their network 
via community or agency-based satellite services.[19] 
In 2017, the programme distributed 67,500 crack 
stems to service users, reaching approximately 
150 people every day.[19] People can order both 
sterile	needles	and	injecting	equipment	alongside	
smoking	equipment	for	free.	The	programme	also	
offers	a	women’s	harm	reduction	programme	and	
an	aboriginal	support	group,	recognising	the	unique	
needs and challenges of both groups.[19]	The	majority	
of	COUNTERfit’s	funding	comes	from	Ontario’s	
Ministry of Health and Long Term Care, with some 
financial	support	from	the	municipal	government	of	
Toronto.[19] 
Other harm reduction interventions, such as 
cannabis	as	a	means	of	reducing	the	frequency	
of crack cocaine consumption, have also been 
made available in Canada,[57] but predominantly as 
research/pilot	studies.	The	first	federally	sanctioned	
supervised inhalation services opened in Lethbridge 
and Calgary, Alberta in 2018.[58]
While there is less evidence on harm reduction 
interventions for people who use stimulants than 
for opioid users, new research and the handful of 
harm reduction programmes for stimulant users 
are showing promising results.[19] More research, 
including into some of the strategies highlighted 
in the 2018 Mainline report, better monitoring of 
impact, and sharing of best practices and funding for 
inclusive harm reduction services for people who use 
stimulants (including cocaine and its derivatives) are 
much needed in North America.[20,19]
Overdose, overdose response and drug 
consumption rooms (DCRs) 
In a 15-year period (2000-2015), the US saw almost 
600,000 fatal overdoses.[60]	This	is	the	equivalent	to	
a population the size of Baltimore disappearing. In 
2016, 63,632 people died from a drug overdose in 
the US, 66.4% of which involved opioids.[59] In New 
York City alone, a fatal overdose occurs every seven 
hours.[59] There are more annual deaths from an 
opioid overdose in New York than fatal car accidents, 
suicides and homicides combined.[60]  
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Important developments have taken place in 
response to the unprecedented number of overdose-
related deaths in North America. Naloxone is a 
highly	effective	opioid	antagonist	used	to	reverse	the	
effects	of	opioid	overdose	in	minutes.	The	medicine,	
which can be delivered in various ways (intra-
nasal, sublingual and buccal) can, however, only be 
effective	if	accessible.[61-64] Many community-based 
naloxone programmes in the US are in operation, 
some	staffed	by	individuals	who	identify	as	peers	
or having lived experience with drug use, and some 
via formal peer-distribution where people are 
given	large	quantities	of	the	medicine	to	distribute	
through their personal networks.[15] The greatest 
barrier to distribution, however, is the fact that 
naloxone remains a prescription medication in the 
US, meaning wider peer/community distribution can 
only operate with a medical gatekeeper who can 
procure a licence to purchase the medicine with the 
authority to distribute it under a standing order.[15] 
Civil society organisations and activists have been 
remarkable in overcoming these challenges, with an 
estimated 1 million doses of naloxone distributed 
across the US via community-based programmes in 
2017.[15] Naloxone programmes have expanded in 
at least seven states (including Nevada, Iowa, North 
Dakota,	Virginia,	Michigan,	Texas,	Florida	and	New	
Hampshire) and several indigenous communities 
in Minnesota and Wisconsin have begun naloxone 
distribution,	including	establishing	the	first	tribal-
approved contracts to purchase and distribute 
the medicine.[15] In 2017, the state of New York 
implemented a naloxone co-payment assistance 
program (N-CAP) through a New York State 
Department	of	Health	access	initiative,	the	first	and	
only subsidised programme for naloxone obtained 
at pharmacies in the United States. This means that 
in over 2,000 pharmacies in New York state, a person 
can pick up naloxone treatment valued at US$40 
(including nasal spray, intranasal and intramuscular) 
at no cost to the individual.[65] 
In an evaluation of community opioid overdose 
prevention, researchers found 83-100% survival 
rates post-naloxone treatment, demonstrating 
that non-medical bystanders trained in community 
opioid	prevention	techniques	were	effectively	able	
to administer naloxone.[61] Yet in some states, public 
health funding for naloxone is being diverted from 
services for people who use drugs into the purchase 
of	naloxone	for	law	enforcement	officers.[15]	Efforts	
to	expand	naloxone	to	first	responders	is	vital,	
but should not supersede community-based peer-
distribution. 
Inflammatory	media	reports	in	the	US	also	
represent a barrier to the roll out of naloxone; for 
example, false narratives on naloxone-resistant 
fentanyl, stories of “narcan parties” and allegations 
of	first	responders’	exposure	to	fentanyl	(by	air	
or	skin)	resulting	in	“overdose”	have	the	effect	of	
transforming an essential medicine into a fabricated 
moral hazard.[15]
Similarly to the US, Canada has witnessed a dramatic 
increase in opioid-related deaths. In 2017, 3,987 
opioid-related deaths were recorded, 72% of which 
involved fentanyl or fentanyl analogues.[10] Canada is 
larger	than	the	US	in	terms	of	landmass	and	has	just	
one tenth of the US population. Canada’s response to 
the overdose crisis has been multifaceted. As noted 
above, the Canadian federal government removed 
many barriers to accessing naloxone in 2016;[4,18] 
now,	instead	of	requiring	a	prescription	for	each	
individual in need of naloxone, pharmacies are able 
to proactively distribute naloxone to those who might 
experience or witness an opioid overdose.[66] 
In May 2017, a new law (Bill C-37) was passed 
in Canada which included amendments to the 
Controlled Drugs and Substances Act to streamline 
and simplify the application process for opening 
supervised consumption sites, and 26 sites were 
approved at the time of publication.[4,67] Across 
Canada, grass roots leaders have established pop-up 
overdose prevention sites (OPS) to better respond to 
the high rates of overdose, and use the language of 
OPS to convey the importance of these interventions 
to the community at large.[18] These new pop-up OPS 
originated in Vancouver in response to delays from 
the government, with members of the community 
setting up a tent in an alley in the Downtown Eastside 
area and stocking it with needles and naloxone, 
enabling	people	to	inject	safely.[68] Activists in Toronto 
and Ottawa followed suit, providing unsanctioned 
spaces for people to use drugs in the presence of 
others (including healthcare and harm reduction 
volunteers) and providing naloxone.[4,69] In April 
2016, in response to the alarming rise in overdose 
deaths, British Columbia’s minister of health declared 
a public health emergency under the provincial 
Public Health Act. By December 2016, the health 
minister had signed a ministerial order to activate 
overdose prevention services as a means to provide 
temporary safe spaces for people who use drugs 
to be monitored in the case of an overdose. Since 
this order, at least 25 of these facilities have been 
established across the province.[4] In other provinces, 
such as Ontario (which saw 850 opioid-related deaths 
in 2016),[70] unsanctioned OPS were established by 
communities in response to the overdose crisis in 
2017.[4] However, a recent change in the Ontario 
provincial government – led by a premier who has 
publicly stated his opposition to overdose prevention 
services – means the future of these in the province 
is unclear.[4] 
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In Vancouver, Sister Space, a women-only overdose 
prevention	site,	also	opened	in	2018	and	is	the	first	
female-only space where women can access NSPs 
and overdose prevention.[27] In late 2017, the federal 
government announced that Health Canada would 
authorise emergency overdose prevention sites 
for	those	provinces	and	territories	that	requested	
them;	the	Ontario	government	formally	requested	
approval, with eight approved sites operating in 
the province at time of publication.[4] OPS sites 
currently operate in four provinces (British Columbia, 
Alberta,	Ontario	and	Quebec),	with	the	first	federally-
sanctioned supervised inhalation service opening in 
Alberta in 2018.[18]
Another harm reduction measure designed to 
contribute towards addressing the overdose crisis 
in North America is drug-checking services. The 
rise in fatal overdoses in the region is driven partly 
by prescribing practices and in part by a surge in 
fentanyl contamination of the street drug market, 
a	synthetic	opioid	significantly	more	potent	than	
heroin. Prescribing practices over the last decade 
have been postulated as resulting in people seeking 
out illicit opioids for pain relief once their prescription 
has been retracted, and receiving fentanyl or 
fentanyl-laced drugs which are much stronger than 
the person is used to and therefore contributing 
heavily to fatal overdose rates.[15,60] In the United 
States, fentanyl deaths have increased by 540% in 
three years.[71]	Given	this,	in	2016	harm	reduction	
service providers and activists began distributing 
fentanyl testing strips,[15]	shown	to	be	an	effective	
overdose prevention strategy within the community 
of people who use drugs.[72] Testing strips, like all 
harm reduction interventions, are dependent on 
funding; although several programmes in the US 
have received monies to provide this service, others 
are forced to raise private funds (some through 
crowdfunding sites) to sustain their activity.[15] 
When the Global State of Harm Reduction last 
reported	in	2016,	there	were	no	safer	injection	
facilities	(SIFs)	in	the	US.	Since	then,	momentum	
has	been	building	around	SIFs,	with	several	cities	
supporting policies on the implementation of these 
spaces,	including	New	York,	San	Francisco,	Seattle,	
Denver and Philadelphia.[15] At time of publication, no 
sanctioned	SIFs	were	operating	in	the	US,	although	
at least one facility was operating “underground” in 
the country.[73] In September 2018, the governor of 
San	Francisco	rejected	legislation	which	would	have	
authorised	the	establishment	of	the	first	SIF	in	the	
US.[17,74]  
o	 Medicaid	is	a	joint	federal	and	state	programme	that	may	assist	with	medical	costs	for	people	with	limited	income	and	resources.
The	US	and	Canada	both	have	Good	Samaritan	laws,	
which protect people from arrest or prosecution 
for drug possession when they call for help in the 
event of an overdose, and support a legal and policy 
environment conducive to harm reduction. In the 
US, 40 states and the District of Columbia have now 
enacted	some	form	of	Good	Samaritan	laws.[75] 
In	May	2017,	the	Good	Samaritan	Drug	Overdose	
Act was passed in Canada, amending Canada’s 
Controlled Drugs and Substances Act to exempt 
a person from being charged or convicted of the 
offence	of	possession	of	drugs	when	emergency	
help is sought for an overdose, and evidence of drug 
possession was obtained or discovered as a result 
of the person having sought assistance or having 
remained at the scene.[4] Seeking emergency help 
could include calling 911, leaving the scene to call 
911 or leaving the scene to locate emergency medical 
assistance.[4] The increase in drug-induced homicide 
laws	undermines	the	provision	of	Good	Samaritan	
laws in the US.
Viral hepatitis
Viral	hepatitis	continues	to	disproportionately	affect	
people	who	inject	drugs	in	North	America.	In	the	
United States an estimated 4.4 million people are 
living with a chronic viral hepatitis infection, with 
the number of new hepatitis C infections increasing 
rapidly, prior progress in reducing new hepatitis 
B infections stalling and hepatitis-related deaths 
increasing.[76]	Injecting	drug	use	continues	to	be	the	
most	common	risk	factor	for	acquiring	hepatitis	
C	through	unsafe	injecting	practices	such	as	the	
sharing or reusing of needles and syringes, and 
between 2010 and 2014 a 350% increase in hepatitis 
C	among	people	who	inject	drugs	was	seen	in	
the US[76] In a research paper examining trends in 
incidence of acute hepatitis C among young people, 
88% of the 34 reporting states in the US observed 
a higher incidence of acute hepatitis C in 2012 than 
2006, with 75% (n=635) of interviewees reporting 
injection	drug	use.[77] Diagnosing and treating people 
who	inject	drugs	improves	health	outcomes	and	
prevents transmission of hepatitis viruses to others; 
however, links to hepatitis C care and treatment 
remain poor.[15,76] 
A central issue in the US is the criteria limiting access 
to	hepatitis	C	treatment	for	people	who	inject	drugs	
via Medicaido programmes.[78] Currently, the most 
effective	treatment	for	hepatitis	C	is	direct-acting	
antivirals	(DAAs),	but	patient	access	is	often	subject	
to	fibrosis	stage,	abstinence	from	drugs	and	alcohol,	
and prescriber eligibility (which can be limited to 
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certain categories of specialist practitioners).[78] 
Although	efforts	have	been	made	to	eliminate	these	
restrictions, 24 states continue to have restrictive 
Medicaid	treatment	policies	that	require	a	period	
of abstinence before receiving treatment, and 18 
states have no laws authorising syringe exchange 
programmes.[79] Access to needles and syringes is 
a public health strategy used to reduce the risk of 
infection from blood-borne viruses such as hepatitis.
In Canada, it is estimated that between 220,697 and 
245,987 people were living with chronic hepatitis C in 
2011.[80]	Similar	to	the	US,	unsafe	injecting	practices	
such as the reusing or sharing of needles and 
syringes	is	considered	the	most	significant	mode	of	
hepatitis C transmission in the country,[3] with 54-70% 
of hepatitis C infections contracted via this route of 
transmission.[81] However, whereas in the US rates of 
hepatitis C are steadily increasing, in Canada the rate 
of reported cases of hepatitis C have decreased from 
40.2 per 100,000 in 2005 to 29.3 per 100,000 in 2014p 
with public health interventions, such as NSP and 
OST provision, believed to have impacted hepatitis 
rates	among	people	who	inject	drugs.[3]
Although Canada does not have a national policy on 
hepatitis C, testing and treatment are theoretically 
available to people who use drugs, with at least eight 
provinces	and	territories	removing	a	fibrosis	stage	
requirement	for	hepatitis	C	treatment	(including	
British Columbia, Ontario, Quebec, Saskatchewan, 
Manitoba, Alberta, Yukon Territory and Prince 
Edward Island).[4] While coverage of testing and 
treatment	is	difficult	to	assess	in	Canada	due	to	a	
lack of centralised data, civil society reports that in 
practice, access remains a challenge for many.[4] In 
Newfoundland, for example, people who use drugs 
have	been	disqualified	from	accessing	hepatitis	C	
treatment.[4] In a national sample of people who 
inject	drugs,	20.2%	of	people	who	tested	positive	
for hepatitis C were unaware of their status[82] and 
only 15.3% of those who knew their status were 
taking medications prescribed for hepatitis C.[82] A 
primary deterrent to seeking testing and treatment 
among people who use drugs in the country remains 
the fear of stigma and discrimination in healthcare 
settings, and the variable degree to which hepatitis 
C testing and treatment is integrated into harm 
reduction or HIV programmes.[4]
Tuberculosis (TB) 
Data on TB prevalence, prevention, treatment 
and	care	among	people	who	inject/use	drugs	in	
the region continues to be scarce, limiting the 
p	 Significantly	higher	rates	of	hepatitis	C	than	the	national	average	of	29.3	have	been	observed	in	British	Columbia,	Alberta,	Saskatchewan,	Ontario,	Nova	Scotia,	
Prince Edward Island, Yukon and the Northwest Territories.
effectiveness	of	policies	and	programmes	designed	
to	address	this	issue	and	making	it	difficult	to	provide	
a useful overview of the situation in the region. In 
Canada, around 1,600 new cases of TB are diagnosed 
each year, with TB rates higher among Indigenous 
populations.[83] There are multiple reasons for this, 
including poor housing conditions, higher rates 
of malnutrition and reduced access to medical 
care, highlighting the health and socio-economic 
disparities often seen in these populations.[84]
Similar to all regions of the world, people who use 
drugs in North America have increased rates of TB 
infection, particularly if they are living with HIV.[85] 
When TB treatment is integrated with HIV, hepatitis 
C and OST, improved outcomes for each condition 
have been observed, as well as improved adherence 
and retention in tuberculosis treatment for those 
living with TB.[85]	International	standards	require	a	
coordinated and integrated response to the needs of 
people who use drugs in order to provide universal 
access to prevention, treatment and care services at 
all entry points.[86] 
Antiretroviral therapy (ART)
In the United States, an estimated 1,122,900 people 
were living with HIV at the end of 2015, with an 
estimated 38,500 new HIV infections that year, 
9%	attributed	to	injecting	drug	use.[89] Among all 
populations in the US, the estimated number of 
new infections declined between 2011 and 2015. 
However, for the 1.1 million people thought to be 
living with HIV, only 48% of people were retained 
in continuous HIV care, and only 49% of people 
had achieved viral suppression.[87] In Canada, an 
estimated 63,111 people are living with HIV, with 
2,165 new infections reported in 2016.[88] Among 
the estimated new infections, approximately 244 
were	among	people	who	inject	drugs,	accounting	for	
11.3%.[88] At the end of 2016, 81% of those diagnosed 
with HIV were estimated to be on treatment, and 91% 
of people on treatment had suppressed viral load.[88] 
In	First	Nation	communities,	of	the	individuals	
known to be living with HIV, 77% were on treatment 
and 75% of those in treatment had achieved viral 
suppression.[88]
People	who	inject	drugs	continue	to	be	at	high	risk	
of	transmitting	or	acquiring	HIV	for	several	reasons,	
including laws criminalising the possession and use 
of drugs, the resulting high rates of incarceration, 
and	variable	access	to	sterile	syringes	and	injecting	
equipment.	Research	has	also	highlighted	a	new	
generation	of	heterosexual	people	who	inject	
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drugs sharing needles and increasingly interested 
in methamphetamine.[89] The changing trends 
in	injecting	drug	use,	particularly	in	terms	of	
methamphetamine	injecting,	has	the	potential	to	
increase vulnerability to transmission of HIV in 
the US.[89] One study found that among men who 
have	sex	with	men	who	admitted	sharing	injecting	
equipment,	their	last	sharing	partner	had	been	a	
woman in 31% of cases and a heterosexual man in 
14% of cases.[89] 
In Canada and the US, although access to HIV testing 
and treatment are available for everyone, people 
who use drugs continue to have trouble accessing 
these services.[4] Persistent stigma and discrimination 
sadly remain, but other systemic factors such as a 
lack of secure housing, a lack of access to healthcare 
services (particularly in rural and remote areas) and 
poverty appear as central barriers to ART initiation 
and adherence among this population.[4,15]
Harm reduction in prisons
As the Global State of Harm Reduction reported in 
2016, the US continues to have the second highest 
rate of incarceration in the world, with 698 people 
incarcerated per 100,000.[91] To put this in context, 
the global average is 144. Nowhere in the world do 
we	see	the	human	consequences	of	the	“war	on	
drugs” as starkly as in the United States, with one in 
nine arrests – one every 25 seconds – being for drug 
possession,[22] and 47% of people incarcerated in 
federal	prisons	sentenced	for	drug	offences.[23] 
In 2010, Michelle Alexander stated “nothing 
has contributed more to the systematic mass 
incarceration of people of color in the United States 
than the war on drugs”.[92] Research clearly illustrates 
the	vastly	unequal	consequences	across	racial	groups	
that the “war on drugs” has perpetuated. Although 
rates of drug use and sales are similar across racial 
and ethnic lines, black and Latinxq people are far 
more likely to be criminalised for a drug-related 
offence	than	white	people.[25] Prosecutors are twice 
as likely to pursue a mandatory minimum sentence 
for black people as for white people charged with 
the	same	offence.[25] One in nine black children has 
an incarcerated parent, with the rates one in 28 
and one in 57 for Latinx children and white children 
respectively; and 40% of those incarcerated in a state 
or federal prison for drug violations are black, 37% 
Latinx.[25] 
A 2015 estimate of the cost of “hyperincarceration” 
stated that each year the US spends $80 billion on 
imprisoning people;[92] however, a later study noted 
q	 Latinx	is	the	gender-neutral	alternative	to	Latino,	Latina	and	Latin@.
that for every dollar spent on correctional costs, 
incarceration generates an additional ten dollars 
in social costs, bringing the aggregate burden per 
year to $1 trillion.[93] Although it is clear there is an 
unmanageable trend for over-incarceration and 
punishment for people who use drugs, former US 
attorney	general	Jeff	Sessions	rescinded	the	2013	
Cole Memo (which allowed federal prosecutors to 
choose	not	to	prosecute	marijuana	offences	in	the	
states that allow adults to consume it) as well as the 
Smart on Crime initiative, which addressed racial 
disparities and disproportionate drug sentencing.[94] 
In Canada, prison numbers are considerably 
lower than the US, with 106 people incarcerated 
per 100,000.[90] However, similarly to the United 
States there is an over-representation of racialised 
communities entering the prison system, particularly 
the Indigenous population.[95] Between 2007 and 
2016, although the general prison population 
in	Canada	increased	by	just	under	5%,	the	
Indigenous prison population increased by 39%, 
and incarcerated Indigenous prisoners were much 
more likely to experience segregation in solitary 
confinement	(36.5%).[95]
Imprisoning people for drug use is not only costly 
and systematically discriminatory, it also appears one 
of the most counterproductive criminal sanctions, as 
drug use continues within the prison setting.[96,97] In 
2014, the World Health Organization estimated that 
every sixth prisoner is thought to be using drugs in 
prisons.[97] A study undertaken in 2015 in Baltimore 
found that incarceration did not only fail to curtail 
injecting	drug	use	among	former	injectors,	but	
that longer periods of incarceration were actually 
associated	with	increases	of	injecting	among	former	
injectors.[98] Between 2012 and 2017 the percentage 
of positive drug tests via random urine analysis in 
Canadian	prisons	fluctuated	between	5.6%-6.3%,	
despite	significant	investments	in	detection	and	
surveillance to stop drugs from entering prisons.[95] 
Despite evidence of drug use in prisons and the 
clear need for harm reduction in these settings, 
provision continues to be extremely limited, falling 
far short of meeting international human rights and 
public health standards.[21] HIV prevalence among 
prisoners in the United States is 3-5 times greater 
than the general population,[99,100] and 20-26% of 
people living with HIV/AIDS in the US will have spent 
time in the correctional system at one point in their 
life.[101] Prevalence of HCV among prisoners is also 
much higher than the general population, with the 
largest population of HCV-positive inmates in the 
world found in North America (553,500-784,000).[102] 
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Tuberculosis has also been reported to be up to 100 
times higher among prisoners,[103] with 29 cases per 
100,000	in	local	jail	inmates,	8	per	100,000	in	state	
prisons, and 25 per 100,000 in federal prisons in 
the United States.[104] Prisons continue to represent 
high-risk environments for the transmission of blood-
borne infections for a number of reasons. These 
include: the over-incarceration of vulnerable and 
disadvantaged	groups	who	are	more	likely	to	suffer	
from poor health; the criminalisation of people who 
use drugs; risky behaviour in prisons, such as unsafe 
injecting	drug	use;	inadequate	health	care	and	late	
diagnosis of disease; substandard prison conditions 
and overcrowding; poor ventilation and repeated 
prison transfers which encourage transmission 
of viruses; and the absence of harm reduction 
services.[103,105] 
Although the US has the largest prison population 
in the world, critically needed harm reduction 
programmes, such as NSPs, remain unavailable 
in 2018. In June 2018, Canadian civil society had a 
breakthrough success in their advocacy for NSPs in 
prisons, with a prison needle exchange programme 
authorised to begin operating in one men’s federal 
prison and one women’s federal prison, where 
people are serving a sentence of two or more years, 
and plans to roll-out the initiative across all federal 
prisons the coming years.[106,107] Details of the new 
programme,	however,	reveal	serious	deficiencies	that	
will likely curtail prisoners’ access, and civil society 
advocates will continue to push for a better model 
that	reflects	the	principle	of	healthcare	equivalency.[4]
OST in the form of methadone or buprenorphine 
remains available in only a small number of American 
state prisons,r meaning coverage for those who have 
been incarcerated remains extremely poor.[15] OST 
is	a	vital	service	to	offer	in	the	prison	setting,	given	
that between 24-36% of people who use heroin 
will pass through the prison system at one point in 
their life,[108] and the fact that this population is also 
between 8 and 129 times more likely to overdose 
in	the	first	two	weeks	post-release	from	prison.[109] 
It is estimated that nearly 90% of people currently 
receiving OST outside prisons in the US would 
have their treatment removed if incarcerated.[110] 
Of the existing OST programmes in state prisons 
in the US, many have severe restrictions (i.e. only 
pregnant women, or a continuation of treatment 
rather than initiation), with Rhode Island and New 
Mexico an exception to this rule. In Rhode Island, 
where OST is available to people in prison in the 
form of methadone, buprenorphine or naltrexone, 
there has been a 61% decrease in post-incarceration 
overdose deaths among those recently released.[111] 
r	 Arizona,	California,	Connecticut,	District	of	Columbia,	Florida,	Illinois,	Maryland,	New	Mexico,	New	York,	Pennsylvania,	Vermont	and	Washington.
The evidence is abundantly clear, yet provision of this 
medication	across	the	majority	of	the	US	remains	
wholly	inadequate,	with	just	40	local/county	jails/
state and federal prisons providing this service out of 
5,000 facilities.[39]
In Canada, OST has been available within some 
prison settings since 1999. OST initiation and 
continuation is available in all 43 of the country’s 
federal prisons.[4] However, in provincial and 
territorial prisons in Canada, OST availability varies, 
with	most	provinces	offering	OST	continuation	but	
some	not	offering	initiation,	citing	difficulties	with	
locating treatment providers, fear of diversion, short 
length	of	incarceration,	and	a	lack	of	staffing	and	
resources,	leaving	inadequate	provision	for	people	
who use drugs.[4,18] Harm reduction measures such as 
OST are also not implemented to the same extent in 
women’s prisons.[27] 
At the time of publication, naloxone provision in 
US prisons was available in New York State and 
New Mexico, and on release only. New York State’s 
Overdose Education and Naloxone Distribution 
Program	was	a	result	of	a	joint	collaboration	
between the Harm Reduction Coalition, the New 
York State Department of Health and the New York 
State Department of Corrections and Community 
Supervision, and at the end of 2017 over 20,000 
people within the prison setting had been trained 
to use naloxone.[15] In mid-2018, the New Mexico 
Corrections Department began a naloxone 
programme similar to the New York model, whereby 
people	are	trained	whilst	incarcerated	and	offered	
naloxone on release.[15] In Canada, a take-home 
naloxone programme began in federal prisons 
in British Columbia in November 2016, and has 
since been expanded country-wide, with 4,950 kits 
expected to be supplied to prisoners on release 
between 2017 and 2020.[112] The programmes are 
aimed at inmates who are already on OST or who 
have a history of opioid use. In federal prisons in 
Canada,	healthcare	and	some	correctional	staff	also	
have access to naloxone.[4] However, the situation 
varies in provincial and territorial prisons.[4]
Research has indicated that prisoners are more 
likely to be exposed to blood-borne viruses in the 
prison setting,[102,113]	and	reports	of	injecting	drug	
use in prisons are found worldwide.[114] In prisons 
in the United States, only 37.9% of people newly 
diagnosed with HIV were linked to HIV services within 
90 days.[115] In Canada, voluntary HIV testing and 
treatment	is	offered	in	all	federal,	provincial	and	
territorial prisons.[4] The estimated HIV prevalence 
among people who are in federal prison has declined 
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in Canada, going from 2.02% in 2007 to 1.2% in 2017, 
with 94% of people known to have HIV receiving ART 
treatment.[116] Disruptions to treatment occurring 
during transfers between institutions and to/from 
the community remain a challenge.[4] 
In Canada, it is estimated that around one in four 
prisoners have hepatitis C.[117] Voluntary testing 
is	offered	in	all	federal,	provincial	and	territorial	
prisons,[4] with the treatment budget for this 
population in federal prisons increasing fourfold 
since 2010 (CAN$16.5 million between 2017-2018).[118] 
All federal prisoners diagnosed with hepatitis C 
in Canada are eligible for treatment, regardless 
of	fibrosis	stage.[4] In the United States, recent 
analysis suggests that only around 10% of the prison 
population who have chronic hepatitis C can access 
medication.[119] Studies also indicate that hepatitis C 
testing is limited for people who use drugs, and that 
treatment for people in prisons is uncommon.[120] 
TB diagnostics and treatment is available for people 
who use drugs in prisons in both Canada and the 
United States.[4,15] However, it is unclear the extent 
and ease of access. Condoms are only available in 
prisons	and	jails	in	three	American	states:	Vermont	
(since 1992), Mississippi (since 1992 and limited 
to	married	prisoners	receiving	conjugal	visits)	and	
California (since 2014), as well as several other 
cities.[121] In Canada, condoms are available in all 
federal prisons, although barriers to access have 
been reported, including as a result of inconsistent 
stock or condoms only being available through 
healthcare	staff.[4]
Policy developments for 
harm reduction
Since the Global State of Harm Reduction last reported, 
important harm reduction policy developments 
have taken place in both the United States and 
Canada. On 22 July 2016, President Obama signed 
into law Section 303 of the Comprehensive Addiction 
and Recovery Act (CARA) in the United States.[37] 
This law aimed to improve access to certain harm 
reduction interventions, such as overdose prevention 
medication and access to OST.[122] That same year 
also saw the 21st Century Cures Act signed into law, 
which over a nine year period (beginning in 2016), 
would authorise US$500 million to cover the costs 
of accelerating medical product development and 
bring new innovations and advances to people 
who need them,[123] having the potential to improve 
provision of OST and naloxone.[15] The amendment 
s	 Naloxone	is	a	highly	effective	opioid	antagonist	used	to	reverse	the	effects	of	opioid	overdose	in	minutes.
to the longstanding federal funding ban on NSP 
also occurred in 2016, with the US government 
changing its position on NSPs, resulting in a partial 
repeal of the ban on federal funding for this service. 
While the use of federal funds to purchase sterile 
needles	or	syringes	to	inject	illicit	drugs	remains	
prohibited, the Consolidated Appropriations Act 
2016 enables federal funds to be allocated to other 
aspects of NSPs, including HIV and HCV testing, 
naloxone provision, human resources, rent and other 
expenditures needed to keep NSPs in operation.[15,31] 
In the two years since CARA’s initiation and the 
partial repeal of the ban on funding, NSP services in 
the US have increased.[15] Although OST in the form 
of buprenorphine is more widely available due to the 
extension of prescribing privileges, over half of US 
states continue to prohibit nurse practitioners from 
prescribing OST.[39] 
In 2016, the Canadian Ministry of Health reformed 
the National Anti-Drug Strategy to become the 
Canadian Drugs and Substances Strategy, which 
includes harm reduction as one of its four core 
pillars.[14] This new strategy led to the adoption 
of regulatory amendments to make naloxones 
available without prescription (enabling pharmacies 
to proactively distribute the medicine to those 
who might experience or witness an opioid 
overdose); supported new front-line harm reduction 
interventions to reduce the risk of blood-borne 
viruses and sexually transmitted infections resulting 
from	sharing	drug	use	equipment	and	other	related	
behaviours; created a streamlined application 
process for communities that wish to open 
supervised consumption sites; noted the importance 
of harm reduction to federally funded health 
services	for	Inuit	and	First	Nations	communities;	
and endorsed public education, awareness and 
monitoring programmes before and after legalising 
and regulating cannabis.[14] Prior to May 2017, 
organisations seeking to operate supervised 
consumption services without the risk of criminal 
prosecution	were	required	to	apply	for	an	exemption	
from Canada’s Controlled Drugs and Substances 
Act by the federal Ministry of Health.[4] Without this 
exemption,	people	who	use	drugs	and	staff	members	
were at risk of criminal charges for drug possession. 
In May 2017, Bill C-37 repealed the 26 onerous 
conditions	required	for	exempting	new	supervised	
consumption sites, making the establishment of 
supervised consumption services more feasible.[18]
At the international level, Canada has also been vocal 
in its support for harm reduction. At the Commission 
on	Narcotic	Drugs	in	March	2018,	Canada	led	efforts	
resulting	in	the	first-ever	resolution	on	stigma	against	
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people who use drugs.[4,18,124] In contrast, the current 
US administration favours a “war on drugs” rhetoric 
and harsher sanctions for people who use drugs, 
despite	their	lack	of	effectiveness.	Since	January	
2017, the US president called for the death penalty 
for people who sell drugs.[125], a tougher stance 
on minimum mandatory sentences for drugs and 
greater use of drug-induced homicide laws.[125]
Civil society and advocacy 
developments for harm 
reduction
Since the Global State of Harm Reduction last reported 
in 2016, important civil society events have taken 
place in both Canada and the US. 
In October 2018, approximately 2,000 delegates 
convened at the 12th National Harm Reduction 
Conference in New Orleans. The conference is the 
only national multidisciplinary conference focused 
on improving the health of people who use drugs.[126] 
In May 2017, the 25th Harm Reduction International 
Conference	took	place	in	Montréal.[127] It was one of 
the largest conferences in the international series to 
date, with approximately 1,000 delegates from over 
70 countries. During the conference, people who 
use drugs protested during a speech by the then 
Canadian minister of health under the banner “They 
Talk, We Die”, in reference to the growing overdose 
rates	in	the	country	and	the	lack	of	adequate	harm	
reduction provision.[128] With overdose deaths 
remaining the leading cause of mortality among 
people who use drugs in Canada, an annual National 
Day of Action on the Overdose Crisis was established 
in 2017.[18] 
Canada’s	Drug	Futures	Forum	took	place	in	Ottawa	
in 2017, where more than 120 researchers, policy-
makers,	public	health	officials,	law	enforcement	
professionals, drug users and community organisers 
met to examine the future of Canada’s domestic and 
international drug policies.[129] The four focus points 
of the conference were international control and 
management of drugs; decriminalisation, regulation 
and harm reduction; integrating policing and public 
health;	and	strategies	for	health	and	social	equity	in	
drug policies.[129] 
Within the US, federal government engagement 
with harm reduction organisations or drug user 
groups appears to be minimal.[15] In Canada, people 
who use drugs and harm reduction organisations 
are increasingly being included at both federal 
t The extent to which this engagement is meaningful and not tokenistic remains ambiguous.
and provincial levels in the development of harm 
reduction and drug policies.[18]t
In Canada, advocacy towards the decriminalisation 
of drug possession for personal use made notable 
progress,	with	two	major	federal	parties	(the	
New Democratic Party and the Liberal Party of 
Canada) passing policy resolutions endorsing the 
decriminalisation of drugs for personal use.[4] 
Drug user networks also operate at the national level, 
although they are not active among all communities 
throughout Canada.[18] The Canadian Association 
of People who Use Drugs[130] is part of the wider 
umbrella network of the International Network 
of People who Use Drugs (INPUD).[131] In the US, 
the National Urban Survivors Union, a grass roots 
coalition of drug users (both former and active) 
dedicated	to	ensuring	respect	and	social	justice	for	
the	community,	operates	in	San	Francisco	and	North	
Carolina,[132]	and	is	affiliated	with	the	North	American	
Network of People who Use Drugs (NANPUD). 
NANPUD is a national peer-based organisation 
working to promote drugs user rights to health and 
address the harm created by the “war on drugs” at 
both national and international level.[15] 
Several organisations in Canada, including the Pivot 
Legal Society, the Canadian HIV/AIDS Legal Network, 
the Canadian Drug Policy Coalition and Aboriginal 
Legal Services, advocate for law and policy reform 
in relation to harm reduction and drug policy. Some 
also provide direct legal assistance and information 
for people who use drugs.[4,18]
Funding developments for 
harm reduction
In 2016, the Global State of Harm Reduction reported 
on the repeal of the federal funding ban on NSPs 
in the US, one of the most important funding 
developments in the region. While some progress is 
documented above, civil society leaders report that 
practical	access	to	this	funding	has	been	difficult	and	
roll out has not been to scale. It is hoped that in the 
next	five	years	the	federal	funding	ban	modification	
could lead to a doubling or tripling of public funding 
for NSPs across the country.[15] 
In Canada, funding for harm reduction has increased 
at both the national and provincial levels, including 
through the Substance Use and Addictions Program 
administered by Health Canada, which provides 
CAN$26.3 million yearly to address substance 
use problems through treatment, prevention, 
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harm reduction and health promotion.[133] The 
federal government also established a new Harm 
Reduction	Fund,	administered	by	the	Public	Health	
Agency of Canada, which will invest CAN$30 
million between 2018 and 2022 to support harm 
reduction	projects.[134]	These	funds	significantly	
contribute to the harm reduction response, yet 
Canada still does not consistently meet international 
recommendations for coverage of services, and could 
improve its adherence to its international human 
rights commitments. 
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Table 2.7.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Oceania 
Country/territory
with reported
injecting
drug usea
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs(%)
Harm reduction responsei
NSPb OSTc
Peer-
distribution 
of naloxone
DCRsd
Australia
93,000 
(68,000-
118,000)[1]
2.1[2] 49[2] 4.0[3]
 
(6,327e)[4]
(2,732)f  
(B, M)[5]
 [6] 2[6]
Federated States of 
Micronesia
nk nk nk nk x x x x
Fiji nk nk nk nk x x x x
Kiribati nk nk nk nk x x x x
Marshall Islands nk nk nk nk x x x x
New Zealand
15,000-
20,000[7,8]
0.2[7] 52-84[7] nk (213g)[8] (B, M)[9] x x
Palau nk nk nk nk x x x x
Papua New Guinea nk nk nk nk x x x x
Samoa nk nk nk nk x x x x
Solomon Islands nk nk nk nk x x x x
Timor Leste nk nk nk nk x x x x
Tonga nk nk nk nk x x x x
Vanuatu nk nk nk nk x x x x
 nk – not known 
a Countries with reported injecting drug use according to Larney et al 2017. The study found no reports of injecting drug use in Nauru or Tuvalu.
b Alloperationalneedleandsyringeexchangeprogramme(NSP)sites,includingfixedsites,vendingmachinesandmobileNSPsoperatingfromavehicleorthroughoutreachworkers.(P)
= pharmacy availability.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
d Drug consumption rooms, also known as supervised injecting sites.
e 2,422 pharmacies, 784 secondary sites and 323 syringe dispensing machines.
f This refers to the number of dosing points in the country.
g 190 pharmacies and 23 peer-based needle programmes.
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Harm reduction in Oceania
h Known as medically supervised injection facilities in Australia.
Overview
The prevalence of injecting drug use in Oceania is 
above the global average, and there are an estimated 
113,000 people who inject drugs in the region (based 
on data from Australia and New Zealand).[1,7,10] 
As a result, harm reduction for injecting drug use 
formsasignificantproportionoftheregion’sharm
reduction services. While opioids have historically 
been the dominant substances used by people 
who inject drugs in the region, methamphetamine 
injection has seen a considerable rise since 2010 in 
both Australia and New Zealand, to the point where 
methamphetamines are now the most common 
category of drugs last injected in Australia (though 
methadone injection remains most common in New 
Zealand).[8,11]Thisis,inpart,theresultofasignificant
shift in usage patterns of methamphetamines from 
powder to more commonly injected crystal forms.[5,10] 
This has coincided with a reduction in the prevalence 
of heroin use from 2000-2015 across the region.[10] 
However, heroin remains a commonly used drug 
among people who inject drugs in the region.[5]
A key limitation in collating an overall picture of the 
state of harm reduction in Oceania is the highly 
variable availability and quality of data across the 
region.FewofthePacificIslandcountriesand
territories report any drug use at all (with the 
exception of cannabis use). However some, such as 
Fiji, acknowledge that this may be due to a lack of 
investigation rather than prevalence.[12,13] Conversely, 
the data collection systems in place in Australia 
are of very high quality. Through the Australian 
Needle and Syringe Program Survey, the National 
Opioid Pharmacotherapy Statistics, and other 
regular surveillance and monitoring publications, 
government, academic and non-governmental 
organisations collect detailed information on 
patterns of drug use and service utilisation in the 
country.[2,5] 
While the provision of harm reduction services is 
relatively extensive in Australia and New Zealand, no 
new evidence has been found for any such services 
anywhere else in the region since the Global State of 
Harm Reduction 2016. There is a noted trend in the 
PacificIslandcountriesandterritoriesforpeople
to be sent to New Zealand or Australia for general 
health treatment.[14] Needle and syringe programmes 
(NSPs) and opioid substitution therapy (OST) are 
available in both Australia and New Zealand, with 
services largely stable since 2016 and no major 
expansions or contractions. With regard to OST, a 
significanttrendistheexpansionintheprescription
of buprenorphine-naloxone combinations, with the 
aim of reducing administration through injection 
(in non-medical contexts) and diversion to the black 
market.[5,9] A notable advance in the region is the 
openingofAustralia’sseconddrugconsumption
room (DCR)h  in Melbourne in 2018, joining the 
facility established in Sydney in 2001.[6,15] These DCRs 
both only serve people who inject drugs, including 
people who inject crystal methamphetamines, 
and do not permit consumption by other routes of 
administration (such as inhalation).[15,16]
Amphetamine-typestimulantsincreasinglyfigure
in harm reduction services in Australia and New 
Zealand. In addition to people who access NSPs 
and DCRs, services also respond to the wider use 
of stimulants at festivals and parties. Instances of 
multiple overdoses at festivals involving high-purity 
MDMA and new psychoactive substances (NPSs) 
in Australia, and up to 45 deaths from NPS use 
in New Zealand, from 2017 to 2018 have drawn 
a new focus to harm reduction services aimed at 
this population.[8,17,18]Australia’sfirsttrialofapill-
checking service was held at one festival in April 
2018,andKnowYourStuffNZhasoperatedpill-testing
services at festivals in New Zealand since 2014 in 
conjunction with the New Zealand Drug Foundation.
[15,19] However, in both countries legal barriers, such 
as limitations on programmes operating in public 
spaces like city centres, prevent these projects from 
being rolled out further.[17]
While harm reduction services in Australia and New 
Zealand are relatively extensive and widely available, 
concern has been shown that some vulnerable 
sub-populationsmayhavedifficultyaccessing
these services. Women, indigenous people and the 
LGBTQIA+ community all face greater stigma added 
to that already experienced by people who use 
drugs,andsufferfromalackofservicesfocused
ontheirspecificneeds.[20-23] Indigenous people and 
gay and bisexual men in particular are more likely 
than the general population to report high-risk 
drug use practices, such as syringe sharing and 
frequent injection.[3,24,25] Where services exist for 
specificpopulations,suchasthoseoperatedfor
LGBTQIA+ people by the AIDS Council of New South 
Wales,evidenceshowsthattheycanbeeffectivein
improving access and health outcomes.[22,26] These 
often involve the use of peer workers and campaigns 
targetedatpracticesprevalentamongspecific
groups.[26-28]
The prevalence of HIV in the general population and 
among people who inject drugs is observed to be 
very low in the region, and anti-retroviral therapy 
(ART) and pre-exposure prophylaxis (PrEP) are widely 
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available in Australia and New Zealand.[6,29] The 
earlyandeffectiveimplementationofNSPhasbeen
identifiedasakeyfactorinthesuccessfulprevention
of an HIV epidemic among people who inject 
drugs.[30] However in both countries, prevalence of 
exposure to hepatitis C among prisoners and people 
who inject drugs is high and is a concern for public 
health.[3,7,31,32] To respond to this, in 2015 Australia 
becamethefirstcountryintheworldtoprovide
free (or heavily subsidised) access to direct-acting 
antivirals without restrictions on disease stage, 
provider type or ongoing drug use, including for 
prisoners and people who use drugs, with the aim 
of eliminating hepatitis C.[6,23] This has seen a large 
increase in the number of people receiving treatment 
for hepatitis C, including people who inject drugs.[15,33]
Developments in harm 
reduction implementation
Needle and syringe exchange programmes 
(NSPs)
NSPs are widespread in both Australia and New 
Zealand,wheretherearesignificantnumbersof
people who inject drugs, but are largely absent in 
the rest of the region. According to national reports 
submitted by the respective ministries of health to 
the Joint United Nations Programme on HIV/AIDS, 
(UNAIDS) there is no evidence of injecting drug use in 
Fiji, Marshall Islands, Nauru, Samoa, Solomon Islands, 
Tonga or Tuvalu.[12,13,34-38]
A total of 3,627 NSP sites operate in Australia, 
2,422 (67%) of which are based in pharmacies.[4] In 
2016/2017, Australian NSPs distributed 49 million 
needles at an average of 631 needles per person who 
regularly injects drugs, a small decrease from 638 
needles per person who regularly injected drugs in 
2015/2016.[4] Syringe-dispensing machines (vending 
machines that dispense needles and syringes for free 
or at a nominal cost) are widespread in Australia, with 
323 operational across the country.[4,15] Their number 
tripled from 2008-2017, and the majority (64%) are 
located outside major cities, where access to NSPs 
in primary care facilities or pharmacies can be more 
difficult.[4] Since 2016, Australian Capital Territory, 
Northern Territory and Tasmania have all passed 
legislation to decriminalise peer distribution of sterile 
injecting equipment, to increase access and coverage 
among the most hard-to-reach populations.[15,17] 
While peer-distribution remains criminalised in other 
states, a recent state parliamentary committee report 
in Victoria recommended removing the ban in the 
interests of preventing the transmission of blood-
borne viruses.[17]
NewZealandwasthefirstcountryintheworld
to have a national state-sponsored needle and 
syringe programme, which now operates from 190 
pharmacies and 23 peer-based services.[8,39] Together, 
these services distribute more than 3.5 million pieces 
of equipment annually (approximately 233 per 
person who injects drugs), and are permitted by law 
to facilitate secondary distribution by distributing 
needles and syringes to key contacts.[8] The peer-
basedservicesincludemobileunitsandarestaffed
by paid workers with life experience of injecting drug 
use,whoareabletoofferadviceonsafeinjecting
and refer people to health services as appropriate.[28] 
As such, they provide not only harm reduction for 
blood-borne viruses, but a broader psychosocial 
peer-led outreach programme. Evidence suggests 
that these types of programme have a greater ability 
to reach marginalised groups, as well as providing 
enhanced acceptance, self-esteem, community 
inclusion and empowerment among these 
populations.[28] The New Zealand Needle Exchange 
Programme is currently in discussions with the 
Ministry of Health to scale up the programme, with a 
particular objective of hepatitis C elimination.[8]
According to data collected in Australian NSPs, 
methamphetamines (41%) are now the most 
commonly reported category of last drugs injected 
in the country, followed by heroin (30%).[2] In 
contrast, the proportion of people reporting heroin 
as their last injected drug remained stable (29% in 
2013 and 30% in 2017).[2] For methamphetamines, 
the proportion rose from 29% in 2013 to 41% in 
2017.[2] Similar changes have been noted in New 
Zealand NSPs, where an increase in the injection 
of methamphetamines has also been observed, 
though methadone remains the most reported 
injected drug.[8] Other drugs injected in the region 
include pharmaceutical opioids such as morphine 
and anabolic steroids.[4,8,11] An emerging trend in 
Australia (though not yet in New Zealand) is the 
prevalence of pharmaceutical fentanyl injection, a 
highly potent opioid that 8% of Australian people 
who inject drugs reported using in a 2018 study using 
data from 2014.[40] Compared with participants who 
injected pharmaceutical opioids other than fentanyl, 
thisgroupweresignificantlymorelikelytoidentifyas
indigenous Australian, inject daily or more frequently, 
inject in public and to have overdosed in the past 
year.[40] 
In New Zealand, a common barrier to people who 
inject drugs accessing NSPs is geography, with low 
coverage in some rural and isolated areas of the 
country.[8] In order to address this, the New Zealand 
Needle Exchange Programme is in the process 
of launching an online NSP.[8] This platform will 
offerpeoplewhoinjectdrugstheopportunityto
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purchase injecting equipment anonymously online 
alongside additional features, such as a pop-up 
offeringaninstantmessagingconversationwith
a harm reduction worker, aimed at replicating the 
experience of visiting a harm reduction service in 
person.[8] Economic barriers are also a consideration 
in increasing coverage, as the government only 
covers 85% of the cost of syringe distribution, leaving 
clients to pay the remaining 15% themselves.[8] The 
New Zealand Needle Exchange Programme reports 
that addressing this barrier is a key priority, as it 
contributes to the re-use and sharing of injecting 
equipment.[8]
An ongoing concern in Australia is the existence 
of barriers to accessing NSP services for certain 
subpopulations. The proportion of people who inject 
drugs in the country who identify as Aboriginal and 
Torres Strait Islander is thought to have increased 
from 12% in 2012 to 18% in 2017,[2,11] but there 
isadearthofservicesspecificallyadaptedto
this population (see box).[6,17] Among women and 
LGBTQIA+ people who inject drugs, there has been 
noted a perception of stigma and discrimination, 
resulting in a reluctance to access NSPs.[21,27] Peer 
outreach programmes have had some success in 
reaching women who inject drugs and supporting 
them to access NSPs, however these projects are 
not widespread.[21] There are also NSP services 
specificallyservingLGBTQIA+peoplewhoinject
drugs, such as those operated by the AIDS Council 
of New South Wales.[26] There is evidence that such 
targeted services can address fears of discrimination 
and stigma, and lead to greater improvements in 
wellbeing and health outcomes.[27] 
The clear need for widespread and accessible NSPs 
in Australia is indicated by a small reported increase 
in the proportion of people attending NSPs reporting 
receptive syringe sharing in the last month, from 
15% in 2013 to 18% in 2017.[2,3] Among certain 
subpopulations the rate is higher, with syringe 
sharing in the last year reported by 28% of Aboriginal 
and Torres Strait Islander people attending NSPs in 
2016.[3] Among a small sample of men who have sex 
with men receiving treatment for methamphetamine 
dependence, 41% reported syringe sharing in the last 
six months.[22] Key reasons given by people who inject 
drugs for sharing injecting equipment are a lack of 
transport and the inconvenience of attending an NSP, 
afearofidentificationasapersonwhousesdrugs
and language barriers.[15,41] For NSP programmes 
to achieve their potential, these issues must be 
addressed and services must be provided to ensure 
the inclusion of marginalised populations.
Opioid substitution therapy (OST)
OST coverage in Australia has remained stable since 
the Global State of Harm Reduction 2016, with only a 
small 3% increase in the number of prescribers from 
2015/2016 to 2016/2017 and no major changes in 
implementation.[6,15] In 2016/2017, there were 3,074 
prescribers and 2,732 dosing points, with 89% of 
these being pharmacies.[5] Each dosing point serves 
an average of 17 clients, with 70% serving fewer than 
20 and only 7% serving more than 50 clients.[5] The 
dosing points with the highest number of clients tend 
to be in correctional facilities and private clinics.[5] 
The number of people accessing OST has remained 
stable since 2010, and in 2017 was estimated at 
49,792 people.[5,15] Two-thirds of these were male 
and10%identifiedasAboriginalorTorresStrait
Islander.[5] The median age of people receiving OST 
was 42 years, an increase of two years since 2016 
andreflectinganincreasingnumberofpeopleover
60 and a decreasing number of people under 30 
accessing the therapy.[5]
Heroin is the primary drug of dependence reported 
by 38% of people receiving OST in 2017.[5,11] 
Oxycodone, morphine, codeine and methadone were 
each reported as the primary drug of use in around 
5% of people (38% of people declined to report their 
primary drug of dependence).[5] In Australia over 
the last two decades, a move has been noted from 
prescribing “weak” opioids to “strong”, longer-acting 
opioids for chronic pain conditions.[42] Research has 
linked this to an increase in hospital admissions for 
overdose and treatment for opioid use.[42] In Samoa, 
non-injecting opiate use is the main form of illicit 
drug use.[13] However, no OST is available in Samoa or 
anyotherPacificIslandcountry.
In New Zealand and Australia, both methadone 
and buprenorphine are widely available.[5,9,15] Since 
2016, doctors are increasingly prescribing combined 
buprenorphine-naloxone for OST with the intention 
of deterring injecting use and diversion.[5,9] Naloxone 
is poorly absorbed in pill form, but can lead to 
an unpleasant withdrawal when injected.[5,9] In 
Australia, methadone still accounts for 60% of all 
OST, though in 2017 buprenorphine-naloxone was 
prescribed more than buprenorphine alone for the 
firsttime.[5] Currently in Australia, buprenorphine-
naloxone and methadone are generally only 
available as a take-home, unsupervised medication 
after at least three months of therapy, and often 
longer.[43] This represents a barrier for people in 
remote areas and increases costs (for example 
travel). Research has indicated that take-home 
unsupervisedbuprenorphine-naloxoneiseffectivein
maintaining people in OST, and poses less of a risk of 
diversion or unsafe use than methadone.[44]
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Access to OST in New Zealand and Australia is 
generally good, but civil society organisations report 
that substantive barriers remain.[8,15,20,21] While 
medication for OST is provided for free in Australia, 
clients enrolled in private programmes (which 
represent the bulk of OST providers) still have to 
pay a minimum of AU$35 per week in prescription 
costs, which may deter enrolment and retention 
among people on low incomes.[45,46] In New Zealand, 
OST is also provided for free, but service users risk 
losing access to the therapy if they continue to use 
other drugs (including alcohol) in a way deemed 
unsafe by service providers.[47] Women also face 
particular barriers to accessing OST: for example, 
greater stigma; fear of inter-partner violence or 
abandonment; and fear of loss of child custody.[21] 
While a few specialised maternal health services for 
women on OST exist in Australia, harm reduction 
services are generally seen to target men who 
injectdrugs,despitewomenbeingasignificant
minority of people who inject drugs.[20,21] Civil society 
organisations report that women are less likely than 
men to enrol in OST, although studies have shown 
they are more likely to access OST at an earlier age 
and to adhere to therapy once enrolled.[21,48]
TheeffectivenessofOSTinpreventingviralhepatitis
and HIV infection among people who inject drugs 
is well documented.[49,50] OST has also been shown 
tobehighlycost-effective:foreverydollarspent
on OST in Australia, it is estimated that AU$4-7 
are saved in reductions on healthcare and crime 
spending.[45] Trials in the use of peer workers in OST 
clinics (people with experience of illicit opioid use 
and/or currently receiving OST) have shown that 
they can create a safer and more caring environment 
forbothclientsandregularstaff,improvingboth
retention and enrolment in OST among vulnerable 
populations.[51]
Amphetamine-type stimulants (ATS) and new 
psychoactive substances (NPS)
InthePacificIslandcountriesandterritories,
amphetamine use was reported to be rising in 
2009, but little research has been undertaken since 
then.[14]Inorderforaneffectiveharmreduction
efforttobemountedinthePacificIslands,further
research into drug use in the region is vital. From 
2013-2016,Australiasawasignificantoverall
decline in amphetamine and methamphetamine 
use, driven mainly by a decline in use among 
people in their 20s.[52] However, there has been an 
increase in the use of crystal methamphetamine 
(also known as “ice” in Australia or “P” in New 
Zealand), which has replaced powder as the main 
form of use of the drug.[10,52] From 2010-2016, the 
proportion of people who use methamphetamines/
amphetamines reporting crystal methamphetamine 
as their main form rose from 22% to 57%, with 
the proportion using powder amphetamine as 
their main form falling from 51% in 2010 to 22% in 
2016.[52]Thisisalsoreflectedintrendsinthemethod
of administration, with smoking (more common in 
crystal methamphetamine use) accounting for 42% of 
use and snorting only 16%.[52] Among people who use 
crystal methamphetamine, the portion injecting rose 
from 9.4% in 2013 to 19.2% in 2016.[52]
Use of the crystal form of methamphetamine is 
associated with a higher likelihood of progressing 
to heavy use and injection than other forms.[53] 
Civil society organisations are disseminating harm 
reduction information to target populations, but 
some civil society actors report concern that the 
national strategy is focused more on abstinence 
than on harm reduction.[6] There is also concern 
that the purity of methamphetamine has increased 
significantlysince2009.[54]
In a 2013 Australian household survey, last-
year prevalence of methamphetamine use was 
significantlyhigheramonggayandbisexualmen
(9.7%) than among heterosexual men (2.5%), 
associated with use in sexual contexts.[22,25] In these 
contexts, methamphetamine use is linked with an 
increased likelihood of engaging in high-risk sexual 
and drug-taking practices associated with HIV and 
viral hepatitis transmission (for example condomless 
sex, multiple sexual partners and injecting drug 
use).[22] Among Australian gay and bisexual men 
who inject drugs, 86% report injecting crystal 
methamphetamine and 41% report sharing injecting 
equipment.[22,55] There is a need for harm reduction 
servicestailoredspecificallytogayandbisexualmen
to address barriers to access, such as stigma and 
a perception that health workers have inadequate 
specificknowledgeofsubstanceuseamongthis
population.[22]
The AIDS Council of New South Wales is an example 
ofoneofthefewLGBTQIA+-specificorganisations
offeringharmreductionservices.Theseinclude
acceptance therapy, cognitive behavioural 
therapy and motivational interviewing, with the 
understanding that the goal of interventions is not 
necessarily abstinence from drug use.[22,26] These 
services are available in person in three cities 
(Sydney, Lismore and Newcastle) and over Skype or 
telephone anywhere in New South Wales.[26]
Overall amphetamine and methamphetamine use 
has been stable in New Zealand since 2011, with 
total population prevalence of use at around 0.8%, 
equal to around 31,000 adults.[56] In 2018, the Ardern 
government and Housing New Zealand, the state 
housing agency, abandoned its policy of testing state-
owned houses for traces of methamphetamine.[57] 
Regional Overview 2.7 Oceania 137
This policy was based on a misinterpretation of 
scientificevidenceandabeliefthatlivingina
house contaminated by methamphetamine use 
was harmful to health. It led to over 400 houses 
beingfalselydeclaredunfitforhabitationand
anunconfirmednumberofpeoplewhouse
methamphetamines being evicted from social 
housing and charged for decontamination.[58,59]
Use of ecstasy has remained relatively stable in 
Australia since 2013, but remains well below the peak 
of use in 2007.[52] However, Students for Sensible 
Drug Policy report that Australia still has the highest 
per capita use of ecstasy in the world.[17] Several 
mass overdose incidents associated with high-purity 
MDMA and NPSs such as GHB (a stimulant that has 
particularly high risks when combined with alcohol) 
have occurred over the past two years at public 
events and festivals.[17] For example in 2017, 25 
people were hospitalised during the Electric Parade 
festival in Melbourne after taking what is believed to 
have been GHB.[60] 
These events, and reports in Australia of ecstasy pills 
containing large amounts of methamphetamine and 
toxic substances such as rat poison,[61] demonstrate 
the need for people who use these drugs to know 
the strength and contents of what they are taking. 
With 70% of ecstasy pills taken at clubs, bars, live 
music events or raves,[62] there is a clear advantage 
in taking harm reduction measures at these 
venues.KnowYourStuffNZhasoperatedafree
pill-testing service at festivals since 2014, and has 
seen the proportion of samples that test negative 
for what the consumer expected fall from 80% 
in 2014/2015 to 30% in 2016/2017.[19,63] Common 
adulterants for MDMA included cathinones (60%) 
and n-ethylpentylone (16%), an NPS associated 
with frequent re-dosing, sleeping problems and 
paranoia.[63,64]Duringthetestingprocess,staff
provided tailored harm reduction advice, and more 
than half of clients intended not to take a substance 
that had tested negative.[63] 
Australia’sfirstpill-testingserviceatadancemusic
festival took place in April 2018, with the support of 
the Australian Capital Territory (ACT) government, 
local health and police authorities, festival organisers 
and the venue at the University of Canberra.[15] The 
trial screened two potentially lethal samples of 
n-ethylpentylone,thefirsttimethedrughadbeen
detected in Australia, and found that more than 
half of samples tested contained no psychoactive 
substances at all.[65] The trial will continue at other 
events in the ACT.[65,66] Surveys have indicated high 
demand for these services in Australia, with 90% of 
people who use stimulants at public events saying 
they would use such a service.[67] Notably, 90% said 
they would not use the service if there was a risk of 
arrest, and 93% were willing to pay up to AU$5 for 
this potentially lifesaving service.[67] 
Outside the Australian Capital Territory, pill-testing 
services still face legal barriers. In New Zealand, 
KnowYourStuffNZandtheNewZealandDrug
Foundation acknowledge that they operate in a legal 
grey area which restricts the expansion of their pill-
testing project into city centres and nightclubs.[17] For 
this reason, other harm reduction interventions for 
drug use at parties remain the predominant forms 
in Australia and New Zealand. Dancewize began its 
activitiesin2012inMelbourne,Australia,offering
peer education to reduce harm from drug use at 
dance parties, festivals and night clubs, and since 
2016 has expanded to new territories.[6,68] The AIDS 
CouncilofNewSouthWalesofferharmreduction
services at LGBTQIA+ events, such as peer education 
and break areas,[26] and the Victorian government 
recently recommended interventions at dance 
parties and festivals, such as cool-down areas, 
messages about spiking and peer-based education.[17] 
While these services are certainly valuable, the 
greatest opportunity for reducing harm from 
adulterated and high-strength substances lies in the 
large-scale roll out of pill-checking projects.[69]
A further emerging issue in New Zealand is the use 
of NPSs, which has increased in the country since 
2016.[8] Since July 2017, up to 45 deaths have been 
attributed to the synthetic cannabinoid category of 
NPS.[70] Synthetic cannabinoid use is mostly prevalent 
among already marginalised groups, and therefore 
requires a tailored harm reduction response which 
so far has been mostly absent from New Zealand.[71]
The regional prevalence of cocaine use in Oceania 
is 1.5%, primarily in Australia and New Zealand.
[10]InAustraliaalone,prevalenceis2.1%(five
times the global average) and there are thought 
to be around 500,000 individuals who have used 
cocaine at least once in the last 12 months.[10,52] 
The availability of cocaine appears to be increasing 
in some parts of New Zealand.[8] Despite the large 
number of people who use cocaine in the region, the 
quantity consumed and frequency of consumption 
by individuals is thought to be low and civil society 
organisations report that the harm related to cocaine 
use is not a primary concern.[6,10] 
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Overdose, overdose response and drug 
consumption rooms (DCRs)
Australia is now home to two DCRs, known in the 
country as medically supervised injection facilities. 
The DCR in Sydney, in operation since 2001, was 
joined in July 2018 by a second DCR in Melbourne 
(currently under a two-year trial).[6,15] The Sydney 
DCR has registered 1.1 million injections since 
its inception, sees approximately 600 individuals 
per month (155 per day) and is open 80 hours 
per week.[15] The centre in Melbourne is expected 
to be used by up to 300 people per day.[72] Civil 
society organisations have raised concerns that the 
AustralianDCRsoffernospecifictimesorservicesfor
women.[20,21] 
The DCR in Sydney allows the injection of 
crystal methamphetamine as well as heroin, 
and methamphetamines currently represent an 
estimated 20% of injections in the facility.[15] The 
Melbourne DCR is also expected to permit the 
injection of both crystal methamphetamine and 
heroin.[16] While methamphetamines are far less 
associated with overdose than opioids, these centres 
allow methamphetamine injection in order to combat 
the transmission of blood-borne viruses among 
all people who inject drugs.[17] Political opposition 
is a cause for concern for the Melbourne DCR, as 
representatives of the main opposition parties in 
Victoria have said that they would shut down the 
facility if they were to gain power in the state.[16] 
Despite permitting methamphetamine injection, 
these DCRs remain unable to serve people who 
smoke methamphetamines. A campaign was 
launched by civil society actors in 2016 to introduce 
drug consumption rooms serving this population, but 
no such facility has yet been opened in Australia.[73]
In Australia, take-home naloxone is now available 
in all states, though with varying coverage. Peer 
distribution networks for naloxone operate in 
some states, but not all.[6] In 2016, naloxone was 
rescheduled to allow over-the-counter purchase 
in pharmacies.[15] However, at AU$70 per dose, it is 
inaccessible to the majority who need it, and most 
still rely on the lower-cost alternative of receiving a 
prescription from a medical practitioner.[17] Australian 
civil society organisations have raised concerns that 
thereachofnaloxoneprogrammesisinsufficient
andthattheysufferfromalackoffunding.[17] In New 
Zealand, civil society organisations are working with 
the Ministry of Health to make naloxone available in 
NSPs and OST services, but take-home naloxone is 
not currently widely available.[8]
Viral hepatitis
Hepatitis C prevalence among people who inject 
drugs attending Australian NSPs has declined from 
57% in 2015 to 49% in 2017.[3] In New Zealand, 
prevalence among people with lifetime prevalence of 
injecting drug use is estimated to be 57%.[7] Injecting 
drug use is the primary driver for hepatitis C infection 
across the region; for example, 83% of people living 
with hepatitis C in New Zealand report a history of 
injecting drug use.[3,31]
In2015,Australiabecamethefirstcountryin
the world to provide free or heavily-subsidised 
direct-acting antivirals for hepatitis C to the whole 
population, including people who use drugs and 
prisoners, at any stage of the disease.[6] This has 
led to record numbers of Australians being treated 
for hepatitis C, with 43,360 individuals initiating 
treatment from March 2016 to June 2017, compared 
with around 2,500 per year before the reforms.[15,33] 
The impact of integrated viral hepatitis services in 
harm reduction projects has been positive in both 
Australia and New Zealand. NSPs have been shown 
to reduce hepatitis C infection among people who 
inject drugs by 25% since their introduction in New 
Zealand, and by between 15% and 43% between 
2000 and 2010 in Australia (averting up to 77,000 
cases).[74,75] Enrolment in OST in Australia has been 
shown to reduce injecting behaviours that increase 
the risk of blood-borne virus infection and to 
increase detection of hepatitis C among people who 
use the service.[49,76]
While access to hepatitis C treatment in Australia 
isofficiallyuniversal,certaingroupsexperience
barriers to participation. Perceived stigma from 
health workers, a lack of information on direct-
acting antivirals and bad experiences with previous 
interferon-based medication all deter people who 
use drugs from accessing services.[6] Studies in 
New South Wales have found that the use of peer 
workers in OST services can contribute to the more 
effectivetreatmentofmarginalisedpopulations,
by preparing clients for hepatitis C treatment and 
testing.[51] The rate of hepatitis C prevalence among 
young Aboriginal and Torres Strait Islander people 
is estimated to be 6.3 times higher than among 
young non-indigenous Australians, and increased 
by 50% from 2012-2016 while the rate among young 
non-indigenous Australians decreased by 14%.[3] 
The development of culturally appropriate harm 
reduction interventions for this population has been 
identifiedasapossiblemeansofaddressingthisgap,
which is associated with higher rates of receptive 
syringe sharing and incarceration among Aboriginal 
and Torres Strait Islander people.[3,77]
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With the introduction of universal access to new 
direct-acting antivirals, Australia is now targeting 
the elimination of hepatitis C as a public health 
concern in the country.[17,78] It is a realistic target 
that will require the continued implementation of 
extensive harm reduction services, such as NSPs and 
OST,aswellasaconcertedefforttoensuretheyare
accessible to all sectors of the population.[78]
InNewZealand,significantmoveshavebeenmade
towards reducing barriers to hepatitis treatment and 
testing for people who inject drugs and integrating 
these services with OST. Hepatitis C clinics, operating 
as partnerships between hospitals and NSPs, exist 
in Auckland, Christchurch and Dunedin, and all NSPs 
are now visited by specialist hepatitis nurses on a 
fortnightly or monthly basis.[8] A number of new 
hepatitis clinics for people who inject drugs were 
opened in 2017 and 2018, and rapid hepatitis C 
testing has been piloted in NSPs with results showing 
thatthisintegrationisaneffectivewayofengaging
with people who inject drugs.[8]
Tuberculosis (TB)
In the general population, TB incidence remains low 
and stable in most of the region. Compared with 
the global incidence rate of 140 cases per 100,000 
people, Australia (6.1), New Zealand (7.3), Samoa 
(7.7) and Tonga (8.6) have exceptionally low rates, 
accordingto2017figures.[79] These countries also 
have approximately 90% treatment coverage.[79] 
However, there are elevated TB incidence rates in 
Kiribati (566), Timor Leste (498) and Papua New 
Guinea (432), where treatment coverage is below 
80%.[79] Data for TB incidence or prevalence among 
people who inject drugs is unavailable.
In Australia, TB diagnosis and treatment is available 
to people who inject drugs and people in detention. 
However, civil society organisations report that 
perceived stigma from health care workers towards 
people who inject drugs acts as a barrier to these 
people accessing treatment.[6]
HIV and antiretroviral therapy (ART)
Prevalence of HIV among the general population and 
people who inject drugs in Oceania is low, and ART 
and pre-exposure prophylaxisi are widely available 
in both Australia and New Zealand.[6,29] In Australia, 
prevalence of HIV among people who inject drugs 
attending NSPs was low and stable from 2012 to 
2017, ranging from 1.4% to 2.1% over this period, and 
injecting drug use was responsible for just 1% (14 
i A course of medication that can reduce the chances of HIV infection before exposure to the virus.
cases) of new diagnoses in 2016.[2,3] In New Zealand, 
just one case of HIV transmission through injecting 
drug use was recorded in 2016, though the overall 
incidence rate saw a small increase from 2015.[29]
Civil society and academic institutions attribute the 
very low rates of HIV prevalence among people who 
inject drugs in Oceania to the success of NSPs.[29,30] 
In particular, they credit the early implementation 
of NSPs at a time when the prevalence of HIV was 
lowandNSPswerethereforeeffectiveinpreventing,
rather than responding to, an HIV epidemic among 
people who inject drugs.[30] The leadership at the 
New Zealand Needle Exchange Programme reports 
thattherearenosignificantbarrierstoaccesstoHIV
testing and treatment for people who inject drugs in 
New Zealand.[8] 
In Australia, increases in HIV prevalence have been 
noted over the past decade among the Aboriginal 
and Torres Strait Islander population, though rates 
remain low.[3] According to surveys carried out in 
Australian NSPs from 2012 to 2016, injecting drug use 
is the source of a higher proportion of HIV infections 
among Aboriginal and Torres Strait Islander people 
(14%) than non-indigenous Australians (3%), and 
from 2013 to 2017 HIV prevalence among Aboriginal 
and Torres Strait Islander people attending NSPs 
rose from 1.3% to 3.6%.[2,3] There are calls for the 
development of culturally appropriate clinical 
management and support for Aboriginal and Torres 
Strait Islander people living with HIV to prevent 
further increases.[3]
Harm reduction in prisons
The overall prison population in Oceania was 54,726 
in 2016, and with the majority in Australia (35,949) 
and New Zealand (8,906).[80] The rate of incarceration 
was 140 per 100,000 people, comparable to the 
global average of 144.[80] Palau is notable for having 
the highest incarceration rate in the region, with 
343 of every 100,000 people imprisoned, while the 
SolomonIslandshavetheregion’slowestfigure
at just 56 per 100,000.[81] Since 2000, the prison 
population in Oceania has grown proportionately 
more than any other region in the world, with a 
59.1% increase compared with a 25.2% increase 
in the general population of the region.[80] Of even 
greater concern, the female prison population has 
doubled over the same period.[80] 
In Fiji, Palau, Marshall Islands, Papua New Guinea, 
Timor-Leste and Samoa, serious concerns have been 
raised about overcrowding, a lack of sanitation and 
a lack of distinction between pre-trial detention and 
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the detention of those convicted of crimes.[82,83,83-87] 
For example, prisons in Timor-Leste were found 
to operate at more than 200% capacity and there 
was no separation between pre-trial and post-trial 
detainees.[87] Prisons in Australia and New Zealand 
generally meet international standards on these 
metrics.[81]
Thenumberofpeopleimprisonedfordrugoffences
rose 18% from June 2016 to June 2017, and this 
population makes up 15% of those incarcerated in 
Australia.[88] An estimated 45% of adult detainees 
report that alcohol or other drug use contributed to 
their detention and 67% report using an illicit drug in 
the 12 months prior to their entry into the detention 
system.[23] More than half of those in detention are 
thought to have a history of injecting drug use.[89] For 
these reasons, prisoners are considered a priority 
population under the Australian National Drug 
Strategy 2017-2026.[23] In New Zealand, a 2016 study 
from the New Zealand Department of Corrections 
found that 87% of prisoners in the country have a 
lifetime diagnosis of a substance use disorder.[90] 
A primary concern in Australian prisons is an 
epidemic of hepatitis C. Overall prevalence of 
hepatitis C in Australian prisons is estimated to 
be 31%, rising to 56% among prisoners who inject 
drugs. Further, more than two-thirds of female 
prisoners who inject drugs are thought to be living 
with hepatitis C.[23,32] These rates represent an overall 
increase in hepatitis C prevalence among prisoners 
since 2013.[23] Because of this, prisoners were also 
considered a priority population in the National 
Hepatitis C Strategy 2014-2017, and hepatitis C 
treatment, including direct-acting antivirals, is 
available and federally funded in prisons.[91] However, 
the strategy was poorly implemented and unevenly 
applied between states and territories.[91] Unsafe 
injecting practices, such as syringe sharing, have 
been noted to increase upon entry to Australian 
prisons,[92] demonstrating the need for access to 
safe injecting equipment in order to prevent the 
transmission of viral hepatitis. Lotus Glen prison in 
QueenslandwasdeclaredAustralia’sfirsthepatitis
C-free prison in May 2017, an indication of the 
efficacyofdirect-actingantiviraltreatmentin
prisons.[93,94]
There are no NSPs in Australian prisons,[6,15] despite 
the inclusion of prisoners as a key population in 
thenationaldrugplan.Thishasbeenidentifiedas
asignificantobstacletocontrollingthehepatitisC
epidemic.[91] In the Global State of Harm Reduction 
2016, it was reported that the government of 
Australian Capital Territory had approved the 
country’sfirstprisonNSPinCanberra,onlyfor
theproposaltobeblockedbytheprisonofficers’
union.[95]Whiletheterritory’sgovernmentremains
supportive, no further progress has been made.[6,96] 
In the absence of NSPs, Fincol, a hospital-grade 
disinfectant that can be used to clean syringes, is 
the only means of sterilising injecting equipment 
available to those incarcerated in Australia.[97] 
However,theuseofFincolisnotsufficienttocontrol
the hepatitis C epidemic and cannot be considered 
a replacement for NSPs. There is limited data on 
theefficacyofFincolinreducingthetransmission
of blood-borne viruses in practice, and people who 
inject drugs report that the need to avoid being 
caughtbyprisonofficerswhileinjectingmeansthat
in practice syringes often go unwashed between 
uses.[97] Furthermore, people who inject drugs in 
prisons report deprioritising washing, with hepatitis C 
becoming a normalised condition in most Australian 
prisons.[97]
OST is available in prisons in both Australia and New 
Zealand; however, access is more limited than in the 
general population.[6,8,47] In New Zealand, OST is only 
available to prisoners who had initiated OST prior to 
incarceration (except in one prison where OST can 
be initiated).[8] In Australia, the availability of OST 
canvaryconsiderablybetweenprisonsindifferent
states and territories, but where it is available it is 
on the same basis as in the general population; in 
2017 there were 33 dosing points and 3,248 clients 
undergoing OST in Australian prisons.[5,6,15] Since 
2016, prisons in Queensland have begun providing 
OST.[15] In both countries, OST initiated outside prison 
can be continued while the person is detained.[6,47] 
Studies from around the world indicate that the 
period immediately following release from prison 
is associated with the highest risk of death due to 
opioid use, largely due to the risk of overdose; this 
isespeciallytrueinthefirstmonthafterrelease.[98] 
Australian studies have found that OST provision 
in prison and, importantly, immediately following 
releasecontributetosignificantlylowermortality
risk.[99] Therefore, the availability of OST in prisons 
should be maximised to the fullest extent possible. 
Naloxone availability in prisons in Oceania is limited. 
InAustralia,itisonlyavailabletohealthstaff.[6] It is 
not made directly available to prisoners in Australia 
or New Zealand, either while incarcerated or 
on release, though civil society organisations in 
Western Australia have advocated for this.[8,15] The 
introduction of naloxone that is directly available 
to prisoners in Oceania, while in detention and on 
release,wouldplayasignificantroleinlowering
overdose deaths among these populations.
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Indigenous peoples and harm 
reduction
IndigenouspeoplesinOceania,specificallytheAboriginal
and Torres Strait Islander population in Australia and 
theMāoripopulationinNewZealand,consistently
show worse health outcomes than other ethnic groups 
in the region.[100,101] This inequality has persisted since 
the arrival of European settlers in the 19th century, and 
has been shown to exist controlling for socio-economic 
factors.[101]
Indigenous groups are over-represented among people 
who inject drugs. In Australia, 18% of people who 
injecteddrugsattendingNSPsin2017identifiedas
Aboriginal and Torres Strait Islander people, up from 
12% in 2016.[11] Aboriginal and Torres Strait Islander 
people were also more likely to report receptive 
syringe sharing (28%) than non-indigenous Australians 
(17%),[3] and in 2017 accounted for 10% of all people 
receiving OST in Australia.[5]MāoripeopleinNew
Zealand have previously been shown to be 3.4 times 
morelikelytouseamphetaminesthannon-Māori
people,andtobesignificantlymorelikelytousecrystal
methamphetamines than other groups.[102,103]
The higher prevalence of injecting drug use and high-
riskdrug-takingpracticesarereflectedinarangeof
data sources. From 2012 to 2016, the prevalence of 
hepatitis C increased by 50% among young Aboriginal 
and Torres Strait Islander people while the prevalence 
among young non-indigenous people fell by 14%.[3] 
This leaves Aboriginal and Torres Strait Islander youth 
with a prevalence 6.3 times higher than young non-
Aboriginal and Torres Strait Islander people.[3] Though 
HIV prevalence is low among all groups in Australia, it 
has increased among the Aboriginal and Torres Strait 
Islander populations over the past decade.[3] Among 
Aboriginal and Torres Strait Islander people who inject 
drugs attending Australian NSPs, HIV prevalence was 
estimated at 3.6% in 2017, up from 1.3% in 2013, 
compared with 1.9% prevalence in 2017 among non-
Aboriginal and Torres Strait Islander people who injected 
drugs.[2] From 2012-2016, injecting drug use accounted 
for 14% of new HIV diagnoses among Aboriginal and 
Torres Strait Islander people, but only 3% for non-
indigenous Australians.[3]InNewZealand,Māoripeople
are known to have a particularly high prevalence of 
hepatitis B.[104]
These patterns are compounded by other socio-
economic inequities, notably disproportionate 
incarceration of indigenous people. Despite forming 
only16%oftheNewZealandpopulation,Māoripeople
accounted for 58% of those incarcerated in New Zealand 
in 2016/2017.[105] Aboriginal and Torres Strait Islander 
people in Australia are even more over-represented in 
prisons, accounting for 2% of the general population and 
28% of those incarcerated in March 2018.[106]
These stark statistics have led to calls from government 
and civil society for health and harm reduction services 
specificallytailoredtotheindigenouspopulationsof
Oceania.[6,17,107] Such services could mitigate the impacts 
of discrimination and distrust of Western health 
practices, and provide culturally appropriate services for 
indigenous conceptualisations of health.[101,107,108] 
In both New Zealand and Australia, health services 
specificallyservingthesepopulationsdoexist,
and have been established by national policy 
documents.[107,109] However, harm reduction interventions 
tailored to indigenous peoples are limited. Though 
substance use facilities exist for Aboriginal and Torres 
Strait Islander people in Australia, they tend to focus 
on alcohol use, and only a minority of the treatments 
offered(31%)useaharmreductionapproach,withmost
focused on abstinence or controlling substance use.[109] 
The introduction of harm reduction services, especially 
NSPs, which incorporate Aboriginal and Torres Strait 
IslanderandMāoripracticesandconceptualisationsof
health,couldhaveasignificantimpactontheprevalence
of blood-borne diseases and drug-related harm among 
these populations.
Policy developments for 
harm reduction
The Australian and New Zealand governments 
remain supportive of harm reduction interventions 
both within the countries and externally, for example 
through vocal support for harm reduction at the UN 
Commission on Narcotic Drugs.[6,8] Harm reduction 
formsoneofthethreepillarsofAustralia’sNational
Drug Strategy 2017-2026 (alongside demand 
reductionandsupplyreduction),whileNewZealand’s
National Drug Policy 2015-2020 also explicitly 
supports harm reduction and a people-centred 
system of interventions.[6,23,74] Harm reduction is also 
mentionedinAustralia’snationalHIVandhepatitisC
strategies.[15] No evidence has been found of policy 
documents declaring explicit support for harm 
reduction in the region outside these two countries.
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With the passage of the Narcotic Drugs Amendment 
Act in October 2016, Australia legalised the 
cultivationofcannabisformedicalandscientific
purposes, though licenses will be restricted to people 
with business experience and no criminal convictions 
inthepastfiveyears.[15] A bill for the legalisation 
of medicinal cannabis is currently in front of the 
New Zealand Parliament, and part of the coalition 
agreement between the current ruling parties 
committed them to a referendum on cannabis 
legalisation before the next parliamentary election.[8]
An inquiry into drug law reform by the Parliament 
of Victoria was published in 2018. It made several 
recommendations for the reform of drug policy, 
including treating personal drug use as a health issue 
rather than a criminal one; removing laws prohibiting 
the distribution of sterile injecting equipment and 
non-injecting drug paraphernalia; government-
facilitated pill-testing at music festivals; and a review 
of threshold quantities for distinguishing between 
traffickingandpersonalpossession.[15,17] 
Civil society and advocacy 
developments for harm 
reduction
There is a strong civil society movement for harm 
reduction in Australia, with both a national harm 
reduction network (Harm Reduction Australia) and a 
national network of people who use drugs (Australian 
Injecting and Illicit Drug Users Leagues, AIVL). AIVL 
has secured renewed government funding since 
2016,isaffiliatedtoregionalequivalentorganisations
in each state and territory, and is considered a 
key partner by the national government in the 
development of drug policy.[6,15] 
Students for Sensible Drug Policy was established 
in Australia in 2016.[15] The organisation operates 
throughuniversity-affiliatedchapters,ofwhich
there are currently four with a further nine seeking 
affiliationwiththeiruniversity.[110] SSDP forms part of 
the consortium that delivered the pill-testing trial in 
April 2018 at the University of Canberra.[15]
Severalsignificantadvocacycampaignshavebeen
launched in Oceania since 2016. The Just One Life 
campaignbytheTedNoffsFoundationandtheTime
to Test campaign by Unharm have both advocated 
for the implementation of pill-testing at music 
festivals.[15]TheSniffOffcampaign,ledbyDavid
Shoebridge of the New South Wales Green Party, 
haspushedforanendtotheuseofsnifferdogs
fordrugdetection,claimingthatitisanineffective
drug control mechanism and a violation of civil 
liberties.[111] This claim is supported by evidence of 
theineffectivenessoftheuseofsnifferdogsasboth
a deterrent and a harm reducing measure.[112] In June 
2018, security at a Sydney music festival refused 
entrytoanyonedrawingtheattentionofsniffer
dogs, regardless of whether they were found to be 
in possession of illicit drugs, drawing criticisms from 
Shoebridge and other civil society actors that this was 
a serious abuse of police power.[113]
Civil society organisations in Oceania have 
participated in movements that have been successful 
in reversing harmful government policy on drugs. In 
2017, an Australian government proposal to subject 
welfare recipients to drug tests was delayed due to 
legislative and civil society opposition.[114] Civil society 
organisationscondemnedthepolicyasineffective,
costly and having unintended consequences 
including driving criminality, and demonising welfare 
recipients and people who use drugs.[115] It was also 
criticisedforthedisproportionateeffectitwould
have on indigenous people and women.[21] In New 
Zealand, civil society, particularly the New Zealand 
Drug Foundation, led opposition to the eviction of 
tenants from methamphetamine-contaminated 
housing, a policy which has now been reversed by 
the new administration.[8]
Inadditiontothesecampaigns,thefirstNew
Zealand Harm Reduction Conference was held 
in October 2018, organised by the New Zealand 
Needle Exchange Programme, and all of the major 
conferencesondrugsinAustraliahavesignificant
streams on harm reduction.[6,8]
Funding developments for 
harm reduction
In both New Zealand and Australia, all investment in 
harm reduction services and advocacy comes from 
the national and state governments.[6,8] In Australia, 
a commitment to harm reduction investment is 
included in the National Drug Strategy. The federal 
government and all nine states and territories 
provide funding; however, the precise volume is 
unknown as no updates have been made available 
since 2015.[6] As reported in the Global State of Harm 
Reduction 2016,thesefiguresshowedthatharm
reduction accounts for only 2.1% of Australian 
government spending on drugs, compared with 66% 
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on law enforcement and 21.3% on treatment.j[95,116] 
Researchshowsthatlawenforcementisineffective
in addressing drug use.[117,118] Redirecting a small 
proportionofineffectivelawenforcementspending
towards harm reduction would enable evidence-
based harm reduction services to be expanded to 
meet need.[6] 
Similarly, New Zealand has seen little change in 
funding for harm reduction since 2016, and despite 
campaigns by civil society organisations, spending on 
drug policy remains predominantly focused on law 
enforcement.[8] Data on harm reduction investment 
as a whole remains unavailable, but it is estimated 
that NSPs in New Zealand were funded to the 
valueofNZ$4.5minthe2017/2018financialyear.[8] 
Drug checking projects in New Zealand receive no 
governmentfundingandareentirelyfinancedby
public donations.[119]
j It should be noted that 12% of government spending on treatment was for OST. However, it is impossible to disaggregate spending on OST for harm reduction 
from spending on OST for treatment.
Regional Overview 2.7 Oceania 145
References
1.  Larney S, Hickman M, Guy R, Grebely J, Dore GJ, Gray RT, et al. (2017) 
‘EstimatingthenumberofpeoplewhoinjectdrugsinAustralia.’BMC Public 
Health 17:757.
2.  Heard S, Iversen J, Geddes L, Maher L (2018) Australian NSP Survey National 
Data Report 2013-2017. Sydney: Kirby Institute, University of New South 
Wales. 
3.  Kirby Institute (2017) HIV, Viral Hepatitis and Sexually Transmissible Infections 
in Australia. Sydney: Kirby Institute, University of New South Wales. 
4.  Heard S, Iversen J, Kwon JA, Maher L (2017) Needle and Syringe Programme 
National Minimum Data Collection: National Data Report 2017. Sydney: Kirby 
Institute, University of New South Wales.
5.  AIHW (2018) National Opioid Pharmacotherapy Statistics (NOPSAD) 2017. 
Canberra: Australian Institute of Health and Welfare. Available from: 
https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/
nopsad-2017/contents/summary/.
6.  McDonald D (2018) Global State of Harm Reduction 2018 survey response.
7.  UNODC (2018) World Drug Report 2018.Vienna:UnitedNationsOfficeon
Drugs and Crime. 
8.  Leafe K (2018) Global State of Harm Reduction 2018 survey response.
9. DeeringD,SellmanJD,AdamsonS(2014)’Opioidsubstitutiontreatmentin
NewZealand:a40yearperspective.’N Z Med J 127(1397):57-66. 
10.  UNODC (2017). World Drug Report 2017.Vienna:UnitedNationsOfficeon
Drugs and Crime. 
11.  Memedovic S, Iversen J, Geddes L, Maher L (2017) Australian Needle Syringe 
Program Survey National Data Report 2012-2016: Prevalence of HIV, HCV and 
injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, 
University of New South Wales.
12.  Ministry of Health (Fiji) (2016) Fiji HIV & AIDS Response Progress Report. 
Geneva: Joint United Nations Programme on HIV/AIDS. 
13.  Ministry of Health (Samoa) (2017) Global AIDS Monitoring Report for Samoa. 
Geneva: Joint United Nations Programme on HIV/AIDS.  
14.  Power R, Schmich L, Nosa V (2015) ‘A response for substance and harm 
reductioninPacificIslandcountriesandterritories.’Harm Reduct J 12:48. 
15.  Ritter A, Hughes C, Dietze P, Maher L, Jauncey M, Heard S (2018) Global 
State of Harm Reduction 2018 survey response.
16.  Willingham R (2018) ‘Victorian Coalition to scrap safe injecting room 
trialamidpolicyconfusion.’ABC News. Available from: http://www.abc.
net.au/news/2018-04-17/injecting-room-trial-to-be-scrapped-by-vic-
coalition/9666472/.
17.  Law Reform, Road and Community Safety Committee (2018) Inquiry into 
Drug Law Reform. Melbourne: Parliament of Victoria.
18. NZHerald(2018)‘Coronerrevealsbigspikeinsyntheticcannabisdeaths.’
NZ Herald. Available from: https://www.nzherald.co.nz/nz/news/article.
cfm?c_id=1&objectid=12096609.
19. KnowYourStuffNZ(2018)Our Service.KnowYourStuffNZ.Availablefrom:
https://knowyourstuff.nz/our-service/.
20.  WHRIN 4 (2018) Global State of Harm Reduction 2018 survey response.
21.  WHRIN 5 (2018) Global State of Harm Reduction 2018 survey response.
22.  Lea T, Kolstee J, Lambert S, Ness R, Hannan S, Holt M (2017) 
‘Methamphetamine treatment outcomes among gay men attending 
aLGBTI-specifictreatmentserviceinSydney,Australia.’PloS One 
12(2):e0172560. 
23.  Commonwealth of Australia (2017) National Drug Strategy 2017-2026. 
Canberra. 
24.  Lea T, Mao L, Hopwood M, Prestage G, Zablotska I, de Wit J, et al. (2016) 
‘Methamphetamine use among gay and bisexual men in Australia: trends 
inrecentandregularusefromtheGayCommunityPeriodicSurveys.’Int J 
Drug Policy 29:66-72. 
25.  Roxburgh A, Lea T, de Wit J, Degenhardt L (2016) ‘Sexual identity and 
prevalence of alcohol and other drug use among Australians in the general 
population.’Int J Drug Policy 28:76-82. 
26.  ACON(2018) Alcohol & Drugs. Sydney: AIDS Council of New South Wales. 
Available from: https://www.acon.org.au/what-we-are-here-for/alcohol-
drugs/.
27.  Burgess K, Parkhill G, Wiggins J, Ruth S, Stoovè M (2018) ‘Re-wired: 
treatment and peer support for men who have sex with men who use 
methamphetamine.’Sex Health 15(2):157-9. 
28. HayB,HendersonC,MaltbyJ,CanalesJJ(2017)‘Influenceofpeer-based
needle exchange programs on mental health status in people who inject 
drugs:anationwideNewZealandstudy.’Front Psychiatry 7. Available from: 
https://www.frontiersin.org/articles/10.3389/fpsyt.2016.00211/full.
29.  NZAF (2018) HIV in New Zealand. Auckland: New Zealand AIDS Foundation. 
Available from: https://www.nzaf.org.nz/hiv-aids-stis/hiv-aids/hiv-in-new-
zealand/.
30.  Iversen J, Wand H, Topp L, Kaldor J, Maher L (2014) ‘Extremely low and 
sustained HIV incidence among people who inject drugs in a setting of 
harmreduction.’AIDS (28):275-83. 
31.  Gane E, Stedman C, Brunton C, Radke S, Henderson C, Estes C, et al. (2014) 
‘Impact of improved treatment on disease burden of chronic hepatitis C in 
NewZealand.’NZ Med J 127(1407):61-74. 
32.  Butler T, Callander D, Simpson M (2015) National Prison Entrants’ 
Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007, 2010 and 
2013. Sydney: Kirby Institute, University of New South Wales. 
33.  Kirby Institute (2017) Monitoring Hepatitis C Treatment Uptake in Australia. 
Sydney: Kirby Institute, University of New South Wales.
34.  Ministry of Health (Marshall Islands) (2017) Global AIDS Progress Report 
2016. Geneva: Joint United Nations Programme on HIV/AIDS.
35.  Ministry of Health (Nauru) (2016) Nauru Global AIDS Progress Report. 
Geneva: Joint United Nations Programme on HIV/AIDS. 
36.  Ministry of Health (Solomon Islands) (2017) Solomon Islands: Global AIDS 
Monitoring 2017. Geneva: Joint United Nations Programme on HIV/AIDS. 
37.  Ministry of Health (Tonga) (2017) Global AIDS Monitoring. Geneva: Joint 
United Nations Programme on HIV/AIDS. 
38.  Ministry of Health (Tuvalu) (2017) Global AIDS Monitoring Report for Tuvalu. 
Geneva: Joint United Nations Programme on HIV/AIDS. 
39.  NZNEP (2018) New Zealand Needle Exchange Programme. Christchurch: New 
Zealand Needle Exchange Programme. Available from: http://www.nznep.
org.nz/.
40.  Geddes L, Iversen J, Memedovic S, Maher L (2018) ‘Intravenous fentanyl 
useamongpeoplewhoinjectdrugsinAustralia.’Drug Alcohol Rev 
37(S1):S314-22. 
41.  Geddes L, Iversen J, Maher L (2015) New South Wales Needle and Syringe 
Program Enhanced Data Collection Report 2015. Sydney: Kirby Institute, 
University of New South Wales. 
42.  Larance B, Degenhardt L, Peacock A, Gisev N, Mattick R, Colledge S, et 
al. (2017) ‘Pharmaceutical opioid use and harm in Australia: the need for 
proactiveandpreventativeresponses.’Drug Alcohol Rev 37(S1):S203-5.
43.  Gowing L, Ali R, Dunlop A, Farrell M, Lintzeris N (2014) National Guidelines 
for Medication-Assisted Treatment of Opioid Dependence. Canberra: 
Commonwealth of Australia. 
44.  Dunlop AJ, Brown AL, Oldmeadow C, Harris A, Gill A, Sadler C, et al. (2017) 
‘Effectivenessandcost-effectivenessofunsupervisedbuprenorphine-
naloxone for the treatment of heroin dependence in a randomized waitlist 
controlledtrial.’Drug Alcohol Depend 174:181-91. 
45. WodakA(2016)‘Weeklydose:methadone,themosteffectivetreatment
forheroindependence.’TheConversation.Availablefrom:https://
theconversation.com/weekly-dose-methadone-the-most-effective-
treatment-for-heroin-dependence-59814.
46.  Maher L (2018) Global State of Harm Reduction 2018 reviewer response.
47. MatuaRaḵi(2014)OST and You: A Guide to Opioid Substitution Treatment. 
Wellington:MatuaRaḵi.
48.  Gisev N, Degenhardt L, Larney S, Larance B, Gibson A, Kimber J, et al. (2014) 
‘A comparative study of opioid substitution therapy utilisation among 
opioid-dependentmenandwomen.’Drug Alcohol Rev 33(5):499-505. 
49.  White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L (2014) ‘Opioid 
substitution therapy protects against hepatitis C virus acquisition in people 
whoinjectdrugs:theHITS-cstudy.’Med J Aust 201(6):326-9.
50.  Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. (2018) 
‘Needle and syringe programmes and opioid substitution therapy for 
preventingHCVtransmissionamongpeoplewhoinjectdrugs:findings
fromaCochraneReviewandmeta-analysis.’Addict 113(3):545-63. 
51.  Treloar C, Rance J, Bath N, Everingham H, Micallef M, Day C, et al. 
(2015) ‘Evaluation of two community-controlled peer support services 
for assessment and treatment of hepatitis C virus infection in opioid 
substitutiontreatmentclinics:theETHOSstudy,Australia.’Int J Drug Policy 
26(10):992-8. 
52.  AIHW (2017) National Drug Strategy Household Survey 2016: Detailed 
findings. Canberra: Australian Institute of Health and Welfare. Available 
from: https://www.aihw.gov.au/getmedia/15db8c15-7062-4cde-bfa4-
3c2079f30af3/21028a.pdf.
53.  McKetin R, Kelly E, McLaren J (2006) ‘The relationship between crystalline 
methamphetamineuseandmethamphetaminedependence.’Drug Alcohol 
Depend 85(3):198-204. 
54.  Scott N, Caulkins JP, Ritter A, Quinn C, Dietze P (2014) ‘High-frequency drug 
purity and price series as tools for explaining drug trends and harms in 
Victoria,Australia.’Addiction 110(1):120-8. 
55.  Hopwood M, Lea T, Aggleton P (2015) ‘Drug, sex and sociality: factors 
associated with the recent sharing of injecting equipment among gay and 
bisexualmeninAustralia.’Int J Drug Policy 26(2):210-3. 
56.  Ministry of Health (New Zealand) (2017) Annual Data Explorer 2016/17: 
New Zealand Health Survey. Available from: https://www.health.govt.nz/
publication/annual-update-key-results-2016-17-new-zealand-health-survey.
57. OtagoDailyTimes(2018)‘Noevictionsfordrugusersinstatehouses.’
Otago Daily Times. Available from: https://www.odt.co.nz/news/national/
no-evictions-drug-users-state-houses.
58. McCammonB(2017)‘400statehomescontaminatedwithP.’RadioNZ.
Available from: https://www.radionz.co.nz/news/national/299072/400-
state-homes-contaminated-with-p.
59.  McCulloch C (2018) ‘Meth evictions: govt has “moral responsibility” to 
putitright.’RadioNZ.Availablefrom:https://www.radionz.co.nz/news/
political/359037/meth-evictions-govt-has-moral-responsibility-to-put-it-
right.
60.  Australian Associated Press (2017) ‘More than 20 drug overdoses at 
Melbournemusicfestival.’TheGuardian.Availablefrom:http://www.
theguardian.com/australia-news/2017/feb/19/more-than-20-drug-
overdoses-at-melbourne-music-festival.
61.  Groves A (2018) ‘“Worth the test?” Pragmatism, pill testing and drug policy 
inAustralia.’Harm Reduct J 15:12. 
62.  Uporova J, Karlsson A, Sutherland R, Burns L (2018) Australian Trends in 
Ecstasy and Related Drug Markets 2017: Findings from the Ecstasy and Related 
Drugs Reporting System (EDRS). Sydney: National Drug and Alcohol Research 
Centre, University of New South Wales. 
63. KnowYourStuffNZ(2018)Our Results.KnowYourStuffNZ.Availablefrom:
https://knowyourstuff.nz/our-results/.
Global State of Harm Reduction 2018146
64.  Measham F, Jones (2018) ‘Pentylone: What is it, why should we care and 
howcanmultiagencysafetytestinghelp?’Volteface.Availablefrom:http://
volteface.me/features/pentylone-care-can-multi-agency-safety-testing-
help/.
65.  Munro K (2018) ‘Two “deadly” samples found in pill-testing trial at Canberra 
musicfestival.’TheGuardian.Availablefrom:http://www.theguardian.
com/politics/2018/apr/30/two-deadly-samples-found-in-pill-testing-trial-at-
canberra-music-festival.
66.  Bushnell I (2018) ‘Government looks to expand pill testing in new 
drugsstrategy.’RiotActNews.Availablefrom:https://the-riotact.com/
government-looks-to-expand-pill-testing-in-new-drugs-strategy/251807.
67.  Barratt MJ, Bruno R, Ezard N, Ritter A (2017) ‘Pill testing or drug checking 
inAustralia:acceptabilityofservicedesignfeatures.’Drug Alcohol Rev 
37(2):226-36. 
68.  Harm Reduction Victoria (2018) DanceWize. Harm Reduction Victoria. 
Available from: https://www.hrvic.org.au/dancewize.
69.  Brunt T (2017) Drug Checking as a Harm Reduction Tool for Recreational Drug 
Users: Opportunities and Challenges. Lisbon: European Monitoring Centre for 
Drugs and Drug Addiction.
70. NZHerald(2018)‘Coronerrevealsbigspikeinsyntheticcannabisdeaths.’
NZ Herald. Available from: https://www.nzherald.co.nz/nz/news/article.
cfm?c_id=1&objectid=12096609.
71. BrownR(2017)‘Weshouldhaveknown.’MattersofSubstance.Available
from: https://www.drugfoundation.org.nz/matters-of-substance/
october-2017/we-should-have-known/.
72. PreissB(2018)‘Upto300peopleadaytouseMelbourne’sfirstsafe
injectingrooms.’TheAge.Availablefrom:https://www.theage.com.au/
politics/victoria/up-to-300-people-a-day-to-use-melbourne-s-first-safe-
injecting-rooms-20180629-p4zojp.html.
73. ParkA(2016)‘DrugexpertsplanAustralia’sfirsticesmokingroomdespite
governmentopposition.’ABC News. Available from: http://www.abc.net.au/
news/2016-06-29/ice-smoking-rooms/7551256.
74.  Inter-Agency Committee on Drugs (2015) National Drug Policy 2015-2020. 
Wellington: Ministry of Health. 
75.  Kwon JA, Anderson J, Kerr CC, Thein H-H, Zhang L, Iversen J, et al. (2012) 
‘Estimatingthecost-effectivenessofneedle-syringeprogramsinAustralia.’
AIDS 26(17):2201-10. 
76.  Larney S, Grebely J, Falster M, Swart A, Amin J, Degenhardt L, et al. (2015) 
‘Opioid substitution therapy is associated with increased detection of 
hepatitisCvirusinfection:a15-yearobservationalcohortstudy.’Drug 
Alcohol Depend 148:213-6. 
77.  Doyle M, Maher L, Graham S, Wand H, Iversen J (2018) ‘Hepatitis C virus 
prevalence and associated risk factors among Indigenous Australians who 
injectdrugs.’Aust NZJ Public Health 42(1):52-6. 
78.  Dore GJ, Hajarizadeh B (2018) ‘Elimination of hepatitis C virus in Australia: 
layingthefoundation.’Infect Dis Clin North Am 32(2):269-79. 
79.  WHO (2017) Global Tuberculosis Report 2017. Geneva: World Health 
Organization.
80.  Walmsley R (2016) World Prison Population List (eleventh edition). London: 
World Prison Brief. Available from: http://www.prisonstudies.org/sites/
default/files/resources/downloads/world_prison_population_list_11th_
edition_0.pdf.
81.  US Department of State (2017) Australia 2017 Human Rights Report. 
Washington DC: US Department of State. Available from: https://www.
state.gov/j/drl/rls/hrrpt/humanrightsreport/index.htm.
82.  US Department of State (2017) Fiji 2017 Human Rights Report. Washington 
DC: US Department of State. Available from: http://www.state.gov/j/drl/rls/
hrrpt/humanrightsreport/index.htm?year=2017&dlid=277081.
83.  US Department of State (2017) Samoa 2017 Human Rights Report. 
Washington DC: US Department of State. Available from: http://www.state.
gov/j/drl/rls/hrrpt/humanrightsreport/index.htm?year=2017&dlid=277113.
84.  US Department of State (2017) Palau 2017 Human Rights Report. 
Washington DC: US Department of State. Available from: http://www.state.
gov/j/drl/rls/hrrpt/humanrightsreport/index.htm?year=2017&dlid=277123.
85.  US Department of State (2017) Marshall Islands 2017 Human Rights Report. 
Washington DC: US Department of State. Available from: http://www.state.
gov/j/drl/rls/hrrpt/humanrightsreport/index.htm?year=2017&dlid=277097.
86.  US Department of State (2017) Papua New Guinea 2017 Human 
Rights Report. Washington DC: US Department of State. Available 
from: http://www.state.gov/j/drl/rls/hrrpt/humanrightsreport/index.
htm?year=2017&dlid=277109.
87.  US Department of State (2017) Timor-Leste 2017 Human Rights Report. 
Washington DC: US Department of State. Available from: http://www.state.
gov/j/drl/rls/hrrpt/humanrightsreport/index.htm?year=2017&dlid=277123.
88.  ABS (2017) Prisoners in Australia, 2017. Canberra: Australian Bureau of 
Statistics. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/
Lookup/by%20Subject/4517.0~2017~Main%20Features~Prisoner%20
characteristics,%20Australia~4.
89.  Reekie JM, Levy MH, Richards AH, Wake CJ, Siddall DA, Beasley HM, et 
al. (2014) ‘Trends in HIV, hepatitis B and hepatitis C prevalence among 
Australianprisoners-2004,2007,2010.’Med J Aust 200(5):277-80. 
90.  Indig D, Gear C, Wilhelm K (2016) Comorbid Substance Use Disorders and 
Mental Health Disorders Among New Zealand Prisoners. Wellington: New 
Zealand Department of Corrections. 
91.  Dolan K, Sacha-Krol D, Vumbaca G (2017) A Needs Analysis for People Living 
with HCV After Leaving Custodial Settings in Australia. Canberra: Australian 
Injecting and Illicit Drug Users League. 
92.  Cunningham EB, Hajarizadeh B, Amin J, Bretana N, Dore GJ, Degenhardt 
L, et al. (2018) ‘Longitudinal injecting risk behaviours among people with 
a history of injecting drug use in an Australian prison setting: the HITS-p 
study.’Int J Drug Policy 54:18-25. 
93.  Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, et al. (2018) 
‘Demonstration of near-elimination of hepatitis C virus among a prison 
population: the Lotus Glen Correctional Centre hepatitis C treatment 
project.’Clin Infect Dis 67(3):460-3. Available from: https://academic.oup.
com/cid/advance-article/doi/10.1093/cid/ciy210/4930770.
94. BatemanD(2017)‘LotusGlenisAustralia’sfirsthepatitisC-freeprison.’
Cairns Post. Available from: https://www.cairnspost.com.au/lifestyle/lotus-
glen-is-australias-first-hepatitis-cfree-prison/news-story/11bf0d315432e07
ecfdb2b1398d76931.
95.  Stone K (2016) Global State of Harm Reduction 2016. London: Harm 
Reduction International. 
96.  White D (2018) ‘Government failing in its duty of care to prisoners: 
drugandalcoholsector.’CanberraTimes.Availablefrom:https://www.
canberratimes.com.au/national/act/government-failing-in-its-duty-of-care-
to-prisoners-drug-and-alcohol-sector-20180419-p4zali.html.
97. LaffertyL,RanceJ,TreloarC(2018)‘Whogoesfirst?Understanding
hepatitisCriskamonginjectingnetworksintheprisonsetting.’Drug Alcohol 
Depend 183:96-101. 
98.  Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, 
et al. (2010) ‘Meta-analysis of drug-related deaths soon after release from 
prison.’Addict 105(9):1545-54. 
99.  Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. (2014) 
‘The impact of opioid substitution therapy on mortality post-release from 
prison:retrospectivedatalinkagestudy.’Addict 109(8):1306-17. 
100.  AIHW (2015) The Health and Welfare of Australia’s Aboriginal and Torres Strait 
Islander Peoples 2015. Canberra: Australian Institute of Health and Welfare. 
101.  Ellison-Loschmann L, Pearce N (2006) ‘Improving access to health care 
amongNewZealand’smaoripopulation.’Am J Public Health 96(4):612-7. 
102.  Ministry of Health (New Zealand) (2016) Amphetamine Use 2015/16: New 
Zealand Health Survey. Wellington: Ministry of Health. 
103.  Ministry of Health (New Zealand) (2016) Drug Use in New Zealand: Key Results 
of the 2007/08 New Zealand Alcohol and Drug Use Survey. Wellington: Ministry 
of Health. 
104.  Lim TH, Gane E, Moyes C, Borman B, Cunningham C (2015) ‘Serological and 
clinical outcomes of horizontally transmitted chronic hepatitis B infection in 
NewZealandMāori:resultsfroma28-yearfollow-upstudy.’Gut 64(6):966-
72. 
105.  Statistics New Zealand (2018) NZ.Stat DataHub. Wellington: Statistics New 
Zealand. Available from: http://nzdotstat.stats.govt.nz/wbos/Index.aspx?_
ga=2.97541657.763868184.1530780566-373924430.1530780566.
106.  ABS (2018) Corrective Services, Australia, March Quarter 2018. 
Canberra: Australian Bureau of Statistics. Available from: http://
www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/
BB11C570629F8579CA2582FF0012BC95?opendocument.
107.  Ministry of Health (New Zealand) (2014) The Guide to He Korowai Oranga: 
Māori Health Strategy 2014. Wellington: Ministry of Health. 
108.RixEF,BarclayL,WilsonS,StirlingJ,TongA(2013)‘Serviceproviders’
perspectives, attitudes and beliefs on health services delivery for Aboriginal 
peoplereceivinghaemodialysisinruralAustralia:aqualitativestudy.’BMJ 
Open 3(10):e003581. 
109.  AIHW (2017) Aboriginal and Torres Strait Islander Health Organisations: Online 
Services Report - Key Results 2015-16. Canberra: Australian Institute of Health 
and Welfare.
110.  SSDP (2018) SSDP: Chapters Within Australia. Students for Sensible Drug 
Policy. Available from: http://ssdp.org.au/chapters/.
111.  Shoebridge D (2018) Sniff Off: No More Drug Dogs! Available from: http://
davidshoebridge.org.au/sniffoff/.
112.  Grigg J, Barratt MJ, Lenton S (2018) ‘Drug detection dogs at Australian 
outdoormusicfestivals:deterrent,detectionandiatrogeniceffects.’Int J 
Drug Policy 60:89-95. 
113.  Australian Associated Press (2018) ‘Above & Beyond festival: activists 
accusepoliceof“seriousabuse”ofpowers.’TheGuardian.Availablefrom:
http://www.theguardian.com/australia-news/2018/jun/10/above-beyond-
festival-activists-accuse-police-of-serious-abuse-of-powers.
114.  Knaus C (2017) ‘Drug testing of welfare recipients may be delayed, Christian 
Portersays.’TheGuardian.Availablefrom:http://www.theguardian.com/
australia-news/2017/nov/22/drug-testing-of-welfare-recipients-may-be-
delayed-christian-porter-says.
115.  Knaus C (2017) ‘Drug-testing will demonise Australians on welfare, experts 
say.’TheGuardian.Availablefrom:http://www.theguardian.com/australia-
news/2017/may/10/budget-2017-drug-testing-will-demonise-australians-
on-welfare-experts-say.
116.  DPMP (2015) Australian Government Spending on Drugs (Drug Budgets). 
Sydney: Drug Policy Modelling Program, University of New South Wales. 
Available from: https://dpmp.unsw.edu.au/project/australian-government-
spending-drugs-drug-budgets.
117.  Hughes CE, Moxham-Hall V, Ritter A, Weatherburn D, MacCoun R (2017) 
‘ThedeterrenteffectsofAustralianstreet-leveldruglawenforcementon
illicitdrugoffendingatoutdoormusicfestivals.’Int J Drug Policy 41:91-100. 
118.  Wodak A (2015) ‘The failure of drug prohibition and the future of drug law 
reforminAustralia.’Aust Prescr 38(5):148-9. 
119.  Allison W (2018) Global State of Harm Reduction 2018 reviewer response.
Regional Overview 2.5 Latin America 147
Regional Overview
2.8 Middle East 
and North Africa
Table 2.8.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in the Middle East and 
North Africa 
Country/territory
with reported
injecting
drug usea
People who
inject 
drugsb[2]
HIV prevalence
among people
who inject 
drugs(%)c[2]
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs (%)
Harm reduction response
NSPd OSTe
Peer-
distribution 
of naloxone[1]
DCRsf
Algeria 21,050 6.5 nk nk xg x x x
Bahrain 2,000 3.9[4] nk nk x[2] h[5] x x
Egypt 93,000 2.4[6] nk nk (9)i[2] x x x
Iran 185,000[7] 13.8[8] 52.2[7] 30.9[9] (580)[2] (7,016)[2] x x
Iraq 18,750 0.6 nk nk x x x x
Israel nk nk 45.3[10] 5[11] (5)[12] [13] x x
Jordan 4,240 0.6 nk nk (10)[2] x x x
Kuwait 3,510 0.6 nk 2[11] x (1)[2] x x
Lebanon 3,200 0.9[6] 28[9] 2[14] (2) (10)[2] x x
Libya 6,800 87.1[8] 94.5[15] 4.5[15] x x x x
Morocco
3,000-
18500[2,6]
7.1[6] 57[16] nk (6)[2] (7)[2] x x
Oman 4,110 0.6 nk 4.8[11] x xj[3] x x
Palestine 5,000 nk 40.3[9] 0.6[17] (2)[2] (1)[2] x x
Qatar 2,220 0.6 nk nk x x x x
Saudi Arabia 10,000 3.5[18] 77.8[10] 7.7[19] x x x x
Syria 10,000 nk 40.8[9] 0.5[20] x x x x
Tunisia 11,000 3.9[8] 29.1[9] 3.0[11] (25)[2] x x xk
United Arab 
Emirates
9,250 0.6 nk nk x xl[2] x x
Yemen 7,030 0.6 nk nk x x x x
 nk – not known 
a There have been reports of injecting drug use in every country in the region according to Larney et al. in 2017.[1]
b As accurate data on estimates in the MENA region is scarce, unless otherwise referenced, numbers represent extrapolations made according to estimations from similar country 
contexts by the Middle East and North Africa Harm Reduction Association (MENAHRA).[2]
c HIV prevalence in Algeria, Iraq, Jordan, Kuwait, Oman, Qatar, United Arab Emirates and Yemen are made by MENAHRA according to similarities with other countries where national 
estimations are unavailable.[2]
d	 All	operational	needle	and	syringe	exchange	programme	(NSP)	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.	(P)	
= pharmacy availability.
e Number of opioid substitution therapy (OST) sites. 
f Drug consumption rooms, also known as supervised injecting sites.
g	 Civil	society	organisations	in	Algeria	are	reported	to	distribute	needles	and	syringes;	however,	purchasing	needles	and	syringes	from	pharmacies	is	difficult	because	some	pharmacists	
refuse	to	sell	them	to	people	who	inject	drugs	or	do	not	have	sufficient	stocks	in	remote	places.[3]
h  Bahrain has begun piloting OST programmes.[5]
i NSPs were widely available within the governorate of Minya in 2014 to 2016 by two local civil society organisations, through funding from MENAHRA; however, these programmes have 
been halted since mid-2016 due to governmental disapproval.[3]
j Currently there is no OST programme in Oman; however, OST has recently been included in national policy documents. During the past two years, many OST advocacy campaigns and 
training workshops have been conducted. Financial constraints are one of the main barriers in delaying the implementation of OST.[3]
k In 2017, it was reported that several safe injection sites were operated by a civil society organisation in Tunisia, including a site exclusively serving women. However, it is unclear if these 
services are still in operation.
l	 OST	is	available	in	the	United	Arab	Emirates	for	detoxification	only.
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Harm reduction in the Middle East and 
North Africa
m The regional proportion of people who inject drugs reporting opioids or stimulants as their main drug does not account for polydrug use and may be based on 
varying methodologies.[10]
n	 Cannabis	consumption	is	thought	to	be	widespread	in	the	region	and	this	figure	may	represent	an	underestimate	due	to	underreporting.[22]
Overview
In a recent systematic review, injecting drug use 
was reported in every country in the Middle East 
and North Africa region.[21] There are an estimated 
349,500-437,000 people who inject drugs in the 
region,[2,10] 96.2% of whom reportedly use opioids 
as their main drug (compared with 14.2% for 
stimulants).m[10] Heroin is the most commonly used 
substance in the region (used by an estimated 
63.9% of people currently using drugs), followed by 
cannabis (46.2%)n and cocaine (32.8%).[23] While use 
of amphetamine-type substances has long been 
established in the Middle East, recent evidence 
indicates that use is increasing is certain countries 
(such as Jordan and Syria) and that use is increasingly 
prevalent in North Africa.[24] 
Despite the prevalence of drug use in the region, 
the implementation of needle syringe programmes 
(NSPs) remains extremely low, with between one 
and four needles distributed per individual per year 
in the region. The provision of opioid substitution 
therapy (OST) is also low (see table 2.8.1). The Middle 
East and North Africa is one of just two regions in the 
world where AIDS-related deaths continue to rise. It 
is estimated that 57% of all new adult HIV infections 
in the region are among people who inject drugs.[25] 
Nevertheless, access to harm reduction services, 
including HIV testing and treatment, is lacking among 
people who use drugs or inject drugs in the region.[2] 
This lack of harm reduction and health services for 
people who use drugs is at risk of being further 
aggravated by the absence of positive changes 
in investment and political commitment to harm 
reduction in the region.[26]
Harm reduction services in the region are 
predominately provided by civil society across 
the region, with governments playing a small role 
in some countries.[23] Five countries (Israel, Iran, 
Lebanon, Morocco and Palestine) have incorporated 
harm reduction strategies into the national HIV 
frameworks, and eight countries (Algeria, Bahrain, 
Egypt, Jordan, Libya, Oman, Syria and Tunisia) refer 
to people who inject drugs as populations requiring 
specific	health	services.[2] There is an absence of 
robust data on people who use drugs living with 
HIV and accessing antiretroviral therapy.[21] There 
have also been large cut backs and closures of 
harm reduction services in some countries: Egypt 
and Oman have ceased to provide harm reduction 
services since 2016,[2] and Jordan has been forced to 
severely restrict service provision due to an ongoing 
funding crisis.[3]
Countries in the region are faced with substantial 
challenges	which	impair	their	ability	to	effectively	
implement national HIV prevention programmes, 
including a drastic decline in HIV and harm reduction 
funding exacerbated by the fact many countries in 
the region rely on singular funding sources.[27] Other 
challenges for addressing blood-borne diseases 
among people who use drugs include an absence of 
effective	surveillance	systems,	a	paucity	of	quality	
and accessible services, and prevailing stigma and 
discrimination. Regional instability caused by the 
ongoing civil wars in Iraq, Libya, Syria and Yemen 
also contribute to communities’ access to quality 
lifesaving harm reduction services.[27]
This fragile socio-political environment has caused 
unprecedented mass movements of people across 
and beyond the region, with growing cohorts of 
refugees, internally displaced people and migrants 
subsisting in poor living conditions that have an 
impact on their mental and physical health. The UN 
Office	on	Drugs	and	Crime	(UNODC)	reports	this	has	
precipitated an increase in drug consumption and 
trafficking,	and	the	region	has	seen	a	rise	in	income	
generation through the production and selling of 
drugs.[24,28] In addition to this regional socio-political 
instability, the Middle East and North Africa Harm 
Reduction Association reports that gender disparity 
and engendered cultural norms lead to women 
in the region, especially women who use drugs, 
being less likely to access health services.[23] There 
is also a paucity of HIV and harm reduction services 
for people who use drugs in closed settings, such 
as those in displacement camps and in prison 
contexts.[29] Experienced or anticipated stigma are 
also reported as barriers to accessing health care for 
people who use drugs, particularly in Egypt, Morocco 
and Tunisia.[23]
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
All 19 countries in the region are reported to be 
home to populations of people who inject drugs, but 
the provision of NSPs is inconsistent. Despite having 
been	first	introduced	in	the	region	over	15	years	ago,	
NSPs are still only available in eight countries, and 
no new countries have implemented NSPs since the 
Global State of Harm Reduction 2016. Where they exist, 
NSPs have seen some growth. Tunisia and Jordan 
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have seen the greatest expansions in NSP service 
provision since 2016. Jordan began implementing 
NSPs	in	five	governorates	in	2013,	and	as	of	2018	
has expanded to include a further 10.[2] Morocco and 
Palestine also increased the number of NSP sites 
in each country.[30] Unfortunately, due to ongoing 
challenges, Egypt’s NSP programme ceased in 2016.[2] 
In	Iran,	there	is	evidence	supporting	the	effectiveness	
of access to sterile syringes in reducing syringe 
sharing practices and syringe reuse among people 
who inject drugs.[31] With 580 state-supported 
NSP sites across the country, Iran is an outlier in 
the region;[2] elsewhere NSPs remain remarkably 
limited in scope and coverage, and there is little 
governmental support and public acceptability.[3]
Challenges to NSP provision in the region include 
limited funding, poor political commitment and 
support, protracted bureaucratic procurement 
processes and regional instability.[2] The Middle 
East and North Africa remains the region with 
the lowest NSP coverage globally (0.5 syringe/
people who inject/year).[32] Pharmacies continue to 
be the most accessible source of sterile syringes, 
particularly in Iran, Jordan and Tunisia,[33] though 
there are legal barriers and communities report 
persistent stigmatisation of people who inject drugs 
from	pharmacy	staff	in	many	countries.[34] With the 
exception of Iran, and to a lesser extent Morocco, 
there is a lack of a supportive legal and socio-cultural 
environment for NSPs, and the possession of 
syringes by people who inject drugs can often lead to 
prosecution.[35]
Opioid substitution therapy (OST)
Opioid substitution therapy as harm reduction is 
currently provided in at least seven countries in the 
region, with methadone distributed in Iran, Israel, 
Morocco and Palestine, and buprenorphine provision 
in Iran, Israel, Kuwait and Lebanon.[2,13] Prior to 2010, 
Iran and Israel were the only countries in the region 
which provided OST for people who use opioids.[2,13] 
Since that time, Morocco (in 2010), Lebanon (in 2012), 
Palestine (in 2014) and Kuwait (in 2015) have initiated 
OST.[2] Since 2016, Bahrain has launched an OST 
pilot.[5] OST has also been available in the United Arab 
Emirates since 2012; however, it is only available for 
detoxification	at	the	National	Rehabilitation	Centre	
and is not available to foreign workers, who make 
up the majority of the population.[2,22] Oman is also 
currently considering moves to initiate OST service 
provision.[3] 
Iran incorporated OST into its national policy in 2003 
and is leading the way in service provision, with over 
7,000 centres providing OST to more than 650,000 
people who use drugs.[2,36] In 2011, Lebanon adopted 
a take-home buprenorphine pilot programme; 
however, provision is limited to authorised 
psychiatrists working within pre-registered treatment 
settings.	The	results	of	the	evaluation	of	the	first	
pilot in Lebanon supported expanding the access to 
buprenorphine in Lebanon and other Middle Eastern 
and North African countries, and is an encouraging 
step towards continued service provision for people 
who use drugs.[5] 
The availability of publicly funded low-threshold 
methadone maintenance therapy services in Iran has 
increased through Ministry of Health drop-in centres 
since the Global State last reported. Methadone, 
buprenorphine and tincture of opium are used for 
opioid maintenance treatment in Iran; coverage 
of OST has also increased since 2016.[3] The main 
barriers to OST in the country include geographical 
obstacles for people in rural settings and costs 
incurred with accessing the service, although since 
2010 insurance coverage for OST services has been 
provided for in national law.[3] Since 2014, the Iranian 
Drug Control Headquarters has allocated funding to 
implement insurance for opioid substitution therapy 
services.[3] 
In Lebanon, three new OST prescribing centres have 
opened: one in the Bekaa, one in Beirut and one in 
a coastal town near Tripoli.[3] Although coverage is 
increasing, imposed weekly urine screening tests for 
people who use drugs dissuade many from accessing 
the service.[3] 
Legal and political constraints limit the provision 
of OST in many parts of Palestine, with a paucity of 
services available in the West Bank and the Gaza 
Strip, and extremely limited psychosocial services 
supporting adherence to the programme.[3] In the 
United Arab Emirates, potential challenges and 
obstacles for adherence to OST for eligible people 
who use drugs include concerns about being forced 
into diversion programmes, poly-substance use 
(particularly the high levels of benzodiazepines), 
unstable housing conditions and geographical 
barriers.[3]
Amphetamine-type stimulants (ATS), cocaine 
and its derivatives, and new psychoactive 
substances (NPS)
Although there is a lack of robust data on the 
variety of drugs used within the Middle East and 
North Africa, polydrug use is prevalent. Among 
people currently using drugs, the most commonly 
used drugs include heroin (in Egypt and Morocco), 
cannabis (mostly in Lebanon, followed by Tunisia and 
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Morocco) and cocaine (especially in Morocco and 
Lebanon).[23] Other types of drugs being consumed 
include MDMA (predominately in Lebanon), 
methamphetamine (with the highest usage reported 
in Iran and Lebanon) and benzodiazepines in 
Tunisia.[23,37] Use of tramadol and Tamol in Egypt are 
also continuing or emerging trends.[23] Prescription 
drugs were used by 22.7% of people who drugs in 
the region.[23] Lebanon has witnessed an increase in 
the use and sale of synthetic cannabinoids.[38] Use of 
khat, a natural stimulant with a long history of use in 
the region, is reportedly increasing in countries such 
as Yemen, Oman and Saudi Arabia.[39]
Fenethylline, a stimulant commonly referred to by 
the brand name Captagon, is the Arabian Peninsula’s 
most consistently consumed narcotic substance,[40] 
particularly in Saudi Arabia where use is reported to 
be high among young men.[41] Captagon is reported 
to be easily accessible, and available in e-commerce 
within the United Arab Emirates, Syria, Iraq and 
Turkey, and widely available on the darknet.[41]
Globally, there is a lack of harm reduction services 
that are responding to the needs of people who 
use ATS and NPS, and the Middle East and North 
Africa is no exception. Iran piloted a number of 
programmes to support people who use ATS 
and NPS in 2014/2015; for example, needle and 
syringe programmes for people who use ATS, safer 
methamphetamine use kits and education about 
drug use.[42] An evaluation of this programme 
published in 2017 found that harm reduction services 
focused on people who use ATS improved health 
outcomes for this population.[42] 
Overdose, overdose response and drug 
consumption rooms (DCRs) 
Although there continues to be little available data 
on overdose in the Middle East and North Africa, 
there have been some positive developments 
addressing overdose since the Global State of Harm 
Reduction 2016.	Lebanon,	in	part	influenced	by	
effective	advocacy	by	civil	society,	has	continued	to	
demonstrate a commitment to overdose prevention. 
This has included lobbying healthcare providers not 
to report patients to law enforcement when they 
access health services for drug overdose symptoms.[3]
Availability of naloxone, an opioid antagonist capable 
of	reversing	the	effects	of	overdose,	is	reported	
to be low across the Middle East and North Africa. 
Overdose prevention programmes are being carried 
out in Algeria, Egypt, Palestine and Tunisia in formal 
medical settings; however, access in all countries 
is reported to be minimal, and often limited to 
information and education rather than medical 
assistance.[3] Syria supports one facility capable of 
addressing overdose with naloxone; however, this 
service is heavily over-burdened and under-funded.[3] 
There were no reported peer-distributed naloxone 
programmes in the Middle East and North Africa 
region at the time of reporting.
Overdose prevention programmes are not available 
(the main barrier being regulations and national 
instability) in Jordan, Libya, Oman and Morocco, 
although Morocco has started discussions on 
developing an overdose response framework.[3] 
In the United Arab Emirates, overdose prevention 
programmes are not currently available; however, 
harm reduction advocates are currently lobbying to 
make	naloxone	kits	available	to	emergency	and	first	
responder	staff,	as	well	as	family	members	of	people	
who inject drugs.[3]
Viral hepatitis
Although the HIV prevention and treatment 
response in the Middle East and North Africa has 
been expanded in the last several years, viral 
hepatitis, particularly hepatitis C, continues to be 
a neglected public health concern. An estimated 
48.1% of people who inject drugs in the region are 
positive for hepatitis C antibodies, with hepatitis 
transmission associated with unsafe injecting 
practices such as sharing needles and syringes.[10] 
Since the Global State of Harm Reduction 2016, the 
World	Health	Organization	Regional	Office	for	the	
Eastern Mediterranean conducted a questionnaire 
survey to review the status of the viral hepatitis 
response programme in the 22 countries of the 
region. Findings from the survey demonstrated that 
although 21 countries were implementing (or at 
the least considering developing) prevention and 
care interventions for hepatitis C, actual delivery 
of testing and treatment was limited in scale and 
scope, and service provision inconsistent across 
the countries.[43] Even though 13 of the 22 countries 
reported as having a strategy for the prevention and 
control of viral hepatitis, baseline data on hepatitis 
C	is	lacking,	and	therefore	effective	strategies	for	
reducing the disease burden among people who use 
drugs and for increasing service coverage have not 
been fully developed.[43] In those countries already 
implementing national hepatitis programmes, 
coverage of screening/diagnostic testing and 
treatment	continues	to	be	insufficient.[43]
Injecting drug use is the main route of transmission 
for hepatitis C in Egypt, Iran, Iraq, Libya, Morocco, 
Saudi Arabia, Tunisia, Yemen, Kuwait, Qatar and 
Syria, with prison populations and those in closed 
settings particularly at risk.[44] Although the risk has 
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been	identified,	coverage	of	treatment	options	in	
the region remains low. Across the region, direct-
acting antivirals (DAAs) have been referred to in viral 
hepatitis treatment protocols and made available 
to the public, yet the costs (borne either by national 
health insurance mechanisms or by the individual) 
are generally prohibitively high. In Lebanon, for 
instance, although hepatitis C testing and treatment 
services are available, the procurement of costly 
DAAs	is	intermittent,	which	impacts	upon	effective	
treatment adherence and many patients must 
cover the costs of supplementary laboratory tests 
themselves.[3] Libya experiences similar challenges, 
with shortages of treatment and costly laboratory 
tests having a negative impact on patient uptake and 
retention.[3] 
A dearth of robust data at the country and regional 
level, and a lack of awareness contributes to a lack 
of political commitment and domestic investment in 
viral hepatitis responses.[43] 
Tuberculosis (TB)
Although	there	is	limited	data	specifically	on	TB	
incidence among people who use drugs, testing and 
treatment of tuberculosis has been mainstreamed 
into public health services across the region. In 
many instances this has occurred as part of the 
HIV response, including in Bahrain,[45] Iran[46] and 
Algeria.[3] In Morocco, the Ministry of Health allocates 
an annual budget for the national tuberculosis 
programme to provide free health services to all 
TB patients, including people who use drugs.[47] The 
TB response programme in Jordan is implemented 
under a grant from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria. The Jordanian Ministry 
of Health’s national TB programme is partially 
integrated into general health services, and operates 
at the central, district and peripheral levels.[3]
HIV and antiretroviral therapy (ART)
Antiretroviral	therapy	is	officially	widely	available	to	
all people living with HIV across the region, including 
people who use drugs, and provision is integrated 
into traditional HIV services.[3] In the Middle East and 
North Africa, as in other regions, there is little data 
on the numbers of people who use drugs currently 
on ART. Regional instability and a number of local-
level	security	concerns	negatively	affect	adherence	
among people who use drugs.[23] A 2017 systematic 
review covering the WHO Eastern Mediterranean 
regiono estimated that 26% of people who inject 
o This region includes Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Syria, Tunisia, the UAE and Yemen. It 
also includes Afghanistan, Djibouti, Pakistan, Somalia and Sudan, which are covered by other chapters in this report.
drugs living with HIV had been diagnosed as such, 
11% of these were on ART, and 44% of these were 
virally suppressed.[48] In a 2017 regional survey 
conducted among people who use drugs accessing 
ART and other harm reduction services, it was 
reported that three quarters of the participants 
believed that services in public healthcare settings 
were not stigma-free; and that they were subjected 
to discrimination, with the majority from Pakistan 
(88.5%), followed by Afghanistan (85%), Morocco 
(84.6%), Tunisia (83.3%) and Egypt (73.7%).[23] 
Along the HIV cascade of care, alarming levels of 
treatment drop-out result from: high levels of stigma; 
discrimination and mistreatment from healthcare 
providers; the lack of privacy and anonymity, and 
breaches	in	confidentiality	when	accessing	the	
medicine; and the absence of collaboration and 
communication among service providers, especially 
with regard to people living with HIV co-infected with 
viral hepatitis or other infectious conditions.[23] As 
reported in the Global State of Harm Reduction 2016, 
Iran continues to be an example of good practice, 
including scaling up the number of antiretroviral 
centres and satellite centres, including ensuring 
service provision in prison contexts.[49] Despite this, 
overall coverage of ART in Iran is estimated be low at 
19%, mainly due to a lack of access to treatment for 
people who inject drugs.[6,50] The country is currently 
developing pilot projects integrating antiretroviral 
therapy into OST services.[50]
Harm reduction in prisons
In 2016, there were an estimated 625,413 people 
imprisoned across the Middle East and North Africa 
(excluding	Palestine),	a	5%	increase	on	the	figure	for	
2010.[51] Of these, 225,624 (36%) were in Iran, 76,000 
(12%) were in Morocco and 62,000 (10%) were in 
Egypt.[51] One third of all incarcerated people are 
reported to be imprisoned for drug-related charges.[3] 
Punitive drug control continues to be the primary 
approach for addressing drug use in the region, with 
countries like Bahrain arresting individuals purely for 
possessing needles or syringes.[3] 
Drug use is reportedly highly prevalent in prison 
contexts in the Middle East and North Africa 
(including in Lebanon, Morocco, Oman, Palestine 
and Syria) and, due to the lack of needle and 
syringe programmes, so too is unsafe injecting drug 
use.[3] While high levels of unsafe injecting drugs 
should precipitate an scale-up of harm reduction 
programmes in prisons, the regional response 
continues to be weak.[3] OST is available in prisons 
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in	five	of	the	19	countries	in	the	region:	Iran,	Israel,	
Lebanon, Morocco and Palestine.[3,6,13] In 2016, 49,785 
people received OST in prison in Iran and 6,000 
prisoners were enrolled in the therapy in Israel.[6,13] 
In Palestine, daily journeys are reportedly made 
by prison authorities to take prisoners to receive 
methadone, though the number of people enrolled 
in prison OST appears to be small.[3] In both Lebanon 
and Morocco, OST services exist in prison, but are 
reported to be largely inaccessible.[3] In Morocco, only 
seven people received OST while in prison in 2016; in 
Lebanon, OST is only available to people who were 
enrolled before entering prison.[3]
No country in the region currently provides NSPs in 
prisons.[3] 
A UNODC programme under the Regional 
Programme in the Arab States (2016-2021) was 
developed to prevent drug use and treat drug use 
disorders, while also including provisions to prevent 
and treat HIV among prison populations.[3,52] The 
UNODC-led programme now reaches over 40,000 
prisoners	and	prison	staff	with	HIV/AIDS	prevention,	
treatment, care and support services.[3] This cohort 
includes 10,000 prisoners in three Egyptian prisons 
(Fayoum, Wadi AlNatroon and Borg Al-Arab); 18,000 
prisoners	in	five	Moroccan	prisons	(Oukacha,	Tangier,	
Tetouan, Salé and Nador); and 15,000 prisoners and 
juvenile detainees in six adult and juvenile prison 
facilities in Tunisia (adult prisons at Mornaguia, Borj 
El Amri, La Manouba and Le Kef; juvenile centres at 
El Mourouj and El Mghira).[3] During 2017, around 
1,000 prisoners were screened for HIV, hepatitis B 
and hepatitis C (though this represents only around 
one in 40 of the total population of the programme 
prisons).[3,51] In the same year, approximately 1,900 
prisoners were tested for tuberculosis.[3] Although 
Iran is celebrated for its harm reduction response 
in prisons, there is a serious lack of gender balance 
in the approach, with women accounting for 
only 4% of methadone treatment participants in 
prison, according to data from 2012.[53] Condoms 
are reportedly accessible to prisoners in Iran and 
Tunisia.[3] 
Women who use drugs
Recent estimates state that women account for one third 
of people who use drugs globally.[54] Yet women who 
use drugs have less access to harm reduction services 
and are at higher risk of HIV infection than men.[55] In the 
Middle East and North Africa region, given the already 
p In 2017, it was reported that several safe injection sites were open. However, it is unclear at the time of writing if these services are still in operation.
scarce base of harm reduction programmes and policies, 
gender-sensitive harm reduction services have received 
little attention. Research on drug use and related 
health issues in the region rarely produces gender-
disaggregated data.[56] 
In 2013, the Middle East and North Africa Harm 
Reduction Association (MENAHRA) conducted a study on 
women	who	use	drugs,	which	confirmed	that	they	face	
marginalisation and are disadvantaged with regards to 
accessing harm reduction services.[57] Many women have 
negative experiences in utilising harm reduction services, 
such	as	breaches	of	confidentiality	and	stigmatisation.	
When attempting to access health or social services, 
many were denied due to discrimination or having 
limited ability to pay for services. Acknowledging this, 
discussions	on	gender-specific	services	for	countries	in	
the region have been initiated by MENAHRA and practical 
guidelines for advocacy for women who use drugs 
were published in 2017.[56] A small number of emerging 
practices for women do exist in countries of the region:
  IRAN: Civil society engagement and research 
activities in Iran increasingly shed light on the 
particular needs of women who use drugs and 
advocate for more gender-sensitive services.[42,58] 
The civil society organisation Khaneh Khorshid 
offers	a	list	of	services	that	seek	to	provide	harm	
reduction services, including provision of OST; 
HIV prevention workshops; medical and legal 
aid services; and referrals to medical centres, 
employment agencies and educational institutions. 
Khaneh Khorshid currently provides methadone 
treatment to over 100 women and provides ancillary 
services to more than 600 women annually.[58] 
  LEBANON: The Inter-Ministerial Substance Use 
Response Strategy 2016-2021 aims to ensure 
gender-sensitive services and calls for targeted 
interventions	for	women	to	address	their	specific	
needs. It further acknowledges that gender-
disaggregated data on substance use is lacking.[59] 
  TUNISIA: The	first	safe	injection	sites	were	
established by a civil society organisation in Tunisia,P 
of	which	one	specifically	works	with	women	who	
use	drugs.	It	is	the	first	reception	centre	for	women	
who use drugs in the region, and provides a safe 
place that protects women who inject drugs with 
health and dignity.[60]
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Despite the positive developments in some countries 
in	the	region,	an	emphasis	on	gender-specific	service	
provision is still lacking and in many countries the needs 
of women who use drugs are not addressed adequately. 
A scale-up of gender-sensitive harm reduction in the 
region is much needed.[56] In order to ensure that women 
who use or inject drugs are reached by harm reduction 
interventions, service providers, programme developers 
and policy makers should acknowledge women’s 
particular vulnerabilities and tailor interventions to their 
needs. Depending on the context, gender-sensitive 
harm reduction may include, but must not be limited 
to: targeted education and awareness for women 
about drug use and its related harms; tailored harm 
reduction services for women, including women-only 
drop in centres; female counsellors; and female condom 
distribution, as well as psychological services and safe 
places for women drug users who are victims of violence 
in the region.[56] 
Policy developments for 
harm reduction
Despite the evidence that drug use is a major issue 
in the Middle East and North Africa region, with 
preventable	adverse	health	and	social	effects,	many	
countries in the region lack an adequate evidence 
base of epidemiological, qualitative and sociological 
data on drug use, key populations and related health 
consequences.[22,61] Barriers to research on harm 
reduction are not only created by the lack of funding, 
but also by the particular socio-cultural, economic, 
policy-related and political situations in each 
country.[61,62] While some countries allow for harm 
reduction interventions to protect a person’s physical 
and mental wellbeing (for example Israel, Iran, 
Lebanon and Morocco), others continue to apply 
a punitive approach against people who use drugs 
and deny harm reduction service provision.[61,62] 
Criminalisation and entrenched stigma associated 
with drug use in Middle Eastern and North African 
countries negatively impacts upon research into 
harm	reduction,	drug	use	and	its	adverse	effects,	
and contributes to the exclusion of people who 
use drugs from national surveillance programmes. 
For example, Bahrain, Iraq, Kuwait, Libya, Oman, 
Qatar, Saudi Arabia, Syria and the United Arab 
Emirates have limited, or lack completely data on key 
populations at risk of HIV, including people who use 
drugs.[62]
 
Since the Global State of Harm Reduction 2016, there 
have been a number of policies addressing the 
health and harm reduction needs of people who 
use drugs in the region. Harm reduction has been 
referenced in: the Iranian National AIDS Strategy for 
2015-2019, which works towards the maintenance of 
HIV prevalence at less than 15% among people who 
inject drugs; the 2016-2020 National AIDS Strategy 
in Lebanon, which includes a commitment to NSP 
and OST, along with naloxone by 2019;[3] Morocco 
has	included	efforts	for	increasing	HIV	education,	
and distribution of syringes and condoms in policy 
documents since 2016; Palestine has been piloting 
methadone maintenance programmes;[3] Saudi 
Arabia’s National AIDS Strategic Plan prioritises HIV 
screening, counselling and treatment;[3] and Tunisia 
made	reference	to	OST	and	NSP	for	the	first	time	in	
their 2015-2018 National AIDS Strategy.[49]
After years of designing drug policies that have 
mainly focused on eliminating drug use, drug 
policy reform is becoming a mainstream discussion 
in Morocco.[63] The Authenticity and Modernity, 
and Al Istiqlal political parties have introduced 
parliamentary bills to legalise the medical and 
industrial use of cannabis.[63] In Yemen, civil 
society reports that there have been no new policy 
developments,	due	to	the	ongoing	conflict.[3]
While Iran has served as a model for other countries 
in the region in its implementation of harm 
reduction policies and deployment of peer-education 
programmes and NSPs, [64] continued criminalisation 
of people who inject drugs, manifested by punitive 
laws, incarceration and prohibitions on harm 
reduction, have a detrimental impact upon access 
to harm reduction services in the country. These 
negative	effects	include	decreased	access	to	NSPs,	
increased risky behaviours of sharing used injecting 
materials, and an increased HIV and hepatitis C 
prevalence among people who use drugs.[29] 
Civil society and advocacy 
developments for harm 
reduction
Since 2007, the Middle East and North Africa Harm 
Reduction Association (MENAHRA), a network of 
knowledge hubs and civil society organisations 
focusing on harm reduction strategies, has led civil 
society	advocacy	efforts	in	the	region.	MENAHRA’s	
mission is to improve the quality of life of people 
who use drugs through advocacy, capacity building 
and technical assistance, and by serving as a 
resource centre in the region.[65] The Middle East 
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and North Africa Network of People who use Drugs 
(MENANPUD) is also active, and acts as a support 
group of activists concerned with harm reduction 
and the rights of people who use drugs.[66]
Civil	society	continues	to	lead	advocacy	efforts	
for the promotion and sustainability of harm 
reduction services for people who use drugs in 
the region. In addition to MENAHRA, in 2016/2017, 
the MENA H Coalition was launched, which aims 
at limiting the spread of HIV, promoting harm 
reduction interventions, and mitigating stigma 
and discrimination in the Middle East and North 
Africa.[66] In early 2018, the MENA H Coalition formally 
announced its interest in applying for the Multi-
Country Request for Proposals launched by the 
Global Fund to address the “Sustainability of services 
for Key Populations in the MENA region”.[67]
The global Support. Don’t Punish campaign is a 
popular platform for harm reduction advocates 
in the Middle East and North Africa. In 2017 and 
2018, the campaign was rolled out in a number of 
countries, including Lebanon and Yemen, and by 
the Forearms of Change Centre in Jordan.[3,68] The 
Forearms of Change Centre also runs a peer-based 
network of people who use drugs in the country.[3]
Civil society organisations contribute greatly to 
reducing stigma towards people who use drugs and 
advocating for the continuation and scaling up of 
harm reduction services, even in increasingly hostile 
environments. Progress can be seen in Morocco, 
Tunisia, Algeria and Lebanon, where civil society 
voices are gaining momentum.[69] In the past few 
years, multiple regional platforms and networks have 
been established or grown, such as the Regional/
Arab Network Against AIDS and a regional chapter of 
the International Treatment Preparedness Coalition 
advocating for access to HIV treatment.[69] 
Funding developments for 
harm reduction
Despite	increasing	efforts	to	advocate	for	the	
establishment of harm reduction policies and 
programmes, people who use drugs in the Middle 
East and North Africa region remain highly vulnerable 
and lack access to health and social services.[2] A 
fundamental	barrier	to	the	effective	and	sustainable	
implementation of harm reduction in the region is 
the scarcity of funding for harm reduction.[3] In most 
countries, interest in allocating resources to harm 
reduction is non-existent at national government 
level. [3] This is exacerbated by a tremendous decline 
in international donor funding in recent years. The 
Global Fund, for instance, spends only around 8% 
of all its investments in the Middle East and North 
Africa region.[3,70] The lack of funds and support for 
harm reduction has forced the closure of some 
established programmes, such as needle and syringe 
programmes in Egypt and Jordan.[3] 
The International Organization for Migration is 
implementing a regional grant to provide TB, HIV 
and malaria services in Jordan, Lebanon, Syria 
and Yemen; however, the majority of these funds 
are directed at support for displaced people.[70] In 
Palestine, there is a lack of donor interest, leading to 
severe shortages in funds allocated for prevention 
of harm and treatment of drug use; the Ministry of 
the Interior in Gaza stated, “there is no support from 
donor agencies and no-one considers this area a 
priority”.[71] 
A number of extenuating factors impact upon 
the availability and distribution of funds for harm 
reduction work in the Middle East and North Africa. 
Services	are	understaffed	in	Oman,	Saudi	Arabia	
and Syria, and as a result these countries have 
been forced to downsize their harm reduction 
plans.[49] Civil society organisations report there is 
insufficient	collaboration	between	research	groups,	
non-governmental organisations, the government 
and private clinics, which results in a lack of data and 
limited distribution of harm reduction resources.[49] 
This is especially present where there are many 
groups working without cohesion, like in Lebanon. 
MENAHRA report that there is poor resource 
allocation, availability or mobilisation in Algeria, 
Bahrain, Kuwait, Lebanon, Palestine, Morocco and 
Yemen.[49] Political challenges and punitive drug 
policies work against the provision of funding for 
services for people who use drugs in Qatar, Bahrain, 
the United Arab Emirates, Saudi Arabia and Kuwait. 
Budget advocacy tends to be largely driven by civil 
society in other regions, meaning that in countries 
with little or no meaningful freedom for civil society 
organisations working for harm reduction (such as 
Kuwait, Bahrain, Oman, Qatar, Yemen, Iraq and the 
United Arab Emirates), there is a lack of a strong 
voice to encourage investment in harm reduction.[49]
The	discontinuation	of	harm	reduction	efforts	is	
particularly alarming in light of rising AIDS-related 
deaths in the Middle East and North Africa and 
regional estimates that indicate more than 50% of 
all new HIV infections among adults occur among 
people who inject drugs.[25] In the absence of any 
change to the lack of funding and evidence, the 
current situation paints a bleak future for the health 
of people who use drugs in the region. Political 
commitment, regional collaboration and investment 
are fundamental to increase and sustain harm 
reduction service availability and accessibility.[26]
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Table 2.9.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Sub-Saharan Africa 
Country/territory
with reported
injecting
drug usea
People who
inject drugs
HIV prevalence
among people
who inject 
drugs(%)
Hepatitis C (anti-
HCV) prevalence
among people
who inject 
drugs(%)
Hepatitis B
(anti-HBsAg)
prevalence among
people who  
inject drugs(%)
Harm reduction response
NSPb OSTc
Peer-
distribution 
of naloxone
Benin nk 5.1[1] nk nk x x x
Burkina Faso nk nk nk nk x x x
Burundi nk nk nk nk x x x
Côte d’Ivoire 500[1]d 5.3[1] 1.8[1] 10.5[1] x [12] x
Democratic Republic 
of the Congo
3,500[1] 13.3[1]e nk nk x x x
Ghana 6,314[3] nk 40.1%[1] nk x x x
Kenya 30,500[1] 42[1] 16.4[1] 5.4[1] 19[12] 7[4,5] xf
Lesotho 2,600[6] nk nk nk x x x
Liberia 457[7]g 3.9[8]h nk nk x x x
Madagascar 15,500[1] 4.8[1] 5.5[1] 5%[1] x x x
Malawi nk nk nk nk x x x
Mali nk 5.1[9]i nk nk [1] x x
Mauritius 11,667[10] 45.5[1] 97.1[1] 6.1[1] 46[11] j 42[11](B, M) x
Mozambique 29,000[1] 46.3[1] 67.1[1] nk 1[12] x x
Nigeria 44,515[9] 3.4[13] 5.8[1]k 6.7[1] x x x
Rwanda 2,000[1] nk nk nk x x x
Senegal 1,324[14]l 9.4[1] 38.9[1] nk 5[15,16] 1[15] x
Seychelles 2,560[17]m 12.7[17] 76[17] 1[17] x n x
Sierra Leone 1,500[1] 8.5[1] nk nk x x x
South Africa 76,000[1] 14.2[1] 54.7[18]o 5[19]nk 4[20] <11
[20]p (M, 
B, B-N)
xq
Tanzania 30,000[21]r 35[22] 57[23] 1.1[1]  6[24] x
Tanzania (Zanzibar) 3,000[25] 11.3[26] 25.4[26] 5.9[26] x[1] [27] xs
Togo 2,500[28] nk nk nk x x x
Uganda nk 17-20[29]t nk nk 2[30] x x
Zambia nk nk nk nk x x x
Zimbabwe nk nk nk nk x x x
 nk – not known 
a The countries included in this table are those with reported injecting drug use according to the 2008 United Nations Reference Group systematic review and/or with operational NSPs or 
OST at the time of data collection. HRI also found data on injecting drug use in Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Djibouti, Ethiopia, Gabon, Gambia, Guinea, Malawi, 
Mali, Niger, Rwanda, Sierra Leone, Somalia, Togo, Zambia and Zimbabwe, but did not find verified data to include on these countries.
b All operational needle and syringe exchange programme (NSP) sites, including fixed sites, vending machines and mobile NSPs operating from a vehicle or through outreach workers.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
d For people who use drugs this number is believed to be between 6,000 to 10,000 people, with smoking rather than injecting more widely practised.
e For Kinshasa.
f Naloxone is available at harm reduction sites in Kenya but can be administered only by trained healthcare personnel.
g Based on sub-national data from six cities in three counties of Liberia.
h Based on sub-national data from Grand Cape Mount, Grand Bassa, Grand Gedeh, Gbarpolu, Lofa, Montserrado, Margibi, Nimba and River Gee.
i Based on sub-national data for Bamako only, with a sample size of 39.
j 35 sites managed by the Ministry of Health and Quality of Life (Government of Mauritius), 11 sites managed by the NGO Collectif Urgence Toxida.
k Based on sub-population data from 2010.
l Based on sub-population data from Dakar only.
m Total number of people using heroin estimated to be 4,318, with 2,560 using injection as the chosen route of administration.
n OST offered by the Agency for the Prevention of Drug Abuse and Rehabilitation, believed to be an abstinence-oriented programme.
o N=940 people who inject drugs in Cape Town, Durban and Pretoria. Data from 2017.
p OST is available in four cities: Cape Town, Durban, Johannesburg and Pretoria (eight sites in Pretoria).
q Naloxone available for administration by first responders/emergency healthcare workers.
r Figure is believed to be an underestimate nationally, but locally adequate in selected sites.
s Naloxone available for administration by first responders/emergency healthcare workers.
t Figure relates to people who use drugs, but women who inject drugs appear disproportionally affected by HIV with more than double the prevalence at 45%.
Global State of Harm Reduction 2018160
Regional Overview 2.9 Sub-Saharan Africa 161
NIGER
SUDAN
NIGERIA
SOUTH
AFRICA
TANZANIA
ZAMBIA
KENYA
SOMALIA
GHANA
GUINEA
MALAWI MAURITIUS
ZANZIBAR
ANGOLA
NAMIBIA
BOTSWANA
ZIMBABWE
LESOTHO
DEMOCRATIC
REPUBLIC
OF CONGO
CHAD
CENTRAL
AFRICAN
REPUBLIC
MALIMAURITANIA
ETHIOPIA
MADAGASCAR
MOZAMBIQUE
SIERRA LEONE
LIBERIA
COTE
D’IVOIRE
BURKINA
FASO
TOGO
BENIN
GUINEA BISSAU
GAMBIA
SENEGAL
SAO TOME
& PRINCIPE
CAMEROON
EQUATORIAL
GUINEA
GABON
REPUBLIC OF CONGO
UGANDA
RWANDA
BURUNDI
DJIBOUTI
ERITREA
CAPE VERDE
SEYCHELLES
SOUTH
SUDAN
Map 2.9.1: Availability of harm reduction services
Both NSP and OST available
OST only
NSP only
Neither available
Not Known
DCR available
Peer-distribution of naloxoneNALOXONE
Harm reduction in Sub-Saharan Africa
u Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Chad, Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Ethiopia, Gabon, Gambia, Ghana, 
Guinea, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritius, Mozambique, Niger, Nigeria, Rwanda, Senegal, the Seychelles, Sierra Leone, Somalia, South Africa, 
Swaziland, Togo, Uganda, Tanzania, Zambia and Zimbabwe.
Overview
Since the previous iteration of this report in 2016, 
sub-Saharan Africa has seen some progress in harm 
reduction policy and services in selected countries. 
Explicit support for harm reduction is now contained 
in national policy documents in 10 countries as 
opposed to seven in 2016, and needle and syringe 
exchange programme (NSP) services have been 
established in Uganda, Mali and Mozambique, which 
brings the total number of countries operating 
an NSP in the region to eight. The number of 
countries with some opioid substitution therapy 
(OST) provision has increased since 2016, with the 
addition of Zanzibar (see Table 2.9.1) having a service 
operating since 2015, and a new OST service having 
been established in August 2018 in Abidjan, Côte 
d’Ivoire. The Global State of Harm Reduction now also 
reports on more countries than ever in the region 
that have demonstrable advocacy efforts for harm 
reduction or with established programmes in place. 
In a systematic review published in 2017, evidence 
was found of injecting drug use in 36 countries in 
the region,u with a broad-ranging estimate of people 
who inject drugs numbering between 645,000 and 3 
million.[1] Reliable information on drug use in sub-
Saharan Africa is, however, limited. Due to differing 
methods for calculating prevalence of blood-borne 
diseases among people who use drugs, with figures 
often stemming from sub-national data, the numbers 
cited in Table 2.9.1 should be viewed with caution. 
Although harm reduction services are generally 
found to be lacking, after an extended period of 
political rejection of harm reduction, some change 
has been observed in the region during the last five 
to 10 years, with epidemiological research being 
undertaken, pilot programmes and endorsements 
of harm reduction found in government policies. 
There has also been programmatic scale up of 
harm reduction services in a select few sub-Saharan 
African countries. 
Since the last iteration of the Global State, the 
first East African harm reduction conference was 
held in Nairobi, Kenya in early 2018 and attracted 
approximately 600 participants from 20 countries. 
The event, co-hosted by the Kenya AIDS NGO 
Consortium (KANCO) and the Kenyan Ministry of 
Health, also saw the Cabinet Secretary for Health 
(Kenya) formally launch the Eastern Africa Harm 
Reduction Network.[5] A decade ago this conference 
would have been hard to imagine, and donor support 
for harm reduction activities in selected countries 
has assisted greatly with these changes. For example, 
Kenya now appears as one of the champions of harm 
reduction in the continent, steadily upscaling its harm 
reduction services over the last three to five years. 
Some politicians and policy makers voiced opposition 
to the criminalisation of drug use and urged a move 
towards drug use being treated as a public health 
issue.[31] Civil society mobilisation in the region has 
led to increased levels of support for harm reduction 
interventions, public awareness of what harm 
reduction is and in some instances to the initiation of 
services, such as pilot NSPs in Uganda.[30] 
In November 2016, a civil society organisation in 
Senegal – Alliance Nationale des Communautés pour 
la Santé (ANCS) – became the principal recipient 
of a Global Fund regional grant programme which 
aims to: produce strategic information about people 
who use drugs; support countries to create harm 
reduction programmes and policies; advocate for 
harm reduction-friendly laws; create advocacy tools 
for harm reduction; and, build capacity for actors 
in the sector, including people who use drugs.[32] 
Importantly, the project calls for the establishment 
and necessity of a favourable environment for harm 
reduction interventions.[33] The programmes are 
due to operate in five countries (Côte d’Ivoire, Cape 
Verde, Burkina Faso, Guinea-Bissau and Senegal) in 
the coming years, all of which at the time of reporting 
had either no or very limited harm reduction 
services.[15,32]
Although increases in harm reduction services 
and support have been achieved, there are also 
examples of regression in the region. In 2014, the 
Global State of Harm Reduction reported a scale-
up in both NSP and OST services in Tanzania.[34] In 
2018, although there has been an increase in OST 
interventions outside Dar es Salaam, NSPs remain 
limited and accessibility is low.[24] The understanding 
of harm reduction interventions appears entwined 
within an abstinence-based approach in Tanzania 
under the current government, and demonstrates 
little focus on the health and wellbeing of people 
who use drugs.[24] As endorsed by the World Health 
Organization (WHO), the United Nations Office 
on Drugs and Crime (UNODC), the Joint United 
Nations Programme on HIV and AIDS (UNAIDS), 
the UN General Assembly, the Economic and Social 
Council, the UN Commission on Narcotic Drugs, 
the UNAIDS Programme Coordinating Board, the 
Global Fund and the President’s Emergency Plan For 
AIDS Relief (PEPFAR), a comprehensive package of 
harm reduction interventions has been scientifically 
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demonstrated to support the prevention and spread 
of HIV and the reduction of other harms.[35] NSPs 
in particular are based on strong evidence for their 
effectiveness in the prevention of HIV[36,36,37] and 
hepatitis C,[36-39] and are known to lead to a reduction 
in injecting risk behaviours, such as the sharing 
of equipment.[39] NSPs are also cost-saving when 
compared with the total lifetime cost of treating a 
person with HIV.[40] 
An inclusive approach: the necessity 
for gender-sensitive harm reduction 
services
Since 2012, the Muslim Education and Welfare 
Association (MEWA) in the coastal region of Kenya 
has partnered with Mainline, an organisation which 
implements harm reduction programmes in different 
parts of the world. The partnership’s focus was on 
improving access to quality HIV prevention, treatment, 
care, support services, socio-economic rehabilitation, 
reintegration and human rights for people who use 
drugs. Starting in 2017, the project added a specific focus 
to deliver inclusive, rights-based and gender-sensitive 
services which were more accessible for women.[41] 
Women who inject drugs often experience 
disproportionately high levels of negative health 
outcomes,[42,43] with studies often illustrating a much 
higher HIV prevalence rate among women who inject 
drugs than their male counterparts. [44,45] Women are 
often less inclined to seek harm reduction services 
due to multiple stigmas (such as external gender-
related stigma, internal self-stigma, stigma from others 
living with HIV),[46] which has clear implications for 
their health.[47-49] Examples of this disparity have been 
reported in the Democratic Republic of the Congo, where 
drug use appears much more taboo among women than 
men,[50] and in Mauritius, where women remain a hidden 
population.[51,52] These attitudes are similarly echoed all 
over the region.[5,20,24,30,50] 
To ensure women and girls are not left behind, the joint 
project in Kenya aims to strengthen and build capacity 
of established drop-in centres and NSPs; distribute 
condoms; improve screening, diagnostics and treatment 
of diseases and infections; improve HIV testing and 
counselling; and improve outreach. It also aims to 
provide expert harm reduction training to female drug 
users to form a “train the trainer” model of peer-to peer 
support, and information and assistance on accessible 
services.[41] The hope is that this approach, although 
currently implemented only in the coastal region, will 
eventually be taken up nationally and investment in it 
increased.[41,53] 
Nigeria continues to be politically resistant to 
harm reduction interventions, even given the high 
lifetime prevalence of use of drugs such as heroin 
(63%) and cocaine (70%) among people who inject 
drugs, and unsafe practices such as the sharing and 
reuse of needles.[16,54] In the Seychelles, the harm 
reduction response has also fallen short, leading 
to the potential for a public health crisis. Between 
2011 and 2017, HIV prevalence among people who 
injected drugs in the country increased from 5.8% 
to 12.7% and HCV prevalence from 53.5% to 76%.[17] 
Zanzibar, where one harm reduction service is in 
operation, has an HIV prevalence among people 
who inject drugs of 11.3%.[26] Although the hepatitis 
C prevalence rate is lower than other countries in 
the region (25.4%), both are likely to rise without 
a range of harm reduction interventions in place 
for this population.[26] The Democratic Republic of 
the Congo lacks many of the WHO-recommended 
harm reduction interventions.[35] Meetings between 
harm reduction advocates in the country and the 
ministers of health and security have not yet resulted 
in improvements to the implementation of essential 
services.[50] 
Prevalence and patterns of drug use also vary 
across the region and, as Table 2.9.1 highlights, 
there remains a serious need to close the gap in 
harm reduction services and healthcare provision in 
sub-Saharan Africa for those at risk of blood-borne 
viruses, such as people who inject drugs, particularly 
in reference to hepatitis C. Research is assisting with 
this in some countries. For example in South Africa, 
between August 2016 and December 2017, 1,165 
people who use drugs (including 941 people who 
inject drugs) were recruited across three cities (Cape 
Town, Durban and Pretoria) to assess prevalence of 
HBV, HCV and HCV-HIV co-infection. The study found 
that hepatitis C prevalence (virological confirmation) 
ranged from 29-73%, with up to 29% of people who 
inject drugs in Pretoria found to be co-infected with 
HIV and HCV.[18] 
Even in the countries in the region which have 
established harm reduction services, significant 
structural barriers to uptake by people who use 
drugs persist. As one study participant in Durban 
notes, “Drug prohibition laws, stigmatisation and 
heavy-handed policing have all led to low levels of 
help or health seeking behaviour, distrust of the 
health system and little faith in the interventions 
that are available among [a] low-income community 
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of people who use drugs”,[55] and there remains 
limited access to legal services for this population.[20] 
Mauritius and Tanzania have taken regressive steps 
in harm reduction-related policy, reducing and/or 
limiting access to comprehensive harm reduction 
services in recent years.[52] 
Although harm reduction services are improving in 
some countries in sub-Saharan Africa, it is clear that 
there continues to be discordance between levels of 
HIV and hepatitis C among people who inject drugs 
and the availability of harm reduction services. Laws, 
policies and practices are inextricably linked to the 
effectiveness of a country’s response to epidemics 
and the ability of people who use or inject drugs 
to gain access to HIV prevention, treatment and 
care services.[56] People who use drugs often feel 
stigmatised and discriminated against when seeking 
HIV testing and treatment, with a lack of integrated 
service provision for this population.[20,24] In addition, 
as in other regions, hepatitis C treatment remains 
beyond the grasp of the vast majority of people 
(both those who use drugs and those who do not) 
due to its cost. People also identified a low sense 
of self-worth, previous negative health care service 
experiences, a sense of hopelessness and long 
waiting times as contributing barriers to accessing 
hepatitis care.[19]
There is a great need in this region, as in others, for 
stability of harm reduction in policy, programming 
and security of its funding, such that these will not be 
undone by a change in government. Harm reduction 
is not a moral question, but an evidence-based, 
established public health approach which works.[57-61] 
The effectiveness of abstinence-based rehabilitation 
treatments has been refuted anecdotally in the 
region, with one harm reduction focus group in 
South Africa finding that every participant had at 
one time or another been enrolled in some form of 
rehabilitation centre, only to return to illicit opioid 
use on departure.[55] Human Rights Watch has also 
reported that abusive and unregulated rehabilitation 
centres which violate international human rights laws 
are operating across the region.[58,62] 
Developments in harm 
reduction implementation
Needle and syringe programmes (NSPs)
NSPs in sub-Saharan Africa have been newly 
implemented in three countries since the Global 
State of Harm Reduction last reported in 2016 – 
Mali, Uganda and Mozambique – bringing the total 
number of countries now implementing this service 
in the region to eight. In September 2017, the 
Ugandan Ministry of Health approved pilot NSPs run 
by the Uganda Harm Reduction Network (UHRN), in 
partnership with Community Health Alliance Uganda, 
in two designated health facilities in one district of 
Uganda (Kampala).[29,30] 
At the time of writing, there are four NSP sites in 
four cities in South Africa (Cape Town, Pretoria, 
Johannesburg and Port Elizabeth), an increase of 
one since the Global State reported in 2016, with the 
City of Tshwane (Pretoria) planning to expand its 
services to eight locations in the future.[20] In Kenya, 
thanks to an increase of funding from the Global 
Fund, NSPs have also increased, going from 13 to 
19 since 2016.[63] In Senegal, the Alliance Nationale 
des Communautés pour la Santé (ANCS) implement 
a syringe programme based in Dakar,[32] and 
provide psychosocial and health specialists who can 
accompany and support people who use drugs when 
using the service.[32] Four further NSP sites are also 
operational, two in Dakar, one in Mbour and one in 
Kaolack.[16] 
NSP sites in Mauritius, although still operational 
and financially supported by both the government 
and the Global Fund, remain restricted to a fixed 
quota of 30,000 needles per month.[51,64] The 
restriction, implemented by the government that 
came to power in 2014, inhibits service providers 
(who cannot respond to need) and is harmful, 
given the increasing number of people who inject 
drugs in the country.[51,52,64] People under the 
age of 18 do not have access to harm reduction 
programmes and, with paraphernalia illegal under 
the Mauritius Dangerous Drugs Act, young and 
old may be arrested for the simple possession of 
a syringe.[52] In Kenya, although NSP services fail to 
reach everyone who needs them, approximately 135 
needles per person who injects drugs per year are 
distributed, a substantial increase since 2015.[65] A 
guideline for young people and harm reduction is 
currently in development in Kenya to enable better 
access to this group in the future.[5] Some NSPs in 
South Africa and Mauritius also solicit feedback on 
people’s experience of the services to inform future 
improvements.[20,51,52]
Despite some increases in the region, coverage of 
existing NSP services remains disproportionately 
low compared to international targets.[35] In 
Tanzania, NSP provision remains poor, and high-
risk behaviours such as needle sharing and the 
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practice of flashbloodv have been reported, with 
an estimated 15.6% of people who inject drugs 
practising flashblood and 14.2% sharing a needle 
with another at last injection.[66] As previously noted, 
the approach taken in the country is predominantly 
abstinence-based in nature and therefore much-
needed NSP services are not yet being scaled-up 
to the same extent as OST.[24] Tanzania is one of 
the main routes of entry for heroin in sub-Saharan 
Africa[67,68] and there is relatively high opioid use 
in the region.[21] There is poor access to screening 
services for blood-borne viruses such as HIV and viral 
hepatitis for people who inject/use drugs.[67] There 
is therefore an urgent need for significant increase 
in coverage of NSP, along with better integrated 
healthcare services for people who use/inject drugs 
and a strengthening of counselling on safe injecting 
and safe sex practices.[66]
NSP provision is currently unavailable in 
Zimbabwe.[69] However, the Zimbabwe Civil Liberties 
and Drug Network (ZCLDN) is currently working 
with the Parliamentary Committee on Health and 
HIV to table a motion to introduce harm reduction 
services, including NSP, in the country.[69] One of the 
major challenges to initiating NSP has been the lack 
of reliable data on injecting drug use. Civil society 
groups, such as the ZCLDN, point to evidence of 
injecting drug use and a clear need for these harm 
reduction services.[69] The Seychelles also has no 
NSP provision in free harm reduction services, but 
needles and syringes are available for purchase from 
pharmacies. From recent data, however, pricing 
appears as a barrier to the safe use of needles, 
with 41% of respondents (n=142) reporting unsafe 
injecting practices.[17] Given the rising rates of HIV 
and hepatitis C among people who use drugs in the 
Seychelles, harm reduction measures such as NSP 
are urgently called for.[17,70] 
Nigeria remains politically resistant to the 
implementation of NSPs, even though unsafe 
practices such as the sharing and the reuse of 
needles is high.[13,71] Needles and syringes are sold 
at pharmacies, but people who inject drugs are 
often asked undesirable questions and worry about 
criminal repercussions. Coupled with this are the 
behavioural norms of needle sharing as a sign of 
trust or brotherhood, and new practices, such as the 
shared purchase of pre-loaded syringes by several 
people, leading to the sharing of a single syringe.[71] 
Civil society organisations in the country, such as 
YouthRISE, continue to advocate for the initiation of 
NSPs as an essential harm reduction service.[16] 
v Flashblood is a high-risk blood-sharing practice that carries a very high probability of viral transmission. A person who has recently injected draws blood back into 
the syringe post-injection and passes the syringe to a peer, who injects the 3ml to 4ml of blood in turn.
In all countries where NSP sites exist (Kenya, Mali, 
Mauritius, Senegal, South Africa, Tanzania and 
Uganda and Mozambique), barriers to access 
remain, including social stigma, geographic coverage 
(often sites are restricted to urban areas with no 
mobile sites operational) and harassment/rights 
infringements by law enforcement, such as the 
confiscation of syringes/needles.[20] 
Opioid substitution therapy (OST)
A total of seven countries in sub-Saharan Africa 
have OST services freely available for people who 
use/inject opioids (see Table 2.9.1). Zanzibar has 
offered this service since 2015 and Côte d’Ivoire since 
August 2017.[2,27] Similarly to NSPs, the majority of 
countries in the region have yet to introduce OST 
programmes. Where it exists, OST is provided in the 
form of methadone or buprenorphine, depending 
on the country, predominantly in directly observed 
treatment settings. Take-home dosing has been 
successfully implemented in South Africa, and 
is beginning on a small scale in Tanzania in the 
municipality of Temeke.[20,24]
Tanzania established its first methadone clinic at 
the Muhimbili National Hospital in Dar es Salaam in 
2011, followed by a second clinic in Mwananyamala 
and an additional site in Dar es Salaam.[72] Since 
then, there has since been significant scale-up of 
OST outside Dar es Salaam, including the Mbeya and 
Mwanza regions, with political endorsement to scale 
up OST in other regions of Tanzania, beginning with 
Dodoma in late 2018.[24] Although the scale-up of 
services is welcome, the primary focus remains on 
injecting drug use; people who smoke rather than 
inject, particularly women, find access to OST more 
challenging.[68] There are also regular drug checks for 
people attending the clinics. The continuation of OST 
is dependent on negative results for illicit drug use, 
and an abstinence-oriented culture is dominant.[24] 
Zanzibar began implementing OST in 2015, offering 
methadone (doses ranging from 8mg-295mg), and 
had enrolled approximately 415 people into the 
programme at the time of reporting.[27] In early 2017, 
the Ministry of Health in Côte d’Ivoire approved the 
first OST programme in the country; the first unit was 
established in August 2018 in Abidjan.[2]
In the last iteration of the Global State in 2016, the 
city of Tshwane (Pretoria) in Gauteng, South Africa 
had entered into an agreement for OST to be made 
available at selected primary healthcare centres, 
with an OST demonstration project at the planning 
stages in Durban. In 2018, these programmes are 
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operational; 606 people were enrolled in OST as 
part of the city-funded low-threshold programme in 
Pretoria, and approximately 50 new people entered 
the service each month.[20] At the time of reporting, 
there were over 11 OST projects being implemented 
in four cities (Pretoria, Cape Town, Durban and 
Johannesburg) in South Africa for people who use 
opioids.[20] However, one of the main barriers to 
accessing substitution treatment remains the cost 
of medication (with no generic products available), 
since the services are not subsidised.[20] There have 
also been limited discussions with the National 
Department of Health in respect of determining 
appropriate budgets for OST; however, at the time 
of publication there was no clear call for a harm 
reduction-specific budget to offer free or subsidised 
care.[20] 
In Kenya, OST was introduced by non-private 
providers in December 2014; since then there has 
been a steady increase in provision and support for 
further roll-out of OST services by USAID and the US 
Centers for Disease Control and Prevention, with 
seven OST clinics now open.[5] Further scaling up of 
this service is needed. Although many people who 
use drugs are keen to access OST programmes, at 
the time of reporting they were reaching less than 
10% of people who inject drugs in the country.[63] 
Barriers to accessing substitution therapy include 
lengthy distances for people to travel to receive daily 
dosages and limited uptake by people living with 
disabilities.[5] 
In 2016, under the newly elected Mauritian 
government, OST distribution was moved from 
health facilities to police stations, with daily fixed 
times and reduced hours (from 6.00 to 8.00 am) for 
people who use drugs to attend, with considerable 
negative impact on access to services. Methadone 
was also replaced with buprenorphine and 
naltrexone.[73] Successful advocacy by a Mauritian 
network of civil society organisations, Collectif 
Urgence Toxida, resulted in the reintroduction 
of methadone in 2017.[52] In the first half of 2018, 
distribution continued to be carried out at police 
stations and at the aforementioned fixed hours. 
However, in July 2018 the health minister of Mauritius 
announced that OST distribution would revert to 
primary healthcare settings with times of distribution 
to be reviewed.[52] The restrictions placed around OST 
in Mauritius highlight the retreat from previously 
well-established services in this country.
OST is available in Senegal, funded by several 
partners including the Global Fund and Expertise 
France, yet coverage is limited.[33] In 2016, the Centre 
de Prise en Charge Intégrée des Addictions de Dakar 
(CEPIAD) had enrolled 425 people in OST, carried 
out more than 3,000 consultations and offered a full 
range of services, including medical, psychological 
and social services plus daily methadone therapy, as 
well as activities such as gardening, literacy, theatre 
and art therapy.[33] There is hope for the service to be 
scaled-up, with take-home methadone available and 
a decentralised community service reaching beyond 
Dakar, yet these plans are funding-dependent. At 
present, women who use drugs make up only 10% of 
people coming to CEPIAD, and methods are still being 
explored to adapt services to meet their needs.[33] 
OST remains unavailable in Zimbabwe. 
Opioids for detoxification are only available in 
rehabilitation clinics or by referral to mental health 
services.[69] Making harm reduction services available 
in the country would be an important step toward 
respecting the health-related and human rights 
of people who use drugs, and enabling access to 
opioids as a harm reduction measure. The Zimbabwe 
Civil Liberties and Drug Network is currently working 
with the Parliamentary Committee on Health and HIV 
to table a draft motion to introduce essential harm 
reduction services, including OST, to Zimbabwe.[69]
After long-term advocacy activities in Uganda, 
PEPFAR (through the US Centers for Disease Control) 
is due to incorporate elements of OST in Uganda’s 
Country Operational Plan 2018 budget.[30] In Côte 
d’Ivoire and Mozambique, the respective Ministries 
of Health have announced plans to launch OST.[12,33] 
Although OST services are not available in the 
Democratic Republic of the Congo, it is believed that 
opioids may be available for substitution therapy via 
clandestine methods. However, further research is 
needed to understand need and subsequent harm 
reduction provision.[50] 
In the Seychelles, OST is offered by the Agency for the 
Prevention of Drug Abuse and Rehabilitation, yet this 
appears linked to an abstinence-oriented approach 
rather than a harm reduction approach. In a recent 
report it was noted that there is an urgent need to 
pursue and scale-up harm reduction programmes 
in the country, particularly given the rising rates of 
HIV and hepatitis C among people who inject/use 
drugs. [17] 
As indicated in Table 2.9.1 and Map 2.9.1, Nigeria still 
lacks OST services. However, [16,74] in 2018 the Ministry 
of Health began a consultation on the development 
of guidelines on the use of methadone for drug 
rehabilitation treatment. The health minister has also 
set up a task force to advise on the implementation 
of harm reduction in the country.[16]
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Human rights violations and 
Stepping Up in South Africa 
Human rights violations of people who use drugs are 
often unreported, underreported, or ignored. The Step 
Up Project, which has provided needle and syringe 
programmes and other core HIV services to people who 
inject drugs in South Africa, has consulted intensively 
with people who use drugs in order to better understand 
their lived realities and needs.[75] In 2016, 683 violations 
were recorded in Cape Town, Durban and Pretoria, 81% 
of which involved the illegal removal of unused injecting 
equipment.[75] 
The Step Up Project emphasises the value of reporting 
violations and the way in which recording violations can 
contribute to positive changes in the environment.[75] An 
example of this was evidenced in Pretoria, where people 
who use drugs reported increased harassment, arrests 
and assaults by South African Police Services (SAPS) 
and members of the local Community Police Forum 
(CPF). When approached by members of the Step Up 
team, SAPS and CPF members reported that increased 
policing actions against people who inject drugs were 
motivated by concerns around the incorrect disposal 
of injecting equipment. Service users acknowledged 
this problem and Step Up implemented an adapted 
needle and syringe service based on needle exchange 
at the location in lieu of the regular distribution of 
full harm reduction packs (although these were still 
supplied where necessary), reducing the number of 
inappropriately discarded needles in the community. 
This measure, combined with informing SAPS and CPF 
that Step Up team members would be recording human 
rights violations, is believed to have led to a reduction in 
human rights violations in the area.[75] This is a small but 
significant example of the ways in which communication, 
understanding, respect and persistence can effect 
necessary changes for both people who inject drugs and 
the broader community. 
 
Amphetamine-type stimulants (ATS) and new 
psychoactive substances (NPS)
Although injecting drug use is believed to be 
relatively low in some of the countries in the 
region, inhalation of substances like crack or heroin 
has been documented as quite commonplace in 
parts of West Africa.[33] With respect to broader 
amphetamine-type stimulant (ATS) and new 
psychoactive substances (NPS) use, evidence points 
to increases seen elsewhere around the globe[76] 
(please see ATS and NPS sections in other regional 
chapters). 
A study of healthcare workers in Kenya found 
8.8% had used cocaine, 6.4% ATS and 5.4% 
hallucinogens.[77] Methamphetamine laboratories 
have been discovered in Nigeria, and civil society 
organisations report a growth in the use of ATS.[74] 
Anecdotal evidence suggests there has been an 
increase in the use of NPS in Mauritius, with more 
seizures being carried out by the anti-drug and 
smuggling unit in the country.[52] Cocaine and its 
derivatives are available in Zimbabwe, but the drug is 
expensive and therefore access is limited.[69] Although 
there is no available data on NPS, sources note a 
rise in use in the Zimbabwean market where these 
substances are popular with younger people. In the 
capital’s two major psychiatric referral hospitals, a 
high prevalence of substance-related psychiatric 
conditions has been noted by local doctors with 
the emergence of NPS.[69,78] Although ATS use is 
prevalent in South Africa, there is very little data 
outside detoxification treatment numbers. A study 
in Cape Town found over 90% of people who inject 
drugs screened for OST (n=<70) reported concurrent 
heroin and methamphetamine injecting.[20,79] Yet the 
response to ATS in all countries is almost exclusively 
abstinence-based, and resistance to harm reduction 
stands as a major barrier for people who use 
stimulants.[24,30,52,80]
Perhaps in light of the reported increase, Expertise 
France is financing six long-terms projects in West 
Africa (and South East Asia) to respond to new 
modes of drug consumption.[33] Given the reported 
increase in the whole region, there is a great need 
for research and development of harm reduction 
services specific to ATS and NPS.
Viral hepatitis
As seen in Table 2.9.1, data on the extent to which 
people who inject drugs are affected by hepatitis 
C (HCV) in the region remain extremely limited. 
From the estimates it is clear that the prevalence 
of hepatitis C in this population is high among 
people who use drugs when compared with national 
estimates.[9] It appears that Kenya is the only country 
in the region where treatment for hepatitis C is 
available free of charge, through funding from both 
the Global Fund and UNITAID, for small pockets of 
people who inject drugs.[5] At the time of publication, 
the treatment programme was available to 200 
individuals as part of a research project; however, 
the Global Fund plans to assist 1,000 people into 
treatment by the end of 2019.[5] For the majority of 
people with limited access to these programmes, 
hepatitis C treatment remains expensive, often 
forming an insurmountable barrier, particularly 
for people who inject drugs and who are most 
vulnerable to the virus.[5]
Regional Overview 2.9 Sub-Saharan Africa 167
In South Africa, National Hepatitis Guidelines 
and a National Hepatitis Action Plan are under 
development and will include a focus on people who 
inject drugs.[20] At time of publication, hepatitis C 
testing was not included in existing harm reduction 
programmes in South Africa, and direct acting 
antivirals (DAAs) were not formally registered with 
the South African Health Products Regulatory 
Authority. Treatment is therefore limited to two 
tertiary hospitals in the public sector, and there is 
limited awareness surrounding hepatitis C and poor 
linkages to care.[81] A study undertaken in three 
locations in South Africa (Cape Town, Durban and 
Pretoria) among 940 people who inject drugs found 
hepatitis C prevalence (virologically confirmed) at 
44%; 224 people in the study who used drugs but 
did not inject had hepatitis C prevalence of 8%.[81] 
The high hepatitis C prevalence among people who 
inject/use drugs highlights an urgent necessity 
for expanded community-based services that are 
accessible and appropriate for key populations.[81,82] 
The findings also support a comprehensive care 
package of needle and syringe exchange 
programmes, opioid substitution and DAA therapy.[82]
In Tanzania, hepatitis B and C testing have recently 
been integrated into OST services, with more 
comprehensive care packages available for people 
who inject drugs.[24] However, hepatitis C treatment 
is inaccessible to much of the population due to 
the price of treatment, and diagnostic tests often 
have recurrent stock-outs.[24] With hepatitis C rates 
significant among people who inject drugs in the 
country (22% reported in 2010 in Zanzibar,[83] 27.7% 
reported in 2013 in Dar es Salaam[84] and 57% 
reported in Tanzania as a whole[23]), integrating 
hepatitis treatment into OST clinics should be 
considered with urgency.
In Uganda, Senegal, Zimbabwe, Zambia, Mauritius, 
South Africa and Nigeria, a lack of availability and 
accessibility of hepatitis C testing and treatment was 
reported for people who use drugs.[16,20,30,32,52,69,74] 
The cost of treatment remains the principal barrier; 
however, punitive laws and fear of reprisals often 
deter people who use drugs from accessing hepatitis 
C testing and treatment services.[69] 
Tuberculosis (TB)
In 2016, an estimated 10.4 million people fell ill 
with TB around the world, 25% in Africa.[85] With 
TB deaths among those infected at approximately 
82% in this region, a long way away from the WHO 
sustainable development goal of 10%, it is clear 
that TB prevention and treatment remain to be 
comprehensively addressed.[85] Sub-Saharan Africa, 
although witnessing a marginal decline in overall 
incidence (in 2016, 254 cases per 100,000 population 
per year as opposed to 263 in 2014), is estimated to 
have nearly double the TB global incidence of 140 per 
100,000.[86] 
Although TB testing and treatment are available 
to everyone in principle, they remain out of reach 
for much of the population in practice, and there 
continues to be a paucity of data regarding TB 
prevalence and treatment access among people 
who inject drugs. Whilst the majority of those who 
have been diagnosed may not develop active TB, 
people who use/inject drugs, together with prisoners, 
are more vulnerable to progressing to active TB 
due to increased HIV co-infection and poor prison 
conditions in many countries.[87]
In 2016, South Africa accounted for the largest share 
of people newly enrolled in HIV care who began TB 
preventive treatment, and it has been noted by WHO 
for its strong efforts in this area.[85] TB diagnosis and 
treatment is available in South Africa and Nigeria, but 
often services also place emphasis on abstinence as 
a condition for treatment, which restricts access.[16,20] 
With this in mind, in 2016 one sub-acute TB hospital 
in Cape Town shifted from running an abstinence-
based intervention to implementing a harm 
reduction approach. This included the development 
of a new screening tool, a “contemplation group” for 
patients and harm reduction practice guidelines for 
staff. The aim of the programme is to assist patients 
to adhere to TB treatment, regardless of substance 
use. Over the first six months of the project, 
attendance in the contemplation group improved 
from 13% to 42%, highlighting how a harm reduction 
approach can be made practical and acceptable in 
a short space of time. However, acceptance of the 
programme has been varied among hospital staff, 
and long-term mentoring and support for hospital 
staff in harm reduction was recommended to 
improve their understanding of a harm reduction 
approach.[88] 
The lack of available access to TB services for people 
who use drugs can also be seen in Uganda.[30] 
TB programmes are often more accessible when 
integrated into other services, such as harm 
reduction sites or HIV testing and treatment facilities. 
TB diagnostics and treatment are available in 
integrated services in Zimbabwe,[69] Senegal,[32] South 
Africa[20] and Kenya.[5] 
In Tanzania, TB testing and treatment are integrated 
into OST services, but there remain challenges 
and a lack of resources in providing care to the 
population of people who use drugs in a friendly 
and non-judgmental way.[24] The criminalisation of 
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drug use, often linked with intense social stigma and 
discrimination faced by people who use drugs in the 
region, can lead to poor health-seeking behaviours.[49] 
Given the high rates of TB in sub-Saharan Africa, 
urgent action is needed to address the gaps in 
service provision.
Antiretroviral therapy (ART)
Data on the number of people who inject drugs 
receiving ART within the sub-Saharan Africa region 
are sparse. It is believed that HIV testing and 
treatment for people who inject drugs in Kenya 
reached approximately 68% of people who inject 
drugs registered in harm reduction services.[5,89] 
Yet adherence can be problematic, with missed 
appointments and a lack of follow-up care.[5] 
In South Africa, Tanzania and Senegal, ART is widely 
available in mainstream public health services. 
However, there are few key population-specific ART 
services in existence, and criminalisation continues 
to contribute to non-disclosure of drug use to service 
providers.[20,24,32] Mandatory drug testing for people 
who inject/use drugs currently inhibits people from 
accessing ART in the current HIV prevention policy 
in Uganda.[30] HIV testing and treatment services in 
Nigeria are often located some distance from where 
people who are using drugs reside, so although ART 
is provided free of charge at government facilities, 
there are some associated costs for registration 
and laboratory tests which form another barrier to 
service uptake.[16]
To protect confidentiality and privacy, HIV data 
systems in South Africa do not routinely collect data 
on key population type.[20] Enrolling people who 
inject/use drugs into ART programmes is imperative, 
and integrated services which enable access should 
be increased in all countries in the region.
Overdose, overdose responses and drug 
consumption rooms
There are no drug consumption rooms or safer 
injecting facilities in sub-Saharan Africa and no peer-
distribution naloxone programmes in operation 
at time of publication. Naloxone, a highly effective 
opioid antagonist used to reverse the effects of an 
overdose, is available outside hospitals in Kenya at 
harm reduction sites.[5] However, although harm 
reduction sites have access to naloxone, it can only 
be administered by medical personnel, which causes 
challenges for community groups and outreach.[5] 
Naloxone can also be administered only by first 
responders and healthcare workers in South Africa[20] 
and Tanzania.[24] The existing harm reduction services 
in South Africa have trained peers and staff in 
overdose and prevention management, but there 
are occasional national stock-outs.[20] Formulations of 
naloxone other than injection (e.g. intranasal) have 
not yet been registered in South Africa, which further 
limits the life-saving support that first responders 
can provide.[20] In 2016, naloxone was added to 
the List of Essential Medicines in Tanzania, but can 
be stored and administered only in hospitals and 
specific medical facilities that have an emergency 
or specialised unit, meaning access is extremely 
limited.[24] 
Naloxone is reportedly unavailable in the majority of 
countries listed in Table 2.9.1, including Mauritius,[52] 
Zimbabwe,[69] Senegal,[32] Nigeria,[16] the Seychelles,[17] 
Democratic Republic of the Congo[50] and Uganda.[30] 
The barriers preventing overdose programmes from 
operating were primarily noted to be prohibitive drug 
laws and restrictions on who is eligible to administer 
the drug.[24,30,52] In the Democratic Republic of the 
Congo, alongside many other countries in the region, 
advocacy efforts are in place to lobby for access to 
naloxone, and the necessity for drug and overdose 
training.[50]
A systematic review in 2014 found between 83-
100% survival rates post-naloxone treatment, 
demonstrating that non-medical bystanders 
trained in community opioid prevention techniques 
are effectively able to administer the life-saving 
treatment.[57] It is widely acknowledged that people 
using drugs, their families, friends and people nearby 
who have access to naloxone form the most effective 
line of defence against opioid overdose; ensuring 
ease of access to this medicine is paramount.[90]
Harm reduction in prisons
Despite some momentum around decriminalisation 
in recent years, the response to drugs remains 
predominantly punitive in sub-Saharan Africa. In 
2014, the West Africa Commission on Drugs called 
for the decriminalisation of both drug use and 
possession for personal use, presenting evidence of 
the ways in which criminalisation negatively impacts 
on health and social problems, and places undue 
pressure on the criminal justice system.[91] Since 
then, Ghana is poised to become the first country in 
the region to decriminalise the personal possession 
and use of all illicit drugs, replacing dated punitive 
legislation with an approach which addresses drug 
use as a public health issue. However, how this would 
work in practice is unknown.[92] 
Research indicates that prisoners are more likely 
to be exposed to blood-borne viruses in the prison 
setting,[93,94] and reports of injecting drug use in 
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prisons are found worldwide.[95] The effectiveness 
of prison NSPs in challenging this has been 
demonstrated,[96] yet no countries in sub-Saharan 
Africa implement NSP harm reduction services 
in prisons and places of detention. Only three 
countries in the region provide OST in the prison 
setting: Mauritius, Kenya and the Seychelles.w In 
2016, the Global State reported that, since the 
change of government in Mauritius in 2014, OST 
had been limited to those who already received it 
prior to incarceration. Thanks to lobbying by groups 
such as Collectif Urgence Toxida, OST in the form 
of methadone can now be initiated in three of the 
six prisons on the island.[52] Given that illicit drugs 
have been reported in all six prisons,[97] a scaling 
up of OST services and implementation of further 
harm reduction measures (such as NSP provision) is 
recommended, particularly given that 85% of people 
who inject drugs have reported being arrested by 
police in Mauritius.[11] In Kenya, only people who had 
received methadone maintenance prior to being 
incarcerated are given access to off-site OST centres 
by prison wardens.[5] However, the extent of ease of 
access to OST services in prisons for people who use 
opioids in all three countries is unclear. 
Prison population rates vary considerably across  
sub-Saharan Africa. The median prevalence of 
incarceration for West African countries is 52 people 
per 100,000, whereas in Southern Africa it is nearly 
quadruple the figure at 188.[98] With the highest per-
capita incarceration rate in the world, greater even 
that that of the United States, the Seychelles has 799 
people imprisoned per 100,000.[98] Perhaps because 
of these figures, the Seychelles replaced its 1990 
drug law with a new Misuse of Drugs Act in 2016 
and convened a special tribunal to review sentences 
for drug offences.[99] The updated act is aimed at 
providing more effective measures in relation to 
drug use, and promoting treatment, education and 
rehabilitation.[99] This may result in a reduced number 
of people incarcerated for drug offences over 
time; however, the Seychelles remains extremely 
limited in its harm reduction approach, both in the 
community and in prisons (see Table 2.9.1). Without 
an appropriate public health-centred harm reduction 
response in the Seychelles, HIV and hepatitis C 
prevalence will continue to rise.[17]
UNAIDS estimated that 56-90% of people who 
inject drugs will be incarcerated at some stage in 
their lives[100] and drug use in the prison setting is 
widely documented.[95] A study involving people who 
use drugs in Dakar, Senegal found that 29.2% had 
consumed drugs whilst in prison.[14] People who 
inject drugs are also most vulnerable to overdose on 
w In Kenya this is an off-site OST service not operating within the prison. In the Seychelles, the extent or accessibility of OST services for people in prison is unclear.
release from prison,[101-104] yet naloxone is reportedly 
unavailable to prisoners post-release in every country 
in the region.[5,16,20,24,30,32,50,52,64,69,74] The provision of 
good-quality and accessible harm reduction, both 
inside and outside prisons, is a binding human rights 
obligation,[105] one which sadly remains unmet in sub-
Saharan Africa. 
HIV testing and treatment (using ART) and TB testing 
and treatment are available within prison settings, 
in theory, in all countries in the region. However, 
in some countries it has been noted that these 
services have limited reach and coverage,[30] stocks 
of essential medicines are often in short supply 
or arrive late[50] and access to ART through prison 
hospital/treatment centres can be difficult.[16,32,69] 
Although ART is available in South Africa to those 
who have been charged with any criminal offence, 
there appears to be limited access to HIV and ART 
services.[20] Put simply, failing to provide access to 
essential medicines in a timely way contravenes 
states’ obligations to respect and protect the health 
and bodily integrity of people who are imprisoned, 
and in extreme circumstances, the very right to life of 
these people.[106,107]
As noted previously and evidenced in Table 2.9.1, 
hepatitis C prevalence among people who inject 
drugs is high. Similarly to naloxone availability, all 
countries in the region lack hepatitis C treatment in 
prisons.[5,16,20,24,30,32,50,52,64,69,74,108] Condom distribution 
is reportedly available in prisons only in Uganda (but 
with limited reach and coverage),[30] and in Lesotho 
and South Africa.[20]
In sub-Saharan Africa, the punitive response to drug 
use remains dominant, and people who use drugs 
continue to be harshly criminalised. It is clear that 
meeting international human rights obligations 
must be urgently prioritised in sub-Saharan African 
prisons, and that national, regional and international 
prison monitoring mechanisms should systematically 
examine issues relating to harm reduction during 
their prison visits.[109] One example of a progressive 
approach can be seen in Kenya, where a magistrate 
based at the Shanzu court in Mombasa offers people 
who use drugs a harm reduction alternative. People 
can be referred to the Muslim Education and Welfare 
Association (MEWA) rather than being imprisoned 
for drug-related crimes, where they are offered 
rehabilitation, psychosocial support, OST or support 
groups.[110] 
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Policy developments for 
harm reduction
Despite progress in the implementation of harm 
reduction services in some countries in the region, 
for the majority of sub-Saharan Africa a continued 
focus on supply reduction in drug policy and the 
criminalisation of drug use overshadows these 
efforts. 
Harm reduction is now explicitly referenced in policy 
documents in 10 countries in the region,x and noted 
in regional guidance.[27] Tanzania endorsed harm 
reduction in its national HIV strategy, and harm 
reduction is present in a number of new policies, 
such as the National Guideline for Comprehensive 
Package of HIV Interventions for Key and Vulnerable 
Populations.[24,111] Although people who use drugs 
are recognised as a key population by the Tanzanian 
government, and included in upcoming policies on 
HIV and hepatitis C, coverage of services does not 
meet the WHO recommended levels in practice.[24]
Harm reduction is mentioned in various policy 
documents in South Africa, including the draft 
South African Hepatitis Guidelines, the draft South 
African Hepatitis Action Plan, and the South African 
National Strategic Plan on HIV, TB and STIs (2017-
2021).[112] Significant advocacy efforts have also gone 
into including references to harm reduction in the 
updated South African National Drug Master Plan, 
which is currently in development. In Kenya, harm 
reduction is endorsed in national policy guidelines 
on HIV, and a multi-country Eastern African Harm 
Reduction Policy was in development at the time of 
publication; it is expected to include explicit reference 
to harm reduction.[5,30] The Kenya AIDS NGO 
Consortium, through support from a Global Fund 
regional grant, took leadership in the development 
of the sub-regional policy group on harm reduction 
at the East African Community (EAC) level.[5] The 
EAC is a regional intergovernmental organisation 
comprised of six countries (Burundi, Kenya, Rwanda, 
South Sudan, Tanzania and Uganda) and at the time 
of publication the policies outlined were due to be 
delivered to the EAC council of ministers for further 
recommendation and approval.[5] 
Harm reduction is not explicitly mentioned in 
national policies or strategies at present in Uganda. 
However, harm reduction issues have been 
submitted to policy makers establishing the new 
draft HIV prevention Action Plan for Uganda.[30] 
PEPFAR, through its linking agency the US Centers 
x As far as we are able to ascertain, harm reduction is explicitly referenced in government policy documents in Ghana, Kenya, Mauritius, Tanzania (including Zanzi-
bar), Zambia, Nigeria, South Africa, the Seychelles and Senegal.
for Disease Control and Prevention, has committed 
to allocate a budget for the development of policy 
guidelines for the delivery of harm reduction 
interventions in Uganda.[30] 
As previously noted, much of sub-Saharan Africa 
continues to follow a predominantly punitive 
approach to drug policy. The African Union, in its 
common position for the United Nations Special 
Session (UNGASS) on drugs, committed to achieving 
a balanced and integrated approach among supply 
reduction, demand reduction and harm reduction.[113] 
At time of reporting, Ghana was the only country 
in the region poised to decriminalise the personal 
possession and use of illicit drugs.[92]
Civil society and advocacy 
developments for harm 
reduction
Civil society organisations continue to be active in 
sub-Saharan Africa, both in implementing harm 
reduction services and lobbying for the need for 
harm reduction where it does not exist and/or where 
services are extremely limited. This mobilisation 
has led to increased levels of support for harm 
reduction interventions, public awareness of what 
harm reduction is through campaigns such as 
Support. Don’t Punish[115] and in some instances the 
initiation of services, such as pilot NSPs in Uganda.[30]. 
The East African Harm Reduction Conference was 
held in Nairobi, Kenya in early 2018 and attracted 
approximately 600 participants from 20 countries. 
The event, co-hosted by the Kenya AIDS NGO 
Consortium and the Kenyan Ministry of Health, 
also saw the Kenyan cabinet secretary for health 
formally launch the Eastern African Harm Reduction 
Network.[5,52] Through the African Union, members 
of the Southern African Development Community 
have also been vocally supportive of harm reduction 
in various forums,[69] and civil society organisations 
in Kenya report better engagement in government 
budget-making processes for harm reduction.[5] 
In South Africa, the second South African Drug Policy 
Week (SADPW) 2017, co-hosted by the South African 
National AIDS Council, brought together various 
stakeholders and people who use NSP and OST 
services to participate in discussions of the National 
Drug Master Plan development process.[20] The 
Southern African Network of People Who Use Drugs 
(SANPUD) was also established.[20,69] In September 
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2017, Mauritius also held its Third International 
Conference on Harm Reduction.[52] 
In Nigeria, a national civil society stakeholders 
meeting on harm reduction was held for the first 
time in 2017. The meeting involved the Ministry 
of Health and the National Drug Law Enforcement 
Agency, which had in the past stood against harm 
reduction, with a national harm reduction coalition 
being formed at the time of publication.[16] A drug 
user network was also established in Nigeria in 
2017, known as the Drug Harm Reduction Advocacy 
Network, and linked to the International Network of 
People who Use Drugs (INPUD).[16,74] This drug user 
network joins a plethora of others in the region, 
some of which are attached to the broader East 
Africa Harm Reduction Network,y including SANPUD 
(also linked to INPUD), [20] Drug Users of Gauteng, 
Drug Users of Cape Town, Drug Users of Durban,[20] 
the Mauritian Network of People who Use Drugs,[51,52] 
Drug Users Network Seychelles (DUNS), the Burundi 
Network of People who Use drugs (BAPUD), Santé 
Espoire et VIE (SAVE) in Senegal,[32] the Tanzanian 
Network of People who Use Drugs (TANPUD),[24] 
the Zanzibar Network of People who Use Drugs, 
the Kenya Network of People who Use Drugs[5] and 
five drug user-led groups in Zimbabwe, including 
the Zimbabwe People who Use Drugs group which 
formed in 2016.[69] The Zimbabwe Lawyers for 
Human Rights group has also assisted members 
of the Zimbabwe Civil Liberties and Drug Network 
at country level to understand their rights.[69] In 
April 2018, a Harm Reduction Association was also 
established in the Democratic Republic of the Congo, 
although limited to harm reduction advocacy work at 
time of publication.[50]
In 2017, YouthRISE Nigeria led the We Are People 
campaign, which focused on the human rights 
of people who use drugs and the need for harm 
reduction services. In 2018, YouthRISE aims to work 
together with the United Nations Office on Drugs and 
Crime (UNODC) to organise training for civil society 
organisations in the country on harm reduction.[16,74] 
Civil society organisations, such as UHRN in Uganda, 
are also helping to shift the trend from arrest and 
detain to arrest and refer to harm reduction by 
engaging with police officers and stations on the 
principles of harm reduction.[30]
y Kenya, Uganda and South Africa.
z The 10 by 20 campaign calls on governments to redirect 10% of law enforcement funding to harm reduction by 2020.
Funding developments for 
harm reduction
As reported in previous iterations of the Global State, 
much of the funding for harm reduction in sub-
Saharan Africa stems from multilateral agencies. 
In 2017, civil society organisations in South Africa 
received funding from the Global Fund through the 
South African National AIDS Council’s work, with the 
monies used to support the continuation of services 
in Cape Town and the scale-up of two new NSPs 
in Port Elizabeth and Johannesburg, and two small 
OST programmes.[20] Although the Global Fund is 
supporting harm reduction in the region and South 
Africa more specifically, there is currently evidence of 
the government prioritising harm reduction funding. 
There have been limited discussions with the 
South African National Department of Health on 
the appropriate budget for OST, but at the time of 
publication there are no reports of plans for a harm 
reduction-specific budget. Funding from PEPFAR of 
services for people who inject drugs through the 
Centers for Disease Control and Prevention has been 
reduced, with no additional funding from USAID 
in the latest round of key population funding.[20] 
Mainline, a Dutch NGO, has been complementing 
PEPFAR and Global Fund harm reduction funding 
through a programme of work called Bridging 
the Gaps in South Africa, focused on OST and 
psychosocial services in three cities and drop-in 
centres.[53] The Open Society Foundations (OSF) fund 
advocacy initiatives in East and West Africa.[20] Harm 
Reduction International’s 10 by 20 campaignz was 
presented at the 2017 South African Drug Policy 
Week.[20] 
Although more than 90% of funding in South Africa 
comes from international donor support, the City of 
Tshwane has allocated 4-5 million Rand (US$300,000 
to $375,000) to harm reduction funding, specifically 
for OST and sterile injecting equipment/harm 
reduction packs, as part of a three-year agreement 
with the University of Pretoria. The programme aims 
to develop and implement a response to drugs that 
is not prohibitionist in nature.[20] 
In Kenya, the United States government contributed 
an estimated US$5.5 billion through PEPFAR between 
2004-2017 to the national AIDS response.[115] Small 
pockets of government funding are being used 
to support OST programmes in Kenya; however, 
the majority of funding continues to come from 
international donors.[5] Through donor support, such 
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as that of the Global Fund, UNITAID, International 
HIV/AIDS Alliance, PEPFAR, USAID and Mainline via 
Bridging the Gaps, harm reduction services in the 
country have increased, including for OST, NSPs, 
naloxone and hepatitis C provision; but the last only 
to a small extent at time of publication.[5,53] In the 
next two to three years, the Global Fund grant (which 
is the primary funding to have sustained and scaled-
up harm reduction programming and advocacy in 
Kenya) will come to an end. There is some concern 
that without a strong transition process and greater 
commitments by governments, the positive changes 
in Kenya, Uganda, Tanzania, Zanzibar, the Seychelles 
and Mauritius may be lost.[5] At present, in Kenya, 
OST coverage still reaches only 9% of people who use 
opioids, and more resources are needed to support 
and scale-up all nine of the WHO recommended 
interventions in the country.[63] 
The Global Fund have supported pilot NSPs in 
Uganda in 2018, with the hope to scale-up to more 
sites with Global Fund assistance in the future.[29] The 
Partnership to Inspire, Transform and Connect the 
HIV response (PITCH), supported by the International 
HIV/AIDS Alliance, is also contributing to harm 
reduction initiatives in Uganda.[30] In Tanzania, harm 
reduction funding comes from a variety of sources.[24] 
OST clinics and the provision of methadone are 
supported primarily by the Centers for Disease 
Control and PEPFAR, with some support from 
the Tanzanian government. Funding for the NSPs 
running in Dar es Salaam comes from the French 
NGO Médecins du Monde (MdM) with support from 
Agence Française de Développement (AFD) and 
harm reduction advocacy is mainly funded through 
the Global Fund, with monies also coming from the 
Open Society Initiative for East Africa (OSIEA) and UN 
agencies.[24] For the first time, pilot NSP activities have 
been integrated into the recent Global Fund grant 
in Tanzania.[24] Due to limited resources and a lack 
of understanding regarding the principles of harm 
reduction in the country, health services which aim 
to address drug users’ needs often lack financing, 
and there is an extremely limited government budget 
dedicated to the care of people who use drugs.[24]
In Senegal, harm reduction continues not to be a 
priority for the government.[32] ANCS, which is one 
of the main implementers of harm reduction in the 
country, receives funding from the Global Fund, the 
International HIV/AIDS Alliance and the Open Society 
Initiative for West Africa (OSIWA). The Global Fund 
grant will end by 2020/2021, and efforts must be 
made to ensure alternative funding is secured before 
then.[32] Similarly in Nigeria, which is yet to implement 
harm reduction programmes, over 80% of funding 
for the national HIV/AIDS programme comes from 
international donor contributions.[16]
The only country in the region that breaks the 
mould is Mauritius, where the government supports 
approximately 70% of harm reduction services and 
the Global Fund provides approximately 30%.[52] In 
the rest of sub-Saharan Africa, government domestic 
investment in harm reduction is poorly documented 
and there remains a heavy reliance on international 
donors; a reliance that risks the sustainability of the 
harm reduction response and leaves services in a 
precarious situation.[115]
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